Government of the Philippines
Department of Health

Philippines COVID-19 Emergency Response Project (P173877) and Additional Financing Project (P175953)

ENVIRONMENTAL AND SOCIAL MANAGEMENT FRAMEWORK (ESMF)

08 JANUARY 2021
# Table of Contents

**Executive Summary**........................................................................................................................................ 1

1 **Introduction and Background** ......................................................................................................................... 7
  1.1 **Purpose of this Document** ......................................................................................................................... 7
  1.2 **COVID-19 World Bank Program** ............................................................................................................... 7
  1.3 **World Bank Programming in the Country Health Sector** .......................................................................... 8

2 **Project Description** ............................................................................................................................................ 10
  2.1 **Development Objectives** .......................................................................................................................... 10
  2.2 **COVID-19 Project Components and Activities** ....................................................................................... 10
  2.3 **Subcomponent Typology** ........................................................................................................................ 11
  2.4 **Prohibited/Negative List** ......................................................................................................................... 14

3 **Policy, Legal and Regulatory Framework** ........................................................................................................ 15
  3.1 **Philippines Legal Framework relevant to the ESF** ................................................................................... 15
    3.1.1 **Philippine Environmental Impact Assessment System of 1978**....................................................... 15
    3.1.2 **Republic Act (RA) 6969 — Toxic Substances and Hazardous and Nuclear Wastes Control Act of 1990** .............................................................................................................................. 15
    3.1.3 **DENR Administrative Order (DAO) 1992-29 established the Implementing Rules and Regulations (IRR) of Republic Act 6969 or Toxic Substances and Hazardous and Nuclear Wastes Control Act of 1990** .............................................................................................................................. 15
    3.1.4 **Republic Act (RA) 9003 – Ecological Waste Management Act and DENR AO 2001-34 (Implementing Rules and Regulations)** ........................................................................................................... 16
    3.1.5 **Joint DOH-DENR DAO Order No. 2005-02 – Policies and guidelines on effective and proper handling, collection, transport, treatment, storage and disposal of health care waste** .............................................................................................................................. 16
    3.1.6 **DAO 2014-02 – Revised Guidelines for Pollution Control Officer Accreditation** .................... 16
    3.1.7 **DAO 2013-22 – Revised Procedures and Standards for the Management of Hazardous Wastes** .................................................................................................................................................. 16
    3.1.8 **DENR Memorandum Circular (MC) 2020-16 – Amendment of the Interim Guidelines on Issuance of Special Permit to Transport (SPTT) for the Transportation of Hazardous Wastes within the Community Quarantine Period** .................................................................................................................................................. 17
    3.1.9 **Memorandum Circular (MC) 2020-20 – Provisional Guidelines on the Hazardous Wastes Management within the Extended Enhanced Community Quarantine** .................................................................................................................................................. 17
    3.1.10 **Philippine Clean Air Act of 1999** ............................................................................................................ 18
    3.1.11 **Chemical Control Order on Ozone-Depleting Substances** .................................................................. 18
    3.1.12 **Department of Energy Administrative Order 110 – Procurement of Energy-Consuming Equipment** ........................................................................................................................................... 19
    3.1.14 **Climate Change Act of 2009 and Relevant DOH Policy Issuances** ..................................................... 20
| 3.1.15 | Disaster Risk Reduction and Management and Relevant DOH Policies | 21 |
| 3.1.17 | Department of Health COVID-19 Interim Guidelines | 27 |
| 3.1.18 | Executive Order no. 121 series of 2020 | 28 |
| 3.1.20 | Bureau of Food and Drug (BFAD) Circular 16, series of 1999 – Amending BFAD MC No. 22 dated September 8, 1994, regarding Inventory, Proper Disposal, and/or Destruction of Used Vials or Bottles | 29 |
| 3.1.22 | FDA Circular No. 2020-028 || Reissuance of the Guidelines for the Registration of Drug Products under Emergency Use (DEU) for the Coronavirus Disease 2019 (COVID-19) | 29 |
| 3.1.23 | Greening and Energy-Efficiency Guidelines of the Department of Health | 30 |
| 3.1.24 | Labor Legislation | 30 |
| 3.1.25 | Persons with Disabilities (PWDs) | 34 |
| 3.1.26 | Indigenous Peoples | 35 |
3.1.27 Republic Act 9184 – An Act Providing for the Modernization, Standardization and Regulation of the Procurement Activities of the Government and for other Purposes

3.1.28 Executive Order 301 series of 2004 – Establishment of a Green Procurement Program in all Government Agencies

3.1.29 GPPB Resolution No. 15, series of 2013 – Approval to Support the Implementation of Sustainable and/or Green Public Procurement Regime in Government

3.2 World Bank Environmental and Social Policies

3.2.1 ESS1 Assessment and Management of Environmental and Social Risks and Impacts

3.2.2 ESS2 Labor and Working Conditions

3.2.3 ESS3 Resource Efficiency and Pollution Prevention and Management

3.2.4 ESS4 Community Health and Safety

3.2.5 ESS7 Indigenous Peoples/Sub-Saharan African Historically Underserved Traditional Local Communities

3.2.6 ESS10 Stakeholder Engagement and Information Disclosure

3.3 International and Regional Regulations and Guidance

3.3.1 Vaccine Introduction Readiness Assessment Tool (VIRAT)/Vaccine Readiness Assessment Framework (VRAF) Integrated Tool

3.3.2 World Health Organization

3.3.3 Stockholm Convention

3.3.4 Kigali Amendment to the Montreal Protocol on Substances that Deplete the Ozone Layer

3.3.5 Doha Declaration on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement and Public Health

3.3.6

4 Environmental and Social Baseline

4.1 Health Care Waste Management of Infectious Wastes Related to COVID-19

4.2 Health Care Waste Transporters and Treatment, Storage, and Disposal Facilities (TSDs)

4.3 Training for Implementers on the COVID-19 Vaccination Activities

4.4 Air Quality and Healthcare Waste Incineration

4.5 Indigenous Peoples

4.6 Disadvantaged and Vulnerable Groups

4.6.1 Persons with Disabilities

4.6.2 Disability-Inclusion in the World Bank’s COVID-19 Response

4.6.3 Gender and Gender-based Violence

4.7 National Immunization Context

4.8 Lessons Learned on the Immunization Roll-out of a Novel Vaccine

5 Potential Environmental and Social Impacts and Mitigation Measures
5.1 Methodology for Assessing Risk and Impacts .......................................................... 59
5.2 Risk Summary ............................................................................................................. 59
  5.2.1 Environmental Risks .......................................................................................... 59
  5.2.2 Social Risks ......................................................................................................... 60
5.3 Construction Stage .................................................................................................... 62
  5.3.1 Environmental Risks .......................................................................................... 62
  5.3.2 Occupational Health and Safety ........................................................................ 62
5.4 Operational Stage ...................................................................................................... 64
  5.4.1 Occupational Health and Safety ........................................................................ 64
  5.4.2 Healthcare Waste Management at Healthcare Facilities ................................. 68
  5.4.3 Wastes from COVID-19 Vaccination ................................................................. 71
  5.4.4 Labor Rights and Gender .................................................................................. 71
  5.4.5 Community Health and Safety .......................................................................... 73
  5.4.6 Social Exclusion ............................................................................................... 75
  5.4.7 Gender-Based Violence (GBV) and/or Violence Against Children (VAC) ......... 77
  5.4.8 Social Stigma .................................................................................................... 77
  5.4.9 Cold Chain Operation ....................................................................................... 78
  5.4.10 Climate-Change Related Risks ....................................................................... 79
6 Procedures to Address Environmental and Social Issues ............................................. 80
  6.1 Screening Process .................................................................................................. 80
  6.2 Environmental and Social Management Plans ...................................................... 81
  6.3 Health-care Waste Management .......................................................................... 82
  6.4 Indigenous Peoples .............................................................................................. 83
7 Stakeholder Engagement, Consultation and Disclosure ................................................. 85
  7.1 Monitoring of Adverse Events Following Immunization (AEFI) .............................. 97
8 Project Implementation Arrangements, Responsibilities, and Capacity Building .......... 100
  8.1 Implementation Arrangements ............................................................................. 100
  8.2 Capacity Building ............................................................................................... 104
  8.3 Estimated Budget ................................................................................................. 104
A. Abbreviations and Acronyms ................................................................................. 107
B. Labor Management Procedures (LMP) ..................................................................... 108
C. Labor Management Procedures (LMP) Monitoring Form Template ........................ 119
D. Screening Form for Potential Environmental and Social Risk .................................. 128
E. Environmental and Social Management Plan Template .......................................... 135
F. Environmental and Social Management Plan Monitoring Report Template ............. 140
G. Environmental Codes of Practice (ECOP) Checklist ............................................. 141
H. Environmental Codes of Practice (ECOP) Monitoring Form Template.............................................148
I. Infection Control and Waste Management Plan (ICWMP).................................................................149
J DENR- Accredited M501 and M503 Waste Transporters .................................................................155
K DENR- Accredited M501 and M503 Waste Treatment, Storage, and Disposal (TSD) Facilities........161
L Vaccine Introduction Readiness Assessment Tool (VIRAT)/ Vaccine Readiness Assessment Framework (VRAF) Tool .........................................................................................................................165
M Resource List: COVID-19 Guidance .................................................................................................208
Executive Summary

**The Project Development Objective** of the COVID-19 Emergency Response Project is to strengthen the Philippines’ capacity to prevent, detect, and respond to the threat posed by COVID-19 and to strengthen national systems for public health preparedness.

**The Environmental and Social Management Framework (ESMF).** The Project consists of a number of different activities and/or investments (subprojects) for which the risks and impacts cannot be determined until implementation. The ESMF describes the principles, processes, and technical guidance for the Project implementing agencies and their consultants to assess the environmental and social risks and impacts of the Project activities.

This ESMF assists the Department of Health (DOH) in identifying the type of environmental and social assessment that should be carried out for the project activities that involve the construction, expansion, rehabilitation and/or operation of healthcare facilities, and the deployment of a safe and effective vaccine in response to COVID-19, and in developing the environmental and social (E&S) management plans in accordance with the World Bank’s Environmental and Social Framework (ESF).

The ESMF is applicable to all investments under the Project. It aims to (a) assess the potential environmental and social (E&S) risks and impacts of the Project and propose mitigation measures which will effectively address these risks/impacts; (b) establish clear procedures for the E&S screening, review, approval, and implementation of activities; (c) specify appropriate roles and responsibilities, and outline the necessary reporting procedures, for managing and monitoring E&S issues related to eligible activities; (d) identify the training and capacity building needed to successfully implement the provisions of the ESMF; (e) address mechanisms for public consultation and disclosure of project documents as well as redress of possible grievances; and (f) establish the budget requirement for implementation of the ESMF.

**Eligible Project Activities.** The Project will be national in coverage and scope, and would finance a number of activities that focus on the (i) provision of medical supplies, including personal protective equipment for ICUs, medicines, and ambulance in existing hospitals at national, provincial and local government levels; (ii) provisions to address capacity building needs of the medical service providers and supporting staff training related to COVID-19 emergency preparedness, infection control and medical waste management; (iii) civil works that involve retrofitting existing hospital buildings to include isolation/negative pressure wards; (iv) establishment of point-of-entry quarantine and decontamination facilities; (v) strengthening laboratory capacity at national and sub-national levels; and (vi) procurement and administration of COVID-19 vaccines. The Project will include the Bangsamoro Autonomous Region in Muslim Mindanao (BARMM) and possibly, areas with indigenous peoples.¹

**Potential Environmental Impacts and Risks.** Overall, the environmental risk is expected to be moderate due to the nature of associated activities and works and the duration of construction period (less than 12 months). The direct and indirect environmental impacts that may arise due to the project activities are:

(i) *Occupational safety and health risks (OSH).* The profiling and screening of patients prior to vaccination, the administration of the vaccine, and the operation of medical

---

¹ Approximately ten percent of the population in the Philippines is considered indigenous peoples.
facilities and laboratories involved in COVID-19 response might expose the health care workers to a higher risk of contracting the virus, if infection prevention and control measures are not implemented, and cause unsafe environment. There are also OSH risks to the workers/laborers due to the possible exposure during the construction activities in the health facilities and laboratories. Occupational safety and health risks for cleaners and waste handlers in health facilities and the waste service providers are present due to the possible exposure to infectious health care wastes during the collection, storage, treatment, and disposal stages.

(ii)  
*Risks from infectious healthcare wastes.* The wastes generated from the COVID-19 testing, other diagnostic procedures, clinical management of patients, and vaccination activities, including waste collection from the health care facility by the facility’s waste handlers and cleaners and by the contracted waste service providers, as well as community health and safety issues related to the handling, transport, treatment, and disposal of the healthcare wastes are present.

(iii)  
*Logistics and distribution risks of the vaccine.* The COVID-19 vaccines require specific temperatures during storage and distribution to maintain efficacy and safety. Hence, the contraindications and storage and transport condition requirements of the vaccine may pose risks. The availability of cold storage and refrigerated transportation suitable to the temperature needs of the vaccine and in the location of vaccine administration is a potential risk to the Project’s implementation. Relatedly, the cold storage to be procured or rented may contain refrigerants which do not conform to the requirements of the Montreal Protocol, Kigali Agreement, and the chemical control order on ozone-depleting substances (ODS) and contribute to the generation of greenhouse gases (GHG). Other refrigerants are also toxic and flammable and can pose risk to people’s health and safety. Cold storage systems also require huge amount of energy to operate that may have an impact on climate change. The compliance with biosafety protocols during the transport of the vaccines is also a risk, as breakage of the vials and spillage of the vaccine might occur. Similarly, natural disasters such as earthquake, landslide, flooding, storm surge and other climate change-related risks as well as unstable power supply resulting to power outages exist in some areas in the country which may affect the security of the delivery and distribution of the vaccines. The possible hot weather in the country may also have an effect on the efficacy of low temperature-requiring vaccines

(iv)  
The small construction activities which are part of the project components, such as the expansion or rehabilitation of existing buildings and facilities, pose occupational health and safety risks to the workers. The project will include limited civil works such as small retrofitting activities on existing premises and there will be no land acquisition and involuntary resettlement involved.

**Potential Social Impacts and Risks.** There are substantial risks related to the direct and indirect social impacts of the eligible activities. These risks can be mainly classified as (i) biosafety issues, (ii) case management of population for vaccination, (iii) regulatory measures, (iv) community health and safety, (v) affordability, social inequity, and risk of
exclusion, (vi) stigma, discrimination, and vaccine acceptance; and (vii) misinformation, lack of information, and disinformation:

i. **Biosafety Issues of the vaccine.** Due to the novelty and relatively shorter timeframe of the development and clinical trials of the COVID-19 vaccine, the communities may have fear and apprehension on its scientific integrity, efficacy, and safety. The contraindications and storage and transport condition requirements of the vaccine may pose risk. Transparency on the vaccine information and manufacturer credibility are important considerations for the public. Misinformation on the adverse health effects of vaccine is also a risk which should be addressed through an effective risk communication strategy.

ii. **Case management of population for vaccination.** There are risks of contraindications and adverse health effects as result of improper or inadequate profiling and screening of individuals prior to vaccination. There is also a risk of not completing the vaccine dose/shots due to the individual’s apprehension and/or schedule mismanagement. The data management of the vaccination program, including the establishment of good surveillance system and schedule monitoring, are also risks. With the use of more than one vaccine during the immunization period, close monitoring of adverse events in vaccinated individuals using information technology, i.e., digital tracking system should be conducted. As the possibility of adverse effects of the vaccine is a risk, tracking of health effects in vaccinated individuals and follow-up assessments should be conducted.

iii. **Regulatory measures.** Due to the global demand for the vaccine and the limited vaccine production, access to the COVID-19 vaccines is a risk. The conduct of strict regulatory measures should be ensured in view of the novelty of the vaccine. Regulation and access concerns should be equally taken into consideration. Moreover, the work of relevant bodies such as the Food and Drug Administration (FDA), the National Immunization Technical Advisory Group (NITAG), and the Health Technology Assessment Committee (HTAC) should be continually aligned and synchronized to ensure the expeditious national approval of the vaccines.

iv. **Community health and safety.** The vaccine administration may also lead to crowding and violation of physical distancing measures, increasing the risk of exposure of the health workers, the vaccinees, and the community, especially the residents within the vicinity of the immunization site. Thus, compliance to minimum public health standards is strongly advised. Infectious health care wastes generated from the vaccination and other COVID-19-related responses pose risk to community health and safety if not handled, transported, treated, and disposed of according to the proper health care waste management practices. Hospital visitors and other non-COVID-19 patients may also be exposed to the virus as well as the workers when establishing or upgrading health facilities. There is also a risk of not completing the vaccine dose/shots due to the individual’s apprehension and/or schedule mismanagement.

v. **Affordability, social inequity, and risk of exclusion.** The accessibility of COVID-19 vaccines due to its price is a risk. Due to the novelty and urgent need of the vaccine,
there is a risk in price regulation and compliance with fair trade guidelines. Although the national government has already identified its eligible population to be immunized from 2021 – 2023, strict adherence to this list to ensure that the most-at-risk are the ones vaccinated first is a risk. There is an indirect risk of social exclusion, in particular, the most vulnerable and marginalized groups such as the indigenous peoples in remote areas from access to the COVID-19 information, treatment, and vaccines, and also the sexual and gender minorities (especially transgender people) or refugees. The elderly, those with underlying medical conditions, and people living with disability, though included in the priority populations to be vaccinated as identified in the WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply\(^2\), may have limited access to the vaccines due to reduced mobility. The vulnerable groups may also be excluded from coverage of the national program and local responses to COVID-19. The vaccine distribution and deployment may also exclude populations based on geographical distribution, i.e., those in far-flung areas, and on socioeconomic status, such as less access for the marginalized.

vi. **Stigma, discrimination, and vaccine acceptance.** The fear and apprehension of individuals and communities on the scientific integrity, efficacy, and safety of the COVID-19 vaccines may lead to people refusing vaccination. The vaccine acceptance may also be affected by the country’s previous experience with the Dengvaxia vaccination. The possibility of having COVID-19 may also cause individuals to hide symptoms, avoid getting tested, and reject hygiene measures, which could lead to further spread of the virus. The health workers involved in the vaccine administration activities may face discrimination and harassment when going back to their communities due to people’s fear in contracting the virus, frustrations over medical care, or misinformation.

vii. **Misinformation, lack of information, and disinformation.** Misinformation and disinformation on COVID-19 and the adverse health effects of vaccines and hearsays on the conspiracy theories and underlying political agenda on the vaccines are widespread. The information materials on COVID-19 and the vaccine to be developed could exclude the most vulnerable or be developed in a way that is not sensitive to the needs and access of these different groups. Messages on COVID-19 and the vaccine may also not be in the language appropriate and may not be readily accessible for communities, especially in geographically isolated and disadvantaged areas (GIDAS).

**Procedures to Address Environmental and Social Issues.** The ESMF provides a screening tool for potential project activities to allow determination of potential environmental and social issues. The screening process identifies possible instruments, e.g., Environmental and Social Management Plan (ESMP), Environmental Codes of Practice (ECOP), to be applied during Project implementation, based on subproject typology. These issues will also be addressed through relevant capacity building activities, observance of the labor management procedures and environmental and social management plans for project sites, conduct of community consultations, and active observance of

the Grievance Redress Mechanism. The Stakeholder Engagement Plan includes provisions for engaging affected and interested stakeholders throughout the project implementation. Measures to address concerns of vulnerable groups, including persons with disabilities and indigenous peoples, are included in the ESMF and SEP.

The National Health Care Waste Management Program in healthcare facilities (HCF) considers the HCF staff and waste management service providers and the community health and safety issues related to the handling, transport, and disposal of healthcare wastes, which are addressed through the ESMF. To ensure the safety of the vaccines to be procured, the vaccine regulatory approval of the Stringent Regulatory Authorities (SRAs)3 identified by the World Health Organization will be required. Appropriate messages are being developed under the risk communication plan to address the vaccine safety and identification of priority population concerns of communities.

The DOH Health Promotion Bureau (HPB) has developed key messages on COVID-19 information, prevention, and treatment through its BIDA Solusyon Campaign. A Communications Campaign Plan will also be developed by the DOH-HPB for the COVID-19 immunization program. It will have a whole-of-government, whole-of-system, and whole-of-society approach which will encompass general information on (i) COVID-19 and the need for sanitation and hygiene practices, (ii) COVID-19 vaccine basic information, (iii) trials results and procurement, and (iv) vaccine program roll-out. The WHO Risk communication and community engagement readiness and response to coronavirus disease (COVID-19) released on 19 March 2020 will also be used as reference in the development of messages and planning of risk communication and community engagement (RCCE) activities.

Serial obtaining of informed consent from the identified vaccinees and counselling shall be conducted prior to the administration of the COVID-19 vaccine. The profiling and screening of candidate individuals to be vaccinated should be performed so as to avoid the risk of vaccine contraindications. A comprehensive data management system is also needed to support the profiling, screening, and scheduling to address the risk of individuals not completing the required shots/doses of the vaccine. Coordination with the local government units as well as the uniformed personnel will be done to assist in crowd management and for the successful conduct of the National Deployment and Vaccination Program.

**Institutional Arrangement for ESMF implementation.** The Department of Health (DOH) shall be responsible for the coordination, management, and implementation of the project at the national and sub-national levels including financial management, procurement, and environmental and social management. The Project’s implementation shall be mainstreamed in the DOH processes and shall involve a Project Management Unit headed by the Bureau of International Health Cooperation (BIHC) under the Office of the Undersecretary for Health Policy and Systems Development Team (HPSDT). This has been strengthened by the recruitment of additional staff responsible for environmental and social management.

The COVID-19 vaccination activities will also be implemented in accordance with the directives of the COVID-19 Vaccine Cluster Organizational Structure. The Inter-Agency Task Force on the Management of Emerging Diseases is Chaired by Secretary Francisco Duque III of the DOH while the National Task Force Against COVID-19 is Chaired by Secretary Delfin Lorenzana of the Department of Defense. Secretary Carlito Galvez, Jr., Presidential Adviser on the Peace Process, is the Chairperson.

---

of the National Incident Command and COVID-19 Vaccine Cluster (Philippine National Vaccine Roadmap or PNVR). Undersecretary Leopoldo Vega of the DOH is the Chairperson of the Response Cluster while the National Economic and Development Authority (NEDA) is the Chair of the Recovery Cluster. Task Groups and Sub-Task Groups were also created for the various aspects of the vaccination activities, as detailed in Chapters 7 and 8.
1 Introduction and Background

1.1 Purpose of this Document

This Environmental and Social Management Framework (ESMF) has been prepared to assess and manage the environmental and social risks and impacts of the Philippine COVID-19 Emergency Response Project. A framework approach is chosen as the specific locations and details of the sub-projects will not be known until implementation. The ESMF assists the DOH in identifying the type of environmental and social assessment that should be carried out for projects that involve the construction, expansion, rehabilitation and/or operation of healthcare facilities, and the deployment of a safe and effective vaccine in response to COVID-19, to the extent possible and based on existing information, the environmental and social management approach that should be taken at the subproject level and the E&S management plans to be developed, in accordance with the World Bank Environmental and Social Framework (ESF).

The purpose of the ESMF is to guide DOH and other proponents on the environmental and social screening, assessment, and management of specific project activities during implementation. The document also provides guidance on the preparation of location specific Environmental and Social Management Plans (ESMPs), when needed, in accordance with the ESF.

Additional financing will be provided to support the costs of expanding activities of the Philippines COVID-19 Emergency Response Project (P173877, the parent project)\(^4\) to enable affordable and equitable access to COVID-19 vaccines and help ensure effective vaccine deployment in the country through enhanced vaccination system and to further strengthen preparedness and response activities under the parent project for additional US $ 300 million. The Parent Project ESMF have been updated to reflect the activities under the Additional Financing and the identified issues related to COVID-19 response based on guidance provided by the Bank.

1.2 COVID-19 World Bank Program

An outbreak of the coronavirus disease (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) has been spreading rapidly across the world since December 2019, following the diagnosis of the initial cases in Wuhan, Hubei Province, China. Since the beginning of March 2020, the number of cases outside China has increased thirteenfold and the number of affected countries has tripled. On March 11, 2020, the World Health Organization (WHO) declared a global pandemic as the coronavirus rapidly spreads across the world. As of March 26, 2020, the outbreak has resulted in an estimated 416,686 cases and 18,589 deaths in 197 countries and territories.\(^5\)

COVID-19 is one of several emerging infectious disease (EID) outbreaks in recent decades that have emerged from animals in contact with humans, resulting in major outbreaks with significant public health and economic impacts. The last moderately severe influenza pandemics were in 1957 and 1968; each killed more than a million people around the world. Although countries are now far more prepared than in the past, the world is also far more interconnected, and many more people today have behavior risk factors such as tobacco use\(^6\) and pre-existing chronic health problems that make


\(^5\)https://www.who.int/emergencies/diseases/novel-coronavirus-2019

viral respiratory infections particularly dangerous.

With COVID-19, scientists are still trying to understand the full picture of the disease symptoms and severity. Reported symptoms in patients have varied from mild to severe, and can include fever, cough and shortness of breath. In general, studies of hospitalized patients have found that about 83% to 98% of patients develop a fever, 76% to 82% develop a dry cough and 11% to 44% develop fatigue or muscle aches. Other symptoms, including headache, sore throat, abdominal pain, and diarrhea, have been reported, but are less common. While 3.7% of the people worldwide confirmed as having been infected have died, WHO has been careful not to describe that as a mortality rate or death rate. This is because in an unfolding epidemic it can be misleading to look simply at the estimate of deaths divided by known cases so far. Hence, given that the actual prevalence of COVID-19 infection remains unknown in most countries, it poses unparalleled challenges with respect to global containment and mitigation. These issues reinforce the need to strengthen the response to COVID-19 across all IDA/IBRD countries to minimize the national and global risks and impacts posed by this disease.

The World Bank is providing support to Governments for preparedness planning to provide optimal medical care, maintain essential health services and to minimize risks for patients and health personnel (including training health facilities staff and front-line workers on risk mitigation measures and providing them with the appropriate protective equipment and hygiene materials). As COVID-19 places a substantial burden on inpatient and outpatient health care services, support will be provided for a number of different activities, all aimed at strengthening national health care systems, including systems for the deployment of safe and effective COVID-19 vaccine.

1.3 World Bank Programming in the Country Health Sector

The project is aligned with the World Bank Group strategic priorities, particularly the WBG’s mission to end extreme poverty and boost shared prosperity. The Program is focused on preparedness which is also critical to achieving Universal Health Coverage. It is also aligned with the World Bank’s support to national plans and global commitments to strengthen pandemic preparedness through three key actions under Preparedness: (i) improving national preparedness plans including organizational structure of the government; (ii) promoting adherence to the International Health Regulations (IHR); and (iii) utilizing international framework for monitoring and evaluation of IHR.

The economic rationale for investing in the MPA interventions is strong, given that success can reduce the economic burden suffered both by individuals and countries. The project complements both WBG and development partner investments in health systems strengthening, disease control and surveillance, attention to changing individual and institutional behaviour, and citizen engagement. The project contributes to the implementation of IHR (2005), Integrated Disease Surveillance and Response (IDSR), and the World Organisation for Animal Health (OIE) international standards, the Global Health Security Agenda, the Paris Climate Agreement, the attainment of Universal Health Coverage and of the Sustainable Development Goals (SDG), and the promotion of a One Health approach.

The Project supports Specific Objective #4 in the Philippines’ National Objectives for Health 2017-2022 that strives to increase access to quality essential health products and services. This includes working toward a resilient health system that has the capacity to absorb, adapt, and transform when

---

exposed to a shock such as pandemics, natural disasters or armed conflict and still retain the same control on its structure and functions. The objective is to enable local government units (LGUs) to mobilise communities to implement Disaster Risk Reduction and Management in Health (DRRM-H), which will be institutionalized in all levels of governance by: (1) developing and implementing DRRM-H plans, (2) organizing trained and equipped health emergency response teams, (3) ensuring availability and accessibility of health emergency commodities, and (4) ensuring functionality of Operation Centers (OPCEN).
2 Project Description

2.1 Development Objectives

The Project objectives are aligned with the results chain of the COVID-19 Strategic Preparedness and Response Program (SPRP). The project development objective (PDO) is to strengthen the Philippines’ capacity to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. Three PDO level indicators are proposed:

- Percentage of hospitals with personal protective equipment and infection control products and supplies according to DOH requirements, without stock-outs in preceding one month;
- Percentage of designated laboratories with COVID-19 diagnostic equipment, test kits, and reagents, without stock-outs in preceding one month; and
- Number of acute healthcare facilities with isolation capacity according to DOH established standards (Number).

Additional financing will be provided to support the costs of expanding activities of the Philippines COVID-19 Emergency Response Project (P173877, the parent project)9 to enable affordable and equitable access to COVID-19 vaccines and help ensure effective vaccine deployment in the country through enhanced vaccination system and to further strengthen preparedness and response activities under the parent project for additional US $ 300 million.

2.2 COVID-19 Project Components and Activities

The Project will finance a broad range of both immediate and near-term priority health sector activities which will include the medical facilities refurbishment and procurement of health care equipment and ambulances, personal protective equipment (PPE), COVID-19 vaccines, and medical consumables that constitute priorities of the Government of the Philippines (GoP) national response to the COVID-19 pandemic. In particular, this will include establishing testing and quarantine facilities at six major international airports in Luzon, Visayas and Mindanao administrations, 21 first-line decontamination facilities at international airports, strengthening the national reference laboratories as well as sub-national and public health laboratories for COVID-19 analysis, refurbishing and establishing negative pressure isolation rooms in about 70 DoH and 30 UHC implementation site public hospitals, extensive provision and training on use of PPE, about 150 land and 10 sea ambulances, COVID-19 test kits, and an array of diagnostic and life support equipment (ventilators, oxygen machines, cardiac monitors, infusion pumps, portable x-ray machines, PCR equipment, dialysis machines).

The Project will be national in scope, supporting the existing network of the health care facilities and services in the Philippines, and providing support to immediate response, e.g., testing, quarantine, decontamination and treatment, and immunization, as well as mid-term activities such as completion of construction of the national reference laboratory complex. The Project will include the Bangsamoro Autonomous Region in Muslim Mindanao (BARMM) and possibly, areas with indigenous peoples. Approximately ten percent of the population in the Philippines is considered

---

indigenous peoples. They live in several regions but are particularly concentrated in the mountains of Northern and Central Luzon as well as in the islands of Mindanao.

Refurbishment and civil works are expected to be of small scale, distributed throughout the health care network providing COVID-19 response, and will take place within the existing compounds of the health care facilities or as designated by the DOH or the National Task Force Against COVID-19.

2.3 Subcomponent Typology

The project involves two distinct phases: a COVID-19 emergency response (Component 1); and a mid-term initiative to strengthen laboratory capacity to support emerging infectious diseases (EIDs) (Component 2). In addition, the project includes a Management/Monitoring and Evaluation component (Component 3), and Contingent Emergency Response Component or CERC (Component 4).

The environmental and social management approaches to Component 1 and 2 will be governed by the urgency of the interventions. Activities under Component 1 will be undertaken in an unpredictable environment determined by the extent of the COVID-19 outbreak in the Philippines, the capacity of the health system and the duration of the pandemic. Environmental and social management measures for Component 1 will need to be adaptable to the circumstances, with the priority necessarily being the public health risks of the virus. Component 2 activities will be undertaken in an orderly and predictable manner, allowing environmental and social management measures to be better calibrated.

Component 1: Strengthening Emergency COVID-19 Health Care Response (Total US$ 381,000,000):

The aim of this component is to strengthen essential health care service delivery system to be able to respond to a surge in demand as a result of anticipated rise in the number of COVID-19 cases in the coming months. As COVID-19 will place a substantial burden on inpatient and outpatient health care services, support will be provided to equip selected health facilities prioritized by DOH for the delivery of critical medical services and to cope with increased demand.

Health system strengthening efforts will therefore focus on provision of medical and laboratory equipment, PPE, medical supplies as well as essential inputs for treatment such as oxygen delivery systems and medicines to selected hospitals and health facilities. Local containment will be supported through the establishment of local temporary isolation units. The component will also finance requirements of infrastructure of quarantine facilities. It is anticipated that any construction involved under this component will be conducted at existing facilities; activities requiring land acquisition or involuntary resettlement are not eligible.

This component also supports the Department of Health in preparing a guidance note on standard design for hospital isolation and treatment centers to manage Severe Acute Respiratory Infections (SARI) patients that will be used in health facilities across the country to ensure standard and quality of COVID-19 health care services. The component has three sub-components.

(a) Sub-component 1.1. Provision of medical and laboratory equipment and reagents (US$ 34,500,000): This sub-component will support selected DOH hospitals and provincial hospitals with laboratory equipment (e.g. Polymerase Chain Reaction machines), test kits, reagents, as well as to upgrade diagnostics and treatment of COVID-19 infection capacity through

---

10 Laboratory support under Sub-Component 1.1 is short-term and includes PCR machines and test kits for selected DOH hospitals and provincial hospitals. Component 2 supports strengthening of reference laboratories at both national and sub-national levels to address EIDs in the short and medium term.
procurement of such intensive care unit equipment and devices as mechanical ventilators, cardiac monitors, portable x-ray, extracorporeal membrane oxygenation (ECMO) machine, portable oxygen generator machine, and continuous positive airway pressure (CPAP). The sub-component will also support provision of oxygen, emergency beds, laboratory reagents, and waste management facilities. This sub-component will also support short trainings on the use of equipment, devices, and tests for health providers and technicians; and to support the necessary logistics and supply chain to ensure that the equipment will reach frontline health facilities without delays.

(b) **Sub-component 1.2. Provision of medical supplies, including Personal Protective Equipment (PPE), COVID-19 vaccines, medicines, and ambulance (US$ 321,300,000):** This subcomponent will support the health system with supplies including PPE such as masks, goggles, gloves, gowns, etc. It will also support medical counter measures and medical supplies for case management and infection prevention, through the procurement of COVID-19 vaccines, drugs such as antivirals, antibiotics, and essential medicines for patients with co-morbidity and complications such as CVDs and diabetes, as well as assistance to support the Borrower’s advance purchase mechanisms. This subcomponent will also support short trainings on the use of medical supplies for health providers and technicians as needed; and support to the necessary logistics and supply chain to ensure that the medical supplies and PPE will reach frontline health facilities without delays. Small part of this sub-component may also support ambulance vehicles to address COVID-19 response, as needed.

(c) **Sub-component 1.3. Enhancing isolation/quarantine facilities (US$ 25,200,000):** This sub-component will support the establishment, construction, retrofitting/refurbishment of quarantine facilities in major points of entry, increase number of regular isolation rooms in DOH and provincial hospitals as well as establishment of negative pressure isolation rooms in DOH and provincial hospitals. It will also support setting up of first line decontamination facilities in international airports (holding areas) as well as establishing isolation tents for triaging in health facilities.

(d) **Sub-component 1.4. Deployment of COVID-19 vaccines and related system strengthening activities** *(Proposed allocation by counterpart fund from GOP: US$XX million):* This subcomponent, to be financed by counterpart fund from the Government of the Philippines, will support safe and effective deployment of COVID-19 vaccines, including delivery, cold chain and logistics system, system strengthening, risk and communication and adverse events monitoring.

Component 2: Strengthening laboratory capacity at national and sub-national level to support Emerging Infectious Diseases (EIDs) Prevention, Preparedness, and Response (Total US$ 11,500,000): The component will support the establishment of national reference laboratories as well as selected subnational and public health laboratories. It will include improving, retrofitting, and refurbishing national reference laboratory – Research Institute for Tropical Medicine (RITM) as well as six sub-national and public health laboratories in Baguio, Cebu, Davao, Surigao City, and Manila. The sub-component may also support constructing and expanding laboratory capacity in priority regions that currently do not have necessary laboratory capacity. The sub-component will also support necessary laboratory equipment, laboratory supplies, reagents, as well as capacity building for relevant laboratory staff. It is anticipated that any construction involved under this component

---

11 Subnational and public health laboratories include (i) Lung Center of the Philippines (QC); (ii) San Lazaro Hospital (Manila); (iii) Baguio General Hospital (Baguio); (iv) Vicente Sotto Memorial Medical Center (Cebu); (v) Caraga Regional Hospital (Surigao City); (vi) Southern Philippines Medical Center (Davao).
will be conducted at existing facilities, and that no new land acquisition or involuntary resettlement are expected.

**Component 3: Implementation Management and Monitoring and Evaluation (Total US$ 7,500,000):**

**Project Management.** The component will support the Department of Health (DOH) as the implementing agency of the project. DOH will be responsible for the coordination, management, and implementation of the project at the national and sub-national levels, financial management and procurement. The project will be implemented through mainstream DOH processes and will not involve a parallel project implementation unit or secretariat. This will be strengthened by the recruitment of additional staff/consultants responsible for overall administration, procurement, and financial management under country specific projects. To this end, the Project would support costs associated with project coordination, management, and implementation. This component will also support costs related to the management of environmental and social risks under the Bank’s ESF, including the implementation of this ESMF and Stakeholder Engagement Plan (SEP).

The implementation arrangements of the Parent Project will be adjusted to enhance the capacity of DOH for implementation related to vaccine procurement, cold chain strengthening, and vaccination delivery support, as well as human resource strengthening in risk communication and community mobilization and M&E. Additional expertise and capacity will also be added as required by the additional financing. Specifically, the COVID-19 vaccination initiatives will be strengthened by the development of the Vaccine Delivery and Distribution Manual and National Deployment and Vaccination Plan (NDVP) and the hiring of a (i) Vaccine Specialist, (ii) M&E Specialist, and a (iii) second Procurement Specialist.

**Monitoring and Evaluation (M&E).** This component would also support monitoring and evaluation of project implementation, prevention and preparedness, building capacity for clinical and public health research, and joint learning across and within countries. Furthermore, the M&E includes a mechanism to review the capacity of the national health systems to deploy vaccines universally and to reach isolated and marginalized communities and those difficult to reach. It will include the maintenance of daily records documenting who received the vaccine from which vial as well records of any adverse vaccination effects. The M&E system will include data and information disaggregated by gender, demography, race-ethnicity, location-residence, socioeconomic status, and disability. As may be needed, this component will also support third-party monitoring of progress and efficient utilization of project investments.

**Component 4: Contingent Emergency Response Component (CERC) (US$0):** In the event of an Eligible Crisis or Emergency, the project will contribute to providing immediate and effective response to said crisis or emergency. A zero-value component has been included to ensure funds can be deployed through the project depending on the specific needs that may arise.

**Project Activities:** Table 1 lists the goods, services, and works that will be financed under the project which will be deployed variously to Department of Health (DOH) hospitals, provincial hospitals, and local government unit (LGU) hospitals as specified.

**Table 1 List of Goods, Services and Works**

<table>
<thead>
<tr>
<th>Goods*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensive Care Unit (ICU) equipment - mechanical ventilator, cardiac monitor, closed-circuit apparatus, suction pump, portable x-ray, dialysis machine (70 DOH hospitals)</td>
</tr>
</tbody>
</table>
Polymerase Chain Reaction (PCR) Machines (70 DOH hospitals; 85 Provincial Hospitals)

Real Time (RT-PCR) Nucleic Acid Detection Kits

Personal protective equipment (300,000 sets)

Ambulances (approximately 180 vehicles plus 10 water ambulances)

COVID-19 vaccines

Cold storage and refrigerated transportation of the COVID-19 vaccines***

Community outreach

Training and capacity building for health care personnel and relevant workers

Support to project implementation and monitoring

Waste collection, treatment, and disposal of the health care wastes generated from the vaccination***

Rental of cold storage and refrigerated transportation of the COVID-19 vaccines***

Strengthen capacity of sub-national and public health laboratories (6 facilities)

Research Institute for Tropical Medicine (RITM) Biosafety Level (BSL) 3 Lab and National Reference Laboratory (NRL) Complex

Point-of-Entry Quarantine Facilities (Luzon (1), Visayas (2) and Mindanao (3))

First line decontamination facilities at International Airports (Manila (Pasay), Clark, Bicol, Cebu, Kalibo, Cagayan de Oro, Davao)

Regular isolation rooms in DOH and Provincial hospitals

Negative pressure isolation rooms in DOH and Provincial hospitals

Construction of warehouse facilities for the storage of the COVID-19 vaccines***

Source:  *Philippines COVID-19 Emergency Response Project Procurement Plan (May 2020)
**Project Appraisal Document (April 23, 2020)
*** For Discussion/Confirmation

2.4 Prohibited/Negative List

The Project will not involve activities with high potential environmental and social risks. Such activities which are not eligible for financing include but are not limited to the following:

- Activities that have potential to cause any significant loss or degradation of critical natural habitats whether directly or indirectly.
- Activities that could adversely affect forest and forest health.
- Activities that could affect sites with archaeological, paleontological, historical, religious, or unique natural values.
- Activities that will result in the involuntary taking of land, relocation of households, loss of assets or access to assets that leads to loss of income sources or other means of livelihoods, and interference with households’ use of land and livelihoods.
- Use of goods and equipment on lands abandoned due to social tension/conflict, or the ownership of the land is disputed or cannot be ascertained.
- Use of goods and equipment to demolish or remove assets, unless the ownership of the assets can be ascertained, and the owners were consulted and had concurred
- Use of goods and equipment involving forced labor, child labor, or other harmful or exploitative forms of labor.
- Use of goods and equipment for activities that would adversely affect indigenous peoples.
- Use of goods and equipment for military or paramilitary purposes aside from vaccination activities involving these personnel.
3 Policy, Legal and Regulatory Framework

3.1 Philippines Legal Framework relevant to the ESF

3.1.1 Philippine Environmental Impact Assessment System of 1978

The Philippine Environmental Impact Assessment System of 1978 which was set forth by Presidential Decree (PD) 1586 is the primary law that establishes the Philippine Environmental Impact Statement (EIS) System. This is one of the series of decrees promulgated in the late 1970s to address emerging environmental issues and concerns. The Philippine EIS System was established to facilitate the attainment and maintenance of a rational and orderly balance between socio-economic growth and environmental protection. This policy provides that "no person, partnership, or corporation shall undertake or operate any such declared ECP or project within an ECA without first securing an Environmental Compliance Certificate (ECC)" which requires the submission of an Environmental Impact Statement. The latest implementing rules for this law is the DENR Administrative Order 30-2003 (DAO 30-2003) which provides criteria for and detailed lists of ECAs and ECPs.

The other related laws are PD 1151 — The Philippine Environmental Policy and PD 1152 — The Philippine Environment Code. The PD 1151 stressed the urgent need to formulate an intensive, integrated program of environmental protection through EIA, requiring all agencies and instrumentalities of the national government, the government-owned and -controlled corporations, the private corporations, firms, and entities, to prepare and submit an Environmental Impact Statement (EIS) for every action, project or undertaking which significantly affects the environment.

3.1.2 Republic Act (RA) 6969 — Toxic Substances and Hazardous and Nuclear Wastes Control Act of 1990

The Philippine Toxic Substances and Hazardous and Nuclear Wastes Control Act of 1990 was enacted to regulate, restrict, or prohibit the importation, manufacture, processing, sale, distribution, use and disposal of chemical substances and mixtures that present unreasonable risk and/or injury to health or the environment; to prohibit the entry, even in transit, of hazardous and nuclear wastes and their disposal into the Philippine territorial limits for whatever purpose; and to provide advancement and facilitate research and studies on toxic chemicals.

3.1.3 DENR Administrative Order (DAO) 1992-29 established the Implementing Rules and Regulations (IRR) of Republic Act 6969 or Toxic Substances and Hazardous and Nuclear Wastes Control Act of 1990

The DENR DAO 1992-29 requires hazardous waste generators to register with the DENR-EMB, properly manage, and dispose of hazardous wastes generated in its facility. The hazardous wastes must be segregated, labelled, kept in proper storage facility, transported, treated/recycled and disposed of through DENR-accredited firms. In compliance with the Section 27 of the IRR, a transporter of health care wastes is required to register and obtain a Transport Permit from the DENR-EMB.
3.1.4 Republic Act (RA) 9003 – Ecological Waste Management Act and DENR AO 2001-34 (Implementing Rules and Regulations)

The law seeks to ensure the protection of public health and the environment through the utilization of environmentally sound methods for treating, handling, and disposing of solid wastes and encourages waste minimization and segregation at source.

Article 4, Section 27 of RA 9003 mandates the Department of Trade and Industry (DTI) to formulate and implement a coding system for packaging materials and products to facilitate waste recycling and reuse.

3.1.5 Joint DOH-DENR DAO Order No. 2005-02 – Policies and guidelines on effective and proper handling, collection, transport, treatment, storage and disposal of health care waste

The Joint DOH-DENR Administrative Order (JAO) 2005-02 dated August 24, 2005 provides definition and classification of health care wastes. The classification includes general waste, infectious waste, pathological waste, sharps, pharmaceutical wastes, genotoxic waste, chemical waste, waste with high heavy metals content, pressurized containers, and radioactive waste. The DENR-DOH JAO clarified the roles and responsibilities of DOH and DENR in regulating the activities of HCFs. All onsite activities are to be managed and supervised by the DOH while movement of hazardous healthcare wastes are required to comply with the requirements of the DENR in accordance with RA 6969 and its implementing rules and regulations.

3.1.6 DAO 2014-02 – Revised Guidelines for Pollution Control Officer Accreditation

The Revised Guidelines for Pollution Control Officer (PCO) Accreditation issued by DENR on February 3, 2014 requires industrial, commercial, and manufacturing establishments and private entities whose activities are potential and actual sources of pollution to designate a PCO. The PCO shall secure accreditation from the DENR in accordance with this DAO.

3.1.7 DAO 2013-22 – Revised Procedures and Standards for the Management of Hazardous Wastes

The DENR AO 2013-22 is a revision of the DAO 2004-36. This policy aims to further streamline the procedures for generation and compliance to the legal and technical requirements of hazardous waste management, including guidelines for waste generators, transporters, and treatment, storage, and disposal facilities.

Under this law, healthcare wastes from hospitals, medical centers, and clinics containing pathological, pathogenic, and infectious wastes, sharps and others are categorized as M501 or pathological or infectious wastes. Meanwhile, pharmaceuticals and drugs (M503) include expired pharmaceuticals and drugs stocked at producers and retailers’ facilities which contain hazardous
constituents harmful to the environment such as antibiotics, veterinary, and phytopharmaceutical and others.

The COVID-19 vaccine vials are categorized under pharmaceutical and drugs (M503) while the syringes, cottons, and other materials used in the vaccination which had contact to the patient will be considered as infectious wastes (M501).

The policy mandates waste generators to avail services of waste transporters and TSD facilities duly registered by the EMB Central Office and whose permits are valid within the period that the wastes are being transported and treated, stored, or disposed of.

3.1.8 DENR Memorandum Circular (MC) 2020-16 – Amendment of the Interim Guidelines on Issuance of Special Permit to Transport (SPTT) for the Transportation of Hazardous Wastes within the Community Quarantine Period

This policy covers registered transporters and registered TSD facilities which respectively haul, treat, and/or dispose healthcare wastes nationwide. The transporters with existing valid regular permit to transport (PTT) for M501 shall continue to collect/haul hazardous COVID-19 wastes and other pathological and infectious wastes from healthcare facilities and are allowed to pass through checkpoints for delivery at designated TSD facility during the community quarantine period. If the PTT will expire during the period, an SPTT is to be secured online. Similarly, TSD facilities with TSD Registration Certificates and transporters with Transporter Registration Certificate (TRC) handling M501 with certificates expiring during the Enhanced Community Quarantine are automatically extended for 60 days and the Application for Renewal shall be immediately processed within 5 days upon lifting of ECQ.

3.1.9 Memorandum Circular (MC) 2020-20 – Provisional Guidelines on the Hazardous Wastes Management within the Extended Enhanced Community Quarantine

DENR MC 2020-20 dated April 30, 2020 provides the guidelines that waste transporters and treatment, storage, and disposal (TSD) facilities need to comply during the extended enhanced community quarantine. It upholds the policy of the government to continuously monitor the transport, treatment, storage, and disposal of hazardous wastes in order to prevent or avoid the likelihood of environmental disaster and contamination and provide temporary protocols for waste handlers, transporters, treaters, local government units, law enforcement authorities, and other stakeholders in the smooth implementation of proper hazardous waste management. It describes the coverage and simplification of existing procedures for the issuance of the Permit to Transport to registered transporters and registered TSD facilities during the extended enhanced community quarantine period to enable them to haul, treat and dispose healthcare wastes and related hazardous wastes. The transporters and TSD facilities are required to follow safety protocols as outlined in the health, safety, and environmental (HSE) plan. The safety protocols should include the preparation and submission of reports such as the report of compliance and completion of transport or the manifest and the Certificate of Treatment (COT) after each completed transport and treatment of the transporter and TSD, respectively. The manifest of the registered transported waste shall be attested by the duly designated representative or PCO of the health care facility or hazardous waste generator and the TSD, within 24 hours for M501 wastes and 7 days for other
hazardous wastes after delivery to the TSD facility. The TSD facility shall also submit a report of compliance and completion of treatment or the COT to be attested by their PCO within 7 days after M501 wastes and 21 days for other types of hazardous wastes, after completion of treatment.

3.1.10 Philippine Clean Air Act of 1999

The **Philippine Clean Air Act of 1999 (Republic Act 8749)** provided for a comprehensive air pollution control policy and recognizes the rights of Philippine citizens to breathe clean air. RA 8749 applies to the project due to the potential for emissions from healthcare waste incineration. Section 20 of RA 8749 states:

*Ban on Incineration - Incineration, hereby defined as the burning of municipal, bio-medical and hazardous wastes, which process emits poisonous and toxic fumes, is hereby prohibited: Provided, however, that the prohibition shall not apply to traditional small-scale method of community/neighborhood sanitation "siga", traditional, agricultural, cultural, health, and food preparation and crematoria: Provided, further, That existing incinerators dealing with bio-medical wastes shall be phased out within three (3) years after the effectivity of this Act: Provided, finally, That in the interim, such units shall be limited to the burning of pathological and infectious wastes, and subject to close monitoring by the Department.*

With due concern on the effects of climate change, the Department shall promote the use of state-of-the-art, environmentally-sound, and safe non-burn technologies for the handling, treatment, thermal destruction, utilization, and disposal of sorted, unrecycled, uncomposted municipal, bio-medical and hazardous wastes.

These provisions of RA 8749 were clarified by a Department of Environment and Natural Resources Memorandum Circular (DMC-2002-05), which:

- states that RA 8749 does not prohibit incineration of wastes except those burning processes which emit poisonous and toxic fumes;
- recognises that appropriate disposal techniques for medical and bio-medical wastes are limited; and
- incineration of these wastes is only permitted in state-of-the-art facilities which are proven to emit minimal air pollutants with concentrations meeting RA 8749 criteria.

The phasing out of bio-medical incinerators contemplated under RA 8749 was deemed impracticable due to lack of affordable best available technology (BAT).

3.1.11 Chemical Control Order on Ozone-Depleting Substances

The Philippines ratified the Montreal Protocol on Substances that Deplete the Ozone Layer on March 21, 1991. The country agreed to phase-out its consumption of all ODS, based on the agreed timetable for Article 5 developing countries. Since the Philippines is neither a producer nor an exporter of ODS, the phaseout involves the reduction of importation and consumption of ODS following the schedule for Article 5 countries. The Montreal Protocol was amended during the 28th Meeting of the Parties through the implementation of the Kigali Agreement that also established the phase-down of hydrofluorocarbon (HFC) with developed countries taking the lead on phasing down HFCs, starting with a 10% reduction in 2019 and delivering an 85% cut in 2036 (compared to the 2011-2013 baseline).
The DENR issued DENR Administrative Order No. 2013-05, also known as the “Revised Regulations on the Chemical Control Order (CCO) for Ozone Depleting Substances” which is the legal basis of the country for the phaseout of ODS. This second revision of the CCO updates the phase-out status of controlled substances covered by the Montreal Protocol and reflects the accelerated phase-out schedule for hydrochlorofluorocarbons (HCFCs) in accordance with the Decision XIX/6 of the 19th meeting of the parties to the Montreal Protocol.

In accordance with the CCO, any importer of ODS must register with the Environmental Management Bureau (EMB) of the DENR. An importer of ODS must secure annually a certificate of registration from EMB and a Pre-Shipment Importation Clearance (PSIC) prior to the entry of each ODS shipment and that importers must follow the updated phase-out schedule for HCFCs\(^\text{12}\). There is a quota allocation for HCFCs that should conform to the “one-shipment, one clearance” policy.

The dealers, resellers, and retailers of ODS that are registered with the EMB and accredited by the Department of Trade and Industry (DTI) are allowed to purchase, re-sell, distribute, and utilize allowable uses of ODS. The dealers and retailers should adhere to the Code of Practice for Refrigeration and Airconditioning (2013 update). Servicing of ODS-using equipment such as air-conditioners and refrigeration equipment must secure a certificate of registration from the DENR to assess their capability to take measures in the handling of ODS to control and minimize emissions and ultimately, phasing out their use by replacing with substitutes or alternatives recognized and certified by the DENR-EMB.

All importation of HCFC-22 for the manufacture of refrigeration and air-conditioning has been prohibited since January 1, 2020 to encourage companies to shift to alternative technologies. Importation of HCFC-123 for as cooling agent for chillers (also as fire-extinguishing agent) will be prohibited by January 1, 2025. Importation of HCFC blends for all sectors will be prohibited by January 1, 2030 to reduce HCFC imports by 97.5% in 2030 based in recorded baseline consumption. The Philippines, as an Article 5 country, has to reduce HFC consumption to 50% of baseline consumption in 2040-2044 based on the Kigali Agreement.

3.1.12 Department of Energy Administrative Order 110 – Procurement of Energy- Consuming Equipment

The order aims to reduce the monthly consumption of electricity and petroleum products by at least 10% through the implementation of the Government Energy Management Program.


The circular prohibits the selling of energy-inefficient products and provides incentives for the judicious and efficient use of energy. For chillers and air-conditioning units and other energy consuming devices and equipment, the DOE circular applies the highest Minimum Energy Performance Standards (MEPS).

\(^\text{12}\) Only HCFCs are allowed to be imported until January 2040 among the ODS. From 2030-204, an annual HCFC importation of 2.5% of the baseline consumption shall be allowed for use in the servicing sector. Other ODS, including chlorofluorocarbon (CFC), halons, and carbon tetrachloride (CTCs) have been banned for importation since January 1, 2010.
3.1.14 Climate Change Act of 2009 and Relevant DOH Policy Issuances

National Framework Strategy on Climate Change (NFSCC) is the roadmap for addressing climate change. It identified adaptation as the anchor strategy and considered mitigation as a function of adaptation. The DOH is one of the first government agency in the country to prepare its sector strategy for climate change adaptation pursuant to the NFSCC 2010-2022. The Health Sector Strategy for Climate Change Adaptation (Department Circular No. 2010-0187) became part of the Philippine Strategy on Climate Change Adaptation. The National Climate Change Action Plan similarly identified health as one of the thematic priorities under Human Security with the intended outcome of health and social protection delivery systems that are responsive to climate change risks. Targets include health personnel and community’s capacity on climate change health adaptation and risk reduction developed; public health surveillance system is developed and implemented in all provinces; and health emergency response, preparedness and post-disaster management implemented at the national and local levels.

The DOH issued Administrative Order No. 2012-005 "National Policy on Climate Change Adaptation for the Health Sector" to set the overall policy directions on addressing the impact of climate change on health and to create an enabling environment for capacity strengthening of health systems, engagement of key partners in supporting comprehensive actions, and in protecting the health of all Filipinos from the impact of climate change. The scope of the order includes all units and instrumentalities of the Department, including its attached agencies, local government units, NGO, professional organizations, private sector and other relevant partners involved in the implementation of climate change adaptation for health programs. Administrative Order No. 2012-0018 was issued as its operational guidelines for strategies on policy, plans and partnerships; service provision, capacity and infrastructure enhancement; health promotion, research, surveillance and monitoring; strengthening organizational structure for climate change at different levels of governance. The AO similarly outlines the organizational structure, roles and responsibilities, and budget and funding for its implementation.

In 2015, DPO No. 2015-5342 created the DOH Climate Change Executive Committee. Since then, the DOH has conducted 5 trainings on Health Vulnerability and Capacity Assessment (HVACA) nationwide with priority to the top 20 provinces identified to be most vulnerable and at risk to climate change. The objectives of the training are to provide LGUs and Centers for Health and Development (CHDs) a clearer view of climate change and health so that better assessment, planning and programming of health interventions toward climate change risk reduction can be accomplished; and to improve the capacity of the CHDs and LGUs on the use of the Climate Change Adaptation Tools (CCAT) for Health. The HVAVA and M&E tools were developed in partnership with the National Economic and Development Authority. Various trainings were also conducted on the use of Climate Change Adaptation Tools for Health from 2013 to 2015.

The DOH continues with its actions to increase the adaptive capacity of the Philippine health sector. Some of the ongoing activities relevant to the ESMF include: Finalization of the standards for green health care facilities and promote green hospitals (DC No. 2019-0059 dated 14 Feb 2019 - Green Certification of Government Healthcare Facility Projects); Implementation of the safe hospitals initiative; Promotion of the greening of hospitals and health facilities through improving energy and water efficiency and conservation, sustainable cooling system and sustainable healthcare waste management in hospitals (Section 37 of the GAA for 2019 General Provisions - RA No. 11260); Assessment of HVACA trained provinces and status of their Local Climate Change Action Plans (LCCAPs); Coordination meeting with Health Promotion and Communication Services (HPCS) for
advocacy and health promotion (in line with Climate Sensitive Diseases, Water and Sanitation Related Diseases, Food and Waterborne Diseases and Emerging and Re-emerging Infectious Disease Program Communication Plan); and Technical Assistance to the HVACA trained provinces.

3.1.15 Disaster Risk Reduction and Management and Relevant DOH Policies

The Republic Act 10121 or Philippine Disaster Risk Reduction and Management Act of 2010 provides guidelines on the development of policies and plans and the implementation of actions and measures pertaining to all aspects of disaster risk reduction and management, including governance, risk assessment and early warning, knowledge building and awareness raising, reducing underlying risk factors, and preparedness for effective response and early recovery. Through this policy, the National Disaster Risk Reduction and Management Council (NDRRMC) was institutionalized.

The National Disaster Risk Reduction and Management Council, headed by the Secretary of the Department of the National Defense (DND) as the Chairperson, is the overall responsible Office for disaster response and management, with the Secretary of Department of the Interior and Local Government (DILG) as Vice-Chairperson for Disaster Preparedness, the Secretary of Department of Social Welfare and Development (DSWD) as Vice-Chairperson for Disaster Response, the Secretary of the Department of Science and Technology (DOST) as Vice-Chairperson for Disaster Prevention and Mitigation, and the Director-General of the National Economic and Development Authority (NEDA) as Vice Chairperson for Disaster Rehabilitation and Recovery, as set forth in the Implementing Rules and Regulations of the Republic Act no. 10121.

The NDRRMC shall provide guidelines on the selection and screening of the civil society organizations (CSOs) and private sector representatives. The NDRRMC, empowered with policy-making, coordination, integration, supervision, monitoring, and evaluation functions, shall have the following responsibilities:

a) Develop a NDRRM Framework which shall provide for comprehensive, all-hazards, multi-sectoral, inter-agency and community-based approach to disaster risk reduction and management. The Framework shall serve as the principal guide to disaster risk reduction and management efforts in the country and shall be reviewed on a five (5) year interval, or as may be deemed necessary, in order to ensure its relevance to the times;

b) Ensure that the NDRRM Plan is consistent with the NDRRM Framework;

c) Advise the President on the status of disaster preparedness, prevention, mitigation, response and rehabilitation operations being undertaken by the government, CSOs, private sector, and volunteers; recommend to the President the declaration of a state of calamity in areas extensively damaged; and submit proposals to restore normalcy in the affected areas, to include calamity fund allocation;

d) Ensure a multi-stakeholder participation in the development, updating, and sharing of a Disaster Risk Reduction and Management Information System and Geographic Information System-based national risk map as policy, planning and decision-making tools;

e) Establish and/or strengthen a comprehensive, all hazards national early warning and emergency alert system to provide accurate and timely advice to national or local emergency response organizations and to the general public through diverse mass media to include digital and analog broadcast, cable, satellite television and radio, wireless communications, and landline communications;

f) Develop appropriate risk transfer mechanisms that shall guarantee social and economic protection and increase resiliency in the face of disaster;
g) Monitor the development and enforcement by agencies and organizations of the various laws, guidelines, codes or technical standards required by the Act;

h) Manage and mobilize resources for disaster risk reduction and management including the National Disaster Risk Reduction and Management Fund;

i) Provide necessary guidelines and procedures, and monitor the Local Disaster Risk Reduction and Management Fund (LDRRMF) releases as well as utilization, accounting, and auditing thereof;

j) Develop assessment tools on the existing and potential hazards and risks brought about by climate change to vulnerable areas and ecosystems in coordination with the Climate Change Commission;

k) Develop vertical and horizontal coordination mechanisms for a more coherent implementation of disaster risk reduction and management policies and programs by sectoral agencies and LGUs;

l) Formulate a national institutional capability building program for disaster risk reduction and management to address the specific weaknesses of various government agencies and LGUs, based on the results of a biennial baseline assessment and studies.

m) Formulate, harmonize, and translate into policies a national agenda for research and technology development on disaster risk reduction and management;

n) In coordination with the Climate Change Commission, formulate and implement a framework for climate change adaptation and disaster risk reduction and management from which all policies, programs, and projects shall be based;

o) Constitute a technical management group composed of representatives of the abovementioned departments, offices, and organizations, that shall coordinate and meet as often as necessary to effectively manage and sustain national efforts on disaster risk reduction and management;

p) Task the OCD to conduct periodic assessment and performance monitoring of the member-agencies of the NDRRMC, and the Regional Disaster Risk Reduction and Management Councils (RDRRMCs), as defined in the NDRRMP;

q) Coordinate or oversee the implementation of the country's obligations with disaster management treaties to which it is a party and see to it that the country's disaster management treaty obligations be incorporated in its disaster risk reduction and management frameworks, policies, plans, programs and projects; and

r) Coordinate or oversee the implementation of the country's obligations with disaster management treaties to which it is a party such as the ASEAN Agreement on Disaster Management and Emergency Response (AADMER), which came into force on 24 December 2009, and see to it that the country's disaster management treaty obligations be incorporated in its disaster risk reduction and management frameworks, policies, plans, programs and projects.

The DND as the Chair of the NDRRMC, is the government organization established to lead, administer, and coordinate all disaster management activities. The DND is the central entity responsible for coordinating risk reduction and emergency management in the country. In the event of a National Declaration of a State of Calamity by the Office of the President of the Republic of the Philippines or the Local Declaration by the Local Government Unit, the NDRRMC and the Local Disaster Risk Reduction and Management Council (LDRRMC), respectively, have the responsibility to administer a comprehensive national civil defense and disaster risk reduction and management program by providing leadership in the continuous development of strategic and systematic approaches as well as measures to reduce the vulnerabilities and risks to hazards and manage the consequences of disasters.
The DOH is mandated to work in close collaboration with the DND as Chairperson of the NDRRMC, the OCD as the implementing arm of the NDRRMC, and other relevant inter-ministerial committees, where relevant support on the technical discussions on DRR and other related activities of the Project, which may include the activation of the Contingency Emergency Response Component (CERC). Moreover, the DOH including other member agencies, is mandated by the Republic Act to (i) establish a disaster office, (ii) maintain a functional operations center, (iii) mainstream disaster risk reduction management (DRRM) in all planning activities, and (iv) orient all their employees on DRRM.

The Republic Act 7160 or the Local Government Code of 1991 mandates DOH to have the following authorities and roles in emergency and disaster risk response and management:

a. Enhance and strengthen the capabilities of LGUs to provide health services and facilities to their constituents;

b. Have the final decision in determining the presence of ‘widespread public dangers’ in a particular area or region [Section 44 (b) and (c)] including situations in calamity areas and in relation to a displaced population [Section 43 (a)];

c. Recommend to the President the issuance of an appropriate order directing the DOH to assume direct supervision and control over local health operations in affected areas; and

d. Prepare, implement, and monitor plans of action in such circumstances, and of evaluation of the local health situation [Section 45, (c) and (f)].

The Local Government Code of 1991 institutionalized a devolved health care system where the responsibility of delivering health care services is assigned to the local government units (LGUs) and not the DOH Central Office. The LGUs have the primary responsibility of providing immediate and direct response to disasters, but in cases where disasters have reached proportions beyond the capability of the LGUs, the national government takes control as stipulated under Section 105 of the Code. Relatedly, Executive Order no. 102 s. 1999 – ‘Redirecting the Functions and Operations of the DOH’ provides that the DOH shall (1) serve as the lead agency in health emergency response services, including referral and networking systems for trauma, injuries and catastrophic events, (2) promote health and well-being through public information and provide the public with timely and relevant information on health risks and hazards, and (3) assume leadership in health in times of emergencies, calamities and disasters, and system failures.

The Health Emergency Management Bureau (HEMB) as the focal unit of the DOH in emergency response, has the following roles and responsibilities:

a) Act as the DOH Coordinating unit and Operation Center for all health emergencies and disasters, as well as incidents with the potential of becoming an emergency, and coordinate the mobilization and sharing of resources;

b) Provide communication linkage among DOH Central Office and other concerned agencies, including the hospitals and the regions, during emergencies and disasters;

c) Maintain updated information of all health emergencies and disasters (except epidemiological investigation reports) and provide such information to other offices and agencies in accordance with existing protocols;

d) Maintain a database of all health emergency personnel, technical experts, and resource speakers. Together with the Health Facilities Development Bureau (HFDB) and the
Health Facilities Enhancement Program Management Office (HFEPMO), HEMB shall maintain a database of capabilities of health facilities;

e) Lead in the development of Disaster Risk Reduction & Management in Health (DRRMH) Plan and the development of protocols, guidelines and standards for health emergency management;

f) Provide technical assistance in the development of programs and planning activities for HEM for other government and non-government organizations;

g) Lead advocacy activities, including simulation exercises;

h) Develop and implement an Integrated Human Resource Training Agenda for the Health Sector for emergencies and disasters;

i) Lead in the networking of hospitals and health sector organizations responding to emergencies and disasters; and

j) Monitor and evaluate the enforcement of compliance to policies and recommend the formulation or amendment of policies related to health emergency management.

Given the crucial role of the DOH in DRRM, the Manual of Operations on Health Emergency and Disaster Response Management was developed in 2015. The Manual provides guidelines on the health emergency and disaster response framework and the management of the event/incident, victims, service providers, information system, and non-human resources.

The development and implementation of a national policy framework for emergencies and disasters in the health sector was established by the DOH Administrative Order no. 168 series of 2004 entitled National Policy on Health Emergencies and Disasters. It aims to decrease mortality and promote physical and mental health, as well as prevent injury and disability on the part of both victims and responders specifically through the (i) development of goals, strategies, plans and policies for ensuring an efficient system for managing emergencies and disasters in the health sector, (ii) improvement of the effectiveness of DOH systems, structures, capacities and mechanisms, and (iii) building up of the preparedness and response activities of both the public and private health facilities for administering mass casualty events, and (iv) strengthening the links between partner agencies and stakeholders in responding to and managing emergencies and disasters in the country. The DOH Administrative Order no. 0024 s. 2008 – ‘Adoption and Institutionalization of an Integrated Code Alert System Within the Health Sector’ provides that there should be a Code Alert System in the mobilization and deployment of resources, including the expected levels of preparation and the most appropriate response by all facilities in emergencies and disasters. Previously, DOH AO no. 182 s. 2001 was issued for the Adoption and Implementation of the Code Alert System for DOH Hospitals During Emergencies and Disasters.

The DOH Policies and Guidelines on the Establishment of Operations Center for Emergencies and Disasters (DOH AO no. 29 s. 2010) describes the policies and guidelines in the establishment of Operations Center (OpCen) at all levels from the national to the local government to ensure a well-coordinated response of the health sector. Its objectives include to i) develop policies and guidelines on the establishment and management of an Operations Center, (ii) identify the functions of the OpCen at the different levels, (iii) set the minimum specification for the design of an OpCen and minimum standards for logistical requirements, human resource requirements, coordination mechanisms, and relationship among Operations Centers, and (iv) provide funds to sustain its functionality. The DOH also issued the Guidelines on Health Emergency Management (HEM): Manual for Operations Center, 2nd edition, in 2008 outlining the (1) requirements and standards for health
emergency management staff, (2) the element, physical attributes, standard operating procedures, information management, human resource development, evaluation of operation centers, and the (3) guidelines for operation centers in DOH CHDs and hospitals. The first volume of the Information Management Manual for Coordinating and Monitoring Health Emergency and Disaster Response: Manual of Guidelines and Procedures on Information Management for Selected Functions of the Health Emergency Management Staff of the Department of Health was issued in 2007 To provide guidance on the information needs of key players in HEM at the national level, information sources and data collection tools, data collection flow and reporting mechanisms, assuring quality of information, and data processing (collation, information dissemination, and storage).

To provide guidance in ensuring an effective and efficient reporting mechanism to yield a responsive evidence-based decision-making process during emergencies and disasters, the DOH released AO no. 14 series of 2012 – Policy and Implementing Guidelines on Reporting in Emergencies and Disasters. The AO required the reporting of units at all levels of the health sector to submit timely, reliable, and continuous reports of all health-related events with standardized reporting mechanisms at all levels for emergencies/disasters. It has the objective of ensuring consistency and compliance of all reporting units with the reporting mechanisms in emergencies and disasters.

With the aim of further improving disaster surveillance, the DOH issued AO 2014- 011 – Policies and Guidelines on the Implementation of Surveillance in Post Extreme Emergencies and Disasters (SPEED). The AO aims to institutionalize SPEED, an early warning system is vital in detecting health conditions or diseases with outbreak potential and in accessing real-time information for prompt and appropriate response, in all levels of health emergency and management response.

The DOH AO no. 13 series of 2012 entitled Policy and Guidelines on Logistics Management in Emergencies and Disasters provides guidelines on the effective and efficient management of logistics support at all levels of the health system in emergency or disaster situations. It mandates the DOH to lead in formulating policies and plans for logistics management in emergencies and disasters and, in coordination with members of the health sector, formulate guidelines, standards, procedures and protocols in relation to logistics management in emergencies and disasters with corresponding reporting systems and tools. The Guidelines on the Acceptance and Processing of Foreign and Local Donations During Emergency and Disaster Situations (DOH AO no. 17 series of 2007) was issued in relation to this to set a rational and systematic procedure for the acceptance, processing and distribution of foreign and local donations that are exclusively for unforeseen, impending, occurring and experienced emergency and disaster situations. Similarly, the Food and Drug Administration has issued the FDA Circular no. 2020-009 or the Guidelines on the Identification, Notification, Evaluation, Regulatory Enforcement Action, and Review and Monitoring of Donated Health Products Solely Intended to Address COVID-19 Public Health Emergency. The Bureau of Customs also issued in 2014 the Guidelines and Procedures on Customs Clearance of International Donations Availing of Duty and/or Tax Exemption During Calamities.

In 2004, the Implementing Guidelines for Managing Mass Casualty Incidents (MCI) During Emergencies and Disasters (AO no. 155 series of 2004) was issued by the DOH. It states that the DOH is the lead in implementing a mass casualty system and procedures for resource mobilization, field management, and hospital reception to a comprehensive and well-coordinated response in MCI.

The DOH AO no. 2013-004 – Policies and Guidelines on Hospitals Safe from Disasters was issued with the goal of reducing disaster risks to ensure protection and continuous operation of hospitals and other health facilities and save lives during emergencies and disasters. It prepares hospitals to
address operation challenges during disasters and emergencies with the vision of remaining as the last building standing and functioning, specifically through (i) strictly enforcing national and local government safety regulations and codes in the construction, expansion, renovation, repair and rehabilitation of hospitals, (ii) inclusion in the hospital licensure requirements of a program for regular maintenance consistent with the most current Hospitals Safe from Disasters indicators, (iii) subjecting hospitals to yearly self-assessments and action planning to address their structural, non-structural, and functional vulnerabilities and capacities using the most current assessment tool, (iv) ensure surge capacity to be able to manage increased demand, and (v) utilize, build and strengthen partnerships and networks and develop corresponding mechanisms in times of emergencies and disasters. The Safe Hospitals in Emergencies and Disasters released by the DOH in 2009 lists the Philippine Indicators for monitoring and evaluation.

The NDRRMC has developed the National Disaster Response Plan outlining the policies, key strategies, guidelines. And roles and responsibilities of agencies in DRR response management. The DOH was the lead in health services including in the areas of water, sanitation, and hygiene (WASH), nutrition, and psychosocial services. As such, the DOH issued the Guidelines in the Provision of the Essential Health Service Packages in Emergencies and Disasters in 2017 (AO 2017-0007). It aims to set the standards for the effective, efficient, and timely delivery of essential health services in emergencies and disasters. Specifically, it (i) sets the guidelines in the delivery of essential health services in emergencies and disasters, (ii) define the essential service components for health, nutrition, water and sanitation hygiene, and mental health and psychosocial support that need to be available and accessible before, during, and after emergencies and disasters, and (iii) delineate the roles and responsibilities of concerned offices, stakeholders, and partners in the delivery of essential health service packages. Moreover, the DOH is currently developing the WASH in Emergencies (WiE) Technical Guidelines and the Green and Safe Health Care Facility Manual.

DOH Administrative Orders – Hospitals and Other Health Facilities and Clinical Laboratories

Joint DOH-DENR Administrative Order No. 2005-02 dated August 24, 2005 defines health care wastes as all wastes generated as a result of the following: 1) diagnosis, treatment, management, and immunization of humans or animals, 2) research pertaining to the above activities, 3) producing or testing of biological products, 4) wastes originating from minor or scattered sources (e.g. dental clinics, alternative medicine clinics, etc.). The DAO also identifies its hazards to people and the strategies to manage these wastes.


Department of Health Administrative Order (AO) No. 2007-0027 “Revised Rules and Regulations Governing the Licensure and Regulation of Clinical Laboratories in the Philippines” prescribes “…a revised minimum standard for clinical laboratories [to]…ensure accuracy and precision of laboratory examinations in order to safeguard public health and safety.” The AO requires all clinical laboratories, government or private, to have written policies and procedures for the provision of laboratory services and for the operation and maintenance of the laboratory, including proper
disposal of waste and hazardous substances, as well as biosafety and biosecurity. This AO applies
directly to activities under the project, most specifically under Component 2.


The DoH issued the DC 2020-0191 last 23 April 2020 institutionalizing the use of the 4th Edition of the Health Care Waste Management Manual. It is intended to serve as the most comprehensive set of guidelines on the safe management of wastes generated from heath care activities in the country. It incorporates the requirements of all Philippine laws and regulations governing HCWM and considers the recommendations of the World Health Organization (WHO) and stakeholders, including end-users.

This edition is intended and designed for the use of individuals, establishments, and other entities involved in the segregation, collection, handling, storage, treatment, and disposal of waste generated.

The DoH Health Care Waste Management (HCWM) Manual 4th edition classifies discarded items used in handling of vaccines, such as vials, or boxes with residues, gloves, and masks, as pharmaceutical wastes.

3.1.17 Department of Health COVID-19 Interim Guidelines

DoH has developed a series of Interim Guidelines specifically targeted at COVID-19 response (https://www.doh.gov.ph/2019-nCov/interim-guidelines?page=1). Relevant guidelines include:

- Department Memorandum No. 2020-0123 - Interim Guidelines on Management of Surge Capacity through the Conversion of Public Spaces to Operate as Temporary Treatment and Monitoring Facilities for the Management of Persons Under Investigation and Mild Cases of
The application of these Guidelines should be considered in comparison with evolving WHO guidance to ensure that contemporary good practice is adopted.

3.1.18 Executive Order no. 121 series of 2020

The Executive Order no. 121 s. of 2020 grants the Director General of the Food and Drug Administration to issue emergency use authorization for COVID-19 drugs and vaccines.


This Circular shall apply to the pharmaceutical industry and government entities such as the national procurer or health program implementors intending to apply for an emergency use authorization (EUA) for drugs and vaccines for COVID-19, and shall pertain only to unregistered (anywhere in the world) drugs and vaccines for prevention, diagnosis and treatment of COVID-19 and granted an EUA by the National Regulatory Authority (NRA) of the country of origin or any other mature and established NRA as identified by FDA.

The EUA is defined as an authorization issued for unregistered drugs and vaccines in a public health emergency. The EUA is not a Certificate of Product Registration (CPR) or a marketing authorization. The evaluation process of the product may be facilitated by reliance and recognition principles, but stricter conditions on the use and monitoring following authorization shall be imposed.

The EUA shall only be issued and remain valid only when all of the following circumstances are present: (1) based on the totality of evidence available, including data from adequate and well-known controlled trials, it is reasonable to believe that the drug or vaccine may be effective to prevent, diagnose, or treat COVID-19; (2) the known and potential benefits of the drug or vaccine, when used to diagnose, prevent, treat COVID-19, outweigh the known and potential risks of the drug or vaccine, if any; and (3) there is no adequate, approved and available alternative to the product for diagnosing, preventing or treating COVID-19. The last condition is deemed present when there exists no registered drug or vaccine in the country for diagnosing, preventing, or treating COVID-19.
3.1.20 Bureau of Food and Drug (BFAD) Circular 16, series of 1999 – Amending BFAD MC No. 22 dated September 8, 1994, regarding Inventory, Proper Disposal, and/or Destruction of Used Vials or Bottles

The BFAD circulars were released to prevent the proliferation of adulterated, misbranded, and counterfeit drugs brought about by the recycling of used pharmaceutical bottles and vials. The circular contains the guidelines on the proper inventory and destruction of bottles and vials. The Chief Pharmacists of government and private hospitals are required to conduct at least, a semestral inventory of the proper disposal and destruction of used vials or bottles. The inventory is to be submitted to the BFAD within five days from the date of the inventory. The nurse administering the drugs must be under strict instruction to return all empty vials to the hospital pharmacy for destruction on a quarterly basis. All inventories and/or destruction shall be done under the supervision of duly authorized representative of BFAD.


In line with DOH Administrative Order No. 2007-0017 – Guidelines on the Acceptance and Processing of Foreign and Local Donations during Emergencies and Disaster Situations, the FDA released Circular no. 2020-009 which covers the identification, notification, evaluation, review and monitoring and other regulatory or enforcement action of FDA covering foreign or locally donated health products solely intended to address the COVID-19 public health emergency. This Circular is applicable to the following: (a) face masks including N-95 masks, (b) shoe covers, (c) gloves, (d) head covers, (e) gowns, (f) goggles/ face shields, (g) COVID-19 diagnostic test kits, (h) alcohol, hand sanitizers, etc., and (i) other health products that may hereinafter be identified and listed by the FDA. The Food and Drug Action Center (FDAC), Center for Drug Regulation and Research (CDRR), Center for Device Regulation, Radiation Health, and Research (CDRRHR), Center for Cosmetics Regulation and Research (CCRR), Center for Food Regulation and Research (CFRR), Field Regulatory Operations Office (FROO), and Testing Laboratories are the focal units for the implementation of the Circular.

3.1.22 FDA Circular No. 2020-028 || Reissuance of the Guidelines for the Registration of Drug Products under Emergency Use (DEU) for the Coronavirus Disease 2019 (COVID-19)

This Circular was issued to amend FDA Circular Nos. 2020-012, -A, and -B with the aim of providing streamlined requirements and application process for the registration of Drug Products under Emergency Use (DEU) for COVID-19, covering all Marketing Authorization Holders (MAH) intending to manufacture and import/distribute the drug products listed in the PSMID Interim Guidelines on the Clinical Management of Adult Patients with Suspected or Confirmed COVID-19 Infection.
3.1.23 Greening and Energy- Efficiency Guidelines of the Department of Health

The DOH is currently developing the Green and Safe Health Care Facilities Manual. The following are existing guidelines circulated to various offices on the greening and energy-efficiency of health care facilities:

- Department Memorandum 2020-0240. Submission of hospital energy consumption and generated health care waste (28 May 2020)
- Department Memorandum 2020-0051. Designation of energy efficiency and conservation officer (EECO) (3 February 2020)
- Department Memorandum 2019-0280. Establishment of green public procurement (GPP) system in the health care facility (4 July 2019)
- Department Circular 2019-0059. Green certification of government health care facility projects (14 February 2019)
- Department Memorandum 2018-0151. Accomplishment and submission of the green healthcare facility components survey questionnaires (3 April 2018)
- Department Memorandum 2018-0035. Submission of energy consumption information of DOH hospitals to establish energy efficiency standards as part of the green healthcare facilities standards (25 January 2018)
- Department Memorandum 2017-0118. Accomplishment and submission of the green healthcare facility self-assessment checklist (20 March 2017)
- Administrative Order 2012-0005. National policy on climate change adaptation for the health sector (13 March 2012)

3.1.24 Labor Legislation

*Labor Code of the Philippines*

Presidential Decree No. 44, as amended by RA 6715, known as the “Labor Code of the Philippines”, governs all employment practices and relations in the country. Provisions of the Code are aligned with international good practice on decent work and shall be strictly implemented. These provisions include:

**Wage and Welfare**

1. Employees shall receive their wages by means of legal tender, at least once every two weeks or twice a month at intervals not exceeding sixteen (16) days.
2. In a contracted work, employees of the contractor and of the latter’s subcontractor, shall also be paid in accordance with the labor code.
3. The wage paid by the employers to the workers shall not be lower than the prescribed minimum wage set by the Regional Tripartite Wages and Productivity Boards.

**Working Time, Rest Days and Holidays**

1. The normal work hours for every employee shall not exceed eight (8) hours a day. If all or any part of the employee’s working hours falls on 10:00 PM to 6:00 AM, he/she shall be entitled to a night shift pay in addition to the regular wage. If the worked performed exceeds the normal working hours, he/she shall be given overtime pay.
2. It is the right of every employee for a rest period not less than twenty-four (24) consecutive hours after every six (6) consecutive normal workdays.

3. Compensation shall be given for work performed during holidays and Sundays.

**Equal Rights**

1. Workers shall have the right to self-organization and to form, join, or assist labor organizations of their own choosing for purposes of collective bargaining.

2. Minimum employable age is 18 years old.

3. Gender discrimination in employment and labor relations shall be prohibited. Male and female employees are entitled to equal compensation for work of equal value and access to promotion and training opportunities.

**International Labour Organisation**

The Philippines became a member of the International Labor Organization (ILO) on 15 June 1948. It was the first country in Asia to participate in a pilot programme on decent work in 2002. The Philippines has ratified thirty-eight (38) ILO Conventions including all of the eight (8) Fundamental Conventions, as follows:

- C.29 Forced Labour Convention, 1930
- C.87 Freedom of Association and Protection of the Right to Organise Convention, 1948
- C.98 Right to Organise and Collective Bargaining Convention, 1949
- C.100 Equal Remuneration Convention, 1951
- C.105 Abolition of Forced Labour Convention, 1957
- C.111 Discrimination (Employment and Occupation) Convention, 1958
- C.138 Minimum Age Convention, 1973
- C.182 Worst Forms of Child Labour Convention, 1999

The 1987 Constitution of the Republic of the Philippines provide the following relevant provisions as legislative framework for labor concerns:

- Sec. 3, Art. XIII – The State shall afford full protection to labor, local and overseas, organized and unorganized, and promote full employment and equality of employment opportunities for all. It shall guarantee the right of all workers to self-organization, collective bargaining and negotiations, and peaceful concerted activities, including the right to strike in accordance with the law. They shall be entitled to security of tenure, humane conditions of work, and a living wage. They shall also participate in policy and decision-making processes affecting their rights and benefits as may be provided by law. The State shall promote the principle of shared responsibility between workers and employers and the preferential use of voluntary modes in settling disputes, including conciliation, and shall enforce their mutual compliance therewith to foster industrial peace. The State shall regulate the relations between workers and employers, recognizing the right of labor to its just share in the fruits of production and the right of enterprises to reasonable returns to investments, and to expansion and growth.

- Sec. 11, Art. II – The State values the dignity of every human person and guarantees full respect for human rights.
• Sec 13, Art. II – The State recognizes the vital role of the youth in nation-building and shall promote and protect their physical, moral, spiritual, intellectual, and social well-being. It shall inculcate in the youth patriotism and nationalism, and encourage their involvement in public and civic affairs.

• Sec. 14, Art. II – The State recognizes the role of women in nation-building, and shall ensure the fundamental equality before the law of women and men.

• Sec. 1, Art III – No person shall be deprived of life, liberty, or property without due process of law, nor shall any person be denied equal protection of the laws.

• Sec. 4, Art. III – No law shall be passed abridging the freedom of speech, of expression, or of the press, or the right of the people to peaceably assemble and petition the government for redress of grievances.

• Sec. 14, Art. XIII – The State shall protect working women by providing safe and healthful working conditions, taking into account their maternal functions, and such facilities and opportunities that will enhance their welfare and enable them to realize their full potential in the service of the nation.

Occupational Health and Safety

The protection against OHS risk to the workers embodied in various international laws, national laws and administrative issuances governing the public sector, shall be observed.

Republic Act 11058 – The Occupational Safety and Health Standards Act

This law strengthens the compliance with Occupational Safety and Health Standards to ensure a safe and healthful workplace for all working people by affording them full protection against all hazards in their work environment. To ensure that the provisions of the Labor Code of the Philippines, all domestic laws, and internationally recognized standards on occupational safety and health are being fully enforced and complied with by the employers. And to protect every worker against injury, sickness or death through safe and healthful working conditions thereby assuring the conservation of valuable manpower resources and prevention of loss or damage to lives and properties. DOLE Department Order No. 198-2018 sets out the implementing rules and regulations of this act.

Department of Labor and Employment (DOLE) Department Order no. 13 series of 1998 – Guidelines Governing Occupational Safety and Health in the Construction Industry

This Department Order was issued to ensure the protection and welfare of workers employed in the construction industry, ensure the protection and welfare of the general public within and around the immediate vicinity of any construction worksite as well as the promotion of harmonious employer-employee relationships, and consider the relevant industry practices and applicable government requirements. This guideline will apply to all construction activities, including demolition, regardless whether private or public property. The Department Order sets forth the inclusion of a ‘Construction Safety and Health Program’ prior to the onset of the construction where in the construction project manager is required to submit a comprehensive plan for the said program to the respective DOLE Regional Office. The said program includes the creation of a Safety and Health Committee, safety policies, penalties and sanction, orientation, instruction and training, and waste disposal. The DO also highlights the need for the use of personal protective equipment, designation of a safety personnel, use of construction safety signages, observance of safety and health information, and the practice of safety inspection and tool box meeting.

The DPWH DO 39 was issued on May 19, 2020 to provide guidelines on the allowed construction activities during the COVID-19 pandemic and the corresponding safety protocols for the workers in the said period. It covers all allowed government and private construction projects as stated in the Inter-Agency Task Force (IATF)-issued Revised Omnibus Guidelines dated 15 May 2020 for areas under enhanced community quarantine (ECQ), modified enhanced community quarantine (MECQ), general community quarantine (GCQ), and modified general community quarantine (MGCQ).


The JMC 20-04-A of DTI and DOLE issued last August 15, 2020 provides guidelines on workplace safety and health during the COVID-19 pandemic which covers all private establishments regardless of economic activity, including those located inside special economic zones and other areas under the jurisdiction of Investment Promotion Agencies (e.g. Philippine Economic Zone Authority (PEZA), Clark Development Corporation (CDC), Authority of the Freeport Area of Bataan (AFAB), Aurora Pacific Economic Zone and Freeport (APECO, etc.).) It describes measures on increasing physical and mental resilience, reducing virus transmission, management of symptomatic and asymptomatic employees in the workplace, COVID-19 testing, notification and reporting, OSH Committees, disinfection and closure of buildings/workplaces, and leave of absences and entitlements.


This convention will enter into force for Philippines on 17 June 2020 which is well within the period of implementation of the Project. The following are National Policy under Section 3:

1. Each Member shall promote a safe and healthy working environment by formulating a national policy;
2. Each Member shall promote and advance, at all relevant levels, the right of workers to a safe and healthy working environment;
3. In formulating its national policy, each Member, in light of national conditions and practice and in consultation with the most representative organizations of employers and workers, shall promote basic principles such as assessing occupational risks or hazards; combating occupational risks or hazards at source; and developing a national preventative safety and health culture that includes information, consultation and training.

1987 Constitution of the Republic of the Philippines

The relevant provisions of the Constitution as regards OHS are as follows:

- Sec. 3, Art. XIII – The State shall afford full protection to labor, local and overseas, organized and unorganized, and promote full employment and equality of employment opportunities for all. It shall guarantee the right of all workers to self-organization, collective bargaining and negotiations, and peaceful concerted activities, including the right to strike in accordance with the law. They shall be entitled to security of tenure, humane conditions of
work, and a living wage. They shall also participate in policy and decision-making processes affecting their rights and benefits as may be provided by law.

- Sec 13, Art. II – The State recognizes the vital role of the youth in nation-building and shall promote and protect their physical, moral, spiritual, intellectual, and social well-being. It shall inculcate in the youth patriotism and nationalism, and encourage their involvement in public and civic affairs
- Sec. 14, Art. XIII – The State shall protect working women by providing safe and healthful working conditions, taking into account their maternal functions, and such facilities and opportunities that will enhance their welfare and enable them to realize their full potential in the service of the nation.
- Sec. 11, Art. II – The State values the dignity of every human person and guarantees full respect for human rights.

Civil Service Commission Administrative Issuances

- Memorandum Circular No. 33, Series of 1997 (Policy on Working Conditions at the Workplace) – all government offices shall provide adequate office ventilation and lighting, clean and adequate comfort room facilities, potable drinking water, First Aid Kit facilities, and all government offices should be non-smoking areas.
- Memorandum Circular No. 08, Series of 2011 (Reiteration of the Physical Fitness Program “Great Filipino Workout”) – requiring all agencies to adopt “The Great Filipino Workout” in order to develop a healthy and alert workforce.
- Memorandum Circular No. 04, Series of 2003 (Promotion of Good Nutrition in the Bureaucracy) – promotion of good nutrition of workers as an effective strategy to achieve and sustain increased organizational productivity.

3.1.25 Persons with Disabilities (PWDs)

Republic Act 7277 – An Act Providing For The Rehabilitation, Self-Development And Self-Reliance Of Disabled Person And Their Integration Into The Mainstream Of Society And For Other Purposes

The RA 7277 or the Magna Carta for Disabled Persons highlights the rights and privileges of disabled persons, such as equal opportunity for employment, access to quality education, inclusion in the national health program, provision of rehabilitation centers, provision of auxiliary social services, access to telecommunications, provision of sign language inset or subtitles, political and civil rights, and accessibility. Accessibility includes a barrier-free environment, mobility, and access to public transport facilities. To ensure the attainment of a barrier-free environment, disabled persons will be provided access to public and private buildings and establishments and such other places mentioned in Batas Pambansa 344 or the Accessibility Law. Related discrimination and corresponding penalties such as in employment, transportation, use of public accommodations and services, and use of government recreational or sports centers were described.
Republic Act 11106 – An Act Declaring the Filipino Sign Language as the National Sign Language of the Filipino Deaf and the Official Sign Language of Government in All Transactions Involving the Deaf, and Mandating its Use in Schools, Broadcast Media, and Workplaces

The RA 11106 or the Filipino Sign Language Act, in compliance with the United Nations Convention on the Rights of Persons with Disabilities, aims to eliminate discrimination in public communications and to promote inclusion through the use of Filipino sign language for the deaf. This RA is also in line with the Early Years Act (Republic Act No. 10410) and the Enhanced Basic Education Act (Republic Act No. 10533), which have recognized Filipino Sign Language in the education of the deaf learners from early childhood up to the secondary level. The Section 8 of this RA or the Filipino Sign Language in the Health System mandates all public health facilities to provide access of health services to the deaf through the free provision of FSL interpreters and accessible materials upon request of deaf patients, or individuals who have family members who are deaf. Meanwhile, private health care facilities are encouraged to provide access to health services to all deaf patients and their family members as part of their corporate social responsibility.

Batas Pambansa (BP) bilang 344 – An Act to Enhance the Mobility of Disabled Persons by Requiring Certain Buildings, Institutions, Establishments and Public Utilities to Install Facilities and Other Devices

The BP 344 or the Accessibility Law mandates the provision of architectural facilities or structural features which will provide access to the PWDs such as ramps, railings, sidewalks and the like in all facilities, establishments, and public utilities, such as educational institutions, airports, sports and recreation centers and complexes, shopping centers, public parking places, and workplaces. Posters and similar signages will also be displayed in prominent areas to generate public awareness on the rights and needs of the PWDs.

3.1.26 Indigenous Peoples

The Republic Act 8371 entitled ‘An Act to recognize, protect and promote the rights of indigenous cultural communities/indigenous peoples, creating a national commission on indigenous peoples, establishing implementing mechanisms, appropriating funds therefor, and for other purposes,’ or the Indigenous Peoples’ Rights Act of 1997 (IPRA), is a landmark legislation that recognizes and respects the rights of indigenous communities in the Philippines, including rights of control of their ancestral lands and right to self-determination. The law requires, among others, that development undertakings within the declared ancestral domains of the ICC/IPs shall be subject to their free, prior informed consent (FPIC) following different procedures depending on the character of activities. The IPRA, inter alia, declares that the State shall recognize and promote the rights of ICCs/IPs to government’s basic health services. The National Commission for Indigenous Peoples (NCIP) is responsible for implementing the IPRA. Likewise, the Joint Memorandum Circular 2013-01 entitled “Guidelines on the Delivery of Basic Health Services for Indigenous Cultural Communities / Indigenous Peoples” will also be considered.

The Department Circular 2020-0192 - Ensuring that people in GIDAs, Indigenous Cultural Communities/Indigenous Peoples are well-informed on COVID-19 and have access to Temporary Treatment and Monitoring Facilities and Referral Hospitals was issued by the Department of Health led by the Bureau of Local Health Systems Development (BLHSD) last April 2020. The Centers for Health Development (CHDs) and the Ministry of Health - Bangsamoro Autonomous Region in Muslim
Mindanao (MOH-BARMM) were tasked to coordinate with the local government units (LGUs) to ensure that the people in geographically-isolated and disadvantaged areas (GIDAs) and the indigenous cultural communities/indigenous peoples (ICCs/IPs) are well informed on COVID-19 and have access to temporary treatment and monitoring facilities (TTMF), whether national- or LGU-managed, and COVID-19 referral hospitals.

3.1.14 Gender-Based Violence (GBV) and Violence Against Women and Their Children (VAWC)

The Republic Act 9262 or the Anti-Violence Against Women and Their Children Act of 2004 upholds the dignity and rights of women and children cognizant of the need to protect the family and its members particularly women and children, from violence and threats to their personal safety and security. This is in accordance with the Constitution and the Provisions of the Universal Declaration of Human Rights, the convention on the Elimination of all forms of discrimination Against Women, Convention on the Rights of the Child and other international human rights instruments of which the Philippines is a party. This law covers the acts of violence against women and their children, penalties, and protection orders.

The Special Protection of Children Against Abuse, Exploitation and Discrimination Act or Republic Act 7610 aims to protect and rehabilitate children gravely threatened or endangered by circumstances which affect or will affect their survival and normal development and over which they have no control. It provides special protection to children from all forms of abuse, neglect, cruelty exploitation and discrimination and other conditions, prejudicial their development; and provide prevention and deterrence of and crisis intervention in situations of child abuse, exploitation and discrimination. The Republic Act 10354, the Responsible Parenthood and Reproductive Health Act of 2012, also highlights the elimination of violence against women and children and other forms of sexual and gender-based violence. In addition, the DOH Administrative Order 1-B entitled “Establishment of a Women and Children Protection Unit in All Department of Health (DOH) Hospitals” was promulgated in response to the increasing number of women and children who consult due to violence, rape, incest, and other related cases.

3.1.27 Republic Act 9184 – An Act Providing for the Modernization, Standardization and Regulation of the Procurement Activities of the Government and for other Purposes

Republic Act 9184 or the Government Procurement Reform Act and its implementing rules and regulations outline the legal framework of the public procurement from procurement planning up to contract implementation. The public procurement process refers to the Generic Procurement Manuals and standard Philippine Bidding Documents (PBDs) for mandatory use by all government procuring entities. The PBDs define the objective, scope, and expected outputs of the proposed contract, the eligibility requirements of the bidders, the expected contract duration and the obligations, duties, and functions of the winning bidder. The technical specifications of goods and infrastructure projects are defined in the PBDs including any green criteria or green technical specifications.
3.1.28 Executive Order 301 series of 2004 – Establishment of a Green Procurement Program in all Government Agencies

Executive Order 301 s. of 2004 establishes a Green Procurement Program for all departments, bureaus, offices, and agencies of the executive branch of government. It promotes the culture of making environmentally-informed decisions in government during the purchase and use of different products and in including environmental criteria in public tenders, whenever possible and practicable. The order also requires the establishment of specifications and requirements for products and services to be considered as environmentally advantageous and incentive programs for suppliers of environmentally sound products and services. The Philippines has a Green Public Procurement Roadmap.

3.1.29 GPPB Resolution No. 15, series of 2013 – Approval to Support the Implementation of Sustainable and/or Green Public Procurement Regime in Government

The resolution was issued by the Government Procurement Policy Board (GPPB) which recognizes that sustainable public procurement (SPP) or GPP must be included in the public procurement system, rules and procedures in line with sustainable consumption and production, green economy, and sustainable development strategies. The GPPB oversees the implementation of the public procurement reform agenda. It is an independent inter-agency body with government and private sector representation that was established by virtue of Section 63 of RA 9184.

3.2 World Bank Environmental and Social Policies

Key aspects of the Philippines legal framework relevant to the Project are described in the previous section. A high-level comparison has been made with the Bank’s ESF, consistent with the template for COVID-19 health projects provided by the World Bank. There are no significant gaps between the national framework and the ESF. However, the Project will apply both the relevant ESSs of the ESF and national legislation relevant to the Project and its E&S risks.

3.2.1 ESS1 Assessment and Management of Environmental and Social Risks and Impacts

ESS1 is relevant given the environmental and social risks to assess and manage. The Philippine environmental regulations, particularly the Philippine Environmental Impact Statement System (PEISS) reflects the spirit of ESS1 and the key elements are covered mostly under its implementing rules and regulations. The PEISS functions as a regulatory and approval tool of projects aside from its intent as a planning tool to ensure environmental, social, and economic sustainability. The process of EIA and decision-making and balancing environment protection and development is reflected as one of DENR’s focus areas of mandate in ensuring implementation of the principles of sustainable development. The ESMF is prepared consistent with both the national legislation and the Bank’s ESF.

The main environmental risks associated are: (i) occupational health and safety risks resulting from the operation of medical facilities and laboratories involved in COVID-19 response and the vaccination activities which inherently expose staff to infection risk; (ii) health care waste management and disposal and community health and safety issues related to the handling,
transportation and disposal of healthcare wastes generated from the vaccine administration; and (iii) possible environmental and safety risks associated with small scale civil works for warehousing of the COVID-19 vaccine, medical facilities refurbishment, or completion of ongoing construction. Occupational health and safety and medical waste management are of particular concern.

Healthcare- associated infections due to inadequate adherence to occupational health and safety standards can lead to illness and death among healthcare and laboratory workers and exposed communities. The laboratories, relevant healthcare facilities, and community settings which will be used for the COVID-19 vaccine administration will generate infectious wastes such as sharps, used vials, syringes, cotton swabs, gloves, PPEs, and masks as well as non-hazardous solid wastes such as packaging materials, syringe wrappers, and syringe capping. Effective management and control measures will have to be in place to avoid and minimize risks of the infectious wastes from contaminating the environment and causing harm to the people. Measures to avoid risks and impacts can be implemented through proper management, treatment, and disposal of healthcare wastes, use of appropriate disinfectants, implementation of quarantine procedure for COVID-19, implementation of occupational health and safety protocols, ensuring proper use of chemicals in the laboratory, use of non-ODS refrigerants in the cold chain, and implementation of environmentally-sound construction practices for any civil works, as documented in this ESMF and in line with guidelines from WHO and applicable GoP regulations. The ESMF includes guidelines for assessing adequacy of the existing Health Care Waste Management system for handling increased quantities of waste and identifying measures for strengthening capacity of the DOH, hospitals and its regional health units, if needed. Direct and indirect social risks include potential exclusion of or inadequate response measures for marginalized and vulnerable social groups, such as persons with disabilities and indigenous peoples, risk of panic/conflicts resulting from false rumors and social unrest (for instance at quarantine and isolation facilities not welcomed by local communities), the social stigma associated with COVID-19, and Sexual Exploitation and Abuse (SEA) and Sexual Harassment (SH), Gender-Based Violence (GBV) and/or Violence Against Children (VAC) for workers (except VAC) and patients.

The Project’s ESMF also provides environmental and social risk management for the Contingent Emergency Response Component (CERC)\(^\text{13}\) should it be activated during project implementation. The CERC may be activated for another health-related emergency with similar needs and eligible activities and within the scope of the Project Development Objective. However, since activation of the CERC for emergency activities outside of the health sector cannot be ruled out, the applicability of the risk management measures of the ESMF will be assessed before activation of the CERC. For eligible emergencies outside of the health sector, e.g. earthquakes, typhoons, and volcanic eruptions, where the measures included in this ESMF do not fit the activities of the activated CERC, an ESMF for the CERC would be prepared with the situation-specific environmental and social risk assessment and management measures. This CERC ESMF will be prepared prior to CERC activation and will cover all activities financed by the CERC in line with the Emergency Action Plan prepared for the CERC. In all circumstances, the ESMF provisions will be reflected in the CERC Operations Manual that will be prepared to guide CERC implementation, including a description of the type of activities eligible for support in response to the emergency and their environmental and social risks and

---

\(^{13}\) The CERC is a project component that is designed to provide swift response in the event of an eligible crisis or emergency, defined as “an event that has caused, or is likely to imminently cause, a major adverse economic and/or social impact associated with natural or man-made crises or disasters.” Project funds may be transferred to respond to such emergencies at the request of the government.
management measures as well as a negative list of activities categorically excluded from support under the activated CERC.

3.2.2 ESS2 Labor and Working Conditions

The Labor Code of the Philippines is the main legislation that protects workers’ rights including security of tenure, self-organization, collective bargaining, and humane working conditions. The Labor Code provides a competent system that allows for speedy resolution of labor disputes and includes a provision on grievance machinery and voluntary arbitration. The Labor Code together with RA 11058 on occupational health and safety plus other Philippine laws prohibiting forced and child labor and sexual harassment provide a suite of national legislation that is relatively aligned with the provisions of ESS 2.

Most activities supported by the Project will be conducted by health and laboratory workers, i.e. civil servants employed by the Government of the Philippines and professional consultants and contractors (hired as contracted workers). Activities encompass the provision of quarantine and isolation rooms, proper storage for medicines, PPEs, laboratory equipment necessary for the proper care of COVID-19 patients which may require minor expansion that would involve small-scale civil works for medical facilities refurbishment or completion of ongoing construction. There is a risk that health care workers are exposed to COVID-19 during the initial screening and vaccine administration in the health facility or community setting. There is also a risk that the cleaners and waste collectors of the health care facilities and waste service providers are exposed to infectious wastes generated from the immunization activities. The key risk is the contamination with COVID-19 (or other contagious illnesses as patients taken seriously ill with COVID-19 are likely to suffer from illnesses which compromise the immune system), which can lead to illness and death of workers.

The project will ensure the application of OHS measures as outlined in the ESMF’s Labor Management Procedures (LMP) (Annex B), the Philippine Labor Code, the Philippine Occupational Health and Safety Act and the International Labor Office Occupational health and safety management systems (ILO- OSH 2001). These laws and guidelines provide basis for the procedures for entry into health care facilities, including minimizing visitors and undergoing strict checks before entering; procedures for the protection of workers in relation to infection control precautions; provision of immediate and ongoing training on the procedures to all categories of workers, and post signage in all public spaces mandating hand hygiene and PPE; ensuring adequate supplies of PPE (particularly facemask, gowns, gloves, handwashing soap, and sanitizer); and overall ensuring adequate OHS protections in accordance with General EHSGs and industry-specific EHSGs and follow evolving international best practice in relation to protection from COVID-19. Also, the project will regularly integrate the latest guidance by WHO as it develops over time and experience addressing COVID-19 globally.

The project’s LMP incorporates issues for the DOH staff and contracted workers: working conditions and management of worker relationships, protecting the workforce and ensuring proper OHS, and a grievance mechanism for project workers whether direct or contracted workers hired for the small-scale civil works. Child labor is forbidden in accordance with ESS2 and Philippines law, and due to the hazardous work situation, no person under the age of 18 will be hired by the Project.

To prevent risks of Sexual Exploitation and Abuse (SEA) and Sexual Harassment (SH), Gender-Based Violence (GBV) and/or Violence Against Children (VAC) from interactions within work forces and
between workers and patients and other community members, the LMP includes provisions for training on community interaction and SEA/SH/GBV/SEA to all teams, staff (civil servants and outsources staff/contractors) to ensure the teams respect local communities and their culture and will not engage in misconduct, including Codes of Conduct (CoC). Other relevant documents, such as letter of DOH’s staff appointment and contracts for contracted workers in line with relevant national laws and legislation to be adopted and applied under the project, will also include the CoC. The LMP includes similar provisions for security personnel that will be involved in project activities, for instance in providing security at health facilities.

3.2.3 ESS3 Resource Efficiency and Pollution Prevention and Management

The Philippines has very comprehensive regulatory mechanism for regulating hazardous wastes. The challenge exists in relation to the availability of hazardous waste transporter and treatment and disposal facilities in various parts of the country. Title III of DAO 29 of RA 6969 defines the legal and technical requirements of hazardous waste management. The requirements for hazardous waste generators, transporters, and treaters are outlined in DAO 2013-22 including the procedures to follow to comply with the provisions of the law. The DENR EMB MC 2020-20 specify the health and safety protocols for compliance of the transporters and TSD facilities to ensure the proper handling of infectious COVID-19 wastes. The safety protocols include the preparation and submission of reports such as the report of compliance and completion of transport or the manifest and the certificate of treatment (COT) after each completed transport and treatment of the transporter and TSD, respectively. The ESMF is prepared based on national legislation as well as ESS3.

Wastes generated by healthcare facilities, laboratories, quarantine and isolation centers, and screening posts may include infectious wastes such as pathological wastes, sharps, pharmaceutical wastes, and chemical wastes (including water, reagents, infected materials, etc.) from the laboratory testing. The COVID-19 immunization activities may also generate infectious wastes in the form of sharps, syringes, vials, cotton swabs and PPEs used by healthcare workers during administration of the vaccine. These types of wastes are classified as hazardous wastes which may have substantial impact on the environment and human health when handled and disposed inappropriately. All facilities will follow the requirements of the ESMF and the national standards and regulations in place such as the DOH Healthcare Waste Management Manual (4th edition). The DENR also sets the requirements for the registration of healthcare facilities as hazardous waste generators and the commissioning of DENR-registered transporters and treaters in cases when the health care wastes are treated and disposed offsite.

Disposal of health care waste will not be permitted at sites which threaten human or environmental health including natural habitats. It similarly includes measures to ensure that standards relevant to the provision and protection of water resources and the effective management of wastewater from the facilities are observed. Measures related to transportation and management of samples and medical goods or expired medications and chemicals are also included in the Infection Control and Waste Management Plan (ICWMP). The project, as documented in the ESMF, will ensure the use of resources (water, air, etc.) in quarantine facilities and laboratories and that standards and measures consistent with the US- Center for Disease Control (CDC), and the WHO environmental infection control guidelines for medical facilities will be followed. As indicated, no major physical works are permitted.

In support to the ESMF, the Project developed healthcare waste management self-assessment audit tools for the adoption and regular use of the project recipient hospitals. The tools aim to monitor
the waste management of hospitals, particularly on COVID-19 vaccination and other related infectious wastes, to ensure the safety of the staff, community, and the environment. Through the self-assessment, hospitals would be able to identify the gaps and barriers in proper infectious waste management. The results of the assessment would also aid the Project to provide informed support to the project recipients such as through capacity building.

3.2.4 ESS4 Community Health and Safety

A variety of national legislations exist that are at par with the provisions of ESS 4. The Philippine EIA review process ensures that assessments of health and safety impacts of projects in the community are conducted. Public health issues are referred to the Department of Health.

The communities may have fear and apprehension on COVID-19 vaccination due to its efficacy and safety. Misinformation on the adverse health effects of vaccines and other rumors remain widespread and add to the fears on vaccine safety. To ensure the safety of the COVID-19 vaccines, the approval of the vaccine by the WHO-identified SRAs as well as the proper storage and transport conditions will be observed. The profiling and screening of candidate individuals to be vaccinated as well as the data management system should done to avoid the risk of vaccine contraindications. Risk communications for the populations will also be done together with counselling and prior informed consent. Ensure existence of protocols regarding consent to vaccinations, process for agreeing to or refusing to be vaccinated, and measures to protect those that refuse to be vaccinated would be in place at regional and local levels.

Health care wastes generated from vaccine administration have a potential of carrying microorganisms that can infect the community at large if they are not properly collected, stored, treated, and disposed of. There is a possibility for the infectious microorganism to be introduced into the environment if not well contained within the health care facility or laboratory or due to accidents or emergencies, such as a fire response or natural phenomena event (e.g., seismic). The health care facilities and possible community settings involved in the vaccine administration, laboratories, quarantine and isolation centers, and screening posts will have to follow appropriate COVID-19 prevention and control protocol, procedures, and guidelines applicable infection prevention and control and health care waste management procedures prescribed by the DOH, DENR and the LGUs where the facilities are located. The operation of quarantine and isolation centers needs to be implemented in a way that staff, patients, and the wider public follow and are treated in line with the international good practices for patient handling and treatment as outlined in the WHO guidance for COVID-19 response.

The Magna Carta for Disabled Persons and the Accessibility Law ensure that persons with disabilities are granted universal access. In 1995, RA 7877 was signed into law which prohibits sexual harassment in the workplace and in educational settings including trainings. In 2019, the Safe Spaces Act expanded the coverage to include online work, all public spaces, and gender-based violence among peers. Payment for ecosystem benefits is a known concept in the country but so far there is no legislation to support its use and is not relevant to the Project at hand. Moreover, the vulnerable groups are considered in the vaccine population prioritization.
The Project’s Stakeholder Engagement Plan (SEP) also ensures engagement with communities in order to disseminate information related to project activities, particularly with communities in the vicinity of health facilities, such as screening and quarantine facilities.

The project will need to mitigate potential risks of Sexual Exploitation and Abuse by applying the WHO Code of Ethics and Professional Conduct for all workers in the quarantine facilities as well as the provision of gender-sensitive infrastructures, such as segregated toilets and enough lighting in quarantine and isolation centers. As noted under ESS2, the LMP includes provisions to prevent SEA/GBV/SEA through training and Codes of Conduct (CoC) to ensure workers respect local communities and their culture and will not be involved in misconduct.

Crowd management in vaccination sites will also be observed. Crowd management for the COVID-19 vaccination sites is to use some uniformed or security personnel to ensure the observance of social distancing and peace and order. In relation to security of the vaccines, supplies, and equipment during delivery, DOH’s freight service provider ensures that all vaccines are delivered intact and safe onsite with the proper storage and transport conditions. DOH reports that security has not been an issue in the delivery of equipment in different areas nationwide. However, as COVID-19 may develop in unpredictable ways and due to potential concerns among the public, the use of additional government security personnel from the local or national police, or in some instances possibly the military, may be directed to implement measures to ensure peace and order in affected areas, including in vaccine administration sites, quarantine, isolation, decontamination, and other health facilities.

The potential scope of such security measures, and potential risks surrounding them, have been assessed as part of preparing the ESMF to manage environmental and social risks concerning project activities and monitored during project implementation. In cases where project activities are supported by private or government security personnel, it will be ensured that the security personnel follow a strict code of conduct and avoid any escalation, taking into consideration protocols consistent with ESS4 and best practice international guidance as outlined in IFC Good Practice Handbook on the Use of Security Forces: Assessing and Managing Risks and Impacts”14. Likewise, any incident involving security personnel will need to be recorded in the Grievance Mechanism, described under ESS10, following WB incident classification: indicative, serious and severe. Any severe incident involving security personnel will need to be reported to the World Bank no later than 48 hours with basic information and a detailed incident report within 10 workings days. Details about incident classification and incident reporting are included under Annex B – Labour Management Procedure (LMP).

3.2.5 ESS7 Indigenous Peoples/Sub-Saharan African Historically Underserved Traditional Local Communities

The Bank’s ESS 7 on Indigenous Peoples/Sub-Saharan African Historically Underserved Traditional Local Communities (IPs or Indigenous Cultural Communities/ Indigenous Peoples (ICC/IPs) in the Philippines context) aims to:

- ensure that the development process fosters full respect for the human rights, dignity, aspirations, identity, culture, and natural resource-based livelihoods of IPs;

• avoid adverse impacts of projects on IPs, or when avoidance is not possible, to minimize, mitigate and/or compensate for such impacts;
• promote sustainable development benefits and opportunities for IPs in a manner that is accessible, culturally appropriate and inclusive;
• improve project design and promote local support by establishing and maintaining an ongoing relationship based on meaningful consultation with IPs affected by a project throughout the project’s life cycle;
• obtain the Free, Prior and Informed Consent (FPIC) of affected IPs in the three circumstances described in ESS7; and
• recognize, respect and preserve the culture, knowledge, and practices of IPs, and to provide them with an opportunity to adapt to changing conditions in a manner and in a timeframe acceptable to them.

When indigenous peoples are present in, or have collective attachment to, a project area ESS7 requires that:

• The IPs should be fully consulted about, and have opportunities to actively participate in, the project design and the determination of project implementation arrangements.
• There should be an assessment of the nature and degree of the expected direct and indirect economic, social, cultural (including cultural heritage), and environmental impacts on them.
• The borrower should develop a consultation strategy and means by which affected IPs will participate in project design and implementation and adopt measures and actions in consultation with the affected IPs to be contained in a time-bound plan (IP Plan) which will be proportionate to the potential risks and impacts of the project.
• Adverse impacts on the IPs should be avoided by exploring alternatives to the project and where adverse impacts are unavoidable, the Borrower will minimize, mitigate and/or compensate for these impacts in a culturally appropriate manner. The mitigation and compensation measures shall include culturally appropriate and sustainable development benefits whether delivered through the community or individually.

The standard requires free, prior, and informed consent (FPIC) when a project may have adverse impacts on the land and natural resources, cause relocation or have significant impacts on IPs’ cultural heritage. None of these circumstances are present in this project.

There are a few differences between the national framework and ESS7. These concern the requirements for FPIC, the scope of undertaking a social assessment, preparing an Indigenous Peoples Plans (IPP), and disclosure and monitoring of such plans. However, given the nature of the project’s activities, these differences do not have material effects and the project would not require free, prior and informed consent under ESS7 or IPRA, nor require the preparation of IPPs. Sections 4.2 and 6.2 of this ESMF describes the measures for engagement with indigenous peoples at health facilities supported by the Project and measures to address particular issues concerning indigenous peoples, including through working with traditional health practitioners and local experts to ensure that affected members of indigenous communities are able to access appropriate health services.

3.2.6 ESS10 Stakeholder Engagement and Information Disclosure

The PEISS provides for information dissemination and the conduct of consultations as required under ESS 10. The DENR Guidelines on Public Participation under the PEISS provides that for the entire EIA process, public participation should be conducted with the stakeholders during the early
and various stages of the process. The stakeholders should be involved in the assessment, management, and monitoring of environmental impacts of a project. Public information/disclosure is required, especially to the stakeholders to enable for them to understand and appreciate their participation in the whole process. The PEISS also has provisions on grievance redress but these are limited to environmental issues and not for all project concerns as required in ESS 10. However, government agencies including DOH have set up their own hotlines and systems for dealing with complaints from the public. These hotlines and systems will be redesigned and reviewed to ensure a mechanism with multiple intake points for feedback and grievances in relation to the vaccine program. As a result, PEISS and DOH will establish an Emergency Operations Center with complete data management systems and tools particularly for the COVID-19 deployment nationwide.

The SEP has been prepared based on ESS10 and PEISS. The project recognizes the need for effective and inclusive risk communication and engagement with all relevant stakeholders and the population at large. Considering the serious challenges associated with COVID-19 pandemic and the COVID-19 vaccines, dissemination of clear messages around physical distancing, high-risk demographics, self-quarantine, and when necessary, mandatory quarantine is critical. Meaningful consultation, particularly when public meetings are counter to local and national advisories on physical distancing, means that meaningful disclosure of appropriate information and innovative and virtual stakeholder engagement assume huge significance for ensuring public health and safety from all perspectives social, environmental, economic, and medical/ health. To address these challenges a Stakeholder Engagement Plan (SEP) has been prepared. The SEP defines a program for stakeholder engagement, including public information disclosure and consultation, throughout the entire project cycle. It outlines the ways in which the DoH and partners will communicate with stakeholders and includes a grievance redress mechanism by which people can raise concerns, provide feedback, or make complaints about the project and any activities related to the project. Provisions have been included to reach and meaningfully engage vulnerable and disadvantaged groups (e.g. elderly, children, poor households, vulnerable groups, people with disabilities and indigenous peoples), including in rural areas with little access to the internet.

Under the parent project, a preliminary vaccine allocation for priority eligible groups as well as mapping of stakeholders was included. Individuals and groups likely to be affected (direct beneficiaries) have been identified. Mapping of other interested parties such as government agencies/authorities, at regional and local levels, NGOs and CSOs, and other international agencies have also been done. The additional financing will support the costs of expanding activities of the Philippines COVID-19 Emergency Response Project (P173877, the parent project)\(^{15}\) to enable affordable and equitable access to COVID-19 vaccines and help ensure effective vaccine deployment in the country through enhanced vaccination system and to further strengthen preparedness and response activities under the parent project for additional US $ 300 million. As a result, the SEP will be revised to strengthen social mobilization, information awareness and risk communication and engagement strategy for the COVID – 19 vaccine deployment nationwide. The strategy will ensure to generate confidence, acceptance, and demand for COVID-19 vaccines.

As a result, the draft SEP will be re-disclosed publicly by DOH and at the World Bank’s external website. The SEP will be updated during implementation and publicly re-disclosed as needed.

3.3 International and Regional Regulations and Guidance

3.3.1 Vaccine Introduction Readiness Assessment Tool (VIRAT)/Vaccine Readiness Assessment Framework (VRAF) Integrated Tool

The Vaccine Introduction Readiness Assessment Tool (VIRAT)/Vaccine Readiness Assessment Framework (VRAF) Integrated Tool was developed by WHO, UNICEF and the World Bank. The introduction of the integrated tool or Readiness Assessment Tool is a national level instrument which aims to assist countries assess readiness to deliver COVID-19 vaccines when they become available; identify gaps and prioritize opportunities for enhanced readiness; and identify opportunities for financial support.

The VIRAT/VRAF tool measures countries’ readiness to administer the COVID-19 vaccine across ten categories namely: a) Planning and Coordination, b) Budgeting, c) Regulatory, d) Prioritization, Targeting and COVID19 Surveillance, e) Service Delivery, f) Training and Supervision, g) Monitoring and Evaluation, h) Vaccine, Cold Chain, Logistics, and Infrastructure, i) Safety Surveillance, j) Demand Generation and Communication. Within these categories are assessment/activity areas. The tool is designed to provide information necessary for identifying gaps in readiness across the various activities, listing actions necessary to meet the gaps and generating financial implications of those actions.

3.3.2 World Health Organization

WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply

The Strategic Advisory Group of Experts (SAGE) on Immunization of the World Health Organization (WHO) has released guidelines on 13 November 2020 on the implementation of national vaccination programs against COVID-19 which include the values framework, prioritization roadmap, and vaccine-specific recommendations. It outlines vaccine allocation, prioritization, and administration recommendations.

WHO SAGE Values Framework for the Allocation and Prioritization of COVID-19 Vaccination

The WHO SAGE published the Values Framework for the Allocation and Prioritization of COVID-19 Vaccination on 14 September 2020 to provide guidance for countries on national prioritization and allocation of COVID-19 vaccines considering the limited supply. The main goal is for the COVID-19 vaccines to contribute significantly to the equitable protection and promotion of human well-being among all people of the world. The guiding principles include the (a) human well-being, (b) equal respect, (c) global equity, (d) national equity, (e) reciprocity, and (f) legitimacy.

Under national equity, the goals include to (1) ensure that vaccine prioritization within countries takes into account the vulnerabilities, risks and needs of groups who, because of underlying societal, geographic or biomedical factors, are at risk of experiencing greater burdens from the COVID-19 pandemic; and to (2) develop the immunization delivery systems and infrastructure required to ensure COVID-19 vaccines access to priority populations and take proactive action to ensure equal access to everyone who qualifies under a priority group, particularly socially disadvantaged populations.

Hence, priority groups and others which need to be consider include the following:
- People living in poverty, especially extreme poverty
- Homeless people and those living in informal settlements or urban slums
- Disadvantaged or persecuted ethnic, racial, gender, and religious groups, and sexual minorities and people living with disabilities
- Low-income migrant workers, refugees, internally displaced persons, asylum seekers, populations in conflict setting or those affected by humanitarian emergencies, vulnerable migrants in irregular situations, nomadic populations
- Hard to reach population groups

**Risk communication and community engagement readiness and response to coronavirus disease (COVID-19)**

This guideline release by WHO on 19 March 2020 provides checklists for risk communication and community engagement (RCCE) readiness and initial responses to the COVID-19 outbreak for countries in preparation for the pandemic as adopted from the adapted from the WHO’s RCCE guidance and training materials. It describes steps on the implementation of effective RCCE strategies which contribute to public health protection. It fosters proactive public communication of experts and authorities and gauges the risk perception of population groups.

**Laboratory Assessment Tool for laboratories implementing COVID-19 testing**

This tool has been designed to assess the capacity of laboratories that have implemented or intend to implement testing for SARS-CoV-2, the virus that causes novel coronavirus disease 2019 (COVID-19). The tool is a shortened version of the 2012 Laboratory assessment tool that is widely used to assess national laboratory systems and the capacity of laboratories.

**Laboratory biosafety guidance related to coronavirus disease (COVID-19)**

The purpose of this document is to provide interim guidance on laboratory biosafety related to the testing of clinical specimens of patients that meet the case definition of the novel pathogen identified in Wuhan, China, that is, coronavirus disease 2019 COVID-19 in all duly accredited laboratories:


**Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19)**

This document summarizes WHO’s recommendations for the rational use of personal protective equipment (PPE) in health care and community settings, as well as during the handling of cargo; in this context, PPE includes gloves, medical masks, goggles or a face shield, and gowns, as well as for specific procedures, respirators (i.e. N95 or FFP2 standard or equivalent) and aprons.

The document includes guidance on PPE in various settings including points of entry in all healthcare facilities, quarantine and isolation rooms and laboratories.
3.3.3 Stockholm Convention

The Stockholm Convention on Persistent Organic Pollutants is a global treaty to protect human health and the environment from chemicals that remain intact in the environment for long periods, become widely distributed geographically, accumulate in the fatty tissue of humans and wildlife, and have harmful impacts on human health or on the environment. Exposure to Persistent Organic Pollutants (POPs) can lead to serious health effects including certain cancers, birth defects, dysfunctional immune and reproductive systems, greater susceptibility to disease and damages to the central and peripheral nervous systems.

The Philippine government ratified the Convention in 2004 and is therefore required (under Article 5) to take measures to reduce or eliminate releases from unintentional POPs production. The Convention requires the promotion of best available techniques and best environmental practices to reduce these releases. Medical waste incineration is a significant source of POPs in the form of dioxins and furans which can be released in the form of emissions from the burning process and in ash remaining after combustion.

3.3.4 Kigali Amendment to the Montreal Protocol on Substances that Deplete the Ozone Layer

The Kigali Amendment to the Montreal Protocol on Substances that Deplete the Ozone Layer, which was adopted in the 28th Meeting of the Parties of the Protocol in 15 October 2016. The Kigali Amendment aims to phase down the consumption and production of hydrofluorocarbons (HCFs) as stated in Decision XXVIII/1. This was ratified by 65 countries and led by the UN Environment Programme (UNEP) with the aim of preventing global warming by up to 0.4°C this century by reducing the production and consumption of hydrofluorocarbons (HFCs) and potent greenhouse gases (GHGs).

3.3.5 Doha Declaration on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement and Public Health

The Doha Declaration in 2001 which was adopted by the member states of the World Trade Organization (WTO) addresses the issue on the access of affordable medicines for developing countries in the context of disease control and public health protection, such as for HIV, tuberculosis, and malaria. It balances the interests of the suppliers with intellectual property rights protection and the consumers with interest on price affordability.

The Doha Declaration ratifies that the TRIPS agreement should not restrict access of countries from affordable drugs and details the ‘right to grant compulsory licenses and the freedom to determine the grounds upon which licenses are granted, the right to determine what constitutes a national emergency and circumstances of extreme urgency, and the freedom to establish the regime of exhaustion of intellectual property rights.’
In relation, the World Trade Organization delays decision on the waiver on COVID-19 drugs and intellectual property rights for COVID-19 vaccines\textsuperscript{16}\textsuperscript{17}.

4 Environmental and Social Baseline

The Philippines moved aggressively to mitigate the COVID-19 pandemic at an early stage when confirmed cases were still at a very low level. The President declared the whole Philippines under a State of Calamity for a period of six months from March 16 and imposed an Enhanced Community Quarantine (ECQ) throughout the island of Luzon (which includes Metro Manila) from March 17 to May, with location-specific community quarantine guidelines per time period.

On March 24, 2020, the Congress passed the Bayanihan To Heal As One Act (Republic Act no. 11469) which declares a national emergency due to COVID-19, and grants the President expanded powers to adopt measure to prevent and suppress the spread of COVID-19 for three months. The Act also authorizes the Executive branch to reallocate and realign savings from the national budget as well as from government corporations. The Bayanihan to Recover As One Act or the Republic Act no. 11494 dated July 27, 2020 provides guidelines on the COVID-19 response and recovery interventions and acceleration of recovery including the economy.

The number of confirmed COVID-19 cases has continued to increase rapidly. After ramping up testing capabilities, current testing capacity is approximately 1,000 per day. Based on the official tally reported by DOH, as of December 14, 2020, there have been 450,733 confirmed cases and 8,757 deaths. Confirmed cases stretch across the age distribution, with a larger share among those age group of 20-30 with mostly male. The epicenter of COVID-19 is Metro Manila, which accounts for 72.6% of confirmed cases. In the COVID-19 Situation Report for the Philippines, the WHO notes that hospitals have faced shortages of active-duty healthcare workers, Personal Protective Equipment, and ventilators.

4.1 Health Care Waste Management of Infectious Wastes Related to COVID-19

DENR Memorandum Circular 2020-16 provides the guidelines with which waste transporters and treatment, storage, and disposal (TSD) facilities need to comply with during the extended community quarantine. In order to avoid the piling of infectious health care wastes and prevent environmental and community contamination, the continuous operations of the waste transporters and TSD facilities are ensured through the simplified permit provisions such as through the issuance of a special permit to transport (SPTT) online and the extension of the validity of the TSD Registration Certificates and Transporter Registration Certificates for 60 days and immediate renewal within 5 days after lifting of the ECQ. Similarly, DENR Memorandum Circular 2020-20 provides for the simplified procedures for permit issuance of transporters and TSDs, as well as safety and health protocols through the submission of manifest or the report of compliance and completion of transport and the certificate of treatment (COT) by the transporter and TSD, respectively. The manifest of the registered transported shall be attested by the duly designated


representative or PCO of the health care facility or hazardous waste generator and the TSD, within 24 hours for M501 wastes and 7 days for other hazardous wastes after delivery to the TSD facility. The TSD facility shall also submit a report of compliance and completion of treatment or the COT to be attested by their PCO within 7 days after M501 wastes and 21 days for other types of hazardous wastes, after completion of treatment.

The DENR Administrative Order 2013-22 entitled Revised Procedures and Standards for the Management of Hazardous Wastes provides the procedures for generation and compliance to the legal and technical requirements of hazardous waste management, including guidelines for waste generators, transporters, and treatment, storage, and disposal facilities. With this policy, pathological, infectious wastes, and sharps are categorized as M501 wastes or pathological or infectious wastes while the vials used in the vaccination activities will be classified as M503 or pharmaceuticals and drugs. Hence, the syringes, cottons, and other materials used in the vaccination which had contact to the patient are considered as infectious wastes (M501). The M501 and M503 health care wastes generated from the vaccination activities will be collected and transported by DENR- registered waste transporters and will be treated and disposed of by DENR- registered TSD facilities.

It is important to conduct a capacity mapping of the health care facilities on their health care waste management. This will be conducted through the HCWM self-audit tools developed under the Parent Project, including the determination if the health facility has existing in-house treatment and contract with DENR- accredited waste service providers. These will be done with consultation and requested assistance from the DOH Health Facilities Development Bureau.

4.2 Health Care Waste Transporters and Treatment, Storage, and Disposal Facilities (TSDs)

As of the May 2020 data of the Department of Environment and Natural Resources- Environmental Management Bureau, not all regions in the Philippines have DENR- accredited waste treaters and treatment, storage, and disposal facilities (TSDs) for health care wastes, specifically for M501 and M503 wastes.

Tables 2 and 3 show the summary of DENR- accredited M501 and M503 waste treaters and TSDs, respectively. The full list of the treaters and TSDs for M501 and M503 wastes are in Annexes J and K, respectively. It should be noted that the MIMAROPA, Central Visayas, Zamboanga Peninsula, Northern Mindanao, Davao, Soccsksargen, Caraga, and BARMM regions have no registered M501 and M503 waste transporters located in their region. Meanwhile, the Cagayan Valley, Bicol, Zamboanga Peninsula, Soccsksargen, and BARMM regions have no accredited M501 and M503 waste TSDs located in their regions.

The unavailability of appropriate DENR- accredited waste transporters and TSD facilities poses health and environment risks, such as exposure of the public to infectious wastes, considering the high volume of health care wastes expected to be generated from the COVID-19 immunization activities.
Table 2. DENR- accredited M501 and M503 waste treaters

<table>
<thead>
<tr>
<th>Region</th>
<th>Transporter</th>
<th>M501 only</th>
<th>M503 only</th>
<th>M501 and M503</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCR</td>
<td>1</td>
<td>9</td>
<td>5</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>CAR</td>
<td>—</td>
<td>—</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>I- Ilocos</td>
<td>—</td>
<td>—</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>II- Cagayan Valley</td>
<td>1</td>
<td>—</td>
<td>—</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>III- Central Luzon</td>
<td>—</td>
<td>7</td>
<td>11</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>IV-A- CALABARZON</td>
<td>1</td>
<td>12</td>
<td>16</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>IV-B- MIMAROPA</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>V- Bicol</td>
<td>1</td>
<td>—</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>VI- Western Visayas</td>
<td>—</td>
<td>—</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>VII- Central Visayas</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>VIII- Eastern Visayas</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>IX- Zamboanga Pen.</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>X- N. Mindanao</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>XI- Davao</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>XII- Soccsksargen</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>XIII- Caraga</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>BARMM</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
</tbody>
</table>

Grand Total 73

Table 3. DENR- accredited M501 and M503 waste TSD facilities

<table>
<thead>
<tr>
<th>Region</th>
<th>No. of DENR- accredited M501/3 TSDs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>NCR</td>
<td>6</td>
</tr>
<tr>
<td>CAR</td>
<td>1</td>
</tr>
<tr>
<td>I- Ilocos</td>
<td>2</td>
</tr>
<tr>
<td>II- Cagayan Valley</td>
<td>—</td>
</tr>
<tr>
<td>III- Central Luzon</td>
<td>19</td>
</tr>
<tr>
<td>IV-A- CALABARZON</td>
<td>7</td>
</tr>
<tr>
<td>IV-B- MIMAROPA</td>
<td>1</td>
</tr>
<tr>
<td>V- Bicol</td>
<td>—</td>
</tr>
<tr>
<td>VI- Western Visayas</td>
<td>1</td>
</tr>
<tr>
<td>VII- Central Visayas</td>
<td>1</td>
</tr>
<tr>
<td>VIII- Eastern Visayas</td>
<td>1</td>
</tr>
<tr>
<td>IX- Zamboanga Peninsula</td>
<td>—</td>
</tr>
<tr>
<td>X- N. Mindanao</td>
<td>2</td>
</tr>
<tr>
<td>XI- Davao</td>
<td>1</td>
</tr>
<tr>
<td>XII- Soccsksargen</td>
<td>—</td>
</tr>
<tr>
<td>XIII- Caraga</td>
<td>1</td>
</tr>
<tr>
<td>BARMM</td>
<td>—</td>
</tr>
</tbody>
</table>

Grand Total 43
4.3 Training for Implementers on the COVID-19 Vaccination Activities

The DOH has developed a set of training modules in support to the upcoming vaccination activities against COVID-19. It aims to provide guidance to health workers and partner implementing agencies on the efficient nationwide implementation of the COVID-19 Immunization Program. Content experts on COVID-19, vaccination, human resource training, data management, logistics, health communication, and counselling, surveillance, and waste management were consulted for development of this training course. The training course encompasses the whole spectrum of the delivery of services from pre- to post-implementation.

This training course shall update the skills and knowledge of our program coordinators and implementers, surveillance teams, community health educators and workers and partner agencies on vaccination in consideration to dealing with a communicable / infectious disease and managing and administration of a new vaccine. This training course is composed of the following modules:

- Module 1 – Microplanning
- Module 2 - Profiling and Data Management
- Module 3 - Supply Chain and Cold Management
- Module 4 - Risk Communication and Community Engagement
- Module 5 - Mental Health and Psychosocial Support (MHPSS) and Counselling
- Module 6 – Immunization
- Module 7 - Managing Adverse Events Following Immunization (AEFI) following COVID-19 Vaccination
- Module 8 - Immunization Waste Management

Each module focuses on specific activities and tasks. The training shall follow a blended learning strategy combining different teaching and learning methodologies. eLearning for didactic topics and face-to-face skills training shall be utilized. Online and offline modules will be made available. Two (2-3) days shall be allotted to complete this whole training course.

A DOH Core and Regional Training Team will be organized to plan, strategize, oversee, and implement the cascading of this training course. They shall act as training lead and resource person on the conduct of training. Mentoring sessions and post-training supervision shall be conducted by trainers to ensure standard delivery of training and services.

The training course shall be monitored and reviewed by the Department of Health.

4.4 Air Quality and Healthcare Waste Incineration

Air quality in the Philippines (and Manila in particular) has improved substantially in the 20 year-period since the enactment of the Clean Air Act of 1999 (CAA). A Japan International Cooperation Agency (JICA, 1997) study cited waste incineration as a major source of air pollution in Manila leading to a ban on incineration in 1999 under the CAA. The incineration ban was subsequently appealed with the Supreme Court ruling that only incinerators that emit poisonous and toxic emissions were banned. Hence, thermal waste treatment is permitted provided that emissions meet standards specified in the CAA. A phase-out of medical waste incinerators under the CAA was also
deemed impractical due to the lack of affordable best available technologies (BAT). Incinerator operators are required to self-regulate emissions and report to the Department of Environment and Natural Resources Environmental Management Bureau (DENR-EMB).

WHO (2019) describes the following HCW management hierarchy:

- The preferred approach is to avoid generating waste and thus minimise the quantity entering the waste stream.
- Where practicable and safe, those waste items that can be recovered for secondary use is the next most preferable method.
- Waste that cannot be recovered must then be dealt with by the least harmful options, such as treatment or land disposal to reduce their health and environmental impacts.

Under COVID-19 conditions the HCW quantities are expected to increase substantially potentially overwhelming thermal treatment capacity with associated OH&S and environmental pollution implications.

The Stockholm Convention recommends that priority consideration should be given to alternative processes, techniques or practices that have similar usefulness, but which avoid the formation and release of dioxins and furans. Non-incineration waste treatment technologies should always be implemented wherever possible. WHO has called on all stakeholders to uphold the Stockholm Convention and work towards incrementally improving safe health care waste management practices to protect health and reduce harm to the environment.

4.5 Indigenous Peoples

The project is likely to take place in areas with indigenous peoples, particularly for some regional health facilities and local health centers. No direct adverse impacts on indigenous peoples are expected from project activities, although as generally a marginalized group they may be more affected by the virus should it spread in their communities. Civil works are expected to be confined to existing premises of health facilities and would not require any land acquisition. Some health facilities in areas with indigenous peoples may be directly supported with vaccines, equipment, supplies, and critical medical services. Stakeholder engagement and information sharing at these sites would be key to ensure that indigenous communities and COVID-19 affected persons are able to avail themselves of health services supported by the Project.

The term “indigenous cultural communities/indigenous peoples” (ICC/IP) is used in the Indigenous Peoples Rights Act (IPRA) of 1997 (Republic Act No. 8371) and includes a wide variety of groups that share certain conditions which set them apart from mainstream society in the Philippines. The IPRA defines ICCs/IPs as a group of people or homogenous societies identified by self-ascription and ascription by others, who have continuously lived as organized community on communally bounded and defined territory, and who have, under claims of ownership since time immemorial, occupied, possessed and utilized such territories, sharing common bonds of language, customs, traditions and other distinctive cultural traits, or who have, through resistance to political, social and cultural inroads of colonization, non-indigenous religions and cultures, became historically differentiated from the majority of Filipinos.

The IPRA definition has been found to be consistent with the identifying characteristics for social groups covered by the Bank’s previous Operational Policy (OP 4.10) on indigenous peoples and is also considered consistent with the new E&S Standard 7 (ESS7) on indigenous peoples. ESS7
identifies social groups covered by the standard as a distinct social and cultural group possessing the following characteristics in varying degrees: (a) Self-identification as members of a distinct indigenous social and cultural group and recognition of this identity by others; and (b) Collective attachment to geographically distinct habitats, ancestral territories, or areas of seasonal use or occupation, as well as to the natural resources in these areas; and (c) Customary cultural, economic, social, or political institutions that are distinct or separate from those of the mainstream society or culture; and (d) A distinct language or dialect, often different from the official language or languages of the country or region in which they reside.

Indigenous peoples live in most areas of the Philippines, but the majority resides in Mindanao (about 60 percent) and North-Central Luzon (about 30 percent). There are no accurate census data regarding the number of indigenous peoples, but it is estimated to be between 10-15 million people. The National Commission on Indigenous Peoples (NCIP) officially recognizes the existence of 110 ethnolinguistic groups in the country. In Luzon, most of the indigenous peoples are concentrated in the northern mountain ranges of the Cordilleras (e.g. the Kalinga, Ifugao, Ibaloy, and Ilongot) and in the Sierra Madre mountain ranges (e.g. the Agta, Dumagat, and Itawis). They are also found in Zambales, Pampanga, Tarlac, Quezon Province, Polillo Island, and the Bicol Peninsula (e.g. the Pinatubo, Baluga and Agta).

The Western Islands Region and Central Philippine Islands Region are home to the Mangyan, Tagbanua, Batak, Tau't Bato, Keney, Sulod, Magahat, Ata and Ati, mainly in Mindoro, Palawan, Panay and Negros. In the island of Mindanao, there are about fifteen major indigenous groups and several subgroups living in the interior rainforest, hills, plateaus, narrow valleys and marginal plains, which include the Mandaya, Manobo, Bilaan, T'boli, Tiruray, Subanun, Higaonon, Tasaday, Bagobo, Manuvu, Matigsalug, Ata, and others; collectively they are called Lumads. The majority Muslim population in Mindanao, called Moro, is not considered to meet the identifying criteria as indigenous peoples and ESS7 is not applicable to them. The Bangsamoro Autonomous Region in Muslim Mindanao or BARMM is inhabited by indigenous peoples, including some marginalized Muslim groups such as the Badjao.

4.6 Disadvantaged and Vulnerable Groups

4.6.1 Persons with Disabilities

As COVID-19 continues to have wide-reaching impacts across the globe, it is important to note how persons with disabilities are uniquely impacted by the pandemic and may have constraints in accessing services. This section serves as a brief overview of emerging impacts and sets out some preliminary steps to mitigate the impact within the Bank’s unfolding operations on COVID-19.

Situation Overview in Key Areas

Health

- Many persons with disabilities have additional underlying health needs that make them particularly vulnerable to severe symptoms of COVID-19, if they contract it.
- Persons with disabilities may be at increased risk of contracting COVID-19 because information about the spread of the disease, the symptoms associated with it, and how to prevent getting it are not provided in accessible formats, such as print materials in Braille or large print, sign language interpretation, captions, audio provision, and graphics.
• Persons with disabilities may be at increased risk of contracting COVID-19, as they may not have the same access to handwashing facilities/alternatives or may have trouble social distancing because they require in-person assistance in various ways.
• Some persons with disabilities who require personal protective gear or other medical supplies, such as ventilators, for their regular health needs may have more difficulty accessing them due to an increased demand for those particular items.
• In addition, in economies where persons with disabilities have personal assistants for essential home-based care social distancing mandates may jeopardize support received, and the burden of care heightened.
• Existing physical and communication barriers that limit the accessibility of health systems still exist and might prevent persons with disabilities from seeking appropriate care for COVID-19 and other needs.
• Reduced access to personal aides and support is likely to have harmful effects on health. In particular, there may be long-term impacts on sexual and reproductive health because of lack of access to clean water, contraceptives, and menstrual hygiene products.

Education

• As schools close nation-wide in over 160 countries and many more at localized levels, over 87% of the world’s student population is out-of-school, interrupting educational progress and risking that children with disabilities have difficulty returning to school.
• Interruption of schooling can also interrupt access to basic services like meal programs; assistive technologies; access to resource personnel; recreation programs; extracurricular activities; and water, sanitation, and hygiene programs, all of which have benefits for children with disabilities.
• In settings where online learning is possible and provided to ensure instructional continuity, children with disabilities may have difficulty accessing the online platforms and content if accessibility features are not considered. They may miss out on important therapies, services, or accommodations they typically receive to support their learning if alternative options are not offered.

Economic and Employment Impacts

• Persons with disabilities already experience higher poverty rates and lower levels of employment. The current economic situation is expected to exacerbate economic and employment instability for persons with disabilities, especially those who are freelance workers or self-employed.
• Persons with disabilities represent a high proportion of informal sector employment, including the gig economy which is particularly adversely affected by the current economic environment and pandemic.
• Workplace accommodations, including physical accommodations or assistive technologies, may be workplace bound and employees with disabilities may face delays in receiving similar setups at home to continue their job tasks.

Transport and Travel

• As public transport systems reduce or stop services, persons with disabilities who rely on these methods for accessible transport may not be able to travel, even for basic necessities or critical medical appointments.
• With rapidly changing guidance and travel restrictions, persons with disabilities might not be able to return to their homes or to places that are more accessible to them.
**Social Protection and Safety Nets**

- There are concerns and reports that existing barriers, isolation, stigma, and discrimination are intensifying amid the outbreak.
- Social protection systems are weak in many countries and do not always cater to the needs of persons with disabilities.
- Safety nets may need to cover caregiving and other expenses particularly those emerging from ruptures in services for persons with disabilities.
- With increased stress, family confinement, and isolation, there is also an increased risk of gender-based violence. Since evidence shows that persons with disabilities, particularly women and girls, experience greater rates of violence and abuse, they are at a heightened risk during this period.

4.6.2 Disability-Inclusion in the World Bank’s COVID-19 Response

With the robust funding commitments to help clients fight COVID-19, there are opportunities to address persons with disabilities and limit the impacts delineated above. DOH has consulted with organizations representing persons with disabilities (PWD) and developed measures to address their particular circumstances and needs.

The DOH Health Facilities Development Bureau (HFDB) has reported that there are 10 provincial hospitals which currently have Filipino sign language interpreters (FSL) who are mostly social workers employed by the hospital. They are as follows:

<table>
<thead>
<tr>
<th>Region</th>
<th>Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCR</td>
<td>Jose Fabella Memorial Hospital, Lung Center of the Philippines</td>
</tr>
<tr>
<td>I</td>
<td>Mariano Marcos Memorial Medical Center, Ilocos Training and Regional Medical Center, Region I Medical Center</td>
</tr>
<tr>
<td>IV</td>
<td>Batangas Medical Center</td>
</tr>
<tr>
<td>VI</td>
<td>Corazon Locsin Montelibano Memorial Regional Hospital, Don Jose Monfort Memorial Medical Center Extension Hospital</td>
</tr>
<tr>
<td>VII</td>
<td>Vicente Sotto Memorial Medical Center</td>
</tr>
<tr>
<td>XII</td>
<td>Cotabato Regional Medical Center</td>
</tr>
</tbody>
</table>

According to the Degenerative Disease Office of the Disease Prevention and Control Bureau (DPCB-DDO), the new education curriculum of social workers has integrated basic FSL. It should be noted that hospitals have at least 1 social worker. It would be ideal if the employed social worker has background on FSL. The Metro Manila and CALABARZON Centers for Health Development (CHDs) are conducting community-based trainings on FSL. It is planned to cascade the training to the other regions in 2021. The Congress is also discussing the provision of FSL interpreters in health facilities. However, the timeline for this is not yet known.

The Project will be conducting a baseline assessment on the capacity of the recipient hospitals to provide accessible health services to vulnerable groups, including provision of virtual FSL services based on parameters such as availability of devices and internet connection. The baseline assessment will also cover GBV, VAWC, and IPs. Based on the results of this assessment, the Project in consultation with and through technical assistance of the DOH Bureaus will determine the support to be provided by DOH to these facilities to improve health service delivery to the vulnerable groups.
The DOH Health Promotion Bureau (HPB) has no COVID-19 health promotion materials for the PWDs at present. Currently, they only have the 30-second video with FSL interpretation for polio. The HPB and the DPCB-DDO have included PWD-accessibility in their Communication Plan for 2021 which will include printer materials with Braille and videos with sign language. The DPCB-DDO in partnership with the Philippine Information Agency (PIA), have previously developed a Communication Plan for PWDs which was also presented to the PWD CSOs.

The concerns of PWDs, particularly accessibility, will be considered in the activities under Component 3, Project Management and Monitoring and Evaluation, of the project by integrating into the prevention and preparedness activities. Project management and monitoring should ensure that the improved capacity of the health care facilities results in improved access for PWDs.

The request for vaccination of children and other vulnerable groups as well as the guidelines for carers/personal assistants of PWDs and children will be relayed to the DOH DPCB, HFDB, and the DOH IATF Focal Team. The PWD CSOs will be requested to submit a formal request to the IATF (iatfsecretariat@gmail.com) and DOH regarding the grievances of the carers/personal assistants.

Other potential responses may include: Immediate, as part of the COVID-19 Support Package:

- Inclusion of vulnerable groups in the priority populations for vaccination in line with the WHO SAGE guidelines.
- Ensure existing health needs of persons with disabilities are met, and not superseded, by additional health system needs.
- Contract health facilities and temporary testing and treatment facilities that comply with universal access standards.
- Provide health information and government guidance in accessible formats. This includes explanations of what is happening during the time of care for deaf, blind and people with cognitive disabilities. Accessible formats may include print materials in Braille or large print, sign language interpretation, captions, audio provision, and graphics.
- Disaggregated monitoring and evaluating for prevention, preparedness, and community-based disease surveillance by disability status and type to understand how persons with disabilities are impacted in pandemic situations. This should include data on differentiated rates of infection, economic impacts, and regarding the burden of care, barriers of access to care for people with disabilities.
- Integrate accessibility and disability considerations into all technical assistance the World Bank provides on supporting the outbreak. Considerations may need to balance disability-related and social distancing needs, including exemptions for personal caregivers during lockdowns/shelter-in-place procedures and access to personal protective equipment (PPE).
- Employ universal design principles in expanding clinical care capacities, including refurbishing ICUs or inpatient hospital facilities.

Long-term actions to ensure the needs of persons with disabilities are met in the coming months and future outbreak situations:

- Train health workers, including community health workers or volunteers in rural communities; government officials; emergency planners; and other stakeholders on interacting with persons with disabilities and how to support their needs.
- Strengthen disability-disaggregated data collection to address and mitigate risks to persons with disabilities during outbreak situations.
- Contract health facilities and temporary testing and treatment facilities that comply with universal access standards.
- Engage persons with disabilities in future public health emergency preparedness planning.
- Strengthen social security networks, particularly for people in the informal sector.
- Ensure that children with disabilities are supported in returning to school.
- Implement universal design standards in the development and use of online and virtual platforms, tools, and applications used to support government services, educational, employment, public awareness, emergency communications, and recreational activities.

4.6.3 Gender and Gender-based Violence

The Project will benefit both men and women by reducing the risks of COVID-19 to their personal health. The Department of Health generates sex and age-disaggregated data and it is expected that slight variations in project benefits will accrue by gender depending on the subgroup of the population being analyzed. Based on trends of DOH information of COVID-19 patients, men constitute around 60 percent of those afflicted with the disease with women comprising the remaining 40 percent. Although health care has shifted much from being a predominantly female profession and there is no gender-disaggregated data on COVID-19 frontline workers yet, anecdotal evidence and inference shows that there will be likely more women nurses, medical technologists, etc. who are involved in taking care of COVID-19 patients.

In the time of COVID-19, gender-based violence can occur in three major areas: in health facilities, at home by spouses or other members of the family, and in the streets by enforcers of community quarantine including the military, police, security personnel, and barangay patrollers. In hospitals and health clinics/centers, women health workers are exposed to sexual harassment by colleagues, patients, or relatives and friends of patients. The added stress of dealing with the pandemic could also result in other forms of workplace harassment including verbal abuse. Women patients are also prone to sexual harassment especially when unaccompanied in quarantine facilities. The medical profession has a code of ethics and it is expected that health facilities will be able to ensure that these are followed including their respective codes of conduct for their employees.

With families under quarantine, the incidence of domestic violence within a household can be expected to increase. This means that households experiencing domestic violence are more likely to experience it more and that domestic violence is not likely to spread across the community. Women are faced with the risk of abuse as they stay at home and the risk of getting infected with the disease when they go out to seek help. However, with service-providers not in operation or overwhelmed with other tasks, women survivors are not able to receive the full support they need. At the very least, hotlines and online psychosocial support needs to be available to survivors.

With enforcers of community quarantine seemingly having more power, violence against women may also increase. In many households particularly in rural areas, women are tasked to go to the market which is the only allowed form of social mobility during quarantine. As they perform this role, women are exposed to formal and informal security forces stationed in their communities. Provided that maximum tolerance will be enforced and there will be no abuse of power, women should be generally safe from gender-based violence when they go outside their homes.

Further, aside from gender-based violence, access to sexual and reproductive care services have become limited due to exhaustion of resources addressing COVID-19. There are alleged reported cases of women who died due to birth-related complications caused by untimely maternal care by certain hospitals. With this, there is a risk of increase in maternal and infant mortality rates.
4.7 National Immunization Context

The DOH Field Health Services Information System (FHSIS) Annual Report 2018 provided data on the Expanded Program on Immunization (EPI). The percentage of fully immunized children in the Philippines in 2018 is 66.18%, with the Caraga Region as the highest at 74.30% and the Region IV-A (CALABARZON) as the region with least vaccinated children (58.47%). Meanwhile, in 2017, the fully immunized children at the national level is at 67.47% and 69.84% in 2016 (FHSIS 2016 and FHSIS 2017). Region 10 has the highest number of fully vaccinated children in 2016 and 2017 at 84.77% and 80.91%, respectively. Region V or Bicol Region has the least fully vaccinated children in 2016 at 51.54% and the BARMM in 2017 at 50.27%. Based on the FHSIS data on full vaccination on children, it can be said that immunization rate has decreased from 2016 to 2018.

4.8 Lessons Learned on the Immunization Roll-out of a Novel Vaccine

The vaccination roll-out of the Dengvaxia against dengue, globally and in the Philippines in 2018 has posed several lessons on immunization of populations using a novel vaccine, as reported by Thomas and Yoon (2019)\(^{18}\), which are as follows:

- A more in-depth understanding of the induction, kinetics, and contributions to safety and protection of long-term homotypic, transient heterotypic, and long-term heterotypic immune responses is required, which will, in turn, require better ways to measure them;
- Multivalent replicating vaccines are at theoretical risk of experiencing immunodominance and immune interference in the recipient, likely necessitating a more iterative development approach to evaluate individual infectivity and immunogenicity (example – exploring monovalent dengue vaccines in separate clinical studies prior to combination);
- Since clinically relevant immune responses can change over time after natural infection or vaccination, the timing of efficacy measurements will need to be taken into account when considering vaccine efficacy and risk;
- Surveillance systems applied to vaccine efficacy trials should be designed to capture clinical end-points of interest for the period of time required to make a maximally informed decision about the vaccine’s potential for clinical benefit (i.e., how many dengue seasons?);
- Exploring immunogenicity and efficacy as a function of vaccine viral strains and contemporary circulating DENV types and genotypes should be considered by Sponsors, especially those using vaccine strains collected many years prior;
- Understanding the impact of age, baseline dengue and non-dengue flavivirus serostatus, infecting serotype, and time from vaccination on immunogenicity, efficacy, and safety should be a focus of Sponsors;
- Expanding and standardizing methods to complete quantitative and qualitative measures of humoral immune responses are required to leverage an understanding of protective and deleterious responses and what constitutes each (i.e., target epitopes);
- Exploring, in a prospective manner, immune correlates or surrogates of protection and risk should be a Sponsor priority, and will likely require collecting baseline blood samples on all trial participants, lengthening the duration of active surveillance, and having secondary efficacy endpoints assessing various time points remote from the vaccination; and

• Use of experimental human infection models should be considered to assist with early development decisions (i.e., antigen selection, dose, and schedule), gaining an early understanding of a vaccine candidate’s potential for clinical benefit prior to large clinical endpoint studies, and potentially adding to a data package supporting pursuit of a specific indication (example – fillings gaps in knowledge from field efficacy studies).

5 Potential Environmental and Social Impacts and Mitigation Measures

5.1 Methodology for Assessing Risk and Impacts

The ESMF is prepared based on an assessment of direct and indirect risks and impacts of the specific project activities. A direct impact is defined under the ESF as “...an impact which is caused by the project, and occurs contemporaneously in the location of the project.” An indirect impact is one “...which is caused by the project and is later in time or farther removed in distance than a direct impact, but is still reasonably foreseeable, and will not include induced impacts”. Induced impacts are those that are unknown, speculative, uncertain, or remote. Induced impacts are not considered further in this document as they cannot be reasonably assessed or mitigated at this time. Induced impacts emerging during project implementation will be managed responsively and the ESMF amended accordingly.

The project will apply the World Bank’s Environment and Social Framework (ESF), procedures for IPF operations designed to respond to COVID-19 and processed as an emergency operation under paragraph 12 of the IPF Policy. The Project will have positive social and environmental impacts as it should improve COVID-19 immunization, surveillance, monitoring, and containment. However, the project could also cause substantial environment and social risks.

5.2 Risk Summary

5.2.1 Environmental Risks

The main environmental risks are the occupational safety and health risks (OSH) to the health care workers brought about by the profiling and screening of patients prior to vaccination, administration of the vaccine, and the operation of medical facilities and laboratories involved in COVID-19 response might expose the health care workers to infection and cause unsafe environment. There are also OSH risks to the workers/laborers due to the possible exposure during the construction activities in the health facilities and laboratories. Occupational safety and health risks for cleaners and waste handlers in health facilities and the waste service providers are present due to the possible exposure to infectious health care wastes during the collection, storage, treatment, and disposal stages. There are risks from infectious healthcare wastes as they are generated from the testing and vaccination activities, including waste collection from the health care facility by the facility’s waste handlers and cleaners and by the contracted waste service providers, as well as community health and safety issues related to the handling, transport, treatment, and disposal of the healthcare wastes are present. The COVID-19 vaccines require specific temperatures during storage and distribution to maintain efficacy and safety. The availability of cold storage and refrigerated transportation suitable to the temperature needs of the vaccine and in the location of
vaccine administration is a potential risk to the Project’s implementation. Relatedly, the cold storage to be procured or rented may contain refrigerants which do not conform to the requirements of the Montreal Protocol, Kigali Agreement, and the chemical control order on ozone-depleting substances (ODS) and contribute to the generation of greenhouse gases (GHG). Other refrigerants are also toxic and flammable and can pose risk to people’s health and safety. Cold storage systems also require huge amount of energy to operate that may have an impact on climate change. The compliance with biosafety protocols during the transport of the vaccines is also a risk, as breakage of the vials and spillage of the vaccine might occur. Similarly, natural disasters such as earthquake, landslide, flooding, storm surge and other climate change-related risks as well as unstable power supply in some areas in the country may affect the security of the delivery and distribution of the vaccines.

Hazardous, infectious, and toxic (HIT) wastes that may be generated from the vaccine administration include liquid contaminated waste (e.g. blood, other body fluids and contaminated fluid) and infected materials (water used; syringes, vials, and Cottons) which require special capacity to manage and dispose. Without proper handling, these infectious wastes may pose risk to the healthcare workers and communities who are in contact or handle the waste and live near its disposal area. Since the healthcare facilities have instituted HCWM protocol in its operations even before the COVID-19 pandemic and the third party hazardous waste TSD facilities as well as the landfill sites are heavily regulated by government to enable proper management of the risks and impacts involved, the environmental risks are considered moderate. Moreover, the unavailability of appropriate DENR-accredited waste transporters and TSD facilities in some regions may pose incapacity to properly handle the high volume of health care wastes expected to be generated from the COVID-19 immunization activities and lead to health and environment risks, such as exposure of the public to infectious wastes, considering the

5.2.2 Social Risks

The social risks are considered substantial, although the direct social impacts and risks associated with the activities proposed by this project are expected to be mostly temporary, predictable, and avoidable. Any construction works that requires land acquisition and resettlement will not be financed by the Project, and it is part of the negative list of activities.

The major areas of social risks are expected to concern the biosafety issues of the vaccine, inequity and exclusion, social acceptability and acceptance of the vaccine, regulatory measures, misinformation surrounding biosafety and deployment and stigma and discrimination. Due to the novelty and relative timeframe of the development and clinical trials of the COVID-19 vaccine, the communities may have fear and apprehension on its scientific integrity, efficacy, and safety. The contraindications and storage and transport condition requirements of the vaccine may pose risk. Transparency on the vaccine information and manufacturer credibility are important considerations for the public. Misinformation and disinformation on the adverse health effects of vaccine is also a risk which should be addressed.

The case management of population for vaccination includes risks of contraindications and adverse health effects as result of improper or incomplete profiling and screening of individuals prior to vaccination. There is a risk of not completing the vaccine dose/ shots due to the individual’s apprehension and/or schedule mismanagement. The data management of cases, surveillance system, and schedule monitoring are also risks. With the use of more than one vaccine during the immunization period, close monitoring of adverse events in vaccinated individuals using information
technology, i.e., digital tracking system should be conducted. As the possibility of adverse effects of the vaccine is a risk, tracking of health effects in vaccinated individuals and follow-up assessments should be conducted.

The global demand for the vaccine and the limited vaccine production makes access to the COVID-19 vaccines a risk. The conduct of strict regulatory measures should be ensured in view of the novelty of the vaccine. Regulation and access concerns should be equally taken into consideration. Moreover, the work of relevant bodies such as the Food and Drug Administration (FDA), the National Immunization Technical Advisory Group (NITAG), and the Health Technology Assessment Committee (HTAC) should be continually aligned and synchronized to ensure the expeditious national approval of the vaccines.

Community health and safety risks consider infectious health care wastes generated from the vaccination and other COVID-19- related responses pose risk to community health and safety if not handled, transported, treated, and disposed of according to the proper health care waste management practices. Hospital visitors and other non- COVID-19 patients may also be exposed to the virus as well as the workers when establishing or upgrading health facilities. There is also a risk of not completing the vaccine dose/shots due to the individual’s apprehension and/or schedule mismanagement. The vaccine administration may also lead to crowding and violation of physical distancing measures, increasing the risk of exposure of the candidates and the residents within the vicinity of the site.

Risks on social inequity and exclusion include the accessibility of COVID-19 vaccines due to its price is a risk. Due to the novelty and urgent need of the vaccine, there is a risk in price regulation and compliance with fair trade guidelines. There is an indirect risk of social exclusion in particular, the most vulnerable and marginalized groups such as the indigenous peoples in remote areas from access to the COVID-19 information, treatment, and vaccines. The elderly, those with underlying medical conditions, and people living with disability, though included in the priority populations to be vaccinated as identified in the WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply, may have limited access to the vaccines due to reduced mobility. The vulnerable groups may also be excluded from coverage of the national program and local responses to COVID-19. The information materials on the COVID-19 vaccine to be developed could exclude the most vulnerable or be developed in a way that is not sensitive to the needs and access of these different groups. The vaccine distribution and deployment may also exclude populations based on geographical distribution, i.e. those in far-flung areas in GIDAS, and on socioeconomic status, such as less access for the marginalized.

Stigma and discrimination risks involve misinformation on the adverse health effects of vaccines and hearsays on the conspiracy theories and underlying political agenda on the vaccines are widespread. The vaccine acceptance may also be affected by the country’s previous experience with the Dengvaxia vaccination. The fear and apprehension of individuals and communities on the scientific integrity, efficacy, and safety of the COVID-19 vaccines may lead to people refusing vaccination. It may also cause individuals to hide symptoms, avoid getting tested, and reject hygiene measures, which could lead to further spread of the virus. The health workers involved in the vaccine administration activities may face discrimination and harassment when going back to their communities due to people’s fear in contracting the virus, frustrations over medical care, or misinformation.
There may also be some risks concerning sexual exploitation and abuse and violence against women and children related to healthcare workers and people in quarantine. Civil works envisaged in the project mainly refer to repair and rehabilitation of existing buildings. New facilities will be on existing premises and activities that would require land acquisition or involuntary resettlement are not eligible for project financing.

The potential risks and impacts will be addressed through the implementation of a Stakeholder Engagement Plan (SEP), including a Grievance Mechanism, and this Environmental and Social Management Framework (ESMF), including Labor Management Procedures (LMP), prepared based on an assessment of environmental and social risks and impacts in line with the applicable WB ESSs of the WB’s ESF, the WHO COVID-19 guidance on risk communication and community engagement, and national laws and regulations.

Women, the elderly, adolescents, youth, and children, persons with disabilities, indigenous populations and minorities generally experience the highest degree of socio-economic marginalization. Marginalized people often become more vulnerable in emergencies due to poor, or lack of, access to health services, information, and lack of effective monitoring and early-warning systems. The Project aims to provide health services to all COVID-19 affected persons, however, in some instances additional measures may be needed to ensure inclusion and outreach to vulnerable and marginalized people.

5.3 Construction Stage

5.3.1 Environmental Risks

Environmental risks at the construction stage are not expected to be significant. Construction works will mainly involve fit-out type activities in existing premises. Minor quantities of construction waste will be generated; however, none is expected to be hazardous and all will be disposed in accordance with local regulations.

Construction activities within health facilities will need to comply with relevant regulations for the specific circumstances to ensure that the integrity of the facility is not compromised. The environmental guidelines that will be complied with include air and water quality, vibration and noise standards, COVID-19 protocol and healthcare wastes management guidelines relevant to the small works construction, management of healthcare equipment and operational activities of the healthcare facilities financed by the project.

5.3.2 Occupational Health and Safety

Risks

Occupational health and safety hazards during construction activities include potential exposure to COVID-19 and regular hazards associated with construction activities. COVID-19 transmission hazards can be considered in terms of work location in accordance with Error! Reference source not found., with works in health facilities carrying the potential for nosocomial transmission (infection contracted because of an infection or toxin that exists in a certain location, such as a hospital). Hence, there is a slightly elevated risk of COVID-19 transmission due to proximity to patients and health workers. Works to establish quarantine facilities and decontamination stations carry similar hazards to normal community activities under COVID-19 restrictions. Depending on location and scope there may be some impacts to local communities near the site, e.g., in terms of dust, noise,
traffic, workers. There may also be fear, mistrust and resistance among the local community. Information disclosure and stakeholder engagement is therefore required in these circumstances following the provisions of the SEP.

Mitigation Measures

All workers involved with construction activities must follow basic hygiene procedures at all times to prevent the transmission of COVID-19:

1. performing hand hygiene frequently with an alcohol-based hand rub if your hands are not visibly dirty or with soap and water if hands are dirty;
2. avoiding touching your eyes, nose, and mouth;
3. practicing respiratory hygiene by coughing or sneezing into a bent elbow or tissue and then immediately disposing of the tissue;
4. workers exhibiting respiratory symptoms must not attend the workplace and should seek immediate medical advice;
5. maintaining social distance (a minimum of 1 meter) from other persons, particularly if they are showing respiratory symptoms.

The contractors shall observe the health protocols and guidelines outlined by the IATF and observe the Labor Management Procedures (LMP). Conduct of training and awareness raising activities will be done to ensure these procedures are followed, as needed. Construction works required under the project are low hazard activities; hence standard construction OH&S principles should be followed as described in Department of Labor and Employment (DOLE) (2020) Occupational Safety and Health Standards.

As an overarching philosophy the OHS hierarchy of controls should be adopted to mitigate OHS risks as shown in Figure 1.

![Hierarchy of Controls](image)

**Figure 1** OHS Hierarchy of Controls

The provisions of Department Order No. 198 (DO 198-18) (Implementing Rules of Republic Act No. 11058) must be complied with by all construction contractors. Specifically, the following provisions must be adhered to:
• All employers, also applicable to contractors, must develop an Occupational Health and Safety Program in accordance with Section 12;
• All workers must undertake the Mandatory 8-hour Safety and Health Seminar for Workers (Section 3); and
• Each construction workforce must have a qualified Safety Officer in accordance with DO 198 Section 14

The Environmental and Social Management Plan (ESMP), Environmental Codes of Practice (ECOP), and the Labor Management Procedures (LMP), Contractor’s Personnel Grievance Redress Mechanism will be developed by the Contractors based on the templates as part of the bidding document. The ESMP, ECOP, LMP and GRM will be implemented, updated, and monitored by the Contractors and project recipient facilities throughout the project duration. Monthly monitoring reports will be prepared accordingly using the templates. To further specify the liability of the contractors to the workers if they contract COVID-19, it will be explicitly stated in the contract that the DOH and the recipient hospitals will not be in-charge of the medical bills and wages of the workers and that it will be covered by the contractor.

5.4 Operational Stage

5.4.1 Occupational Health and Safety

Occupational health and safety (OHS) risks in the operational stage are predominantly associated with COVID-19 transmission risk. There is a risk that health care workers are exposed to COVID-19 during the initial screening and vaccine administration in the health facility or community setting if the proper infection and prevention control measures are not observed. The hazard will vary according to the location of the activities and the exposure to the main modes of COVID-19 transmission. WHO notes “COVID-19 virus is primarily transmitted between people through respiratory droplets and contact routes.” Contact routes involve viral particles emitted from the respiratory tract of an infected individual landing on a surface. Then another person touches that object then touches their nose, mouth or eyes and the virus enters the body via the mucous membranes, infecting the second person. These are the predominant modes of COVID-19 transmission.

A secondary transmission mode is airborne. Airborne transmission is different from droplet transmission as it refers to the presence of microbes within droplet nuclei, which are generally considered to be particles less than 5 microns (μm) in diameter which can remain in the air for long periods of time and be transmitted to others over distances greater than one metre. This transmission mode “...may be possible in specific circumstances and settings in which procedures or support treatments that generate aerosols are performed; i.e., endotracheal intubation, bronchoscopy, open suctioning...” etc.¹⁹

Noting the above “WHO continues to recommend droplet and contact precautions for those people caring for COVID-19 patients. WHO continues to recommend airborne precautions for circumstances and settings in which aerosol generating procedures and support treatment are performed, according to risk assessment¹⁹.”

Rational use of Personal Protective Equipment (PPE)

WHO\textsuperscript{20} (March 19 2020) noted “The current global stockpile of PPE is insufficient, particularly for medical masks and respirators; the supply of gowns and goggles is soon expected to be insufficient also. Surging global demand – driven not only by the number of COVID-19 cases but also by misinformation, panic buying, and stockpiling – will result in further shortages of PPE globally”. The European Centre for Disease Prevention and Control (ECDC) \textsuperscript{21} (May 2020) noted:

“...countries worldwide affected by COVID-19 have been experiencing difficulties in accessing personal protective equipment (PPE) and hand hygiene materials. Coordinated supply chains for PPE should ensure distribution of such materials to healthcare systems in order to reduce the potential of healthcare-associated transmission to vulnerable groups and healthcare workers.”

In these circumstances it is important that PPE is allocated in a rational way to ensure that those at highest risk of disease transmission are protected from infection. Judgements on the rational use of PPE should be guided by WHO\textsuperscript{20} (Table 1) reproduced in part in Table 2.

\textbf{Infection Control}

To ensure that infection is controlled, DOH has instituted a containment strategy that includes extensive testing, quarantine, isolation, and treatment either in a medical facility or at home. Details of the infection control measures are discussed in Annex I.

\textbf{Cargo Handling}

To date, there is no epidemiological information to suggest that contact with goods or products shipped from countries affected by the COVID-19 outbreak have been the source of COVID-19 disease in humans\textsuperscript{20}.

\textbf{Training}

WHO has developed a free course - \textit{Infection Prevention and Control (IPC) for Novel Coronavirus (COVID-19)} (https://openwho.org/courses/COVID-19-IPC-EN) – targeted at healthcare workers and public health professionals. The course includes information on what facilities should be doing to be prepared to respond to a case of an emerging respiratory virus such as COVID-19, how to identify a case once it occurs, and how to properly implement IPC measures to ensure there is no further transmission to HCW or to other patients and others in the healthcare facility.

Guidance on the proper use of PPE will be promoted to participating health facilities based on WHO interim guidance on the rational use of PPE reflected in Table 2.

\begin{footnotesize}
\begin{enumerate}
\item WHO (2020) \textit{Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19) Interim guidance}. 19 March 2020
\end{enumerate}
\end{footnotesize}
Table 2 Recommended PPE during the outbreak of COVID-19 outbreak, according to the setting, personnel, and type of activity

<table>
<thead>
<tr>
<th>Setting</th>
<th>Target personnel or patients</th>
<th>Activity</th>
<th>Type of PPE or procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inpatient facilities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient room</td>
<td>Health care workers</td>
<td>Providing direct care to COVID-19 patients</td>
<td>Medical mask; Gown; Gloves; Eye protection (goggles or face shield)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aerosol-generating procedures performed on COVID-19 patients</td>
<td>Respirator N95 or FFP2 standard, or equivalent; Gown; Gloves; Eye protection; Apron</td>
</tr>
<tr>
<td>Cleaners</td>
<td>Entering the room of COVID-19 patients</td>
<td>Medical mask; Gown; Heavy duty gloves; Eye protection (if risk of splash from organic material or chemicals); Boots or closed work shoes</td>
<td></td>
</tr>
<tr>
<td>Visitors</td>
<td>Entering the room of COVID-19 patients</td>
<td>Medical mask; Gown; Gloves</td>
<td></td>
</tr>
<tr>
<td>Other areas of patient transit (e.g. corridors).</td>
<td>All staff, including health care workers.</td>
<td>Any activity that does not involve contact with COVID-19 patients</td>
<td>No PPE required</td>
</tr>
<tr>
<td>Triage</td>
<td>Health care workers</td>
<td>Preliminary screening not involving direct contact.</td>
<td>Maintain spatial distance of at least 1 metre. No PPE required</td>
</tr>
<tr>
<td>Patients with respiratory symptoms</td>
<td>Any</td>
<td>Maintain spatial distance of at least 1 metre. Provide medical mask if tolerated by patient</td>
<td></td>
</tr>
<tr>
<td>Patients without respiratory symptoms</td>
<td>Any</td>
<td>No PPE required</td>
<td></td>
</tr>
<tr>
<td>Laboratory</td>
<td>Lab technician</td>
<td>Manipulation of respiratory samples</td>
<td>Medical mask; Gown; Gloves; Eye protection (if risk of splash)</td>
</tr>
<tr>
<td>Administrative areas</td>
<td>All staff, including health care workers.</td>
<td>Administrative tasks that do not involve contact with COVID-19 patients.</td>
<td>No PPE required</td>
</tr>
<tr>
<td><strong>Outpatient facilities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consultation room</td>
<td>Health care workers</td>
<td>Physical examination of patient with respiratory symptom</td>
<td>Medical mask; Gown; Gloves; Eye protection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Physical examination of patient without respiratory symptom</td>
<td>PPE according to standard precautions and risk assessment.</td>
</tr>
<tr>
<td>Patients with respiratory symptoms</td>
<td>Any</td>
<td>Provide medical mask if tolerated.</td>
<td></td>
</tr>
<tr>
<td>Patients without respiratory symptoms</td>
<td>Any</td>
<td>No PPE required</td>
<td></td>
</tr>
<tr>
<td>Cleaners</td>
<td>After and between consultations with patients with respiratory symptoms.</td>
<td>Medical mask; Gown; Heavy duty gloves; Eye protection (if risk of splash from organic material or chemicals); Boots or closed work shoes</td>
<td></td>
</tr>
<tr>
<td>Setting</td>
<td>Target personnel or patients</td>
<td>Activity</td>
<td>Type of PPE or procedure</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Waiting room</td>
<td>Patients with respiratory symptoms</td>
<td>Any</td>
<td>Provide medical mask if tolerated. Immediately move the patient to an isolation room or separate area away from others; if this is not feasible, ensure spatial distance of at least 1 metre from other patients.</td>
</tr>
<tr>
<td></td>
<td>Patients without respiratory symptoms</td>
<td>Any</td>
<td>No PPE required</td>
</tr>
<tr>
<td>Triage</td>
<td>Health care workers</td>
<td>Preliminary screening not involving direct contact.</td>
<td>Maintain spatial distance of at least 1 metre. No PPE required</td>
</tr>
<tr>
<td></td>
<td>Patients with respiratory symptoms</td>
<td>Any</td>
<td>Maintain spatial distance of at least 1 metre. Provide medical mask if tolerated.</td>
</tr>
<tr>
<td></td>
<td>Patients without respiratory symptoms</td>
<td>Any</td>
<td>No PPE required</td>
</tr>
</tbody>
</table>

Points of entry

<table>
<thead>
<tr>
<th>Points of entry</th>
<th>Administrative areas</th>
<th>Screening area</th>
<th>Temporary isolation area</th>
</tr>
</thead>
<tbody>
<tr>
<td>All staff</td>
<td>Staff</td>
<td>First screening (temperature measurement) not involving direct contact.</td>
<td>Entering the isolation area, but not providing direct assistance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Second screening (i.e. interviewing passengers with fever for clinical symptoms suggestive of COVID-19 disease and travel history)</td>
<td>Assisting passenger being transported to a health care facility</td>
</tr>
<tr>
<td>Cleaners</td>
<td></td>
<td>Cleaning the area where passengers with fever are being screened</td>
<td>Cleaning isolation area</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical mask</td>
<td>Medical mask; Gown; Heavy duty gloves; Eye protection (if risk of splash from organic material or chemicals); Boots or closed work shoes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Medical mask; gown; gloves; eye protection</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Medical mask; Gown; Heavy duty gloves; Eye protection (if risk of splash from organic material or chemicals); Boots or closed work shoes</td>
</tr>
</tbody>
</table>
5.4.2 Healthcare Waste Management at Healthcare Facilities


Natural disasters and conflicts, by their nature, are highly disruptive and dangerous events. Their consequences are unpredictable, and it is inevitable that many essential public services will be interrupted. HCFs, public health and municipal services, such as waste management, may totally or partially cease due to destroyed buildings, damaged equipment, dislocation of staff and blocked roads.

In such situations, all forms of wastes including hazardous healthcare wastes (HCW) remains uncollected and untreated. It is inevitable that wastes will accumulate, and serious environment and health hazards (e.g. hepatitis B and C) may affect communities. Therefore, measures need to be taken to remove wastes as soon as possible after an emergency. The purpose is to reduce the proximity of people to accumulated wastes and so reduce the potential for disease transmission.

The purpose of HCWM in an emergency is to avoid wastes from being scattered indiscriminately around medical buildings and their grounds and reduce the likelihood of secondary infections. As a basic starting point and to avoid sharps injuries, HCW generated by emergency medical care activities (in tents, field hospitals, mobile hospitals) should be segregated using a “two-bin solution” that is, sorting waste into used sharps and non-sharps wastes (including general wastes and infectious, pathological, and pharmaceutical residues). The two bins should be kept segregated until final disposal. Basic considerations in emergency response in HCWM. Safety boxes are to be used for sharps. The following management measures are to be observed:

- All non-sharps wastes, without exception, should be collected in medical areas in rigid containers, such as plastic buckets with a cover, to prevent waste items from being exposed to disease transmission by contact by hand, airborne particles and flying insects.
- Containers and covers should be washed and disinfected daily after being emptied.
- Reuse of rigid waste containers after disinfection with a chlorine (0.2%) solution may be the most practical option to introduce quickly in an emergency situation and is low cost at a time when resources for better forms of waste segregation and storage may be scarce.
- Sharps wastes should be stored safely in puncture-proof and leak-proof containers.

Burial of non-sharps and sharps wastes in pits or trenches may be considered as a pragmatic option in emergency situations.

Hazards and Risks

Actual cases of non-sharps waste being demonstrated to cause an infection in health care personnel and waste workers are rarely documented. HCW handlers are at greatest risk from infectious hazards which
include chemical exposures such as chemotherapeutic drugs, disinfectants and sterilants; physical hazards such as ionizing radiation; and ergonomic hazards. The COVID-19 health care wastes may not be properly segregated with the general health care wastes, posing threat to the waste collectors and general public.

Mitigation Measures

The following preventive measures can also be implemented during an emergency response phase to reduce public and occupational health risks:

- Provide hepatitis B vaccination to all health care personnel and waste handlers.
- Encourage hand hygiene (washing, preferably followed by disinfection).
- Use gloves and masks for handling HCW.
- Raise the awareness of staff about simple post exposure prophylaxis in the event of an occupational injury (e.g., needle-stick injury).
- Contain and promptly clean up spillages of infectious materials and disinfect quickly to avoid pathogen transmission.
- Disinfect body fluids before their discharge.
- Conduct on-site awareness-raising activities (whenever possible) to remind health care personnel about occupational exposures and the safe practices for managing HCW.

Table: HCWM practice in emergencies

<table>
<thead>
<tr>
<th>Segregation and packaging</th>
<th>All containers and bags should be filled to three quarters of their capacities to avoid spillage and kept covered to prevent casual access by people or disease vectors.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Should colour coding of plastic bags and containers not be possible, signs or marks can be put on containers to differentiate between hazardous health-care waste and general waste.</td>
</tr>
<tr>
<td></td>
<td>Segregated waste should be regularly removed and safely stored to reduce the risk of transmission of pathogens and improve general standards of cleanliness and hygiene in medical areas.</td>
</tr>
<tr>
<td></td>
<td>If plastic bags are not available, containers for non-sharps wastes should be washed and disinfected after being emptied.</td>
</tr>
<tr>
<td>Collection</td>
<td>Exclusively allocated carts or trolleys with lids should be used to collect and transport health-care waste. Carts should be regularly cleaned and disinfected.</td>
</tr>
<tr>
<td></td>
<td>Highly infectious wastes (e.g. laboratory wastes and wastes from persons with contagious diseases) should be collected quickly and carried to a single, secure central storage area; on no account should collected waste be left anywhere other than at a central storage point.</td>
</tr>
</tbody>
</table>
### Storage

Segregated waste should preferably be stored in specific restricted areas. The storage area should be a locked room or guarded enclosure.

If this is not available, large containers with lids may be used for temporary storage of segregated waste and should be placed in restricted areas to minimize contact with people and animals.

Mark the storage area with the biohazard symbol, or put a sign or mark that is understood locally to differentiate between hazardous and non-risk wastes.

### Treatment and Disposal

Should resources not be available, minimal treatment and disposal practices should continue to be used as follows:

- onsite burial in pits or trenches;
- disposal in special cells in municipal dumping sites;
- incineration in low-cost double-chamber incinerators;
- encapsulation of sharps waste or small quantities of pharmaceuticals followed by onsite burial or burial in special cells in municipal dumping sites;
- incineration in high-temperature industrial incinerators (provided that there is a safe means of transportation);
- disinfection of infectious and sharps wastes with a small autoclave (when resources are available); non-sharps disinfected wastes should join the general waste stream.
- Body parts should be safely stored and disposed of according to local culture and customs.


Reference to the DOH Health Care Waste Management Manual 4th edition should be made for in-depth discussion on the management protocol on COVID-19 and Emerging Infectious Diseases.

An ongoing assessment is being done by the Project to evaluate the existing health care waste management system in the facilities that will be covered by the project to ensure that it will be able to handle the anticipated increase in HCW load, fulfills international standards, and to propose mitigating measures if found otherwise in the project’s environmental and social risk management instruments. This is being done using health care waste management self-audit tools developed by the project. The HCWM self-audit tools will be provided to the hospitals to aid in their regular assessment, recording, reporting, and monitoring of their health care waste management practices. This will assist the facilities in improving their practices, especially the segregation of infectious and general health care wastes. Results of the self-assessment of the hospitals will inform the Project if there is a need for provision of supplies and training on health care waste. Moreover, it should be ensured that the waste contractors or treatment, storage, and disposal facilities (TSDs) personnel observe proper practices of the health care waste management streams as inspected by the health facilities upon renewal of service contract.
5.4.3 Wastes from COVID-19 Vaccination

Risks

The vaccination activities will produce wastes such as sharps and infectious non-sharp wastes that can cause direct negative health impacts on the community and healthcare workers. There are also indirect health effects to the community and environment resulting from inadequate treatment and disposal of these wastes.

Mitigation Measures

The management of wastes from the vaccination program will be in accordance with the DOH Health Care Waste Management Manual, 4th edition. Measures to be implemented include the following:

- Waste segregation and packaging
  - Segregation of sharps from non-sharps
  - Discard entire syringe with needle into a safety box immediately after use
  - Placement of the safety boxes (when full) into plastic bags closed hermetically and with clear marking to avoid leakage during transportation
  - Placement of empty vials into waste containers with plastic lining to avoid leakage.

- Waste treatment and final disposal
  - Placement of sharp boxes and containers of empty vials into secure septic vaults for on-site burial.
  - If septic vaults are not available, employ the services of a DENR-licensed hazardous waste treatment facility for the off-site transportation and treatment of the vaccination wastes.

- Return Back to Supplier

The vaccine procurement program will apply the Extended Producer Responsibility (EPR) concept or return back condition as a green procurement approach in managing vaccine wastes. The return-back condition in the contract agreement with vaccine suppliers will be specifically applied in areas with limited capacities for safe onsite disposal or in areas with no available third-party hazardous waste treatment facilities or whose municipal landfills do not have dedicated cells for hazardous wastes.

5.4.4 Labor Rights and Gender

Risks

The following potential risks at health facility may occur:

- Workers, in particular health personnel (especially nurses) and cleaners, may be asked to work overtime to respond to the COVID-19 pandemic. It is important that these personnel are able to access overtime pay as needed and required by law;
- Women in particular, if they are single heads of household and have child-care duties may have difficulties responding to requests for overtime;
• Health care and other staff, including cleaners, or workers in upgrade/rehabilitation may need medical care if they contract COVID-19;
• Health workers, a big proportion who are female, may face mental issues or burnout as result of an outbreak; and
• Health workers, cleaners or workers involved in upgrades experiencing respiratory symptoms may fear not getting paid and continue to show up at work.
• There is a risk that health care workers are exposed to COVID-19 during the initial screening and vaccine administration in the health facility or community setting.
• There is also a risk that the cleaners and waste collectors of the health care facilities and waste service providers are exposed.

There is a minor risk of underage workers working as cleaners in medical facilities or transporting medical supplies or equipment. Labor law prohibits anyone under 18 years being involved in hazardous work.

Mitigation Measures

The following mitigation measures are applicable to labor rights and gender as per the Philippines labor law and consistent with ESS2:

• All workers must be paid for overtime in accordance with Government labor laws;
• All workers must be provided with security of medical care, in particular ensuring they can access free medical care if they contract COVID-19.
• Ensure that staff with lower qualification or less experienced working in the health sector (e.g., cleaners, part-time workers, etc.) - often female workers - also have access to the required Personnel Protection Equipment (PPE) – including gloves, gowns, masks and eye protection if exposed to patients with COVID-19, their waste, clothes or linen – and training to make sure they work in a safe environment;
• Vulnerable workers should be identified, such as female single heads of household, who may need additional support in order for them to do their job (for instance, female nurses who are single heads of household may need additional support if they have to work overtime). Additional support to consider may include cash grants, access to food support or provision of childcare services;
• Health care workers must be actively supported by their employers and commended for their work, as well as offered psychological, emotional or mental support if possible;
• All workers must be reassured that they will continue to get paid if they need to self-isolate if they are showing with COVID-19/respiratory symptoms. These provisions must be made including for contracted staff and are included in the Labor Management Plan (LMP);
• Child labor or indentured labor is absolutely prohibited in the project. All medical staff, cleaners, and all others handling equipment, tests, wastes, etc. or involved in the transportation of medical equipment and supplies related to the project must be over 18 years.
5.4.5 Community Health and Safety

Risks

Potential community health and safety risks associated with the project activities include:

- Transport of wastes, transport of lab tests, transport of people who have tested positive with COVID-19 and movement of health workers and other staff in contact with patients with COVID-19, has the potential to spread the virus in the community (note transport of medical supplies and equipment is not expected to result in virus transmission);
- Communities may have fear and apprehension on COVID-19 vaccine efficacy and safety due to the novelty and relative timeframe of development;
- The proper storage conditions and transport of the vaccines are also major risks as they are needed to ensure the efficacy and safety of the vaccine.
- Misinformation and disinformation on the adverse health effects of vaccines and hearsays on the conspiracy theories and underlying political agenda on the vaccines are widespread.
- There is a risk of adverse health effects if the profiling and screening of candidate individuals to be vaccinated and proper data management were not observed to consider vaccine contraindications.
- Crowding or influx of people in the vaccination sites as well as the violation of physical distancing are also risks.
- Use of Security and Military personnel in the delivery and distribution of the vaccines may also exist.
- Health workers may face discrimination and harassment when going back to their communities due to people’s fear in contracting the virus, frustrations over medical care or misinformation;
- Screening of people entering the country, in particular land borders with migrants coming back into Philippines, as well as checks and/or enforcement of any community movement restrictions or quarantine/lockdown or social restriction measures, could lead to abuse of power by law enforcement, fear from community members (especially the elderly), a potential for discrimination of marginalized groups, GBV, Sexual Exploitation and Abuse (SEA) and/or VAC;

Mitigation Measures

The SEP provides measures for stakeholder engagement at participating health facilities to inform local communities of project activities, seek their feedback on potential risks and mitigation measures. The following community health and safety measures will be applied and for civil works included in the ESMP:

- Transport of all COVID-19 wastes and lab tests, blood samples, etc., should be collected safely in designated containers and bags, treated and then safely disposed;
- Collection of samples, transport of samples and testing of the clinical specimens from patients meeting the suspect case definition should be performed in accordance with biosafety measures and WHO guidelines on Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases;
• Transport of medical equipment/supplies is not expected to be a vector in transmitting the virus, however, workers transporting materials should be reminded to wash hands appropriately and to avoid touching their face;
• To ensure the safety of the vaccines to be procured, the vaccine regulatory approval of the Stringent Regulatory Authorities (SRAs)\(^\text{22}\) identified by the World Health Organization will be required;
• Appropriate messages will be developed under the risk communication plan to address the vaccine safety concerns of communities;
• A Communications Campaign Plan will also be developed by the DOH Health Promotion Bureau (HPB) for the COVID-19 immunization program. It will have a whole-of-government, whole-of-system, and whole-of-society approach which will encompass general information on (i) COVID-19 and the need for sanitation and hygiene practices, (ii) COVID-19 vaccine basic information, (iii) trials results and procurement, and (iv) vaccine program roll-out. The WHO Risk communication and community engagement readiness and response to coronavirus disease (COVID-19) released on 19 March 2020 will also be used as reference in the development of messages and planning of risk communication and community engagement (RCCE) activities.
• A series of counselling and obtaining of informed consent will be conducted prior to the administration of the COVID-19 vaccine;
• The profiling and screening of candidate individuals to be vaccinated should be performed so as to avoid the risk of vaccine contraindications;
• A comprehensive data management system is also needed to support the profiling, screening, and scheduling to address the risk of individuals not completing the required shots/doses of the vaccine;
• Coordination with the local government units as well as the uniformed personnel will be done to assist in crowd management;
• Training must be provided to medical and other staff (doctors, nurses, cleaners, lab technicians, etc.) in contact with patients with COVID-19 and/or their wastes, clothes, linen or tests, on disinfection procedures when going back to their homes/communities. In extreme cases, this may involve isolating medical and other personnel involved with COVID-19 patients;
• Any medical or other hospital staff (including cleaners) experiencing symptoms of COVID-19 or a respiratory illness (fever + cold or cough) must remain at home/isolated and report symptoms immediately to supervisors;
• Communication materials must reinforce the positive contribution of health care workers and other essential workers and their need to be supported by community members;
• Communication materials should make clear the steps health workers and other staff are taking to protect themselves against the virus and their use of PPE;
• Ensure widespread engagement with communities in order to disseminate information related to community health and safety, particularly around social distancing, hand washing, high-risk demographics, self-quarantine, and mandatory quarantine. Workers and law enforcement personnel must adhere to Code of Conduct (CoC), including fair treatment and non-discrimination when carrying out their duties. Key points in CoC must be publicly available as

part of disclosure and law enforcement personnel must be made aware and trained in key items (especially non-discrimination, OHS and issues relating to GBV).

- Security and military personnel may be utilized for vaccine deployment. It will be ensured that the security personnel follow a strict code of conduct and avoid any escalation consistent with the ESF and IFC guidance on the use of security personnel (IFC Good Practice Handbook on the Use of Security Forces: Assessing and Managing Risks and Impacts). In these cases, DOH will assess risks posed by these security arrangements to project workers and the local community. Security personnel will provide security services in a manner consistent with the applicable laws and code of practices and will be consistent with the relevant requirement of the World Bank’s ESS4.

- DOH will ensure that the workers and local community are informed about the security arrangements and the project’s GRM. DOH will review any allegations of unlawful or abusive acts of security personnel, take action (or urge appropriate parties to take action) to prevent recurrence and, where necessary, report unlawful abusive acts to the relevant authorities. Any incidents, concerns or grievances regarding the conduct of security personnel will be received, monitored, documented (taking into account the need to protect confidentiality), and resolved through the Project’s grievance mechanism following incident classification: Indicative, serious and severe. Any severe incidents with such personnel need to be reported to the Bank no later than 48 hours with basic information and a detailed incident report within 10 working days. Details about incident classification and incident reporting are included under the Labour Management Procedure (LMP).

Regular community consultations will be conducted continuously to identify the additional risks and mitigation measures in the health care facilities as well as their additional needs. The Grievance Redress Mechanism is already in place.

5.4.6 Social Exclusion

Risks

The following potential risks of social exclusion have been identified:

- Planning and design of measures to screen people for COVID-19 and information materials developed could exclude the most vulnerable, including the poor, elderly, indigenous peoples, people living with a disability and households headed by single women, who are also less likely to have access or be active on social media.

- Limited access to COVID-19 testing and other public health services, especially in rural areas.

- Restrictions on travel, general movement, etc. have the potential to enhance negative impacts to the vulnerable groups, who may have lower incomes, lack social support, lose jobs, have childcare duties, and may also be the most vulnerable to contracting COVID-19.

- The information materials on the COVID-19 vaccine to be developed could exclude the most vulnerable or be developed in a way that is not sensitive to the needs and access of these different groups.
• Communication materials may not reach the most vulnerable, in particular the elderly, IPs and workers from the informal sector, a lot of whom are women, who tend to have lower levels of education, lower incomes and may have lower literacy.
• There is an indirect risk of social exclusion, in particular, the most vulnerable and marginalized groups such as the indigenous peoples in remote areas from access to the COVID-19 vaccines.
• The elderly, those with underlying medical conditions, and people living with disability, though included in the priority populations to be vaccinated as identified in the WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply\textsuperscript{23}, may have limited access to the vaccines due to reduced mobility.

**Mitigation Measures**

The following mitigation measures are considered for social exclusion impacts:

• Planning of quarantine measures and social distancing restrictions need to take into account the livelihood impact it will have for the population, in particular the most vulnerable (the poor, elderly, women single heads of household, IPs, those with disabilities);
• Communication materials must be clear and concise and in a format/language that is understandable to all people, in particular the most vulnerable. Messages should be clear and concise, focusing on hygiene measures (hand washing, coughing), what to do if suspect have COVID-19, as well as restrictions if applicable (for instance specific guidelines on social-distancing). This may require different media (social media, radio, tv) plus engaging existing formal and informal public health and community-based networks (schools, healthcare service providers at local level, etc), including information on the vaccine and its administration.
• Communication materials must also be clear about (i) how to avoid contracting COVID-19 (good hygiene measures); (ii) symptoms of COVID-19; (iii) what to do if suspect have COVID-19.
• Workplaces should be encouraged to post and provide communication materials, in particular workplaces which may face a higher risk of COVID-19 spread, such as construction sites and factories.
• Transport assistance for vulnerable groups for increased access to vaccination sites or identification of strategic locations for vaccine administration.
• Information on how to protect oneself from COVID-19, the symptoms of COVID-19, where and how to get tested should be made available to everyone and ensure they are accessible to IPs, marginalized groups, those with disabilities, other vulnerable groups and the elderly.
• Identify trusted community groups (local influencers such as community leaders, religious leaders, health workers, community volunteers, celebrities) and local networks (such as women’s groups, youth groups, business groups, and traditional healers) that can help to disseminate messages.
• Stakeholder Engagement Plan (SEP) includes consultations with NGOs and other stakeholders that can provide recommendations on how to communicate information.

5.4.7 Gender-Based Violence (GBV) and/or Violence Against Children (VAC)

Risks

GBV and VAC risks may include the following:

- Quarantine measures, together with fears over COVID-19, livelihood impacts as a result of any restrictions in movement, social isolation and increased economic pressures and loss of jobs (informal or formal sector) may exacerbate household tensions and lead to an increase in GBV and VAC.
- School closures mean children are at home and this could increase risk of VAC and GBV, in particular if family members are stressed, drinking or violent. Young females may be in particular risk.
- Project staff (civil servants and outsourced staff/contractors) may be involved in misconduct behaviours impacting women and children at local level.

Mitigation Measures

The following measures should be considered in mitigating GBV and VAC risks:

- Communication materials should include advice to cope with psychological aspects of the COVID-19 pandemic, including loss of jobs and quarantine measures. For instance, there should be information on how to cope with stress and anxiety, recommendations on how to talk to children, etc. Information materials should provide links to resources/organizations that can provide support.
- Ensure that GBV-resolution mechanisms and GBV and other mental health services continue to be well resourced as there may be increased demand for their services. NGOs or other organizations working on GBV or mental health may need to be supported to increase their services (or, for instance, enhancing support to a hotline to report cases or to women’s shelters).
- Apply the WHO Code of Ethics and Professional Conduct -Code of Conduct (CoC) for all workers in the quarantine facilities as well as the provision of gender-sensitive infrastructure, such as segregated toilets and enough light in quarantine and isolation centers.
- Codes of Conduct (CoC) included in the letter of PIU’s staff appointment and contracts (for contracted workers) in line with relevant national laws and legislations and the project’s Labor Management Procedures (LMP).
- Training on community interaction and GBV/VAC to be provided for all teams, staff (civil servants and outsources staff/contractors) to ensure the teams respect local communities and their culture and not engage in misconduct.

5.4.8 Social Stigma

Risks

Indirect risks include social stigma that could be precipitated by COVID-19 both to and from sufferers as follows:
• Risk of fear and/or stigma towards the virus, which may make people hide symptoms, avoid getting tested and even reject hygiene measures or wearing PPE equipment (or masks if recommended).
• Health workers may suffer stigma, in particular when coming back to their communities, as they may be seen as potential “carriers”.
• Misinformation on the adverse health effects of vaccines and hearsays on the conspiracy theories and underlying political agenda on the vaccines are widespread.
• The fear and apprehension of individuals and communities on the scientific integrity, efficacy, and safety of the COVID-19 vaccines may lead to people refusing vaccination activities.
• The vaccine acceptance may also be affected by the country’s previous experience with the Dengvaxia vaccination.

Mitigation Measures

Mitigation of social stigma should include the following measures:

• When developing communication messages about COVID-19, it is important to have social stigma issues in mind and choose language that does not exacerbate stigma. It is best to not refer to people with the disease as “COVID-19 cases”, “victims” “COVID-19 families” or “the diseased”. It is better to refer as “people who have COVID-19”, “people who are being treated for COVID-19”, or “people who are recovering from COVID-19”.
• Ensure accurate information about the virus is widely disseminated, and that there is also a focus on people who have recovered.
• Engage social influencers, such as religious leaders, who can help communicate accurate messages and help to reduce social stigma as well as support those who may be stigmatized.
• Communication materials must reinforce the positive contribution of health care workers and other essential workers and their need to be supported by community members.
• Communication materials should make clear the steps health workers and others are taking to protect themselves against the virus and their use of PPE.
• Engage community leaders of indigenous peoples when it comes to vaccination activities.

5.4.9 Cold Chain Operation

Risks

Refrigeration\textsuperscript{24} in the cold chain system for vaccine storage and distribution is necessary to maintain efficacy of the vaccines. Through proper refrigeration, the potential to generate vaccine rejects is also avoided. However, the refrigeration facilities (cold storage and refrigerated road transport), require huge amount of energy to operate and use different kinds of cooling agents/refrigerants in their cooling

\textsuperscript{24} In the 2017 UNEP Report of the Technology and Economic Assessment Panel (Montreal Protocol on Substances that deplete the ozone layer), industrial refrigeration accounts for approximately 2% of HFC consumption in terms of CO2-eq and is projected to grow by approximately 6.7% annually between 2015 and 2050.
systems. The use of refrigerants in the cold chain system can cause depletion of the ozone layer and can contribute to greenhouse gas emissions that cause global warming. The lack of proper maintenance and knowledge very often translates into an inadequate management of the life cycle of refrigerant gases. More refrigerant leakage results to less efficient equipment and higher emission of high global warming potential (GWP) gases into the atmosphere.

Refrigerants are toxic and some are flammable and could form explosive mixture with air if leakage occurs, posing risk to people’s health and safety. Some cold storage warehouses use ammonia as a refrigerant which has negligible GWP but is toxic and mildly flammable, with the potential to cause health hazards. It is therefore necessary that safe practices are applied. Moreover, some cold storage may not be energy-efficient.

**Mitigation Measures**

- Use of alternative refrigerants with zero or low climate impact in the refrigeration system
- Use of more energy-efficient technology for the refrigeration system
- To include relevant technical specifications as part of procuring cold storage/chain equipment and transport and/or stipulating performance standards for the cold chain service providers
- Ensure that the refrigeration system including its maintenance and servicing, complies with the requirements of the CCO on ODS
- Improve energy efficiency of refrigeration systems through maintenance of the refrigeration systems, implementation of procedures and best practices that reduces energy consumptions of chillers and refrigeration systems, e.g. closing the doors of cold rooms during operation, switching-off mobile refrigeration units while opening doors of refrigerated trucks, parking refrigerated trucks in the shade, regular controls and monitoring of all equipment parameters, such as energy performance, pressure, and temperature.
- Observe proper handling of refrigerants and during servicing and ensure that workers involved in servicing are trained to avoid leakage of refrigerant in the atmosphere and use PEEs to avoid exposure to refrigerants.

**5.4.10 Climate-Change Related Risks**

**Risks**

The potential impact of climate and geophysical hazards on the project’s investments is rated based on exposure ratings for the location, and an understanding of the project’s historical and future sensitivity to these risks. It is important to assess the effect that these impacts may have on the investment, and the ability of the project to sustain and enhance these investments under a changing climate.

In terms of health infrastructure, extreme temperatures can reduce comfort in health clinics and increase the need for heating and cooling devices, while extreme precipitation and flooding, strong winds or sea level rise and storm surge can damage hospitals and health care equipment and cause power outages in clinics and cold chain storages of vaccines. Building climate smart health infrastructure should be highly considered when enhancing resilience in these contexts.
In terms of other project activities pertaining to different subsectors, extreme precipitation and flooding or sea level rise and storm surge can prevent community health workers from traveling to provide education, treatment, or health care services in the community, while extreme temperature may disrupt the delivery of nutrition supplies.

**Mitigation Measures**

Information collection and development of management systems including early warning systems, improve risk management systems, and strengthening health systems to take into account these impacts from climate and geophysical hazards should be considered to enhance resilience.

Climate and disaster risk management plans of hospitals and health care facilities will be reviewed and updated consistent with the DOH Administrative Order No. 2012-005 "National Policy on Climate Change Adaptation for the Health Sector."

Greening of health care facilities and related establishments is a long-term measure. To ensure operation of vaccine cold storage during power outages, generators should be available.

6 Procedures to Address Environmental and Social Issues

6.1 Screening Process

Annex D. Screening Form for Potential Environmental and Social Issues comprises a screening form that should be used by the BIHC and DPCB in DoH to screen for the potential environmental and social risks and impacts of specific activities. Screening will allow BIHC and DPCB to identify the relevant Environmental and Social Standards (ESS), establish an appropriate environmental and social risk rating, and specify the type of environmental and social risk management measures required, including specific instruments, if needed.

In addition to Annex D, results from the VIRAT/VRAF (see Annex L) can inform the procedures to address environmental and social issues that will guide the development of the Vaccine Delivery and Distribution Manual and National Deployment and Vaccination Plan (NDVP). The VIRAT/VRAF has key indicators related to environmental and social risk management for the deployment of the COVID-19 vaccine including planning and coordination; budgeting, regulatory planning, and coordination; budgeting; regulatory framework; prioritization, targeting and COVID-19 surveillance; service delivery; training and supervision; monitoring and evaluation; cold chain, logistics and infrastructure; safety surveillance; and demand generation and communication. Based on the initial assessment, the planning and coordination for vaccine deployment will build on and enhance the existing structures in the DOH and the Inter-Agency Task Force for Management of Emerging Infectious Diseases (IATF) to provide oversight for COVID-19 vaccine introduction; the STWG on Vaccine Development will be reconstituted to support the IATF in its oversight function; and a Vaccine Cluster established under National Task Force (NTF) against COVID-19 to promote whole government approach with participation of all government
agencies. The government will be guided by the National COVID-19 Vaccine Roadmap and COVID-19 Vaccine Deployment and Immunization Plan in exploring complementary options for accessing vaccines including COVAX facility, advance market commitments and bilateral negotiations with countries manufacturing vaccines. In addition, the management of wastes from the vaccination program as outlined in the criteria on waste management protocols for COVID-19 vaccination, both hazardous and non-hazardous, including development and dissemination of practices and guidelines for disposal routes, appropriate waste management systems in all relevant sites, and adequately trained human resources, and identification and mobilization of properly-licensed waste management providers for hazardous waste storage, transportation and disposal.

Various activities in the VIRAT/VRAF are in progress, albeit mostly in early stages related to Vaccine service delivery, cold chain, logistics and infrastructure. The HCWM self-audit tools developed under the Parent Project will assist DOH and health care facilities identify gaps and areas for improvement in HCWM specifically for COVID-19 wastes (i.e., COVID-19 Waste Management Self-Assessment - Compliance Audit Checklist, Monthly Ward / Department Review, and Healthcare Facility Compliance Statement). A COVID-19 Waste Management Operations Manual has been developed under the Parent Project to provide supplemental guidance on the requirements of the Government to manage wastes/recyclables correctly in line with current legislation and relevant health policies (e.g. Infection Control and OHS). The manual covers pharmaceutical waste which includes COVID-19 vaccines and residues. Philippine government policies and regulations identified in the preceding section will similarly inform the action required to get a completed (or more than 90%) status of the VIRAT/VRAF activities. The COVID-19 Waste Management Operations Manual will be reviewed and the next steps on the use of the Manual will be vetted upon by the relevant DOH Bureaus.

Additional findings based on the initial VIRAT/VRAF assessment also shows that public consultation will be conducted in January 2021 other partners, government agencies, NGOs, and private sector and activities will be included in the SEP. Likewise, the Government is in the process of establishing an Emergency Operations Center with the complete data management systems and tools, including the management of the GRM system, starting on January 2021. In terms of risk communication and stakeholder engagement, the government will strengthen human resources including communication organizers and developing a risk communication strategy including data collection systems, including 1) social media listening and rumour management, and 2) assessing behavioural and social data.

6.2 Environmental and Social Management Plans

For activities involving civil works or construction activities an Environmental and Social Management Plan (ESMP) template has been prepared by DoH. The ESMP or ECOP, together with the LMP, and Contractor’s Personnel GRM will be accomplished by the Contractors together with the bid documents. The DoH will evaluate the capacity of the Contractors to implement the ESMP together with the aforementioned requirements. This will be included in the indicators for the selection of the bidders. The ESMP shall be site-specific, and proportionate and relevant to the hazards and risks associated with the particular activity and will be implemented by the health facility and contractors. For example, activities such as establishment of isolation tents and first line decontamination facilities are simple construction activities and the ESMP aside from the Labor Management Plan (LMP), may comprise simple standard management and mitigation measures such as those defined in the ECOPs provided in
Annex G. Establishment of quarantine facilities involving the expansion of a new wing within the compound of a health facility, the possible establishment of warehousing for the vaccines, or the rehabilitation of an existing building that may involve extensive construction, a more comprehensive ESMP will be prepared and implemented.

An ESMP will comprise a simple matrix in the format shown in Annex E. When designing mitigation measures the ESMP should address site-specific environmental and OHS issues and shall draw on the Environmental Codes of Practice (ECOP) included in Annex G and relevant, up-to-date guidance from WHO, DOH, DENR and other relevant government agencies on COVID-19 specific advice.

The site specific ESMP or ECOP will include as attachments, as needed, the LMP, GRM, and ICWMP. For each identified environmental and social risk, the format shows (1) proposed risk mitigation measures, including measures to be implemented by the construction contractor; (2) responsibility for each risk mitigation measure, (3) Timeline (e.g. pre-construction, during construction, etc.); and (4) Budget. For mitigation measures that are the responsibility of the construction contractor, the supervising engineer will verify that measure have been properly implemented. Implementation of E&S risk mitigation measures will be reported and will be a condition for approval of payments.

6.3 Health-care Waste Management

The project is supported by a consultant to provide technical assistance and capacity building to DOH on health-care waste management until materials and tools to supplement the DOH Health Care Waste Management Manual 4th Edition on management of health care wastes related to COVID-19 and emerging infectious diseases have been developed, and capacity building of concerned health workers are completed. HCWM is well-regulated in the Philippines through the Fourth Edition of the Health Care Waste Management Manual (April 2020) of DOH. However, capacity gaps in the implementation of the Manual still occurs.

The technical assistance program will involve provision of real-time capacity building support to DOH on immediate priorities for safely managing COVID-19 HCW. A second pre-testing of the developed health care waste management self-audit tools is being undertaken for six health facilities to establish a compliance baseline and assess the contents and user-friendliness of the tools. Using this baseline, a video training package will be developed for distribution across all health-care facilities. Annex I contains an Infection Control and Waste Management Plan (ICWMP) template which can be used as a checklist during the capacity building exercise and cross-referenced with the DOH Manual to determine any gaps or opportunities for improvement.

I DOH will coordinate with the Department of Environment and Natural Resources- Environmental Management Bureau (DENR-EMB) to discuss the surge of M501 and M503 health care wastes due to the COVID-19 vaccination activities. It is important to guarantee the capacity of the waste transporters and TSD facilities to accommodate the influx of health care wastes and that a clear road map/strategy is developed by the DOH in coordination with the DENR to strengthen capacity of the country to manage health care wastes. It should be noted that not all regions have DENR-accredited M501 and M503 wastes transporters and treatment, storage, and disposal facilities (TSDs) based on their area, as discussed in Chapter 4.
The DOH will also be conducting trainings for the implementers of the vaccine deployment and administration on proper health care waste management of infectious and pharmaceutical wastes.

6.4 Indigenous Peoples

Despite the strong rights provided by the IPRA and the historic recognition of indigenous peoples in the Philippines, conflicts over their identities and access to land and natural resources continue. And despite being relatively well-organized, including the existence of numerous local and national indigenous peoples’ organizations, they still face social and political marginalization. They are among the poorest population groups in the Philippines, far worse in terms of health and education indicators and are affected by civil conflicts such as in Mindanao.

Given these vulnerabilities, the COVID-19 pandemic poses particular risks to indigenous peoples. The United Nations’ Department of Economic and Social Affairs has noted that indigenous peoples often “experience poor access to healthcare, higher rates of communicable and non-communicable diseases, lack of access to essential services, sanitation, and other key preventive measures, such as clean water, soap, disinfectant, etc.” Likewise, most nearby local medical facilities, if and when there are any, are often under-equipped and under-staffed. Even when indigenous peoples are able to access healthcare services, they can face stigma and discrimination.

A key factor is to ensure these services and facilities are provided in indigenous languages as part of the BIHC’s support to the DOH Centers of Health Development, and as appropriate to the specific situation. It is also noted that indigenous peoples’ traditional lifestyles are a source of their resilience, but can also pose a threat to spreading of the virus, e.g. through traditional gatherings to mark special events and living in multi-generational housing. Many communities in relative isolation and remote areas may be less exposed to the virus, but if it does reach such communities the risks would be heightened due to their lack of access to adequate health and social services and effective monitoring and early-warning systems.

Health facilities close to the indigenous communities are available to provide health services to nearby IPs. The upgraded facilities are to be located within existing premises of health facilities or government premises. As such, construction does not pose risks to indigenous peoples, but they would need to be included in stakeholder engagement processes for civil works activities. This is also prescribed in the SEP.

It has been found that providing health care to indigenous peoples can be more effective when integrating Western medicine with traditional knowledge, systems, and practices of healing, which may include herbal medicines, acupressure, acupuncture, and hilot, an ancient Filipino art of healing derived from shamanic traditions that uses different techniques of manipulation and massage to achieve the treatment outcome. A study of health perceptions and practices of the Lumads of Mindanao finds that they recognize the benefits of Western medicine provided through the government’s health services. However, they continue to combine such health care with their indigenous health and treatment beliefs, practices and rituals provided by the bayian or traditional healer when confronted with health problems.

The active participation of IPs, their organizations and health practitioners, is critical in providing efficient and culturally appropriate health services in indigenous communities. Such as an approach is
recognized by DoH in the “Guidelines on the Delivery of Basic Health Services for Indigenous Peoples/Indigenous Cultural Communities” or Joint Memorandum Circular No. 2013-01 agreed to between DOH, NCIP, the Department of Interior and Local Government (DILG) on April 19, 2013, which will guide the project’s approach to supporting health services in areas with indigenous peoples.

The project will not develop a stand-alone indigenous peoples instrument (e.g. an Indigenous Peoples Plan). Instead, the requirements of ESS7 will be addressed through a targeted engagement strategy, included in the Project’s Stakeholder Engagement Plan and in ESMPs when these are required for civil works. This is appropriate given the project activities to support hospitals and local health facilities to combat COVID-19, through procuring equipment and PPEs for health workers and enhancing testing, quarantine, and treatment capabilities. It is consistent with ESS7’s emphasis on developing plans that are proportionate to the potential risks and impacts of the project (paragraphs 13 and 17). No civil works outside of existing health premises are expected to be financed by the project and no activities that would require any land acquisition will be financed. Therefore, no circumstances requiring free, prior, and informed consent under ESS7 are present in project activities. It should also be noted as part of the vulnerable groups, the indigenous peoples should be considered in the priority eligible population for COVID-19 vaccination, as aligned with the WHO SAGE Values Framework for the Allocation and Prioritization of COVID-19 Vaccination.

Stakeholder engagement and public consultations with representatives of indigenous peoples and their organizations are provided for in the SEP. These organizations and representatives will be consulted during project implementation. The NCIP at national, regional, and local levels will also be consulted, particular for any project activities taking place within the ancestral domain of indigenous communities, and indigenous peoples in areas of site-specific project activities will be engaged and consulted consistent with the IPRA, the Joint Memorandum Circular No. 2013-01 and ESS7.

For site-specific project support to regional and local health facilities in areas with indigenous communities, DoH and local partners (e.g. LGUs) will consult with indigenous peoples, their representatives and NCIP; local NGOs or CSOs may also be consulted.

Project activities in areas with indigenous communities will be informed by the Joint Memorandum Circular, which provides guidelines around five key principles for delivering health services to indigenous peoples:

1) **Making basic health services available and culture-sensitive.**

‘Culture-sensitive’ health care, means policymakers and health workers acknowledge and respect cultural diversity among the populace since this affects values, learning, behaviour, health practices and outcomes. Health care providers will recognize existing beliefs and practices to the extent that these are not a hindrance to effective measures against the COVID-19 pandemic, and ‘culture-sensitive’ orientation and training to health workers, managers and other stakeholders is provided as appropriate.

Indigenous health care practitioners in communities should be informed about COVID-19 symptoms and local outbreaks, and should be involved in engagements with indigenous communities and patients, as appropriate (indigenous practitioners are likely to be the first point of contact for indigenous peoples seeking medical services).

2) **Providing equitable distribution of needed health resources.**
At project-supported health facilities in areas with indigenous peoples, they and their support organizations will be informed of the services provided and efforts will be made to ensure the indigenous peoples affected by COVID-19 will receive the same treatment as non-indigenous patients.

Indigenous health care providers/staff at DoH and LGU facilities, when available, are provided with the same resources, including PPEs and information about COVID-19. These may also be provided to indigenous health practitioners.

3) **Ensuring non-discrimination of ICCs/IPs in the delivery of health services.**

‘Culture-sensitive’ orientation and training to health workers, managers and other stakeholders is provided as appropriate.

Indigenous health care providers at DoH and LGU facilities, when available, and indigenous health practitioners are involved in providing health care services to indigenous communities and patients, as appropriate.

4) **Managing geographical, financial and socio-cultural barriers so that IPs can access basic health services.**

As the project is financing emergency responses to COVID19 this principle is not applicable. However, once the emergency subsides additional measures to enhance IPs’ access to health services may be considered.

5) **Strengthening recognition, promotion, and respect of safe and beneficial traditional health practices.**

Efforts to hire indigenous health care workers should be made to the extent possible. Existing indigenous health care workers at DoH and LGU facilities will be involved in providing services to indigenous communities. An IP health care worker or an IP-oriented health care worker at health facilities should be designated to care for, or oversee care for, indigenous patients. Indigenous health practitioners are involved in providing health care services to indigenous communities and patients, as appropriate.

Measures to enhance benefits and avoid adverse impacts will be developed in consultation with representatives of the indigenous peoples as appropriate in the local context and in a manner proportional to the project activities’ risks and potential impacts or benefits. Physical distancing and other COVID-19 restrictions will be respected.

7 **Stakeholder Engagement, Consultation and Disclosure**

The Stakeholder Engagement Plan (SEP) has been developed to ensure that stakeholders are informed about project risks and mitigation measures, information is disclosed properly, communities and local government units are engaged, and social preparation for areas that will host isolation and quarantine facilities will be conducted.

Consultations with affected and interested stakeholder on the ESF documents of the Parent Project were conducted on 18-19 August 2020. Due to the physical distancing restrictions, the engagement process was conducted virtually through a WebEx meeting.

The ESF documents, i.e. ESMF, ESCP, and SEP, updated for the Additional Financing will be disclosed in the DOH website on 10 January 2021. Public consultation will be conducted in January 2021 with other partners, government agencies, civil society organizations, and private sector based on the initial inputs in the VIRAT/VRAF.

The key feedback of the stakeholders in the said Consultation are as follows:

1. Highlight of the VAWC and GBV in the ESMF and SEP and awareness was suggested to be part of the project activities;

2. Development of guidelines for watchers, carers, and personal assistants, especially for the PWDs and children, in health care facilities, testing facilities, and quarantine areas is recommended;

3. Revision of the ESMF to include RA 11106 and 7277 to emphasize institutional mandate for support to PWDs;

4. Recommended provision of health promotion materials and virtual sign language interpretation for PWDs in health care facilities, testing facilities, and quarantine areas;

5. Recommended inclusion of disaggregated COVID-19 data on indigenous peoples;

6. Recommended provision of vaccines, e.g., pneumococcal, flu, and hepatitis B, for health care workers and vulnerable groups such as persons with disabilities (PWDs), children and the elderly;

7. Declaration of contractor’s liability on workers for medical bills and wages once they contract COVID-19;

8. Stricter compliance of waste generators and waste service providers (treatment, storage, and disposal facilities/ TSDs) to the DENR Environmental Management Bureau guidelines on health care wastes as improper disposal is still observed; and

9. Proposed extension of the Project benefits to other health care facilities.
Below are the detailed feedback of stakeholders during the National Stakeholders Consultation on 18-19 August 2020 and the responses and updates from DOH:

<table>
<thead>
<tr>
<th>Topic</th>
<th>Stakeholder</th>
<th>Comment / Feedback</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stakeholder Engagement</td>
<td>Save the Children Philippines</td>
<td>Query on the difference in the engagement among groups or if the groupings were made to facilitate consultation</td>
<td>The SEP is a guide for stakeholder engagement throughout the project implementation. It is a living document which will be revised as appropriate, considering the feedback of the stakeholders. The SEP distinguishes between affected and interested stakeholders and identifies vulnerable stakeholders that may require special attention.</td>
</tr>
<tr>
<td></td>
<td>Philippine Coalition on the UNCRPD</td>
<td>VAWC is an important issue. We should raise awareness, provide information on how to access, and provide help desks.</td>
<td>VAWC and GBV are highlighted in the ESMF and SEP and awareness will be integrated in the project activities.</td>
</tr>
<tr>
<td></td>
<td>Saint Anthony Mother and Child Hospital</td>
<td>Risk of transmission is high for patient watchers within hospitals. Guidelines for control and mitigation measures of transmission and accommodation for them for social distancing is recommended to be provided.</td>
<td>The patient watchers are covered by the guidelines on the rational use of personal protective equipment (PPE). There are no accommodations for them due to the high number of cases needed to be catered and the risk of infection.</td>
</tr>
<tr>
<td>Strengthening capacity in the regions</td>
<td>MIMAROPA Center for Health Development (CHD)</td>
<td>Health care manpower is the main challenge, especially in geographically isolated and disadvantaged areas (GIDAs). Health care facilities are existing but there are no applicants.</td>
<td>The project activities include mostly provision of equipment to build COVID-19 response capacity and some repairs of health care facilities and laboratories, including the isolation rooms. There will also be a capacity building component for health care workers.</td>
</tr>
<tr>
<td></td>
<td>CARAGA CHD</td>
<td>The locally stranded individuals or LSIs are major sources of COVID-19 infection (56%) in the MIMAROPA region. Ways in which the project can help address this problem are sought.</td>
<td></td>
</tr>
</tbody>
</table>
Moreover, ways to strengthen capacity at the regional and facility levels are sought. Project consultations and trainings will be provided. These will mostly be online due to challenges in the implementation of the project due to the pandemic.

| Services for persons with disabilities (PWDs) and children | National Commission on Disability Affairs (NCDA) | The accessibility of services and infrastructure (e.g. ramps) and hospitalization support for PWDs who will contract COVID-19 should be provided. It was also pointed out that each type of disability has specific needs and support services which may need capacity building of health care personnel. There is a need for virtual sign language interpretation services in health care facilities, testing centers, and quarantine/isolation areas. There are networks who may be able to provide sign language interpreters but they are mainly based in Manila. TFSL interpretation in health facilities through video calls provided by service providers is recommended. It was also pointed out that the DOH and DILG should comply with RA 11106 or the Filipino Sign Language Law by providing such services in health facilities, workplaces, and the media. Guidelines on FSL interpreter qualifications, including skills and ethical considerations is needed. Access to information for PWDs is also a main concern as sign language interpretation is still very limited. Unlike national TV news, regional TV news do not have sign language interpretation. Grassroots organizations have turned to social media to disseminate information. They requested that the project stress the importance of access to information through DOH, even if the COVID IEC funds come from a different donor source. | The DOH Health Facilities Development Bureau (HFDB) has reported that there are 10 provincial hospitals which currently have Filipino sign language interpreters (FSL) who are mostly social workers employed by the hospital. They are as follows:

<table>
<thead>
<tr>
<th>Region</th>
<th>Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCR</td>
<td>Jose Fabella Memorial Hospital, Lung Center of the Philippines</td>
</tr>
<tr>
<td>I</td>
<td>Mariano Marcos Memorial Medical Center, Ilocos Training and Regional Medical Center, Region I Medical Center</td>
</tr>
<tr>
<td>IV</td>
<td>Batangas Medical Center</td>
</tr>
<tr>
<td>VI</td>
<td>Corazon Locsin Montelibano Memorial Regional Hospital, Don Jose Monfort Memorial Medical Center Extension Hospital</td>
</tr>
<tr>
<td>VII</td>
<td>Vicente Sotto Memorial Medical Center</td>
</tr>
<tr>
<td>XII</td>
<td>Cotabato Regional Medical Center</td>
</tr>
</tbody>
</table>

According to the Degenerative Disease Office of the Disease Prevention and Control Bureau (DPCB-DDO), the new education curriculum of social workers has integrated basic FSL. It should be noted that hospitals have at least 1 social worker. It would be ideal if the
| Philippine Coalition on the UNCRPD | Assistance to the deaf in finding hospitals which are deaf- accessible and providing counseling services should be given.  
There is a need to accommodate and entertain carers/personal assistants of PWDs and children in health care facilities, testing centers, and quarantine/isolation areas.  
Vaccination for children and other vulnerable sectors should be provided.  
The PWD groups have expressed their interest in being engaged and involved in the project implementation. The need to recognize vulnerable groups, e.g. PWDs and IPs, were pointed out. | employed social worker has background on FSL. The Metro Manila and CALABARZON Centers for Health Development (CHDs) are conducting community- based trainings on FSL. It is planned to cascade the training to the other regions in 2021.  
The Congress is also discussing the provision of FSL interpreters in health facilities. However, the timeline for this is not yet known.  
The Project will be conducting a baseline assessment on the capacity of the recipient hospitals to provide accessible health services to vulnerable groups, including provision of virtual FSL services based on parameters such as availability of devices and internet connection. The baseline assessment will also cover GBV, VAWC, and IPs. Based on the results of this assessment, the Project in coordination with HFDB and DPCB- DDO, will determine the feasibility of the virtual FSL services which would be in partnership with the FSL interpreters and PWD representatives to be financed by the Project.  
The DOH Health Promotion Bureau (HPB) has no COVID-19 health promotion materials for the PWDs. Currently, they only have the 30- second video with FSL interpretation for polio. The HPB and the DPCB- DDO have included PWD- accessibility in their Communication |
Plan for 2021 which will include printer materials with Braille and videos with sign language. The DPCB-DDO in partnership with the Philippine Information Agency (PIA), have previously developed a Communication Plan for PWDs which was also presented to the PWD CSOs.

The concerns of PWDs, particularly accessibility, will be considered in the activities under Component 3, Project Management and Monitoring and Evaluation, of the project by integrating into the prevention and preparedness activities.

Project management and monitoring should ensure that the improved capacity of the health care facilities results in improved access for PWDs.

The PWDs and other vulnerable sectors will be highly considered in the project. The ESMF will also be revised to include Republic Acts 11106 and 7277 and Batas Pambansa 344 to further strengthen the framework.

The request for vaccination of children and other vulnerable groups as well as the guidelines for carers/personal assistants of PWDs and children will be relayed to the DOH DPCB, HFDB, and the DOH IATF Focal Team. The PWD CSOs will be requested to submit a formal request to the IATF (iatfsecretariat@gmail.com) and DOH
<table>
<thead>
<tr>
<th>Philippines (PIDSP)</th>
<th></th>
<th>regarding the grievances of the carers/personal assistants. The HFDB, with assistance from the Project, will develop a policy issuance to consider the carers of PWDs and children in health facilities.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indigenous Peoples</td>
<td>Tebtebba Foundation</td>
<td>It was recommended to include disaggregated data for Indigenous Peoples related to the COVID-19 response. The group also relayed that they have conducted an assessment on IPs and COVID-19 which they may share with the Project Team. The DOH Epidemiology Bureau (EB) which is in-charge of the data management on COVID-19 does not have disaggregated data for IPs. The request has been communicated to EB. The Tebtebba Foundation has submitted their request for data on Indigenous Peoples (identified as to their ethnicity) infected by COVID-19 and history of infection aside from the usual data provided to the EB. The Project will further assist Tebtebba Foundation on this request. To ensure that IPs will have access to the COVID-19 related health services, the DOH Bureau of Local Health Systems Development (BLHSD) has issued Department Circular 2020-0192 last April 2020 entitled ‘Ensuring that people in GIDAs, Indigenous Cultural Communities/Indigenous Peoples are well-informed on COVID-19 and have access to Temporary Treatment and Monitoring Facilities and Referral Hospitals.’</td>
</tr>
<tr>
<td>BARMM</td>
<td>Community and Family Services International</td>
<td>Coordination with BARMM MOH and project coverage inclusion was asked. BARMM is covered by the project. The Amai Pakpak Medical Center is included in the tentative list of recipient facilities. Coordination with BARMM MOH will be done through the Field Implementation and Coordination Team- Visayas and Mindanao</td>
</tr>
<tr>
<td>Grievance Redress Mechanism</td>
<td>Save the Children Philippines</td>
<td>It was raised that if the grievance pertains to the service received from a local health facility or LGU, submitting the grievance to them may prevent the community to raise concern.</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>ESMF</td>
<td>Philippine Medical Association</td>
<td>The provision of pneumococcal, flu, and hepatitis B vaccines for health workers was recommended.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>There is a need to address health hazards brought about by the improper disposal of face masks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Occupational safety and health risks during construction should be addressed. It was inquired whether specific guidelines will be issued due to the COVID-19 pandemic, aside from the usual OHS and DOH issuances.</td>
</tr>
</tbody>
</table>
The coverage of medical bills and wages of workers who will contract COVID-19 was queried. Experience on symptomatic workers in which the hospitalization costs and compensation were covered by the hospital was relayed.

The Republic Act 11058, Department Order 198, and the IATF issuances set liability on the contractor. To further highlight the contractor's responsibility, the liability clause will be explicitly stated in the contract. The ESMF includes Labor Management Procedures.

The health facilities which will be covered by the project and the equipment to be given were asked. The hospitals invited in the National Stakeholders Consultation are included in the initial list of recipients recommended by the HFEPMO. The local government units through the provincial, city, and municipal health offices were invited for their information and guidance on the project.

It is envisioned to expand the testing in the rural areas also. However, the project recipients are chosen based on the ongoing application for testing accreditation. The hospitals to be included as recipients of the World Bank loan are the 70 retained DOH hospitals and the 30 hospitals part of the Universal Health Care implementation sites which were first approved by the NEDA.

Other hospitals not part of the project may be covered by other projects such as that of ADB. The recipient facilities were selected based on capacity to test, i.e., ongoing application for accreditation.

The local government units through the provincial, city, and municipal health offices were invited for their information and guidance on the project.
It was also clarified that the project is different from the existing project of HFPMO.

The HFPMO will finalize the list of hospitals and equipment to be distributed.

<table>
<thead>
<tr>
<th>Project Implementation</th>
<th>Mariano Marcos Memorial Hospital and Medical Center</th>
<th>The project requirements and expectations from recipients, e.g., proposal, timelines, funding approval, project termination, and monitoring and evaluation.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corazon Locsin Montelibano Memorial Regional Hospital</td>
<td>It was queried if the civil works component of the project will cover only the existing facilities.</td>
<td></td>
</tr>
<tr>
<td>Project Sustainability</td>
<td>Tebtebba Foundation</td>
<td>The COVID-19 recovery will take a “heal as one” approach, aside from the direct results of the project, entailing community mobilization.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To extend the benefits of the project, the recipient hospitals will have to and are expected to take good care of the project donations, such as the equipment. Training of</td>
</tr>
</tbody>
</table>
It was asked if there would be an exit strategy to guaranteed sustainability of project benefits. It was also inquired how the exit strategy ensure that indigenous health care, knowledge and management systems, as well as traditional health care providers would be acknowledged and recognized, given their significant roles in community health.

Personnel will also be part of the sustainability initiatives.

In areas with IP, the ESMF includes measures to coordinate with traditional health care providers, consistent with DoH’s Guidelines on the Delivery of Basic Health Services for Indigenous Peoples/Indigenous Cultural Communities.
The SEP provides further details on the consultations on the draft documents and the plan for continued stakeholder engagement during project implementation. The SEP has been developed to ensure that stakeholders are informed about project risks and mitigation measures, information is disclosed properly, communities and local government units are engaged, and social preparation for areas that will host isolation and quarantine facilities will be conducted. The SEP will be implemented in a way that takes into consideration specific circumstances for indigenous peoples, other vulnerable groups, and the locality’s ways of information dissemination and conducting consultations while communities or households may be in quarantine or physical distancing restrictions. The SEP includes a grievance redress mechanism by which people can raise concerns, provide feedback, or make complaints about project related activities.

A series of consultations will be conducted with the implementers of the GRM and with the implementers and stakeholders of the COVID-19 vaccination activities, in consultation with and per directive of the COVID-19 Vaccine Cluster Organizational Structure. These consultations will involve the Centers for Health Development, the Food and Drug Administration, local government units (LGUs), the recipient health facilities, priority eligible population for vaccination, and the private sectors involved in cold chain management. The priority eligible population includes the following:

<table>
<thead>
<tr>
<th>Priority Group A</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Frontline Health Workers</td>
<td></td>
</tr>
<tr>
<td>▪ Public and private health facilities (Hospitals, Treatment and Rehabilitation Centers or TRCs, and Treatment and Monitoring Facilities or TTMFs)</td>
<td></td>
</tr>
<tr>
<td>▪ Public health workers (all Rural Health Units [RHUs]/ City Health offices [CHO] personnel; Provincial Health Office [PHO], Provincial Department of Health Offices [PDOHO], Center for Health Development [CHD] and Central Office [CO] field workers) and LGU contact tracers</td>
<td></td>
</tr>
<tr>
<td>▪ Barangay Health Workers including Barangay Health Emergency Response Teams [BHERTS]</td>
<td></td>
</tr>
<tr>
<td>▪ Other National Government Agencies [NGAs] including DSWD, DepEd, DILG, BJMP, and Bureau of Correction</td>
<td></td>
</tr>
<tr>
<td>• Indigent Senior Citizens</td>
<td></td>
</tr>
<tr>
<td>• Remaining Senior Citizens</td>
<td></td>
</tr>
<tr>
<td>• Remaining Indigent Population</td>
<td></td>
</tr>
<tr>
<td>• Uniformed Personnel</td>
<td></td>
</tr>
<tr>
<td>▪ Philippine National Police (PNP)</td>
<td></td>
</tr>
<tr>
<td>▪ Armed Forces of the Philippines (AFP)</td>
<td></td>
</tr>
<tr>
<td>▪ Philippine Coast Guard (PCG)</td>
<td></td>
</tr>
<tr>
<td>▪ Bureau of Fire Protection (BFP)</td>
<td></td>
</tr>
<tr>
<td>▪ Citizens Armed Forces Geographical Unit (CAFGU)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Priority Group B</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Remaining workforce in the health and social sector</td>
<td></td>
</tr>
<tr>
<td>• All government workers (National and Local Government)</td>
<td></td>
</tr>
<tr>
<td>• Teachers and school workers (public and private)</td>
<td></td>
</tr>
<tr>
<td>• Students</td>
<td></td>
</tr>
<tr>
<td>• Essential workers in agriculture, food industry, transportation, and tourism</td>
<td></td>
</tr>
<tr>
<td>• Sociodemographic groups at significantly higher risk other than the senior citizens and indigent population (PDLs, PWDs, Filipinos living in high-density areas)</td>
<td></td>
</tr>
</tbody>
</table>
Overseas Filipino Workers (OFWs)
Other remaining workforce

Priority Group C  All remaining Filipino Citizens.

It should be noted that the prioritization of population groups are based on the following goals:

**Primary Goals**
- Direct reduction of morbidity and mortality.
- Maintenance of most critical essential services.

**Secondary Goals**
- Substantially control transmission
- Minimize disruption of social, economic and security functions.

**Tertiary Goal**
- Resumption to near normal.

7.1 Monitoring of Adverse Events Following Immunization (AEFI)

The National Adverse Events Following Immunization Committee was created to monitor and assess the possible adverse effects of the COVID-19 vaccine on individuals. The roles and responsibilities of the Committee include the following:

- Review all reported serious and cluster of AEFI cases presented for expert opinion and provide a final causality assessment of the AEFI cases as well as the cases that were not classified by the Regional AEFI Committee.
- Ensure evidence-based causality assessment by recommending further investigation and data collection as needed.
- Make final decisions on causality assessment of inconclusive investigations.
- Ensure standard protocols for AEFI surveillance and investigation are correctly followed.
- Engage with other national and international experts when requirements arise in establishing causality and vaccine quality issues.
- Provide recommendations to the National Immunization Program, EB and National Cold Chain Manager on improving immunization service delivery, compliance with injection safety and effective vaccine management based on lessons from the AEFI cases.
- Serve as technical advisory group on vaccine and immunization safety-related issues of highest consideration such as immediate recall of vaccine from the market or temporary/permanent withdrawal of a vaccine from the immunization program.
- Serve as resource person in other AEFI related meetings, conferences or capacity building activities as requested.

The draft DOH training modules on the COVID-19 vaccine administration provides guidelines on the Adverse Events Following Immunization (AEFI). The working objectives of the module are as follows:
Objectives:

1. To know the overall safety surveillance framework
2. To identify, manage, report and communicate effectively all adverse effects following immunization (AEFI) concerns
3. To be oriented on the basics of Immunization Safety
4. To be able to discuss AEFIs to patients and vaccine-recipients

By the end of this module, the health care worker should be able to:

1. Understand the safety surveillance framework and activities
2. Rapidly identify AEFI signs and symptoms for COVID-19 vaccines
3. Administer initial management of AEFI
4. Report AEFI cases to the national database timely and accurately
5. Able to discuss AEFIs to patients and vaccine-recipients
6. Vaccinator should be able to discuss Immunization Safety
7. Vaccinator should be able to discuss Injection Safety

The content of the module will include:


II. Overview of COVID-19 vaccines clinical trial results

III. Basics of what to look out for vaccine-recipients suspected for AEFI
    Source: https://www.doh.gov.ph/sites/default/files/publications/AEFI_MOP%202014%20Final.pdf,
    Recognition and Treatment of Anaphylaxis from AEFI MOP (2014)

IV. AEFI case management protocols (experiences from previous campaigns)

V. Significance of AEFI reporting (minor, serious, minor clusters)

VI. Procedural reporting of AEFI cases

VII. Procedural follow-up of vaccination cohort (with and with AEFI case)

VIII. FAQs on AEFI

IX. Counselling techniques on AEFI risk communications

X. Importance of Immunization Safety

XI. Ultra-Cold Chain Management

XII. Personnel and Equipment

XIII. Procedures, Vaccine Schedule and Storage

XIV. What is injection safety?

XV. Injection equipment

XVI. Effects of unsafe injection practices

XVII. Expired vaccines
XVIII. Practices that can harm recipient, health worker, and the community (in the context of COVID-19 pandemic)

As part of the module, it is preliminarily envisioned in the working plan that the vaccinators/program implementers should be able to develop a final operational plan for the COVID Vaccine Program Implementation, including a system or plan for AEFI monitoring with the AEFI Monitoring Protocol/Plan as an output with the identified persons responsible for AEFI Monitoring.
8 Project Implementation Arrangements, Responsibilities, and Capacity Building

8.1 Implementation Arrangements

The Department of Health (DOH) will be the implementing agency for the Project. The DOH has appointed a Project Director (Undersecretary level), and a Project Manager (Director level). The Project Director and Project Manager will be acting through DOH’s technical departments and national programs, as well as the regional health units, LGUs, referral hospitals, and health centers. Within the DOH, the Project will be implemented through the Bureau of International Health Cooperation (BIHC), Health Facility Enhancement Program Management Office (HFEPMO), Disease Prevention and Control Bureau (DPCB), Health Emergency Management Bureau (HEMB), Procurement Service (PS), Finance Management Service (FMS), and relevant units, with BIHC as the main project focal point. A Task Force will be created through a Department Personnel Order consisting of the focal persons of the DOH Bureaus to facilitate more effective coordination with the technical units involved.

The project implementation will use mainstream DOH processes and will not involve a parallel project implementation unit or secretariat. However, the DOH has assigned officials who will be in charge of project implementation. The project will have a provision to strengthen DOH units’ capacity and skills through additional consultants or advisors. Additional consultants or advisors will be recruited with an aim to strengthen the overall fiduciary, ESF functions as well as to support implementation of project activities. DOH will also ensure effective implementation at the sub-national levels and close coordination with relevant LGUs.

The Project Operations Manual, includes guidance on standard project fiduciary, environmental and social risk management (a summary of the ESMF and SEP provisions and arrangements, including for GRM), implementation, and M&E requirements, as well as relevant official documents to be developed. However, the SEP and ESMF, along with the ESCP, are the documents that describe the ESF provisions and implementation arrangements. In addition, Annual Work Plan and Budget (AWPB) will be submitted for no-objection to the World Bank no later than October 30 of each year, detailing the project work program and budget for each government fiscal year and specifying the allocation and sources of funding for all project components.

While the DOH had limited experiences working on Bank operations in recent years, lessons learned from previous projects could guide DOH to avoid past challenges in future projects. The last two health projects in the Philippines were National Sector Support for Health Reform (2006-2012) and Women’s Health and Safe Motherhood Project (2005-2013). The support from the first project led to an increase in the coverage of PhilHealth, from 13.6 million poor receiving subsidized coverage in 2007 to 31.4 million in 2013. This, in turn, contributed to the increased use of health services by the poor. The second project led to a large increase in the number of facility-based deliveries. However, there were key implementation challenges faced by both projects, including slow implementation by DOH, delays in delivery of key reports, limited support to LGUs. The implementation of the second project was so slow that only 18 percent of funds were disbursed in the first five years of the project. At project closing, 35 percent of project funds were not used and had to be cancelled.
DOH does not have recent experience or dedicated capacity implementing World Bank financed projects and is not familiar with the Bank’s safeguards or Environmental and Social Framework (ESF) requirements. It is, however, familiar with the Philippines’ relatively well-developed regulatory framework for environmental and social management as it pertains to the health sector.

DoH has a designated team of DOH’s civil service officials, led by a project director and project manager, and with one Environmental and one Social Risk Management Focal Points to coordinate ESF implementation, including the environment and social risk screening of the activities and the compliance reviews of the ESMPs and other ESF measures. DoH designated the Focal Points already during project preparation. While the project management is at the central level, the roles, duties, and responsibilities of the personnel in the health care facilities and workers in the project sites will be re-defined based on their contracts.

The implementation of ESF instruments will be supported and monitored by World Bank staff throughout project implementation to assist the implementing agencies to undertake the planned environmental and social risk management measures, including stakeholder engagement and preparation of required management plans to be applied under the Project and provide training to the assigned staff.

The COVID-19 vaccination activities will be implemented in accordance with the directives of the COVID-19 Vaccine Cluster Organizational Structure. The Inter-Agency Task Force on the Management of Emerging Diseases is Chaired by Secretary Francisco Duque III of the Department of Health while the National Task Force Against COVID-19 is Chaired by Secretary Delfin Lorenzana of the Department of Defense. Secretary Carlito Galvez, Jr., Presidential Adviser on the Peace Process, is the Chairperson of the National Incident Command and COVID-19 Vaccine Cluster (Philippine National Vaccine Roadmap or PNVR). Undersecretary Leopoldo Vega of the Department of Health is the Chairperson of the Response Cluster while the National Economic and Development Authority (NEDA) is the Chair of the Recovery Cluster. The following are the COVID-19 Vaccine Clusters and the S-b - Task Groups under the TG COVID-19 Immunization Program:

<table>
<thead>
<tr>
<th>COVID-19 Vaccine Cluster</th>
<th>Task Group (TG)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TG Vaccine Evaluation and Selection</td>
<td>TG Cold Chain and Logistics Management</td>
</tr>
<tr>
<td>Lead: DOST</td>
<td>Lead: TGRML</td>
</tr>
<tr>
<td>Members: DOH, FDA, RITM, Vaccine Experts</td>
<td>Members: DOH, DBM, DILG (PNP), DND (AFP, OCD)</td>
</tr>
<tr>
<td>TG Diplomatic Engagement and Negotiations</td>
<td>TG Immunization Program</td>
</tr>
<tr>
<td>Lead: DFA (Special Envoy of the President and Presidential Assistant on Foreign Affairs)</td>
<td>Lead: DOH (PHST)</td>
</tr>
<tr>
<td>Members: DOF, DOH, NTF, DOST</td>
<td>Members: DOJ, FDA, DILG, DSWD, DepEd, AFP, DOTr, DICT</td>
</tr>
<tr>
<td>TG Procurement and Finance</td>
<td>TG Demand Generation &amp; Communications</td>
</tr>
<tr>
<td>Lead: DBM (Procurement Service)</td>
<td>Lead: PCOO</td>
</tr>
<tr>
<td>Members: DOH, DOF</td>
<td>Members: DOH, NTC, PIA</td>
</tr>
</tbody>
</table>

Sub - Task Groups (STGs) under the TG COVID-19 Immunization Program

| STG Planning, Policy & Technical Support | STG Registry, Data Management & M&E |
| Lead: DOH (DPCB OD IV) | Lead: DOH (EB and KMITS) |
| Member: DOJ, OCPLC, DepEd, DILG | Member: DICT, DSWD, DepEd |
| STG Sec | STG Sec |
### STG Program Implementation

**Lead:** DOH (DPCB OD III)  
**Members:** DILG (BFP, PNP, BJMP), DSWD, DepEd, DND (AFP), DOJ (BuCor), DOTr (PCG)  
**STG Sec**

<table>
<thead>
<tr>
<th>Team</th>
<th>Roles and Responsibilities</th>
</tr>
</thead>
</table>
| TG Vaccine Evaluation and Selection       | • Review results of clinical trials  
• Coordinate and Collaborate with the TGs and STGs, NITAG and HTAC                                                                                                                                                    |
| TG Diplomatic Engagement and Negotiation  | • Meet with international parties and entities.  
• Provide feedback and updates to the other respective TGs pertaining to vaccine development in the global market.  
• Coordinate and collaborate with TG Procurement and Finance in identifying viable global market vaccine manufacturers and entities.                                          |
| TG Procurement and Finance                | • Facilitate advanced market commitment and/or framework contracting and/or procurement through international facilities (COVAX)  
• Activate price negotiation board subject to HTA’s cost-effective price  
• Coordinate with DBM and legislators, as may be necessary on budget and co-payment ceilings  
• Explore local vaccine production and supply                                                                                                               |
| TG Cold Chain and Logistics Management    | • Map the potential port(s) of entry, points of storage (stores), and fallback facilities in the country with their respective cold chain and transportation/capacity distribution for vaccines, and ancillary products and assess dry storage and cold chain capacity at all levels  
• Facilitate acceptance and inventory of vaccines and logistics  
• Facilitate and ensure storage, distribution and delivery of vaccines and logistics to target areas  
• Monitor cold chain practices and ensure that vaccines are handled and disposed correctly and properly                                                                 |
| TG Immunization Program                   | • Plan and craft policies, guidelines and standard operating procedures related to the COVID-19 vaccine deployment and program implementation.  
• Estimate potential numbers of target populations that will be prioritized for access to vaccines stratified by target group and geographic location  
• Identify potential COVID-19 vaccine delivery strategies  
• Create a data information system for all vaccine recipients                                                                                               |

### STG Safety Surveillance & Response

**Lead:** FDA (Office of the Director)  
**Member:** DOH (EB, DPCB, FICT)  
**STG Sec**

The following are the roles and responsibilities of the COVID-19 Vaccine Cluster Organizational Structure:
| **TG Demand Generation and Communications** | • Design a demand and risk communication plan  
• Implement social mobilization and community engagement activities  
• Ensure social preparation of target population groups and geographical areas prior to vaccination |
| **National Immunization Technical Advisory Group (NITAG)** | • Review the latest position papers, studies, international guidelines and recommendations from internationally acknowledged resources [i.e., World Health Organization (WHO), Strategic Advisory Group of Experts for Immunization (SAGE)] for possible adoption in the country policies and plans for the National Immunization Programme.  
• Conduct existing policy analysis, review of the program data and evidence in order to provide evidence-based technical advice and recommendations for the development of appropriate and sustainable immunization policies, guidelines, strategies and approaches related to immunization program.  
• Advise the DOH in the formulation of policies, plans and strategies for research and development of existing and new vaccines and the vaccine delivery technology. |
| **National Adverse Events Following Immunization Committee** | • Review all reported serious and cluster of AEFI cases presented for expert opinion and provide a final causality assessment of the AEFI cases as well as the cases that were not classified by the Regional AEFI Committee.  
• Ensure evidence-based causality assessment by recommending further investigation and data collection as needed.  
• Make final decisions on causality assessment of inconclusive investigations.  
• Ensure standard protocols for AEFI surveillance and investigation are correctly followed.  
• Engage with other national and international experts when requirements arise in establishing causality and vaccine quality issues.  
• Provide recommendations to the National Immunization Program, EB and National Cold Chain Manager on improving immunization service delivery, compliance with injection safety and effective vaccine management based on lessons from the AEFI cases.  
• Serve as technical advisory group on vaccine and immunization safety-related issues of highest consideration such as immediate recall of vaccine from the market or temporary/permanent withdrawal of a vaccine from the immunization program. |
| Health Technology Assessment Council | • Serve as resource person in other AEFI related meetings, conferences or capacity building activities as requested.  
• Oversee and coordinate the health technology assessment process of candidate COVID-19 vaccine.  
• Review and assess existing evidences of COVID-19 vaccines undergoing/undergone clinical trials.  
• Coordinate and provide recommendations to the TG Vaccine Evaluation and Selection. |

8.2 Capacity Building

The Philippines, together with almost all countries, has capacity issues in responding to the unprecedented COVID-19 pandemic including infection control, testing and laboratory analysis, establishment and operation of quarantine and isolation facilities and waste management. Additionally, the citizen and stakeholder engagement process is continually evolving in response to the unpredictable disease outbreak.

The Project will provide funding, training, and capacity building to support these critical initiatives, building on international expertise to achieve international best practices in line with WHO guidelines as follows:

- supporting DOH in preparing a guidance note on standard design for hospital isolation and treatment centers to manage Severe Acute Respiratory Infections (SARI) patients;
- training on use of medical and laboratory equipment, devices, and testing kits for health providers and technicians; and supporting the necessary logistics arrangements to deploy goods and equipment to health facilities without delay;
- training on the appropriate use of PPE, guided by the WHO (2020) interim guidance Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19), 19 March 2020;
- capacity building for laboratory staff and technicians on COVID-19 testing; and
- health care waste management and infection prevention and control in health care facilities;
- training of relevant DOH personnel and designated logistics team for the management and maintenance of cold chain and effective management for maximizing efficiencies

The DOH will be conducting trainings for the implementers of the vaccine distribution and administration prior to vaccine roll-out with the lead of the Public Health Services Team.

8.3 Estimated Budget

The costs of implementing the ESMF relate to activities and costs beyond the costs of the dedicated E&S personnel involved in various measures and actions of the ESMF. The main costs of implementing this ESMF relate to (i) training and workshops, (ii) development of E&S due diligence as well as measures and other tools, (iii) information and communication, and (iv) supervision, monitoring, and reporting. A budget estimate for these costs is provided in Table 3; it may be readjusted during project implementation to ensure adequate management of environmental and social risks.
**Table 3 ESMF Implementation Costs**

<table>
<thead>
<tr>
<th>ESMF Activities</th>
<th>Description of Activities</th>
<th>Estimated Cost (USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Training and capacity building</td>
<td>Development of annual work plans. Training on good practice environmental and social management, including healthcare waste management at national, provincial and local government level.</td>
<td>150,000</td>
</tr>
<tr>
<td>Development of E&amp;S Due Diligence</td>
<td>Recruitment of consultants for preparation/adaption of ECOPs, ESMPs, etc.</td>
<td>120,000</td>
</tr>
<tr>
<td>Information and Communication</td>
<td>Development of communication strategy and stakeholder engagement. Production and dissemination of communication materials targeting vulnerable groups and indigenous peoples</td>
<td>50,000</td>
</tr>
<tr>
<td>Supervision, monitoring, and reporting</td>
<td>Travel to provinces for training and conducting monitoring and reporting</td>
<td>60,000</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td><strong>$380,000</strong></td>
</tr>
</tbody>
</table>
A  Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19</td>
<td>Coronavirus Disease 2019</td>
</tr>
<tr>
<td>CERC</td>
<td>Contingent Emergency Response Component</td>
</tr>
<tr>
<td>CoC</td>
<td>Code of Conduct</td>
</tr>
<tr>
<td>DBF</td>
<td>Department of Budget and Finance</td>
</tr>
<tr>
<td>DA</td>
<td>Designated Account</td>
</tr>
<tr>
<td>ECQ</td>
<td>Enhanced Community Quarantine</td>
</tr>
<tr>
<td>EOC</td>
<td>Emergency Operation Center</td>
</tr>
<tr>
<td>ESMF</td>
<td>Environmental and Social Management Framework</td>
</tr>
<tr>
<td>FMM</td>
<td>Financial Management Manual</td>
</tr>
<tr>
<td>FM</td>
<td>Financial Management</td>
</tr>
<tr>
<td>GCQ</td>
<td>General Community Quarantine</td>
</tr>
<tr>
<td>GRS</td>
<td>Grievance Redress Service</td>
</tr>
<tr>
<td>IDA</td>
<td>International Development Association</td>
</tr>
<tr>
<td>IBRD</td>
<td>International Bank for Reconstruction and Development</td>
</tr>
<tr>
<td>IHR</td>
<td>International Health Regulations</td>
</tr>
<tr>
<td>IPF</td>
<td>Investment Project Financing</td>
</tr>
<tr>
<td>IMF</td>
<td>International Monetary Fund</td>
</tr>
<tr>
<td>M&amp;E</td>
<td>Monitoring and Evaluation</td>
</tr>
<tr>
<td>DOH</td>
<td>Department of Health</td>
</tr>
<tr>
<td>PDO</td>
<td>Project Development Objective</td>
</tr>
<tr>
<td>SEP</td>
<td>Stakeholder Engagement Plan</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operational Procedures</td>
</tr>
<tr>
<td>SPRP</td>
<td>Strategic Preparedness and Response Program</td>
</tr>
<tr>
<td>STEP</td>
<td>Systematic tracking of Exchanges in Procurement</td>
</tr>
<tr>
<td>UNICEF</td>
<td>United Nations Child'en's Fund</td>
</tr>
<tr>
<td>WBG</td>
<td>World Bank Group</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
B Labor Management Procedures (LMP)

Under ESS2 on Labor and Working Conditions, Borrowers are required to develop labor management procedures (LMP). The purpose of the LMP is to facilitate planning and implementation of the project. The LMP identifies the main labor requirements and risks associated with the project, and helps the Borrower to determine the resources necessary to address project labor issues. The LMP is a living document, which is initiated early in project preparation, and is reviewed and updated throughout development and implementation of the project.

B.1 Labor and Working Conditions

Labor Use

The Project will employ about a hundred contracted workers to refurbish existing or construct new quarantine facilities or isolation rooms in various parts of the Philippines. The Project will benefit thousands of health workers including medical technicians mostly in major cities in the country including Baguio City, Cebu, Metro Manila, and Surigao City, including through the procurement of PPE. Waste management personnel who are expected to be part of the labor force of health facilities will also benefit from the protection and safety equipment to be provided by the Project.

Security personnel in hospitals are usually contracted out. Civil servants of the Department of Health and local government units will be involved as part of the project implementation team. Community workers will not be employed.

Characteristics of Project Workers

The minimum legal working age in the Philippines is 18 years old. All workers must meet this requirement. Contracted workers, mainly for civil works, will most likely be male. Health workers will most likely be female. Health workers will consist of medical professionals directly employed by the health facilities as organic staff or contracted on a temporary basis. There may also be some volunteers.

A small number of civil servants from the Department of Health at the national and local levels and LGUs will be involved in project implementation. Construction workers will be hired in time for the refurbishment or construction of the isolation facilities.

Health workers are expected to already be working in the hospitals and laboratories. Provision of laboratory equipment may entail the need to hire additional technicians. Contracted workers are expected only for the construction of quarantine facilities which will not constitute major civil works. These will most likely be small, temporary buildings scattered in various areas of the country with local hospitals in partnership with LGUs in charge of procuring these small contracts.

Health workers will be at the forefront in the fight against COVID-19. As such, they are at the most risk of infection but with the provision of PPEs, reagents, and technology against the virus, they are also the main beneficiaries.

Civil servants from the Department of Health and LGUs will be involved in project management and are expected to abide by social distancing measures and proper hygiene as they carry out their tasks.
Waste management workers are expected to be part of the labor force of health facilities including the quarantine facilities to be constructed. Like the health workers, they are highly at risk and will benefit from the PPEs and other safety measures to be provided by the Project.

Security personnel including the military who will be involved in the Project are expected to receive the appropriate PPEs from the project. They will abide by a Code of Conduct (CoC) and DoH will ensure that they are informed about the CoC and receive appropriate training, as needed.

Migrant workers are not expected to be involved. Likewise, community workers are not expected to be involved. No risks concerning child labor and serious safety issues are identified or expected concerning primary supply workers as most of the Project’s supplies will be medical equipment and PPE with a high level of standards and quality control.

B.2 Assessment of Potential Labor Risks

Health workers, waste management and security personnel will be more at risk of infection without the provision of PPE and the use of disinfectants that will be provided by the project. With physical mobility being restricted and given the nature of construction activities, labor influx is not expected. However, the movement of laborers from the worksite to the community may increase the risk of infection in both areas.

COVID-19 specific risks relate to the activities being carried out by the workers, in the context in which the project is being conducted. Potential risks could include workers mobilized from adjoining provinces or regions, or local workers returning from abroad, become vectors for transmission of COVID-19 to other workers in construction project sites and nearby communities.

These risks may be minimized and addressed through:

- conducting pre-employment health checks
- controlling entry and exit from site/workplace
- reviewing accommodation arrangements, to see if they are adequate and designed to reduce contact with the community
- reviewing contract durations, to reduce the frequency of workers entering/exiting the site
- rearranging work tasks or reducing numbers on the worksite to allow social/physical distancing, or rotating workers through a 24-hour schedule
- providing appropriate forms of personal protective equipment (PPE)
- putting in place alternatives to direct contact, like telemedicine appointments and livestream of instructions.

Another example of potential risk is where the project activity is the treatment by health care workers of COVID-19 patients. In this case the risks could include pathogen exposure, infection and associated illness, death, illegal and untenable overtime, psychological distress, fatigue, occupational burnout, stigma and passing on infections to family and community.

B.3 Labor Legislation

Presidential Decree No. 44, as amended by RA 6715, known as the “Labor Code of the Philippines”, governs all employment practices and relations in the country. Provisions of the code are aligned with international good practice on decent work and shall be strictly implemented. These provisions include:
**Wage and Welfare**

1. Employees shall receive their wages by means of legal tender, at least once every two weeks or twice a month at intervals not exceeding sixteen (16) days.

2. In a contracted work, employees of the contractor and of the latter’s subcontractor, shall also be paid in accordance with the labor code.

3. The wage paid by the employers to the workers shall not be lower than the prescribed minimum wage set by the Regional Tripartite Wages and Productivity Boards.

**Working time, Rest Days and Holidays**

1. The normal work hours for every employee shall not exceed eight (8) hours a day. If all or any part of the employee’s working hours falls on 10:00 PM to 6:00 AM, he/she shall be entitled to a night shift pay in addition to the regular wage. If the worked performed exceeds the normal working hours, he/she shall be given overtime pay.

2. It is the right of every employee for a rest period not less than twenty-four (24) consecutive hours after every six (6) consecutive normal workdays.

3. Compensation shall be given for work performed during holidays and Sundays.

**Equal Rights**

1. Workers shall have the right to self-organization and to form, join, or assist labor organizations of their own choosing for purposes of collective bargaining.

2. Minimum employable age is 18 years old.

3. Gender discrimination in employment and labor relations shall be prohibited. Male and female employees are entitled to equal compensation for work of equal value and access to promotion and training opportunities.

**Occupational Health and Safety**

According to Chapter III of Republic Act No. 11058 (the OSH Law), the following are the duties of every employer, contractor or subcontractor, and any person who manages, controls or supervises the work:

1. Equip a place of employment for workers free from hazardous conditions that are causing or are likely to cause death, illness or physical harm to the workers where physical distancing can be observed. Sanitation and hygiene facilities should also be present and well-disinfected regularly for the safety of workers.

2. Provide complete job safety instructions and proper orientation to all workers including, but not limited to, those entering the job for the first time and to those relating to familiarization with their work environment.

3. Inform the workers of the hazards associated with their work, health risks involved or to which they are exposed to, preventive measures to eliminate or minimize the risks, and steps to be taken in case of emergency.

4. Use only approved specific industry set of standards of devices and equipment for the workplace as applicable.
5. Comply with OSH standards including training, medical examination, and when necessary, provisions on protective and safety devices such as PPE and machine guards. Training for workers shall include health promotion, hazards associated with their work, health risks involved or to which they are exposed to, preventive measures to eliminate or minimize risks, steps to be taken in case of emergency, and safety instructions for the jobs, activities and tasks to be handled by workers.

6. Make arrangements for workers and their representatives to have the time and resource to participate actively in the processes of organizing, planning and implementation, monitoring, evaluation and action for improvement of the OSH management system.

7. Provide, when necessary, for measures identifying trainings and drills, evacuation plans, etc., to deal with emergencies, fires and accidents including first-aid arrangements.

To comply with the OSH standards, every employee/worker shall:

1. Participate in the capacity building activities on safety and health and other OSH related topics and programs.
2. Proper use of all safeguards and safety devices furnished for workers’ protection and that of others.
3. Comply with instructions to prevent accidents or imminent danger situations in the workplace.
4. Observe prescribed steps to be taken in cases of emergency including participation in the conduct of national or local disaster drills.
5. Report to their immediate supervisor or any other responsible safety and health personnel any work hazard that may be discovered in the workplace.

Employed citizens, employees shall have the following common rights:

1. To refuse to work without threat or reprisal from the employer if an imminent danger situation exists.
2. To report accidents, dangerous occurrences, and hazards to the employer, to DOLE, and to other concerned competent government agencies.
3. To receive personal protective equipment, to be provided by their employer, contractor or subcontractor, free of charge, for any part of the body that may be exposed to hazards, and other lifeline.
4. To receive information on workplace conditions, risks that can impose danger to health, industrial dangerous and poisonous factors.

The Occupational Safety and Health Standards, in compliance with Article 162 of the Labor Code of the Philippines, was formulated to protect every working man against the dangers of injury, sickness or death through safe and healthful working conditions. For this project, chapters discussing standards for personal protective equipment and devices, construction safety, and hazardous materials are necessary and should be complied.

DPWH Department Order 56 series of 2005: Guidelines for the Implementation of Department of Labor and Employment (DOLE) No.13 series of 1998, Guidelines in the Governing Occupational Safety and Health in the Construction Industry, it is expected that the contractors should follow the said guidelines to
eliminate or reduce occupational safety and health hazards in all work places, and institute new, and
update existing programs to ensure safe and healthful working conditions in all places of employment.

The following international conventions, and directives may also support measures for addressing health
and safety issues relevant to COVID-19:

• ILO Occupational Safety and Health Convention, 1981 (No. 155)
• ILO Occupational Health Services Convention, 1985 (No. 161)
• ILO Safety and Health in Construction Convention, 1988 (No. 167)
• WHO International Health Regulations, 2005
• WHO Emergency Response Framework, 2017

B.4 Grievance Redress Mechanism

DOH Workers

Management of DOH personnel is governed by the Civil Service Commission which requires the
establishment of a Grievance Redress Committee in charge of preventing and addressing grievances as
stipulated in the following provisions:

• The Grievance Committee shall develop and implement pro-active measures or activities to
  prevent grievance such as employee assembly which shall be conducted at least once every
  quarter, “talakayan” counseling and other HRD interventions;
• Conduct continuing information drive on Grievance machinery among officials and employees in
  collaboration with the Personnel Administration Division;
• Conduct dialogue between and among the parties involved;
• Conduct investigation and hearing within ten (10) days from receipt of the grievance and render
  decision within five (5) working days after the investigation. Provided, however where the
  object of the grievance is the grievance committee, the aggrieved party may submit the
  grievance to top management;
• Direct the documentation of the grievance management process including the preparation and
  signing of written agreements reached by the parties involved:
• Issue Certification on the Final Action on the Grievance (CFAG) which shall contain, among other
  things, the information, history and final action taken by the agency on the grievance, and;
• Submit a quarterly report of its accomplishments and status of unresolved grievance to the Civil
  Service Commission Regional Office concerned.

Contractors

Contractors are expected to hire much of their laborers upon assuming the civil works contract. At the
time of recruitment, workers will be informed of the grievance mechanism and the measures put in
place to protect them against any reprisal for its use. The grievance mechanism shall be made easily
accessible to all project workers. Regular meetings with the project workers to discuss any work-related
issues and concerns will be conducted. Every grievance raised by a worker will be documented with the
actions undertaken by the office to address such grievance. The aggrieved worker may raise any issue
anonymously through a letter which shall be submitted to his/her immediate supervisor’s office. All non-
anonymous grievances relative to adequate working conditions, standard occupational safety and health
and other concerns from the workers shall be addressed following the procedures outlined below:
• The grievance shall be filed by the workers to the Contractor who shall follow the DOLE procedures in handling the complaints. The Contractor shall act within 15 days upon receipt thereof;
• If no understanding or amicable solution can be reached, or if the complainant does not receive a response from the Contractor within 15 days of registry of the complaint, he/she can appeal to the project grievance focal person within DOH, which should act on the complaint/grievance within 15 days from the day of its filing. If the PIU does not see itself fit to address the complaint it will immediately bring the matter to the concerned DOLE office.
• If the complainant is not satisfied with the resolution offered by the PIU, he/she can appeal to the concerned DOLE office, which should act on the complaint/grievance within 15 days from the day of its filing.

B.5 Contractor Management

Responsibilities of BIHC

1. The BIHC will request details in writing before a contract is signed from the Contractor of the measures being taken to address labor and working conditions risks. The construction contract should include health and safety requirements, and these can be used as the basis for identification of, and requirements to implement, COVID-19 specific measures. The measures may be presented as a contingency plan, as an extension of the existing project emergency and preparedness plan or as standalone procedures. The measures may be reflected in revisions to the project’s health and safety manual.

2. The BIHC should require the Contractor to convene regular meetings with the project health and safety specialists and medical staff (and where appropriate the local health authorities), and to take their advice in designing and implementing the agreed measures.

3. The contractor shall assign a senior staff as a focal point to deal with COVID-19 issues during construction. This can be a work supervisor or a health and safety specialist. This person can be responsible for coordinating preparation of the site and making sure that the measures taken are communicated to the workers, those entering the site and the local community. It is also advisable to designate at least one back-up person, in case the focal point becomes ill; that person should be aware of the arrangements that are in place.

4. The BIHC may provide support in identifying appropriate mitigation measures, particularly where these will involve interface with local services, in particular health and emergency services. In many cases, the BIHC can play a valuable role in connecting the Contractor with local Government agencies, and helping coordinate a strategic response, which takes into account the availability of resources.

5. Workers should be encouraged to use the existing project grievance mechanism to report concerns relating to COVID-19, preparations being made by the project to address COVID-19 related issues, how procedures are being implemented, and concerns about the health of their co-workers and other staff.
6. The BIHC, in coordination with local LGU and health facility, shall issue construction quarantine pass to the individual qualified personnel of the contractors, subcontractors, and suppliers, clearly stating the identification, designation, nature of work, validity and destination. It is understood that the pass shall cover transit of personnel from (a) General Community Quarantine (GCQ) area to Enhanced Community Quarantine (ECQ) area, and vice versa and (b) an area not under community quarantine to a GCQ or ECQ area, and vice versa.

**Responsibilities of the Contractor**

**Prior to Deployment**

1. Only persons from eighteen (18) to fifty-nine (59) years of age, without pre-existing health conditions, such as, but not limited to, immunodeficiency, comorbidities, or other health risks, including any person who resides with the aforementioned; and who did not come into contact with someone with COVID-19 shall be allowed to be included in the workforce, in accordance with the Omnibus Guidelines on the Implementation of Community Quarantine in the Philippines ("OG") dated 22 October 2020 and relevant DPWH guidelines

2. Construction personnel shall be required to undergo any available COVID-19 test, as may be prescribed by DOH, and retested as the need arises. In this regard, consultation with medical doctors (duly accredited by DOH, if possible) prior to the conduct of COVID-19 test shall be made.

3. The contractors, subcontractors, and suppliers shall provide for their personnel/workers the necessary welfare facilities and amenities, such as employees’ quarters for board and lodging, ensuring compliance to social distancing, proper hygiene, etc. Contractors shall submit the design for the said welfare facilities and amenities, for monitoring, to BIHC.

4. Contractors shall ensure compliance with DOLE D.O. NO. 13 series of 1998. Contractors shall provide their personnel and workers continuous supply of vitamins, particularly vitamin C, other over-the-counter medicines, quarantine facilities, and oxygen tanks for emergency purposes.

5. Contractors shall provide disinfection facilities in their respective project sites in compliance with pertinent DOH and IATF Guidelines, to be placed at strategic locations to ensure the safety and welfare of all personnel.

6. Proper information dissemination regarding COVID-19 construction protocols on top of existing construction safety practices shall be conducted by Safety Officers to all personnel.

7. For Government construction projects, personal records of all personnel necessary for contact tracing shall be submitted by the contractors, subcontractors, and suppliers to the DPWH IO and shall be resubmitted and updated monthly, or as the need arises.

**During Deployment**

1. Conduct an inventory of works for the construction sequencing to be followed and undertaken to uphold the required social distancing. Break times shall be conducted in a staggered manner.
2. Employees shall be housed in their respective quarters for the entire duration of the project covered by the ECQ and GCQ. Otherwise, “Prior to Deployment” procedures shall be conducted at every instance of re-entry.

3. Errands to be conducted outside the construction site premises shall be kept to a minimum. Number of personnel running errands shall be limited and shall be properly disinfected and closely monitored for symptoms within fourteen (14) days upon re-entry.

4. Field offices, employees’ quarters, and other common areas shall be regularly maintained including the daily disinfection of such facilities.

5. Adequate food, safe/potable drinking water, disinfectants, and hand soaps shall be made available by the concessionaires, contractors, subcontractors, and suppliers to its in–house personnel.

6. Daily monitoring of the pre- and post- work health conditions of workers shall be undertaken by the contractors, subcontractors, and suppliers including, but not limited to, temperature, health, and exposure monitoring, as preventive measures. Personnel with manifestations or symptoms relative to COVID-19 shall be immediately isolated and quarantined for fourteen (14) days and if necessary, brought to the nearest DOH COVID-19 treatment facility under strict confidentiality and privacy. Proper protocols in accordance with the DTI and DOLE Interim Guidelines on WorkPlace Prevention and Control of COVID-19 shall likewise be strictly observed. For Government construction projects, a daily health monitoring report to be prepared by the Safety Officer shall be submitted to the DPWH IO. The Contractor will also cover the medical bills and wages of the workers should they be infected by the virus.

7. Work activities shall be under daily strict monitoring by the Safety Officer at site to ensure compliance to safety standards and quarantine protocols.

8. For government construction projects, the DPWH Engineers assigned at the site shall ensure strict compliance to DOLE D.O. 13, series of 1998, and implementation of wearing additional Personal Protective Equipment (PPE) required such as, but not limited to, face masks, safety glasses/goggles, face shields, and long sleeve T-shirts, to contain the spread of COVID-19 in the workplace. On the other hand, contractors for essential private construction projects under GCQ shall assign a full-time safety officer devoted to ensure compliance with D.O. 13, series of 1998 and implementation of social distancing measures provided herein.

9. For off-site employees’ quarters, transport service, duly disinfected before and after use, shall be provided, with social distancing observed.

10. Sharing of construction and office equipment is discouraged. However, if necessary, the shared equipment must be disinfected in between transfers amongst personnel.

11. All material and equipment delivery and disposal shall be conducted by a specific team of personnel on an isolated loading/unloading zone while limiting contact with the delivery/disposal personnel. All material and/or equipment entering the construction site shall be duly disinfected, as possible.
12. Non-essential personnel, visitors, and the general public shall be restricted to enter the construction site, employees’ quarters, and field offices. Otherwise, all personnel entering the construction site premises on a temporary basis (e.g. Delivery truck drivers, inspectors, etc.) shall be properly logged and checked for symptoms. Gatherings, Liquors, and/or merry – making are strictly prohibited within the construction site premises.

13. Proper waste disposal shall be provided for infectious waste such as PPEs and other waste products coming from outside the construction premises.

14. Requirements on general hygiene should be communicated and monitored, to include:

- Training workers and staff on site on the signs and symptoms of COVID-19, how it is spread, how to protect themselves (including regular handwashing and social distancing) and what to do if they or other people have symptom.
- Placing posters and signs around the site, with images and text in local languages.
- Ensuring handwashing facilities supplied with soap, disposable paper towels and closed waste bins exist at key places throughout site, including at entrances/exits to work areas; where there is a toilet, canteen or food distribution, or provision of drinking water; in worker accommodation; at waste stations; at stores; and in common spaces. Where handwashing facilities do not exist or are not adequate, arrangements should be made to set them up. Alcohol based sanitizer (if available, 60-95% alcohol) can also be used.
- Setting aside part of worker accommodation for precautionary self-quarantine as well as more formal isolation of staff who may be infected.
- Conducting regular and thorough cleaning of all site facilities, including offices, accommodation, canteens, common spaces. Review cleaning protocols for key construction equipment (particularly if it is being operated by different workers).
- Providing cleaning staff with adequate cleaning equipment, materials and disinfectant.
- Reviewing general cleaning systems, training cleaning staff on appropriate cleaning procedures and appropriate frequency in high use or high-risk areas.
- Where it is anticipated that cleaners will be required to clean areas that have been or are suspected to have been contaminated with COVID-19, providing them with appropriate PPE: gowns or aprons, gloves, eye protection (masks, goggles or face screens) and boots or closed work shoes. If appropriate PPE is not available, cleaners should be provided with best available alternatives.
- Training cleaners in proper hygiene (including handwashing) prior to, during and after conducting cleaning activities; how to safely use PPE (where required); in waste control (including for used PPE and cleaning materials).
- Any medical waste produced during the care of ill workers should be collected safely in designated containers or bags and treated and disposed of following relevant requirements (e.g., national, WHO).

15. Consider whether existing project medical services are adequate, taking into account existing infrastructure (size of clinic/medical post, number of beds, isolation facilities), medical staff, equipment and supplies, procedures and training. Where these are not adequate, allocate in the project cost the upgrading of services, including:

- Training medical staff, which should include current WHO advice on COVID-19 and recommendations on the specifics of COVID-19. Where COVID-19 infection is suspected,
medical providers on site should follow WHO interim guidance on infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected.

- Assessing the current stock of equipment, supplies and medicines on site, and obtaining additional stock, where required and possible. This could include medical PPE, such as gowns, aprons, medical masks, gloves, and eye protection. Refer to WHO guidance as to what is advised.
- If PPE items are unavailable due to world-wide shortages, medical staff on the project should agree on alternatives and try to procure them. Alternatives that may commonly be found on constructions sites include dust masks, construction gloves and eye goggles. While these items are not recommended, they should be used as a last resort if no medical PPE is available.
- Ventilators will not normally be available on work sites, and in any event, intubation should only be conducted by experienced medical staff. If a worker is extremely ill and unable to breathe properly on his or her own, they should be referred immediately to the local hospital.
- Review existing methods for dealing with medical waste, including systems for storage and disposal.

16. Given the limited scope of project medical services, the project may need to refer sick workers to local medical services. Preparation for this includes:

- Obtaining information as to the resources and capacity of local medical services (e.g. number of beds, availability of trained staff and essential supplies).
- Conducting preliminary discussions with specific medical facilities, to agree what should be done in the event of ill workers needing to be referred.
- Considering ways in which the project may be able to support local medical services in preparing for members of the community becoming ill, recognizing that the elderly or those with pre-existing medical conditions require additional support to access appropriate treatment if they become ill.
- Clarifying the way in which an ill worker will be transported to the medical facility, and checking availability of such transportation.
- Establishing an agreed protocol for communications with local emergency/medical services
- Agreeing with the local medical services/specific medical facilities the scope of services to be provided, the procedure for in-take of patients and (where relevant) any costs or payments that may be involved.

B.6 Use of security personnel

Health facilities supported by the project is expected to use some security personnel. Military and security personnel may also be involved in the deployment and administration of the COVID-19 vaccines. Normally a security agency is contracted on a long-term basis by health care facilities to ensure safety of employees and the facility, including the equipment and supplies. In relation to security of the equipment during delivery, DOH’s freight service provider ensures that all equipment is delivered intact and safe onsite. DOH reports that security has not been an issue in the delivery of equipment in different areas nationwide.

The Project is not expected to use government security personnel in construction of facilities financed by the Project. However, as COVID-19 may develop in unpredictable ways and due to potential concerns among the public, the use of additional government security personnel from the local or national police,
or in some instances possibly the military, may be directed to implement measures to ensure peace and order in affected areas, including at quarantine, isolation, decontamination, and other health facilities.

The potential scope of such security measures, and potential risks surrounding them, will be assessed and monitored during implementation and this LMP may be revised accordingly to manage environmental and social risks concerning project activities. The World Bank’s ESS4 on Community Health and Safety encourages disclosure of government security arrangements and that clients ensure that government personnel act in a manner consistent with the provisions of the standard.

In case project activities are supported by private or government security personnel, it will be ensured that the security personnel follow a strict code of conduct and avoid any escalation consistent with the ESF and IFC guidance on the use of security personnel (IFC Good Practice Handbook on the Use of Security Forces: Assessing and Managing Risks and Impacts). In these cases, DOH (through BIHC) will assess risks posed by these security arrangements to project workers and the local community. Security personnel will provide security services in a manner consistent with the applicable laws and code of practices and will be consistent with the relevant requirement of the World Bank’s ESS4. DOH will ensure that the workers and local community are informed about the arrangements and the project’s GRM. DOH will review any allegations of unlawful or abusive acts of security personnel, take action (or urge appropriate parties to take action) to prevent recurrence and, where necessary, report unlawful abusive acts to the relevant authorities. Any incidents, concerns or grievances regarding the conduct of security personnel will be received, monitored, documented (taking into account the need to protect confidentiality), and resolved through the Project’s grievance mechanism following incident classification: Indicative, serious and severe. Any severe incidents with such personnel need to be reported to the Bank no later than 48 hours with basic information and a detailed incident report within 10 working days.

**Incidents categorization:**

**There are three levels of classification: Indicative, Serious and Severe Indicative –**

**Indicative:** A relatively minor, small-scale, localized incident that negatively impacts a small geographical area or a small number of people and does not result in significant or irreparable harm to people or the environment, or failure to implement required E&S measures with limited immediate impacts. Although relatively minor and limited in its immediate effects, this type of incident may be indicative of wider-scale issues or underlying organizational weaknesses within a project that could lead to serious or severe incidents if left uncorrected.

**Serious:** An incident that caused or may cause significant harm to the environment, workers, communities, or natural or cultural resources, is complex or costly to reverse and may result in some level of lasting damage or injury; or failure to implement E&S measures with significant impacts or repeated non-compliance with E&S policies; or failure to remedy Indicative non-compliance that may potentially cause significant impacts. Examples of serious incidents may include injuries to workers that require off-site medical attention, exploitation or abuse of vulnerable groups, consistent lack of Occupational Health and Safety (OHS) plans in a civil works project, and large-scale deforestation.
Severe- Incidents that caused or may cause great harm to individuals or the environment, or present significant reputational risks that could hamper the Bank’s ability to operate in a country or region. The Borrower’s inability or unwillingness to remedy situations that could result in serious or severe harm would be a factor in classification. A severe incident is complex and expensive to remedy (if possible) and is likely irreversible. A fatality is automatically classified as severe, as are incidents of major environmental contamination, forced or child labor, abuses of community members by project security forces or other project workers (including GBV) violent community protests a project, kidnapping, and trafficking in endangered species.

Severe incidents need to be reported to the World Bank no later than 48 hours with basic information and a detailed incident report within 10 working days.

Incident Report:

The Incident Report should be 1 – 2 pages and include, at a minimum, the following information:

- Country, Name of Project,
- Preliminary classification of the incident,
- What was the incident? What happened? To what or to whom?
- Where and when did the incident occur?
- When and how did the Project find out about it?
- Are the basic facts of the incident clear and uncontested, or are there conflicting versions? What are those versions?
- What were the conditions or circumstances under which the incident occurred (if known at this stage?)
- Is the incident still ongoing or is it contained?
- Is loss of life or severe harm involved?
- What is their response to date?
- What measures have been or are being implemented by the Project/Contractor?

C. Labor Management Procedures (LMP) Monitoring Form Template

Additional inputs may be provided based on the LMP submitted by the Contractor and the project recipient facility.

<table>
<thead>
<tr>
<th>Item</th>
<th>Status (Complied/Not Complied)</th>
<th>Timeline</th>
<th>Gaps/ Barriers for Implementation of Item</th>
<th>Actions to be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>B1. Labor and Working Conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Workers are above minimum legal age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Workers are provided and are wearing proper PPEs at all times</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Workers are aware and practice the Code of Conduct (CoC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Designated OHS Committee and Safety Personnel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>B2. Assessment of Potential Labor Risks</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-employment health checks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controlled entry and exit from site/workplace</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provision of accommodation arrangements to reduce contact with community which enables physical distancing with regular disinfection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provision of sanitation and hygiene facilities which are regularly disinfected</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewed contract durations, to reduce the frequency of workers entering/exiting the site</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rearranged work tasks or reducing numbers on the worksite to allow social/physical distancing, or rotating workers through a 24-hour schedule</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provided appropriate forms of personal protective equipment (PPE) to all personnel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alternatives to direct contact such as telemedicine appointments and livestream of instructions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>B3. Labor Legislation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wage and Welfare</strong></td>
</tr>
<tr>
<td>Employees shall receive their wages by means of legal tender, at least once every two weeks or twice a month at intervals not exceeding sixteen (16) days.</td>
</tr>
<tr>
<td>In a contracted work, employees of the contractor and of the latter’s subcontractor, shall also be paid in accordance with the labor code.</td>
</tr>
<tr>
<td>The wage paid by the employers to the workers shall not be lower than the prescribed minimum wage set by the Regional Tripartite Wages and Productivity Boards.</td>
</tr>
<tr>
<td><strong>Working time, Rest Days and Holidays</strong></td>
</tr>
</tbody>
</table>
The normal work hours for every employee shall not exceed eight (8) hours a day. If all or any part of the employee’s working hours falls on 10:00 PM to 6:00 AM, he/she shall be entitled to a night shift pay in addition to the regular wage. If the worked performed exceeds the normal working hours, he/she shall be given overtime pay.

It is the right of every employee for a rest period not less than twenty-four (24) consecutive hours after every six (6) consecutive normal workdays.

Compensation shall be given for work performed during holidays and Sundays.

Equal Rights
Workers shall have the right to self-organization and to form, join, or assist labor organizations of their own choosing for purposes of collective bargaining.

Gender discrimination in employment and labor relations shall be prohibited. Male and female employees are entitled to equal compensation for work of equal value and access to promotion and training opportunities.

Occupational Health and Safety
Equip a place of employment for workers free from hazardous conditions that are causing or are likely to cause death, illness or physical harm to the workers where physical distancing can be observed. Sanitation and hygiene facilities should also be present and well-disinfected regularly for the safety of workers.

Provide complete job safety instructions and proper orientation to all workers including, but not limited to, those entering the job.
for the first time and to those relating to familiarization with their work environment.

Inform the workers of the hazards associated with their work, health risks involved or to which they are exposed to, preventive measures to eliminate or minimize the risks, and steps to be taken in case of emergency.

Use only approved specific industry set of standards of devices and equipment for the workplace as applicable.

Comply with OSH standards including training, medical examination, and when necessary, provisions on protective and safety devices such as PPE and machine guards.

Training for workers shall include health promotion, hazards associated with their work, health risks involved or to which they are exposed to, preventive measures to eliminate or minimize risks, steps to be taken in case of emergency, and safety instructions for the jobs, activities and tasks to be handled by workers.

Make arrangements for workers and their representatives to have the time and resource to participate actively in the processes of organizing, planning and implementation, monitoring, evaluation and action for improvement of the OSH management system.

Provide, when necessary, for measures identifying trainings and drills, evacuation plans, etc., to deal with emergencies, fires and accidents including first-aid arrangements.

Report to their immediate supervisor or any other responsible
safety and health personnel any work hazard that may be discovered in the workplace

Report accidents, dangerous occurrences, COVID-19 cases, and hazards to the employer, to DOLE, and to other concerned competent government agencies.

### B4. Contractor’s Personnel Grievance Redress Mechanism (GRM)

<table>
<thead>
<tr>
<th>Activity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development of a GRM for the project site</td>
<td></td>
</tr>
<tr>
<td>Implementation and monitoring of the GRM for civil works</td>
<td></td>
</tr>
</tbody>
</table>

### B5. Contractor Management

#### Prior to Deployment

Only persons from 21 to 59 years of age, without pre-existing health conditions, such as, but not limited to, immunodeficiency, comorbidities, or other health risks, including any person who resides with the aforementioned; and who did not come into contact with someone with COVID-19 shall be allowed to be included in the workforce.

Construction personnel shall be required to undergo any available COVID-19 test, as may be prescribed by DOH, and retested as the need arises. In this regard, consultation with medical doctors prior to the conduct of COVID-19 test shall be made.

The contractors, subcontractors, and suppliers shall provide for their personnel/workers the necessary welfare facilities and amenities, such as employees’ quarters for board and lodging, ensuring compliance to social distancing, proper hygiene, etc. Contractors shall submit the design for the said welfare facilities and amenities, for monitoring to DPCB.

Contractors shall provide their personnel and workers continuous...
supply of vitamins, particularly vitamin C, other over-the-counter medicines, quarantine facilities, and oxygen tanks for emergency purposes.

Contractors shall provide disinfection facilities in their respective project sites in compliance with pertinent DOH and IATF Guidelines, to be placed at strategic locations to ensure the safety and welfare of all personnel.

Information dissemination regarding COVID-19 construction protocols on top of existing construction safety practices shall be conducted by Safety Officers to all personnel.

For Government construction projects, personal records of all personnel necessary for contact tracing shall be submitted by the contractors, subcontractors, and suppliers to the DPWH IO and shall be resubmitted and updated monthly, or as the need arises.

**During Deployment**

Conduct an inventory of works for the construction sequencing to be followed and undertaken to uphold the required social distancing. Break times shall be conducted in a staggered manner. Employees shall be housed in their respective quarters for the entire duration of the project covered by the ECQ and GCQ. Otherwise, “Prior to Deployment” procedures shall be conducted at every instance of re-entry.

Errands to be conducted outside the construction site premises shall be kept to a minimum. Number of personnel running errands shall be limited and shall be properly disinfected and closely monitored.
for symptoms within fourteen (14) days upon re-entry.

Field offices, employees’ quarters, and other common areas shall be regularly maintained including the daily disinfection of such facilities.

Adequate food, safe potable drinking water, disinfectants, and hand soaps shall be made available by the concessionaires, contractors, subcontractors, and suppliers to its in-house personnel.

Daily monitoring of the pre- and post-work health conditions of workers shall be undertaken by the contractors, subcontractors, and suppliers including, but not limited to, temperature, health, and exposure monitoring, as preventive measures.

Personnel with manifestations or symptoms relative to COVID-19 shall be immediately isolated and quarantined for fourteen (14) days and if necessary, brought to the nearest DOH COVID-19 treatment facility under strict confidentiality and privacy.

Work activities shall be under daily strict monitoring by the Safety Officer at site to ensure compliance to safety standards and quarantine protocols.

The Contractor will also cover the medical bills and wages of the workers should they be infected by the virus.

Implementation of wearing additional Personal Protective Equipment (PPE) required such as, but not limited to, face masks, safety glasses/goggles, face shields, and long sleeve T-shirts, to contain the spread of COVID-19 in the workplace.

For off-site employees’ quarters, transport service, duly disinfected
before and after use, shall be provided, with social distancing observed.

Sharing of construction and office equipment is discouraged. However, if necessary, the shared equipment must be disinfected in between transfers amongst personnel.

All material and equipment delivery and disposal shall be conducted by a specific team of personnel on an isolated loading/unloading zone while limiting contact with the delivery/disposal personnel.

Non-essential personnel, visitors, and the general public shall be restricted to enter the construction site, employees’ quarters, and field offices.

Proper waste disposal shall be provided for infectious waste such as PPEs and other waste products coming from outside the construction premises.

Training workers and staff on site on the signs and symptoms of COVID-19, how it is spread, how to protect themselves, and what to do if they or other people have symptoms.

Placing posters and signs around the site, with images and text in local languages.

Ensuring handwashing facilities supplied with soap, disposable paper towels and closed waste bins exist at key places throughout site, including at entrances/exits to work areas; where there is a toilet, canteen or food distribution, or provision of drinking water; in worker accommodation; at waste stations; at stores; and in common spaces.

Setting aside part of worker accommodation for precautionary
| self-quarantine as well as more formal isolation of staff who may be infected. |
| Conducting regular and thorough cleaning of all site facilities, including offices, accommodation, canteens, common spaces. |
| Provision of cleaning staff with adequate cleaning equipment, materials, and disinfectant. |
| Review of general cleaning systems, training cleaning staff on appropriate cleaning procedures and appropriate frequency in high use or high-risk areas. |
| Where it is anticipated that cleaners will be required to clean areas that have been or are suspected to have been contaminated with COVID-19, providing them with appropriate PPE: gowns or aprons, gloves, eye protection (masks, goggles or face screens) and boots or closed work shoes. |
| Training cleaners in proper hygiene (including handwashing) prior to, during and after conducting cleaning activities; how to safely use PPE (where required); in waste control (including for used PPE and cleaning materials). |
| Any medical waste produced during the care of ill workers should be collected safely in designated containers or bags and treated and disposed of following relevant requirements (e.g., national, WHO). |
| Consider whether existing project medical services are adequate, taking into account existing infrastructure (size of clinic/medical post, number of beds, isolation facilities), medical staff, equipment and supplies, procedures and training. |

**B6. Use of security personnel**
In case project activities are supported by private or government security personnel, it will be ensured that the security personnel follow a strict code of conduct and avoid any escalation consistent with the ESF and IFC guidance on the use of security personnel (IFC Good Practice Handbook on the Use of Security Forces: Assessing and Managing Risks and Impacts).

Is there any support needed from DOH?

____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________

D. Screening Form for Potential Environmental and Social Risk

This form is to be used by DOH to screen for the potential environmental and social risks and impacts of specific project activities. It will help the BIHC identify the relevant Environmental and Social Standards (ESS), establishing an appropriate E&S risk rating for these activities and specifying the type of environmental and social assessment required (if any), E&S risk management measures and specific instruments if required (e.g. ESMP/ECOP, SEP, LMP). Use of this form will allow DOH to form an initial view of the potential risks and impacts. **It is not a substitute for specific E&S assessments or specific mitigation plans, if needed.**

The screening form will be used both for participating health facilities benefiting from the project (e.g. receiving equipment and PPE) and for health facilities that will involve civil works. Participating health facilities that will not involve civil works will follow the guidance and requirements of the ESMF, for instance concerning health care waste management. If they are located in areas with indigenous peoples additional efforts will be made to engage with them and provide additional measures as described in the ESMF. The use of security personnel will also be assessed and addressed as needed.
Annex E provides a template for an ESMP that will be prepared for project activities that include civil works. It also provides standards Environmental and Social Codes of Practice for various project activities.

A note on Considerations and Tools for E&S Screening and Risk Rating is included in this Annex to assist the process.

<table>
<thead>
<tr>
<th>Activity</th>
<th>Location</th>
<th>Health Care Facility</th>
<th>Estimated Investment</th>
<th>Start/Completion Date</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Questions</th>
<th>Answer</th>
<th>ESS relevance</th>
<th>Due diligence / Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the activity include any of those in the negative list?</td>
<td></td>
<td></td>
<td>If yes, activity is not eligible</td>
</tr>
<tr>
<td>Does the project activity involve civil works inside the compound of the healthcare facilities including new construction, expansion, upgrading or rehabilitation of healthcare facilities and/or waste management facilities?</td>
<td></td>
<td>ESS1</td>
<td>If yes, prepare ESMP or ECOP</td>
</tr>
<tr>
<td>Does the project activity involve land acquisition and/or restrictions on land use?</td>
<td></td>
<td>ESS5</td>
<td>If yes, activity is not eligible</td>
</tr>
<tr>
<td>Does the project activity involve acquisition of assets for quarantine, isolation or medical treatment purposes?</td>
<td></td>
<td>ESS5</td>
<td>If yes, activity is not eligible</td>
</tr>
</tbody>
</table>
| Is the local health facility associated with any external waste management facilities such as a sanitary landfill, incinerator, or wastewater treatment plant for healthcare waste disposal? |        | ESS3          | In both cases (Y/N), prepare ESMP or ECOP (scope and substance will depend on risks)
<table>
<thead>
<tr>
<th>Question</th>
<th>ESS</th>
<th>If yes, prepare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is there a sound set of practices, protocols, procedures and institutional capacity in place for healthcare facility infection control and healthcare waste management?</td>
<td>ESS1</td>
<td>In both cases, prepare ESMP or ECOP (scope and substance will depend on risks)</td>
</tr>
<tr>
<td>Does the local health facility have an adequate system in place (capacity, processes and management) to address healthcare waste?</td>
<td>ESS3</td>
<td>In both cases, prepare ESMP or ECOP (scope and substance will depend on risks)</td>
</tr>
<tr>
<td>Does the project activity involve recruitment of workers including direct, contracted and/or community workers?</td>
<td>ESS2</td>
<td>If yes, prepare LMP and observe SEP</td>
</tr>
<tr>
<td>Does the local health facility have appropriate OHS procedures in place, and an adequate supply of PPE (where necessary)?</td>
<td>ESS2</td>
<td>In both cases, prepare LMP, ESMP</td>
</tr>
<tr>
<td>Does the project activity involve transboundary transportation (including Potentially infected specimens may be transported from healthcare facilities to testing laboratories, and transboundary) of specimen, samples, infectious and hazardous materials?</td>
<td>ESS3</td>
<td>If yes, prepare LMP, ESMP</td>
</tr>
<tr>
<td>Does the project activity involve use of security or military personnel during construction and/or operation of healthcare facilities and related activities including deployment of COVID-19 vaccines?</td>
<td>ESS2, ESS4</td>
<td>If yes, prepare Assessment of Risks, Code of Conduct, Training and report any incidents base on WB incident categorization: indicative, serious, severe. Severe incidents need to be reported to the WB within 48 hours.</td>
</tr>
<tr>
<td>Question</td>
<td>ESS</td>
<td>Answer</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Is the project activity located within or in the vicinity of any ecologically sensitive areas that will cause to generate significant impacts?</td>
<td>ESS6</td>
<td>If yes, activity is not eligible</td>
</tr>
<tr>
<td>Are there any indigenous groups (meeting specified ESS7 criteria) present in the subproject area and are they likely to be affected by the proposed project activity negatively or positively?</td>
<td>ESS7</td>
<td>If yes, observe SEP provisions. Meaningful consultations with IP community and traditional health practitioners, coordination with traditional health practitioners</td>
</tr>
<tr>
<td>Is the project activity located within or in the vicinity of any known cultural heritage sites that will cause the generation of significant impacts?</td>
<td>ESS8</td>
<td>If yes, activity is not eligible</td>
</tr>
<tr>
<td>Does the project area present considerable Gender-Based Violence (GBV) and Sexual Exploitation and Abuse (SEA) risk?</td>
<td>ESS1, ESS2, ESS4</td>
<td>If yes, prepare Code of Conduct and Training</td>
</tr>
</tbody>
</table>

**INFECTION CONTROL: CONSIDERATIONS AND TOOLS TO ASSIST IN E&S SCREENING AND RISK RATING:**

In the context of global COVID-19 outbreak, this project will adopt a containment strategy that includes extensive testing, quarantine, isolation and treatment either in a medical facility or at home.

This COVID-19 response project will include the activities below. Details are found in Annex I.

- construction of and/or operational support to medical laboratories, quarantine, and isolation centers at multiple locations and in different forms, and infection treatment centers in existing healthcare facilities
- procurement and delivery of medical supplies, equipment and materials, such as reagents, chemicals, and Personal Protective Equipment (PPEs)
- transportation of potentially infected specimens from healthcare facilities to testing laboratories
- construction, expansion or enhancing healthcare waste and wastewater facilities
• training of medical workers and volunteers
• community engagement and communication

1. Screening E&S Risks of Medical laboratories

This project will include capacity building and operational support to existing medical laboratories. It is important that such laboratories put in place procedures relevant to appropriate biosafety practices. WHO advises that non-propagative diagnostic work can be conducted in a Biosafety Level 2 (BSL-2) laboratory, while propagative work should be conducted at a BSL-3 laboratory. Patient specimens should be transported as Category B infectious substance (UN3373), while viral cultures or isolates should be transported as Category A “Infectious substance, affecting humans” (UN2814). The process for assessing the biosafety level of a medical laboratory (including management of the laboratory operations and the transportation of specimens) should consider both biosafety and general safety risks. OHS of workers in the laboratory and potential community exposure to the virus should be considered.

The following documents provide further guidance on screening of the E&S risks associated with a medical laboratory. They also provide information for assessing and managing the risks.

• WHO; Prioritized Laboratory Testing Strategy According to 4Cs Transmission Scenarios
• WHO COVID-19 Technical Guidance: Laboratory testing for 2019-nCoV in humans:
• WHO Laboratory Biosafety Manual, 3rd edition
• USCDC, EPA, DOT, et al; Managing Solid Waste Contaminated with a Category A Infectious Substance (August 2019)

2. Screening E&S Risks of Quarantine and Isolation Centers

According to WHO:

• Quarantine is the restriction of activities of or the separation of persons who are not ill but who may have been exposed to an infectious agent or disease, with the objective of monitoring their symptoms and ensuring the early detection of cases

• Isolation is the separation of ill or infected persons from others to prevent the spread of infection or contamination.

This project will include construction, renovation and equipping of quarantine and isolation centers at Point of Entry (POE), in urban and in remote areas. There may also be circumstances where tents are used for quarantine or isolation. Public or private facilities such as a stadium or hotel may also be acquired for this purpose.

In screening for E&S risks associated with quarantine and isolation, the following may be considered:

• contextual risks such as conflicts and presence or influx of refugees
• construction and decommissioning related risks
• land or asset acquisition
• use of security personnel or military forces
• availability of minimum requirements of food, fuel, water, hygiene
• whether infection prevention and control, and monitoring of quarantined persons can be carried out effectively
• whether adequate systems are in place for waste and wastewater management

The following documents provide further guidance regarding quarantine of persons.

• WHO; Considerations for quarantine of individuals in the context of containment for coronavirus disease (COVID-19)
• WHO; Key considerations for repatriation and quarantine of travelers in relation to the outbreak of novel coronavirus 2019-nCoV
• WHO; Preparedness, prevention and control of coronavirus disease (COVID-19) for refugees and migrants in non-camp settings

3. SCREENING E&S RISKS OF TREATMENT CENTERS

WHO has published a manual that provides recommendations, technical guidance, standards and minimum requirements for setting up and operating severe acute respiratory infection (SARI) treatment centers in low- and middle-income countries and limited-resource settings, including the standards needed to repurpose an existing building into a SARI treatment center, and specifically for acute respiratory infections that have the potential for rapid spread and may cause epidemics or pandemics.

• WHO Severe Acute Respiratory Infections Treatment Centre
• WHO Covid-19 Technical Guidance: Infection prevention and control / WASH
• WBG EHS Guidelines for Healthcare Facilities

4. SCREENING E&S RISKS RELATING TO LABOR AND WORKING CONDITIONS

A COVID-19 project may include different types of workers. In addition to regular medical workers and laboratory workers who would normally be classified as direct workers, the project may include contracted workers to carry out construction and community workers (such as community health volunteers) to provide clinical support, contact tracing, and data collection, etc. The size of the workforce engaged could be considerable. Risks for such a workforce will range from occupational health and safety to types of contracts and terms and conditions of employment. Further details relevant to labor and working conditions for COVID-19 projects are discussed in the LMP section.
E. Environmental and Social Management Plan Template

I. Subproject Information

<table>
<thead>
<tr>
<th>Subproject Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Subproject Location</td>
<td></td>
</tr>
<tr>
<td>Subproject Proponent</td>
<td></td>
</tr>
<tr>
<td>Estimated Investment</td>
<td></td>
</tr>
<tr>
<td>Start/Completion Date</td>
<td></td>
</tr>
</tbody>
</table>

II. Site/Location Description

Concisely describes the proposed location and its geographic, ecological, social, and temporal context including any offsite investments that may be required (e.g., access roads, water supply, etc.). Normally includes a map showing the location and project areas of influence.

III. ESMP Matrix

<table>
<thead>
<tr>
<th>Potential E&amp;S Risks and Impacts</th>
<th>Proposed Risk Mitigation Measures</th>
<th>Responsibility</th>
<th>Timeline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community Health and Safety</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Below is a sample of accomplished ESMP Matrix

<table>
<thead>
<tr>
<th>Potential E&amp;S Risks and Impacts</th>
<th>Proposed Risk Mitigation Measures</th>
<th>Responsibility</th>
<th>Timeline/Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legal issues of the construction</td>
<td>All legally required permits have been acquired for construction and/or rehabilitation. The public has been notified of the works through appropriate notification in the media and/or at publicly accessible sites (including the site of the works).</td>
<td>Contractor</td>
<td></td>
</tr>
<tr>
<td>Issue</td>
<td>Description</td>
<td>Recommendation</td>
<td>Responsible Party</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>----------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Dust due to construction activities</td>
<td>Demolition debris shall be kept in controlled area and sprayed with water mist to reduce debris dust. During pneumatic drilling/wall destruction, dust shall be suppressed by ongoing water spraying and/or installing dust screen enclosures at site. The surrounding environment (sidewalks, roads) shall be kept free of debris to minimize dust. During interior demolition, debris-chutes shall be used above the first floor.</td>
<td>Contractor</td>
<td></td>
</tr>
<tr>
<td>Road blockage/ heavier traffic due to construction activities.</td>
<td>There will be no excessive idling of construction vehicles at sites. Allocation of designated areas for construction vehicles.</td>
<td>Contractor</td>
<td></td>
</tr>
<tr>
<td>Increased community solid waste.</td>
<td>There will be no open burning of construction/waste material at the site. The site will establish appropriate erosion and sediment control measures such as e.g. hay bales and / or silt fences to prevent sediment from moving off site and causing excessive turbidity in nearby streams and rivers. Waste collection and disposal pathways and sites will be identified for all major waste types expected from demolition and construction activities. Proper waste collection, storage, and disposal of wastes generated from construction activities. Construction waste will be collected and disposed properly by licensed collectors. Mineral construction and demolition wastes will be separated from general refuse, organic, liquid, and chemical wastes by on-site sorting and stored in appropriate containers.</td>
<td>Contractor</td>
<td></td>
</tr>
<tr>
<td>Increased wastewater discharge.</td>
<td>The approach to handling sanitary wastes and wastewater from building sites (installation or reconstruction) must be approved by the local authorities.</td>
<td>Contractor</td>
<td></td>
</tr>
</tbody>
</table>
Before being discharged into receiving waters, effluents from individual wastewater systems must be treated in order to meet the minimal quality criteria set out by national guidelines on effluent quality and wastewater treatment.

| Noise from construction activities | Construction noise will be limited to restricted times agreed in the permit. During operations, the engine covers of generators, air compressors and other powered mechanical equipment shall be closed, and equipment placed as far away from residential areas as possible. Monitoring of new wastewater systems (before/after) will be carried out. Construction vehicles and machinery will be washed only in designated areas where runoff will not pollute natural surface water bodies. | Contractor |

| Community exposures to physical hazards (dust, noise, traffic) | Compliance of contractors to DOLE Department Order No. 198 (DO 198-18) (Implementing Rules of Republic Act No. 11058) | Contractor |

| Fear, mistrust and resistance among the local community | Conduct of community consultations and open feedback loop for communities. | Contractor |

| Potential discrimination of marginalized groups, GBV, Sexual Exploitation and Abuse (SEA) and/or VAC | Law enforcement personnel must adhere to Code of Conduct (CoC), including fair treatment and non-discrimination | Contractor |

| Civil servants and outsourced staff/contractors may be involved in misconduct impacting women and children at local level. | Training on community interaction and GBV/VAC | Contractor, DOH |

**Occupational Health and Safety**

| Transfer of potentially infected specimens and exposure to contaminated working/construction area | Observance of biosafety practices. Patient specimens should be transported as Category B infectious substance (UN3373), while viral cultures or isolates should be transported as Category A “Infectious substance, affecting humans” (UN2814). Disinfection of area prior to construction. | RITM, Contractor |

| Exposure of workers and visitors as the | Designation of respective areas and re-routing scheme | RITM |
| Construction activity might coincide with COVID-19 vaccination | Compliance to construction regulations.  
All employers must develop an Occupational Health and Safety Program in accordance with DO 198-18 Section 12  
All workers must undertake the Mandatory 8-hour Safety and Health Seminar for Workers (Section 3).  
Each workforce must have a qualified Safety Officer in accordance with DO 198 Section 14 | Contractor |
|---|---|---|
| **Occupational, Health, and Safety (OHS) risks for project workers associated with the upgrading activities** | Rational use of PPE.  
All workers involved with construction activities must follow basic hygiene procedures at all times to prevent the transmission of COVID-19.  
Conduct on-site awareness-raising activities to remind personnel about occupational exposures and safe practices.  
Practice of minimum public health standards.  
Practice of occupational Safety and Health Standards. | Contractor |
| **OHS risks related to the spread of the virus** | Workers may be asked to work overtime | Provide OT pay.  
Consult with workers. | Contractor |
| | Occupational health risks: Exposure to infectious waste (chemical and physical hazards) | Encourage hand hygiene (washing, preferably followed by disinfection).  
Use gloves for handling waste.  
Raise the awareness of staff about simple post exposure prophylaxis in the event of an occupational injury (e.g., needle-stick injury). | Contractor |
| | Workers experiencing respiratory symptoms may fear not getting paid and continue to show up at work | All workers must be reassured that they will continue to get paid if they need to self-isolate if they are showing with COVID-19/respiratory symptoms. These provisions must be made including for contracted staff and are included in the Labor Management Procedures (LMP). | Contractor |
| | Possibility of underaged workers | Ensure that all staff must be over 18 years and below 60 years old. | Contractor |
IV. Attachments

ECOPs*, ICWMP*, Contractor’s Personnel GRM, and LMP

*= not mandatory

V. Review & Approval

<table>
<thead>
<tr>
<th>Prepared By: ..........................(Signature)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Position: ........................................</td>
</tr>
<tr>
<td>Date .............................................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reviewed By: ..........................(Signature)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Position: ........................................</td>
</tr>
<tr>
<td>Date .............................................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Approved By: ..........................(Signature)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Position: ........................................</td>
</tr>
<tr>
<td>Date .............................................</td>
</tr>
</tbody>
</table>
F. Environmental and Social Management Plan Monitoring Report Template

I. Subproject Information

<table>
<thead>
<tr>
<th>Subproject Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Subproject Location</td>
<td></td>
</tr>
<tr>
<td>Subproject Proponent</td>
<td></td>
</tr>
<tr>
<td>Estimated Investment</td>
<td></td>
</tr>
<tr>
<td>Start/Completion Date</td>
<td></td>
</tr>
</tbody>
</table>

II. Site/Location Description

Concisely describes the proposed location and its geographic, ecological, social and temporal context including any offsite investments that may be required (e.g. access roads, water supply, etc.). Normally includes a map showing the location and project areas of influence.

III. ESMP Matrix

<table>
<thead>
<tr>
<th>Potential E&amp;S Risks and Impacts</th>
<th>Proposed Risk Mitigation Measures</th>
<th>Responsibility</th>
<th>Target Timeline</th>
<th>Budget</th>
<th>Status (Complied or Not)</th>
<th>Actual Timeline (Date Complied/to be Done)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IV. Attachments

ESMP, ECOPs*, ICWMP*, Contractor’s Personnel GRM, and LMP
* = not mandatory

V. Review & Approval

<table>
<thead>
<tr>
<th>Prepared By: ..........................(Signature)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Position: .................................. Date ..................................</td>
</tr>
<tr>
<td>Reviewed By: ..........................(Signature)</td>
</tr>
<tr>
<td>Position: .................................. Date ..................................</td>
</tr>
</tbody>
</table>
### General Infection Prevention and Control

✓ Procedures for entry into health care facilities, such as minimizing visitors and visitor hours, taking temperature checks and having separate area (including entry area) for patients presenting with COVID-19 symptoms/respiratory illness, who should be taken to a different area and given a face mask. All persons visiting hospitals should wash hands before entering and before leaving.

✓ Minimize contact between patients and other persons in the facility: health care professionals should be the only persons having contact with patients suspected of having COVID-19 and this should be restricted to essential personnel only (except in cases of young children or other persons requiring assistance, then a family member may be present but they must also be wearing PPE – at least gloves and mask – and adhering to protocols).

✓ Provide alcohol-based hand sanitizer (60-95% alcohol), tissues and facemasks in waiting rooms and patient rooms.

### Isolation and Treatment

✓ Isolate patients as much as possible, separate from people presenting with COVID-19. People with COVID-19 should be separate from each other by curtains or in different rooms if possible. Only place together in the same room patients who are have all contracted COVID-19. People with COVID-19 must be separated at all times from other hospital patients and health and other staff. This means there must be dedicated toilet facilities (or bedpans), hand washing facilities, and medical equipment (stethoscope, blood pressure machine, etc.) for patients with COVID-19 only.

✓ Use of Personnel Protection Equipment (PPE) at all times for medical staff and cleaners as needed (particularly facemask, gowns, gloves, eye protection and potentially face shield) when in contact with someone who may have COVID-19.

### Staff Occupational Health and Safety

✓ Immediate and ongoing training on the procedures to all categories of workers (lab technicians, doctors, nurses, cleaning staff, etc.) on use of PPE, personal hygiene and thorough disinfecting of surfaces on a regular basis (multiple times per day using a high-alcohol based cleaner to wipe down all surfaces and when COVID-19 patients are discharged; wash instruments with soap and water and then wipe down with high-alcohol based cleaner; dispose of rubbish by burning etc.) Put signage in hospital as a reminder.

✓ Make particular efforts to ensure that all staff (such as cleaners and those doing the washing) are able to understand these procedures and have access to the necessary PPE.

✓ Laboratories undertaking testing for COVID-19 virus should adhere strictly to appropriate biosafety practices and WHO guidelines on Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases.

✓ Labor personnel needs to be trained and acquainted with key provisions in Labor Management Plan (LMP), in particular Occupational Health and Safety (OHS) aspects.

### Sanitation and Waste Management

✓ Ensure that the designs for medical facilities consider the collection, segregation and treatment of medical waste

✓ The treatment of healthcare wastes produced during the care of COVID-19 patients should be collected safely in designated containers and bags, treated and then safely dispose

✓ General cleaning strategies: (i) proceed from cleaner to dirtier areas to avoid spreading dirt and microorganisms; (ii) proceed from top areas to bottom areas to prevent dirt and microorganisms from dripping or falling down and contaminating already cleaned areas (for example clean mattress first, then clean bed legs); (iii) proceed in a methodical, systematic manner to avoid missing areas (for example, proceed from left to right or clockwise). Provide training to cleaning staff on these procedures, as well as on the use of PPE equipment, and put signage of reminders throughout health centers.

Hospitals/health centers will also need to develop procedures and facilities for handling dirty linen and contaminated clothing, and preparing and handling food. For instance, social distancing measures (people 2m apart) should be implemented for those preparing and serving food in hospitals, ensuring...
thorough handwashing as per above guidelines, with reminders in kitchen and eating areas, and cooks/servers should wear masks.

REFERENCES
➢ WHO interim guidance on Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected;
➢ WHO technical brief water, sanitation, hygiene and waste management for COVID-19;
➢ WHO guidance on infection prevention and control at health care facilities (with a focus on settings with limited resources);
➢ WHO interim practical manual for improving infection prevention and control at the health facility;
➢ CDC Guidelines for isolation precautions: preventing transmissions of infectious agents in healthcare settings;
➢ CDC guidelines for environmental infection control in healthcare facilities
# CHECKLIST  2 Environmental and Social Codes of Practice –
## COVID 19 WASTE MANAGEMENT PROCEDURES

**Target:** Health Care Workers/Health Care Facilities/Laboratories

<table>
<thead>
<tr>
<th>General Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ All health care waste produced during the care of COVID-19 patients must be considered as infectious waste and should be collected safely in designated containers and bags, treated and then safely disposed (WHO).</td>
</tr>
<tr>
<td>✓ Train the staffs who are assigned in handling and disposal of waste management</td>
</tr>
<tr>
<td>✓ Train staffs on how to put and remove PPE.</td>
</tr>
<tr>
<td>✓ Ensure necessary PPE (Gown, gloves, face mask, goggles or face shield, gumboots) is provided to all staffs.</td>
</tr>
<tr>
<td>✓ Ensure staff wear PPE when handling and disposing waste according to HCW guideline.</td>
</tr>
</tbody>
</table>

**General Waste** - Food waste, paper, disposable cups, plates, spoons etc

- ✓ Collect in black bag
- ✓ Close and tie when 2/3rd full
- ✓ Transfer the waste to a temporary storage point for general waste along a specified route at a fixed time point and store the waste separately at a fixed location
- ✓ Transport to landfill away from facility

**Infectious Waste** - Gown, gloves, apron, shoe cover, disposable items, mask etc

- ✓ Collect in small biohazard red bags
- ✓ Close, seal the bag with cable ties and tie lose when 2/3 full
- ✓ Transfer the waste to a temporary storage point for medical waste along a specified route at a fixed time point and store the waste separately at a fixed location
- ✓ Securely transfer out for incinerating
- ✓ Transport outcome as general waste

**Sharps Waste**

- ✓ Put in puncture proof plastic container
- ✓ Close the lid and seal the container when 2/3 full
- ✓ Put in the red bag and tie lose
- ✓ Transfer the waste to a temporary storage point for medical waste along a specified route at a fixed time point and store the waste separately at a fixed location
- ✓ Securely transfer out for incinerating or appropriate disposal

## REFERENCES

- WHO interim guidance on infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected;
- WHO technical brief water, sanitation, hygiene and waste management for COVID-19;
- WHO guidance on infection prevention and control at health care facilities (with a focus on settings with limited resources);
- WHO interim practical manual for improving infection prevention and control at the health facility;
- CDC Guidelines for isolation precautions: preventing transmissions of infectious agents in healthcare settings;
- CDC guidelines for environmental infection control in healthcare facilities
CHECKLIST  3 Environmental and Social Codes of Practice – COVID 19 COMMUNITY AND SOCIAL INCLUSION

Target: General Population/Vulnerable Groups/

**General Communication**

✓ When developing communication materials it is important to ensure that they are clear and concise, and that they are in a format/language that is understandable to all people, in particular the most vulnerable. Messages should be clear and concise, focusing on hygiene measures (hand washing, coughing), what to do if suspect have COVID-19, as well as restrictions if applicable (for instance specific guidelines on social-distancing).

✓ Utilize appropriate media needs to be used (social media, radio, tv) plus engaging existing formal and informal public health and community-based networks (schools, healthcare service providers at local level, etc).

✓ Communication materials must also be clear about (i) how to avoid contracting COVID-19 (good hygiene measures); (ii) symptoms of COVID-19; (iii) what to do if suspect have COVID-19.

✓ Place signages in the project site/vicinity visible to the public informing on the construction activities and associated risks, e.g. falling debris.

✓ Identify trusted community groups (local influencers such as community leaders, religious leaders, health workers, community volunteers, celebrities) and local networks (such as women’s groups, youth groups, business groups, and traditional healers) that can help to disseminate messages. Define clear and easy mechanisms to disseminate messages and materials based on community questions and concerns

✓ A focus of information materials should be on women, as they tend to be the best venue of communication for children and the elderly in the household.

✓ RGC/MOH should consider having a dedicated hotline for people to call for questions and recommendations on what to do if they suspect they may have COVID-19.

**Infection Prevention**

✓ Information on how to protect oneself from COVID-19, the symptoms of COVID-19, where and how to get tested should be made available to everyone and ensure they are accessible to IPs, marginalized groups, those with disabilities, other vulnerable groups and the elderly, and in a manner that is culturally appropriate to the respective groups and specific needs.

✓ Promote large scale social and behaviour change. Introduce preventive community and individual health and hygiene practices with a focus on handwashing. Could include gifting of soap bars, distributed by commune authorities or District health officials.

✓ Workplaces should be encouraged to post and provide communication materials, in particular workplaces which may face a higher risk of COVID-19 spread, such as construction sites and factories. This may include social isolation measures in workplaces, separating people from each other (2m), opening spaces to allow for natural ventilation, providing hand sanitation facilities (soap/water or hand sanitizer), etc.

**Stakeholder Engagement**

✓ Stakeholder Engagement Plan (SEP) must use different communication methods.

✓ Stakeholder Engagement Plan (SEP) should ensure consultations with NGOs and other stakeholders that can provide recommendations on how to communicate information and develop Risk Communication and Community Engagement Plan (RCCE).

**REFERENCES**

➢ WHO interim guidance on Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected;


CHECKLIST  4 Environmental and Social Codes of Practice – COVID 19 SMALL SCALE CONSTRUCTION, UPGRADES, REHAB, EXPANSION

Target: Construction Workers OHS/Project Supervisor/Facility Manager

Community Health and Safety
✓ The local construction and environment inspectorates and communities have been notified of upcoming activities
✓ The public has been notified of the works through appropriate notification in the media and/or at publicly accessible sites (including the site of the works)

Worker Safety
✓ Designate Safety Officer/s.
✓ Access to sanitation facilities in the project site.
✓ Access to clean and safe transient quarters for workers allowing social distancing and with regular disinfection.
✓ Access to clean and safe drinking-water.
✓ Workers’ PPE will comply with international good practice (always hardhats, as needed masks and safety glasses, harnesses and safety boots)

General Rehabilitation and/or Construction
✓ The Contractor formally agrees that all work will be carried out in a safe and disciplined manner designed to minimize impacts on neighboring residents and environment.
✓ All legally required permits have been acquired for construction and/or rehabilitation
✓ During interior demolition debris-chutes shall be used above the first floor
✓ Demolition debris shall be kept in controlled area and sprayed with water mist to reduce debris dust
✓ During pneumatic drilling/wall destruction dust shall be suppressed by ongoing water spraying and/or installing dust screen enclosures at site
✓ The surrounding environment (sidewalks, roads) shall be kept free of debris to minimize dust
✓ There will be no open burning of construction / waste material at the site
✓ There will be no excessive idling of construction vehicles at sites
✓ Construction noise will be limited to restricted times agreed to in the permit
✓ During operations the engine covers of generators, air compressors and other powered mechanical equipment shall be closed, and equipment placed as far away from residential areas as possible
✓ The site will establish appropriate erosion and sediment control measures such as e.g. hay bales and / or silt fences to prevent sediment from moving off site and causing excessive turbidity in nearby streams and rivers.

Waste Management
✓ Waste collection and disposal pathways and sites will be identified for all major waste types expected from demolition and construction activities.
✓ Mineral construction and demolition wastes will be separated from general refuse, organic, liquid and chemical wastes by on-site sorting and stored in appropriate containers.
✓ Proper waste collection, storage, and disposal of wastes generated from construction activities.
✓ Construction waste will be collected and disposed properly by licensed collectors

Wastewater Treatment
✓ The approach to handling sanitary wastes and wastewater from building sites (installation or reconstruction) must be approved by the local authorities
✓ Before being discharged into receiving waters, effluents from individual wastewater systems must be treated in order to meet the minimal quality criteria set out by national guidelines on effluent quality and wastewater treatment
✓ Monitoring of new wastewater systems (before/after) will be carried out
✓ Construction vehicles and machinery will be washed only in designated areas where runoff will not pollute natural surface water bodies.
REFERENCES
➢ WHO technical brief *water, sanitation, hygiene and waste management for COVID-19*;
➢ WHO guidance on *infection prevention and control at health care facilities (with a focus on settings with limited resources)*;
H. Environmental Codes of Practice (ECOP) Monitoring Form Template

I. Subproject Information

<table>
<thead>
<tr>
<th>Subproject Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Subproject Location</td>
<td></td>
</tr>
<tr>
<td>Subproject Proponent</td>
<td></td>
</tr>
<tr>
<td>Estimated Investment</td>
<td></td>
</tr>
<tr>
<td>Start/Completion Date</td>
<td></td>
</tr>
</tbody>
</table>

II. Checklist Monitoring and Evaluation

Date of Accomplishing the Checklist: ________________________________________________________________

<table>
<thead>
<tr>
<th>Checklist</th>
<th>Items not Practiced/Complied</th>
<th>Gaps/ Barriers for Implementation of Item</th>
<th>Actions to be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>1: COVID-19 Exposure at Health Care Facility</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2: COVID-19 Waste Management Procedures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3: COVID-19 Community and Social Inclusion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4: COVID-19 Small Scale Construction, Upgrades, Rehab, Expansion</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Are there any support needed from the DOH Project Team?

____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________

III. Review & Approval

| Prepared By: ...........................(Signature) |
| Position: ................................. Date .......................... |
| Reviewed By: ..............................(Signature) | Approved By: ...............................(Signature) |
| Position: ................................. Date .......................... | Position: ................................. Date .......................... |
I. Infection Control and Waste Management Plan (ICWMP)

1. Introduction

1.1 Describe the project context and components

1.2 Describe the targeted healthcare facility (HCF):

- Type: e.g. general hospital, clinics, inpatient/outpatient facility, medical laboratory, quarantine or isolation centers;

- Special type of HCF in response to COVID-19: E.g. existing assets may be acquired to hold yet-to-confirm cases for medical observation or isolation;

- Functions and requirement for the level infection control, e.g. biosafety levels;

- Location and associated facilities, including access, water supply, power supply;

- Capacity: beds

1.3 Describe the design requirements of the HCF, which may include specifications for general design and safety, separation of wards, heating, ventilation and air conditioning (HVAC), autoclave, and waste management facilities.

2. Infection Control and Waste Management

2.1 Overview of infection control and waste management in the HCF

- Type, source and volume of healthcare waste (HCW) generated in the HCF, including solid, liquid and air emissions (if significant)

- Classify and quantify the HCW (infectious waste, pathological waste, sharps, liquid and non-hazardous) following WBG EHS Guidelines for Healthcare Facilities and pertaining GIIP.

- Given the infectious nature of the novel coronavirus, some wastes that are traditionally classified as non-hazardous may be considered hazardous. It’s likely the volume of waste will increase considerably given the number of admitted patients during COVID-19 outbreak. Special attention should be given to the identification, classification and quantification of the healthcare wastes.

- Describe the healthcare waste management system in the HCF, including material delivery, waste generation, handling, disinfection and sterilization, collection, storage, transport, and disposal and treatment works

- Provide a flow chart of waste streams in the HCF if available

- Describe applicable performance levels and/or standards

- Describe institutional arrangement, roles and responsibilities in the HCF for infection control and waste management
2.2 Management Measures

- Waste minimization, reuse and recycling: HCF should consider practices and procedures to minimize waste generation, without sacrificing patient hygiene and safety considerations.

- Delivery and storage of specimen, samples, reagents, pharmaceuticals and medical supplies: HCF should adopt practice and procedures to minimize risks associated with delivering, receiving and storage of hazardous medical goods.

- Waste segregation, packaging, color coding and labeling: HCF should strictly conduct waste segregation at the point of generation. Internationally adopted method for packaging, color coding and labeling the wastes should be followed.

- Onsite collection and transport: HCF should adopt practices and procedures to timely remove properly packaged and labelled wastes using designated trolleys/carts and routes. Disinfection of pertaining tools and spaces should be routinely conducted. Hygiene and safety of involved supporting medical workers such as cleaners should be ensured.

- Waste storage: A HCF should have multiple waste storage areas designed for different types of wastes. Their functions and sizes are determined at design stage. Proper maintenance and disinfection of the storage areas should be carried out. Existing reports suggest that during the COVID-19 outbreak, infectious wastes should be removed from HCF’s storage area for disposal within 24 hours.

- Onsite waste treatment and disposal (e.g. an incinerator): HCFs with their own waste incineration facilities installed onsite should practice due diligence to examine its technical adequacy, process capacity, performance record, and operator’s capacity. In case any gaps are discovered, corrective measures should be recommended. For new HCF financed by the project, waste disposal facilities should be integrated into the overall design and ESIA developed. Good design, operational practices and internationally adopted emission standards for healthcare waste incinerators can be found in pertaining EHS Guidelines and GIIP.

- Transportation and disposal at offsite waste management facilities: Not all HCF has adequate or well-performed incinerator onsite. Not all healthcare wastes are suitable for incineration. An onsite incinerator produces residuals after incineration. Hence offsite waste disposal facilities provided by local government or the private sector are probably needed. These offsite waste management facilities may include incinerators, hazardous wastes landfill. In the same vein, due diligence of such external waste management facilities should be conducted to examine its technical adequacy, process capacity, performance record, and operator’s capacity. In case any gaps are discovered, corrective measures should be recommended and agreed with the government or the private sector operators.

- Wastewater treatment: HCF wastewater is related to hazardous waste management practices. Proper waste segregation and handling as discussed above should be conducted to minimize entry of solid waste into the wastewater stream. In case wastewater is discharged into municipal sewer sewerage system, the HCF should ensure that wastewater effluent comply with all applicable permits and standards, and the municipal wastewater treatment plant (WWTP) is capable of handling the type of effluent discharged. In cases where municipal sewage system is not in place,
HCF should build and properly operate onsite primary and secondary wastewater treatment works, including disinfection. Residuals of the onsite wastewater treatment works, such as sludge, should be properly disposed of as well. There’re also cases where HCF wastewater is transported by trucks to a municipal wastewater treatment plant for treatment. Requirements on safe transportation, due diligence of WWTP in terms of its capacity and performance should be conducted.

3. Emergency Preparedness and Response

Emergency incidents occurring in a HCF may include spillage, occupational exposure to infectious materials or radiation, accidental releases of infectious or hazardous substances to the environment, medical equipment failure, failure of solid waste and wastewater treatment facilities, and fire. These emergency events are likely to seriously affect medical workers, communities, the HCF’s operation and the environment.

Thus, an Emergency Response Plan (ERP) that is commensurate with the risk levels is recommended to be developed. The key elements of an ERP are defined in ESS 4 Community Health and Safety (para. 21).

4. Institutional Arrangement and Capacity Building

A clearly defined institutional arrangement, roles and responsibilities should be included. A training plan with recurring training programs should be developed. The following aspects are recommended:

- Define roles and responsibilities along each link of the chain along the cradle-to-cradle infection control and waste management process;
- Ensure adequate and qualified staff are in place, including those in charge of infection control and biosafety and waste management facility operation.
- Stress the chief of a HCF takes overall responsibility for infection control and waste management;
- Involve all relevant departments in a HCF, and build an intra-departmental team to manage, coordinate and regularly review issues and performance;
- Establish an information management system to track and record the waste streams in HCF; and
- Capacity building and training should involve medical workers, waste management workers and cleaners. Third-party waste management service providers should be provided with relevant training as well.

5. Monitoring and Reporting

Many HCFs in developing countries face the challenge of inadequate monitoring and records of healthcare waste streams. HCF should establish an information management system to track and record the waste streams from the point of generation, segregation, packaging, temporary storage, transport carts/vehicles, to treatment facilities. The HCF is encouraged to develop an IT based information management system should their technical and financial capacity allow.

As discussed above, the HCF chief takes overall responsibility, leads an intra-departmental team and regularly reviews issues and performance of the infection control and waste management practices in the HCF. Internal reporting and filing systems should be in place.
Externally, reporting should be conducted per government and World Bank requirements.
## ICWMP Table

<table>
<thead>
<tr>
<th>Activities</th>
<th>Potential E&amp;S Issues and Risks</th>
<th>Proposed Mitigation Measures</th>
<th>Responsibilities</th>
<th>Timeline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>General HCF operation – Environment</td>
<td>General wastes, wastewater and air emissions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General HCF operation – OHS issues</td>
<td>- Physical hazards;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Electrical and explosive hazards;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Fire;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Chemical use;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Ergonomic hazard;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Radioactive hazard.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCF operation - Infection control and waste management plan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waste minimization, reuse and recycling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delivery and storage of specimen, samples, reagents, pharmaceuticals and medical supplies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Storage and handling of specimen, samples, reagents, and infectious materials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waste segregation, packaging, color coding and labeling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onsite collection and transport</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waste storage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onsite waste treatment and disposal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waste transportation to and disposal in offsite treatment and disposal facilities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCF operation – transboundary movement of specimen, samples, reagents, medical equipment, and infectious materials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emergency events</td>
<td>Emergency response plan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Spillage; - Occupational exposure to infectious; - Exposure to radiation; - Accidental releases of infectious or hazardous substances to the environment; - Medical equipment failure; - Failure of solid waste and wastewater treatment facilities; - Fire; - Other emergent events</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operation of acquired assets for holding potential COVID-19 patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>To be expanded</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## J DENR- Accredited M501 and M503 Waste Transporters

<table>
<thead>
<tr>
<th>Region</th>
<th>Name of Transporter</th>
<th>Address</th>
<th>Contact No.</th>
<th>Email Address</th>
<th>Date of Expiration</th>
<th>Waste Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR</td>
<td>Cybertechnologies Co.</td>
<td>Km. 12, ACOP, Tublay, Benguet</td>
<td>0928-6898770; 0919-0017547</td>
<td><a href="mailto:yollycybertech@yahoo.com">yollycybertech@yahoo.com</a></td>
<td>16-Jan-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Edgardo Rivera Trading</td>
<td>2848 Int. 4 Lorenzo Dela Paz St., Barangay 839, Pandacan, Manila</td>
<td>(02) 748-4263</td>
<td><a href="mailto:riveraegay@gmail.com">riveraegay@gmail.com</a></td>
<td>02-Jul-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>EK2 Marketing</td>
<td>1151 Oliveros Cpd. F. Bautista St. Ugong, Valenzuela City</td>
<td>02-4428663</td>
<td><a href="mailto:ek2.eddieong@gmail.com">ek2.eddieong@gmail.com</a></td>
<td>17-Sep-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>RiveRainier General Merchandise</td>
<td>1121 A-2 New Antipolo Street, Tondo, Manila</td>
<td>353-6675</td>
<td><a href="mailto:riverainier@yahoo.com">riverainier@yahoo.com</a></td>
<td>02-Jul-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Eco Safe Hazmat Treatment Inc.</td>
<td>Lot 7 West Los Angeles Street, California Village, San Bartolome Novaliches, Quezon City</td>
<td>417-8888</td>
<td><a href="mailto:ecosafe_hazmat@yahoo.com">ecosafe_hazmat@yahoo.com</a></td>
<td>30-Jan-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>NCR</td>
<td>OASIS RECYCLING &amp; RECOVERY MANAGEMENT CORP.</td>
<td>Unit 305 Emerald Place Bldg. 604 Shaw Blvd., Kapitolyo, Pasig City / Garage Address: 3406-A Lubiran St., Baco, Sta. Mesa, Manila</td>
<td>(02) 358-7557</td>
<td><a href="mailto:oasisrrmc@gmail.com">oasisrrmc@gmail.com</a></td>
<td>02-Jul-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Mr. Trustbin Environmental and Maintenance Services</td>
<td>14 Maria Teresa St., Commonwealth, Quezon City; Garage Address: 483 Manotok Compound, Tullahan Road, Sta.Quiteria, Brgy. 162, District 1, Caloocan City</td>
<td>0977-0492567</td>
<td><a href="mailto:mrtrustbin@gmail.com">mrtrustbin@gmail.com</a></td>
<td>06-May-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Blue Sea Energy Technology Corp.</td>
<td>439 C3 Road, Kaunlaran Village, Caloocan City</td>
<td>282-5344</td>
<td>info@blueseacomp tackled.com</td>
<td>09-Jan-21</td>
<td>M501</td>
</tr>
<tr>
<td>NCR</td>
<td>Marpila Trading</td>
<td>22-I Maysan Rd., Malinta, Valenzuela City</td>
<td>298-3582</td>
<td><a href="mailto:marpilatradping02@gmail.com">marpilatradping02@gmail.com</a></td>
<td>02-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>JM ECOTECH SOLUTIONS CO.</td>
<td>168 Gen. Luis St., Brgy. Kaybiga, Caloocan City</td>
<td>(02) 936-4632</td>
<td><a href="mailto:docs@jmecotech.com">docs@jmecotech.com</a>; <a href="mailto:sales@jmecotech.com">sales@jmecotech.com</a></td>
<td>30-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Company Name</td>
<td>Address 1</td>
<td>Contact Numbers</td>
<td>Email Addresses</td>
<td>Date</td>
<td>Notes</td>
</tr>
<tr>
<td>-----</td>
<td>--------------</td>
<td>-----------------------------------</td>
<td>-----------------</td>
<td>----------------------------------------</td>
<td>------------</td>
<td>--------</td>
</tr>
<tr>
<td>NCR</td>
<td>Adcan Petroleum Products, Inc.</td>
<td>144 F. Dulalia St., Lingunan, Valenzuela City</td>
<td>294-6764, 282-2358</td>
<td><a href="mailto:adcanpetroleumproducts@yahoo.com">adcanpetroleumproducts@yahoo.com</a></td>
<td>09-Jan-21</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Trame Oil &amp; Environmental Specialist, Inc.</td>
<td>L2 B2 Pearl Island Industrial Compound, Brgy. Punturin, Valenzuela City</td>
<td>02-9689575</td>
<td><a href="mailto:trameoil.environmental@gmail.com">trameoil.environmental@gmail.com</a></td>
<td>04-Mar-21</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Udenna Environmental Services, Inc.</td>
<td>4 Sta. Maria Drive, Sta. Maria Industrial Estate, Bagumbayan, Taguig City</td>
<td>(02) 551-7235</td>
<td><a href="mailto:adrian.borebor@udenna.ph">adrian.borebor@udenna.ph</a></td>
<td>13-Jun-20</td>
<td>M503, M501</td>
</tr>
<tr>
<td>NCR</td>
<td>HAZARD WASTE MANAGEMENT SERVICES</td>
<td>165 Isagani st. Rizal Village Alabang Muntinlupa City</td>
<td>7889339, 8420612</td>
<td><a href="mailto:hazardwaste2002@yahoo.com.ph">hazardwaste2002@yahoo.com.ph</a></td>
<td>16-Jan-21</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>A. Sevidal Trading</td>
<td>Block 1 Lot 12 Saint Urcising St., Saint Joseph Subd., Pulanglupa Dos, Las Piñas City</td>
<td>874-0169, 872-5330, 874-0250</td>
<td><a href="mailto:asevidaltrading@gmail.com">asevidaltrading@gmail.com</a>; <a href="mailto:Anastacia.sevidal@yahoo.com">Anastacia.sevidal@yahoo.com</a></td>
<td>28-Nov-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Myra A. Osbuna Transport Services</td>
<td>No5 Puerto Azul St, Camella Homes 4, Poblacion, Muntinlupa City</td>
<td>850-3302</td>
<td><a href="mailto:obsuna.mao@yahoo.com.ph">obsuna.mao@yahoo.com.ph</a></td>
<td>12-Dec-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>I</td>
<td>Servo-Treat Philippines, Incorporated</td>
<td>Brgy. Pinmaludpod, Urdaneta City, Pangasinan</td>
<td>0917-8058448</td>
<td><a href="mailto:servotreat_phils@yahoo.com.com">servotreat_phils@yahoo.com.com</a></td>
<td>02-Aug-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>II</td>
<td>R2 Safewaste Management Services</td>
<td>Ipil St., District 1, Cauayan City, Isabela</td>
<td>0917-8469774</td>
<td><a href="mailto:r2sms@yahoo.com">r2sms@yahoo.com</a></td>
<td>30-Jan-21</td>
<td>M501</td>
</tr>
<tr>
<td>III</td>
<td>ADL Waste Management</td>
<td>Sitio Binasak, Brgy. Mabiga, Hermosa, Bataan 2111</td>
<td>(047) 250-0385</td>
<td><a href="mailto:adlwastemanagement@yahoo.com">adlwastemanagement@yahoo.com</a></td>
<td>17-Sep-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Envirocare Mgt. Precision, Inc.</td>
<td>53 C Mercado St., Poblacion, Guiguinto, Bulacan</td>
<td>(02) 242-9810 loc. 106</td>
<td><a href="mailto:info@envirocare.ph">info@envirocare.ph</a></td>
<td>17-Sep-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Aide Environmental Management</td>
<td>B8 L20 Ph 1 Pescoville Subdivision, Brgy. T. Mangga, District 1, San Jose del Monte, Bulacan</td>
<td>(02) 504-5859</td>
<td><a href="mailto:aemanagement19@yahoo.com">aemanagement19@yahoo.com</a></td>
<td>02-Jul-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Fuelcycle Int’l. Co. Ltd.</td>
<td>Tibagan, Sta. Rosa II, Marilao, Bulacan</td>
<td>0926-0569203</td>
<td><a href="mailto:admin@fuelcycleph.com">admin@fuelcycleph.com</a></td>
<td>14-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Wacuman Incorporated</td>
<td>Sitio Tiakad, Brgy. San Mateo, Norzagaray, Bulacan</td>
<td>(02) 573-7710</td>
<td><a href="mailto:info_wacuman@yahoo.com">info_wacuman@yahoo.com</a></td>
<td>15-Aug-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>JCZS TRADING</td>
<td>Warehouse 316, Brgy. Sulucan, Bocaue, Bulacan</td>
<td>(02) 261-4205</td>
<td><a href="mailto:litazafra@yahoo.com">litazafra@yahoo.com</a>; <a href="mailto:litazafra14@gmail.com">litazafra14@gmail.com</a></td>
<td>27-Sep-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Name</td>
<td>Address</td>
<td>Contact</td>
<td>Email</td>
<td>Date</td>
<td>Code</td>
</tr>
<tr>
<td>-----</td>
<td>------</td>
<td>---------</td>
<td>---------</td>
<td>-------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>III</td>
<td>ALL WASTE SERVICES, INC.</td>
<td>Km 32 McArthur Highway, Tuktukan, Guiguinto, Bulacan</td>
<td>(044) 794 2669, 794 2668</td>
<td><a href="mailto:pco@aws.ph">pco@aws.ph</a></td>
<td>12-Dec-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Far East Fuel Corporation</td>
<td>888 Purok 5, Irabagon St., Brgy. Anyatam, San Ildefonso, Bulacan</td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>16-Jan-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Asia United Oil Industry Corp.</td>
<td>Muralla St., Iba, Meycauyan, Bulacan</td>
<td>(044) 764-9525/0926670-8114</td>
<td><a href="mailto:asiauoi@yahoo.com.ph">asiauoi@yahoo.com.ph</a></td>
<td>27-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Positive A Envirotech Specialist</td>
<td>#651 Tibagan Road, Brgy. Sta. Rosa II, Marilao, Bulacan</td>
<td>0915-8412353</td>
<td><a href="mailto:positivea.es@gmail.com">positivea.es@gmail.com</a></td>
<td>12-Feb-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>DCH Egogreen Solutions</td>
<td>No. 29 R. Nicolas Sr. St., Poblacion, Sta. Maria, Bulacan</td>
<td>(044) 913-6193</td>
<td><a href="mailto:dch.ecogreensolutions@gmail.com">dch.ecogreensolutions@gmail.com</a></td>
<td>08-Nov-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Globaltec Waste Management, Inc.</td>
<td>9 Westmont Industrial Subdivision, Brgy. Loma De Gato, Marilao, Bulacan</td>
<td>0927-2781300; 0918-3337600</td>
<td><a href="mailto:gtwminc@gmail.com">gtwminc@gmail.com</a></td>
<td>27-Sep-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Safewaste Incorporated</td>
<td>Bldg. 9801 A-C DOST-Technology Resource Center, Mabalacat City, Pampanga</td>
<td>(045) 436-6008</td>
<td><a href="mailto:safewaste@ymail.com">safewaste@ymail.com</a></td>
<td>01-Aug-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Semirecycling Co., Inc.</td>
<td>Phase II Lot 1-A, CPIP, IES, M.A. Roxas Highway, Clark Freeport Zone, Pampanga</td>
<td>045-599-6953; 499-3150/1</td>
<td><a href="mailto:srci@semirecycling.com">srci@semirecycling.com</a></td>
<td>08-Nov-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>DoloMatrix Philippines, Inc.</td>
<td>Angeles Industrial Park, Inc. Calibutbut, Bacolor, Pampanga</td>
<td>(02) 671-4060, 671-5295</td>
<td><a href="mailto:pco@dolomatrix.com.ph">pco@dolomatrix.com.ph</a></td>
<td>08-Nov-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Unified Hazwaste Expert, Inc.</td>
<td>1-E-4 Brgy. Gandus Mexico, Pampanga</td>
<td>0917-8451140</td>
<td><a href="mailto:unifiedhazwaste@yahoo.com">unifiedhazwaste@yahoo.com</a></td>
<td>03-Mar-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Joechem Environmental Corporation</td>
<td>Brgy. Aranguren, Capas, Tarlac</td>
<td>(02) 281-3227; (045) 493-0474</td>
<td><a href="mailto:pco.joechemenvironmental@gmail.com">pco.joechemenvironmental@gmail.com</a>; <a href="mailto:joechemenvironmental@gmail.com">joechemenvironmental@gmail.com</a></td>
<td>02-Jul-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Cleanway Environmental Management Solutions, Inc.</td>
<td>Barangay Cutcut II, Capas, Tarlac</td>
<td>9178677629</td>
<td><a href="mailto:dean.castaneda@cleanway.com.ph">dean.castaneda@cleanway.com.ph</a></td>
<td>01-Apr-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Earthclean Environmental Management Corp.</td>
<td>T.M Kalaw St. Brgy. 3 Lipa City, Batangas; Garage Address: Purok Almasiga, Brgy. Inicbulan, Bauan, Batangas</td>
<td>(043) 302-1080; 706-6058</td>
<td><a href="mailto:earthclean.2014@yahoo.com">earthclean.2014@yahoo.com</a></td>
<td>06-May-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>-----</td>
<td>---------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>-----------------------------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>IV-A</td>
<td>Sanikleen Laundry Corporation</td>
<td>Brgy. Pinagkawitan, Lipa City</td>
<td>(043) 756-5541</td>
<td><a href="mailto:sanikleen15@yahoo.com">sanikleen15@yahoo.com</a></td>
<td>03-Sep-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>258 Global Ventures, Inc.</td>
<td>Sitio Muzon, Brgy. Puting Kahoy, Silang, Cavite</td>
<td>(046) 404-3650</td>
<td><a href="mailto:258globalventures@gmail.com">258globalventures@gmail.com</a></td>
<td>22-Jan-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Dynamo Trucking &amp; Development Corporation</td>
<td>Brgy. Mambugan, Antipolo City, Rizal; Garage Address: Unit 307 J &amp; F Bldg. 2, V.V. Soliven Avenue 3, San Isidro, Cainta, Rizal</td>
<td>(02) 477-7613</td>
<td><a href="mailto:ddc_philippines@yahoo.com">ddc_philippines@yahoo.com</a></td>
<td>03-Sep-20</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Jen and Janette Junkshop</td>
<td>Brgy. Tinurik, Tanuan, Batangas</td>
<td>(043) 406-1598</td>
<td><a href="mailto:jhen.perilla_19@yahoo.com">jhen.perilla_19@yahoo.com</a></td>
<td>15-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Solvtech Consultancy Resources</td>
<td>BIK 11 Lot 6A Phase 1 Sterling Technopark Maguyam,Silang Cavite</td>
<td>(02) 994-2241, 826-3285</td>
<td><a href="mailto:aav@navsolvtech.com">aav@navsolvtech.com</a>; <a href="mailto:navsolvtech@gmail.com">navsolvtech@gmail.com</a></td>
<td>13-Jun-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Green Eco Techwin, Inc. (Formerly Clean Echo Techwin, Inc.)</td>
<td>B2 L8 P2 Golden Gate Business Park Buenavista II General Trias Cavite</td>
<td>(046) 428-1846, 423-1846</td>
<td><a href="mailto:ad.cleanecho@gmail.com">ad.cleanecho@gmail.com</a>; <a href="mailto:orly.julian@yahoo.com">orly.julian@yahoo.com</a></td>
<td>24-Jul-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Waste and Resources Management, Inc.</td>
<td>Pineapple St., Sitio Pag-asa I, Brgy. Aguado, Trece Martires City, Cavite</td>
<td>(046) 419-1100</td>
<td><a href="mailto:lmcarino@warmphilippines.com">lmcarino@warmphilippines.com</a></td>
<td>20-Aug-20</td>
<td>M501</td>
</tr>
<tr>
<td>IV-A</td>
<td>Danvis Trading</td>
<td>Barangay Lambingan, Tanza, Cavite</td>
<td>(046) 450-2722</td>
<td><a href="mailto:danvistrading@yahoo.com">danvistrading@yahoo.com</a></td>
<td>18-Oct-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Cleanway Environmental Management Solutions, Inc.</td>
<td>Meridian Industrial Complex II, Brgy. Maguyam, Silang, Cavite</td>
<td>(02) 529-8329, 865-2952</td>
<td><a href="mailto:marosel@cleanway.com.ph">marosel@cleanway.com.ph</a></td>
<td>27-Sep-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Red Stallion Trading</td>
<td>Alano Compound Brgy. Mabuhay, Carmona, Cavite</td>
<td>0977-853-3206</td>
<td><a href="mailto:redstalliontrading@yahoo.com">redstalliontrading@yahoo.com</a></td>
<td>02-Jul-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Jorm Trading Corporation</td>
<td>595 General Trias Drive, Tejero, General Trias, Cavite</td>
<td>(046) 437-8623, 509-4274</td>
<td><a href="mailto:jormtrading@yahoo.com">jormtrading@yahoo.com</a></td>
<td>07-Feb-21</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>VDGP ENTERPRISES</td>
<td>10-A Tagaytay Sta. Rosa Road, Purok IV, Barangay Putting-Kahoy, Silang, Cavite City</td>
<td>(046) 404-6346</td>
<td><a href="mailto:vdgp@orangehub.com">vdgp@orangehub.com</a></td>
<td>17-Sep-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Eco Care Trading and Waste Management Services (Formerly J.I.T TRADING,HAULING AND-sorting SERVICES)</td>
<td>#37, 38 Block 4, Sitio Manalo, Brgy. Sampaloc, Dasmariñas City, Cavite</td>
<td>046-5385113</td>
<td><a href="mailto:acpullon@yahoo.com">acpullon@yahoo.com</a></td>
<td>15-Aug-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Blue Ocean General Merchandise</td>
<td>Block 4 Lot 6, Golden Gate Business Park I, Brgy. Buenavista II, General Trias, Cavite</td>
<td>(02) 243-3429</td>
<td><a href="mailto:blueocean.general@yahoo.com">blueocean.general@yahoo.com</a></td>
<td>01-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Ecoserv Environmental Technologies &amp; Services</td>
<td>Lot 2 Block 30, Zone 1, Bulihan, Silang, Cavite</td>
<td>(046) 424-0865</td>
<td><a href="mailto:francis.phillip.armena@gmail.com">francis.phillip.armena@gmail.com</a></td>
<td>18-Oct-20</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>AUGUST-10 ENTERPRISE CO</td>
<td>192 Brgy.Sto.Tomas Binan Laguna</td>
<td>(049) 512-6421/542-9693</td>
<td><a href="mailto:august_10_enterprises@yahoo.com">august_10_enterprises@yahoo.com</a></td>
<td>07-May-21</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Maritrans Recycler, Inc</td>
<td>Unit 3 D.M. Ragasa Warehouse, #763 National Highway, Parian Calamba City, Laguna</td>
<td>(049) 545-9055, 545-9056</td>
<td><a href="mailto:meselag@pldtsl.net">meselag@pldtsl.net</a>; <a href="mailto:norie_genove@maritransrecycler.com">norie_genove@maritransrecycler.com</a></td>
<td>03-Dec-20</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Riffa Antonio Gen. Merchandise &amp; Services</td>
<td>Blk. 5A2 Lt-16C, Juana 6 Subdivision, Gabriel St., San Francisco, Biñan, Laguna</td>
<td>(02) 664-4024/529-2157</td>
<td><a href="mailto:benjie.razalan@yahoo.com">benjie.razalan@yahoo.com</a></td>
<td>01-Aug-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Something Nice Environmental Corp.</td>
<td>No. 67 Purok 1, Brgy. Milagros, Calamba, Laguna</td>
<td>(049) 511-8245</td>
<td><a href="mailto:sales@sne-corp.com">sales@sne-corp.com</a></td>
<td>02-Dec-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>F.R.O.A. Enterprises</td>
<td>0190 Unit A, Purok III, Brgy. Timbao, Timbao, Biñan City, Laguna</td>
<td>0908-8155021; 0917-3044053</td>
<td><a href="mailto:frolenterprises@gmail.com">frolenterprises@gmail.com</a></td>
<td>07-Jul-20</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Tritek Reverse Logistics Corporation</td>
<td>7270 Magsaysay Rd., San Antonio, San Pedro, Laguna</td>
<td>(02) 869-8404</td>
<td><a href="mailto:hsbarawid@tritek.com.ph">hsbarawid@tritek.com.ph</a></td>
<td>02-Jul-20</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>RV CABRERA TRADING</td>
<td>1490 Espiritu Compound, Pooc, Sta. Rosa City, Laguna</td>
<td>530-2581</td>
<td><a href="mailto:rvcabreratradings@yahoo.com">rvcabreratradings@yahoo.com</a></td>
<td>15-Aug-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>AR-BI ABERGOS ENTERPRISES</td>
<td>Block 9 Lot 1 Brgy. Don Jose, Sta. Rosa City, Laguna</td>
<td>0918-3037066; 0927-8851877</td>
<td><a href="mailto:arbiabergos@yahoo.com">arbiabergos@yahoo.com</a></td>
<td>02-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Greensouth Waste Transport Services (Formerly Christian and Aileen’s Trading)</td>
<td>329 Barangay Talangan Nagcarlan, Laguna</td>
<td>(049) 559-1615</td>
<td><a href="mailto:greensouth.wts@yahoo.com">greensouth.wts@yahoo.com</a></td>
<td>29-Jan-21</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>CleanHAUL Environmental Services Inc.</td>
<td>Lot 31, 32 &amp; 33 Block 1 Pines Street. Pinesville, Brgy. Dolores, Taytay Rizal</td>
<td>02-727-9005, 727-9001</td>
<td><a href="mailto:admin@cleanhaul.ph">admin@cleanhaul.ph</a></td>
<td>28-Nov-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>New Parbuilt Construction &amp; Services Corporation</td>
<td>67 Gen. Luna St., Ampid 2, San Mateo Rizal</td>
<td>570-2059, 997-7220, 571-9627</td>
<td><a href="mailto:newparbuiltcs@yahoo.com">newparbuiltcs@yahoo.com</a>; <a href="mailto:newparbuiltcorp@gmail.com">newparbuiltcorp@gmail.com</a></td>
<td>17-Sep-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Royal Earth Enterprises</td>
<td>Road 20 Extension, Nagting, Brgy. San Juan, Taytay, Rizal</td>
<td>(02)298-7385, 0938435008, 0956-5960195</td>
<td><a href="mailto:royalearthent@gmail.com">royalearthent@gmail.com</a></td>
<td>17-Sep-20</td>
<td>M503</td>
</tr>
<tr>
<td>V</td>
<td>Philippine Geothermal Production Company, Inc.</td>
<td>Brgy. Libjo, Tiwi, Albay</td>
<td>7976-6108</td>
<td><a href="mailto:apvs@pgpc.com.ph">apvs@pgpc.com.ph</a></td>
<td>12-Feb-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>V</td>
<td>Zigs Eco Sanitation Corporation</td>
<td>Sitio Banasian, Brgy. San Ramon, Daraga, Albay</td>
<td>9199990706</td>
<td><a href="mailto:zigseco@gmail.com">zigseco@gmail.com</a></td>
<td>22-Apr-21</td>
<td>M501</td>
</tr>
<tr>
<td>VI</td>
<td>Westy Transporter (Formerly Westy Used Cooking Oil Trading)</td>
<td>Sitio Airport, Caticlan, Malay, Aklan</td>
<td>(036) 288-9518</td>
<td><a href="mailto:hazwastewestytransporter@gmail.com">hazwastewestytransporter@gmail.com</a></td>
<td>01-Aug-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>VII</td>
<td>One Stop Logistics Solutions, Inc.</td>
<td>Warehouse 16, Benedict Ventures, Inc., P. Basubas St., Tipolo, Mandaue City, Cebu; Garage Addresses: c/o Tell Trans, Inc., Tayud, Consolacion, Cebu; c/o San Remegio Trucking Services, E.O. Perez St., North Reclamation Area, Subangdaku, Cebu City</td>
<td>(02) 527-5555</td>
<td><a href="mailto:oisi@msl.com.ph">oisi@msl.com.ph</a></td>
<td>07-Feb-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>VII</td>
<td>Pollution Abatement Systems Specialist Inc</td>
<td>Rm 10 A. Geson Bldg D. Jakosalem St. Cebu City; Garage Address: Sanitary Landfill, White Road Inayawan, Cebu City</td>
<td>(032) 2551535, 5203251</td>
<td><a href="mailto:mailfwd.passi@gmail.com">mailfwd.passi@gmail.com</a></td>
<td>13-Jun-20</td>
<td>M501</td>
</tr>
<tr>
<td>VII</td>
<td>Davao City Environmental Care, Inc.</td>
<td>Dumpsite Road, Plaridel St., Barangay Paknaan, Mandaue City</td>
<td>(032) 236-2011</td>
<td><a href="mailto:dceci_ph2012@yahoo.com.ph">dceci_ph2012@yahoo.com.ph</a></td>
<td>12-Feb-21</td>
<td>M501</td>
</tr>
</tbody>
</table>
K DENR- Accredited M501 and M503 Waste Treatment, Storage, and Disposal (TSD) Facilities

<table>
<thead>
<tr>
<th>Region</th>
<th>Name of Transporter</th>
<th>Address</th>
<th>Contact No.</th>
<th>Email Address</th>
<th>Date of Expiration</th>
<th>Waste Type</th>
<th>TSD Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR</td>
<td>Lepanto Consolidated Mining Company (LCMC)</td>
<td>Lepanto, Paco, Mankayan, Benguet</td>
<td>09154760056</td>
<td><a href="mailto:rolando.reyes@lepantomining.com">rolando.reyes@lepantomining.com</a></td>
<td>10-Jul-20</td>
<td>M501</td>
<td>A</td>
</tr>
<tr>
<td>NCR</td>
<td>Eco Safe Hazmat Treatment Inc.</td>
<td>Lot 7 West Los Angeles Street, California Village, San Bartolome, Novaliches, Quezon City</td>
<td>417-8888, 419-9267</td>
<td><a href="mailto:ecosafe_hazmat@yahoo.com">ecosafe_hazmat@yahoo.com</a></td>
<td>17-Sep-20</td>
<td>M501, M503</td>
<td>E</td>
</tr>
<tr>
<td>NCR</td>
<td>Integrated Waste Management, Inc.</td>
<td>Lung Center of the Philippines Compound, Quezon Ave. Quezon City</td>
<td>(02) 519-4583, 519-4583</td>
<td><a href="mailto:michai.marzan@gmail.com">michai.marzan@gmail.com</a>, <a href="mailto:policarpiobernie@yahoo.com">policarpiobernie@yahoo.com</a></td>
<td>18-Oct-20</td>
<td>M501</td>
<td>B</td>
</tr>
<tr>
<td>NCR</td>
<td>Green Planet Management, Inc.</td>
<td>Lot 9 Block 4, Joy Street, Pearl Island Industrial Compound, Punturin, Valenzuela City</td>
<td>984-8647, 984-8648</td>
<td><a href="mailto:gpmi_planeta@yahoo.com.ph">gpmi_planeta@yahoo.com.ph</a></td>
<td>29-Aug-20</td>
<td>M503</td>
<td>E</td>
</tr>
<tr>
<td>NCR</td>
<td>Trame Oil &amp; Environmental Specialist, Inc.</td>
<td>L2 B2 Pearl Island Compound, Punturin, Valenzuela</td>
<td>27968957</td>
<td><a href="mailto:trameoil.environmental@gmail.com">trameoil.environmental@gmail.com</a></td>
<td>22-Jan-21</td>
<td>M503</td>
<td>E</td>
</tr>
<tr>
<td>NCR</td>
<td>JM Ecotech Solutions Co.</td>
<td>168 Gen. Luis St., Kaybiga, Caloocan City</td>
<td>(02) 936-4632</td>
<td><a href="mailto:mail@jmecotech.com">mail@jmecotech.com</a>; <a href="mailto:docs@jmecotech.com">docs@jmecotech.com</a></td>
<td>18-Oct-20</td>
<td>M503</td>
<td>E</td>
</tr>
<tr>
<td>NCR</td>
<td>Maya Med Waste Corporation</td>
<td>WH#30, Toprite Industrial Compound, 1617 P. Jacinto St. Sitio Malinis, Bagbaguin, Valenzuela City</td>
<td>02 281-8513</td>
<td><a href="mailto:mayamedwastecorp@yahoo.com">mayamedwastecorp@yahoo.com</a>; <a href="mailto:info@mayawastesolutions.com">info@mayawastesolutions.com</a></td>
<td>01-Aug-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>Company Name</td>
<td>Address</td>
<td>Contact Person</td>
<td>Phone Numbers</td>
<td>Email Addresses</td>
<td>Date</td>
<td>MGC</td>
</tr>
<tr>
<td>---</td>
<td>--------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------------</td>
<td>---------------------------------------------------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>I</td>
<td>La Union Medical Center</td>
<td>Nazareno, Agoo, La Union Engr. Rodney Abibuag</td>
<td></td>
<td>09178058448, 09176304103</td>
<td><a href="mailto:servotreat_phils@yahoo.com">servotreat_phils@yahoo.com</a> M</td>
<td>28-Apr-21</td>
<td>M501</td>
</tr>
<tr>
<td>I</td>
<td>Servo-Treat Philippines, Incorporated</td>
<td>Zone 6, Brgy. Pinmaludpod, Urdaneta City, Pangasinah</td>
<td></td>
<td>(02) 551-7235</td>
<td><a href="mailto:christopher.ambito@udenna.ph">christopher.ambito@udenna.ph</a></td>
<td>06-Mar-21</td>
<td>M501</td>
</tr>
<tr>
<td>III</td>
<td>Udenna Environmental Services, Inc.</td>
<td>Brgy. Mambog, Hermosa, Bataan</td>
<td></td>
<td>(02) 732 2230, 7322564</td>
<td><a href="mailto:info_wacuman@yahoo.com">info_wacuman@yahoo.com</a></td>
<td>07-Feb-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Wacuman Incorporated</td>
<td>Sitio Tiakad, Brgy. San Mateo, Norzagaray, Bulacan</td>
<td></td>
<td>(044) 7649525, 09266708114</td>
<td><a href="mailto:asiauoi@yahoo.com">asiauoi@yahoo.com</a></td>
<td>15-Aug-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Holcim Philippines, Inc.</td>
<td>Norzagaray, Bulacan</td>
<td></td>
<td>0915-8412353</td>
<td><a href="mailto:markanthony.torres@lafargeholcinm.com">markanthony.torres@lafargeholcinm.com</a></td>
<td>23-Jul-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Asia United Oil Industry Corporation</td>
<td>Muralla Street, Iba, Meycauayan, Bulacan</td>
<td></td>
<td>(044) 7942669, 09266708114</td>
<td><a href="mailto:asiauoi@yahoo.com">asiauoi@yahoo.com</a></td>
<td>25-Jul-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Far East Fuel Corporation</td>
<td>Purok 5, Irabagon St., Brgy. Anyatam, San Ildefonso, Bulacan</td>
<td></td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>09-Jul-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>All Waste Services, Inc.</td>
<td>Km32 McArthur Highway, Tuktukan, Guiguinto, Bulacan</td>
<td></td>
<td>(044) 7942669 loc 227; 794-2668</td>
<td><a href="mailto:pco@aws.ph">pco@aws.ph</a></td>
<td>14-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Total Organic Environmental Solutions, Inc.</td>
<td>Brgy. Longos, Pulilan, Bulacan</td>
<td></td>
<td>044-892-0475</td>
<td><a href="mailto:melbamangabat@ymail.com">melbamangabat@ymail.com</a></td>
<td>26-May-21</td>
<td>M501</td>
</tr>
<tr>
<td>III</td>
<td>Recytechphil Inc.</td>
<td>138 Provincial Road, Brgy. Tambubong, Bocaue</td>
<td></td>
<td>(044) 893-6688</td>
<td><a href="mailto:recytechphilinc@yahoo.com">recytechphilinc@yahoo.com</a></td>
<td>18-Oct-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Globaltec Waste Management, Inc.</td>
<td>9 Westmont Industrial Subdivision, Brgy. Loma De Gato, Marilao, Bulacan</td>
<td></td>
<td>(044) 896-4181</td>
<td><a href="mailto:gtwminc@gmail.com">gtwminc@gmail.com</a></td>
<td>23-May-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Glochem Marketing &amp; Recycling Corp.</td>
<td>Purok 6, Brgy. San Roque, San Isidro, Nueva Ecija</td>
<td></td>
<td>(044) 806-2432</td>
<td><a href="mailto:office@gmrsp.ph">office@gmrsp.ph</a>, <a href="mailto:secglochem.office@gmail.com">secglochem.office@gmail.com</a></td>
<td>18-Oct-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Dolomatrix Philippines, Inc.</td>
<td>Angeles Industrial Park, Inc. (AIPI), Brgy. Calibutbut, Bacolor, Pampanga</td>
<td></td>
<td>(02) 671-9086; 671-1975</td>
<td><a href="mailto:santy.mallari@dolomatrix.com.ph">santy.mallari@dolomatrix.com.ph</a></td>
<td>17-Sep-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>SafeWaste Incorporated</td>
<td>9801 A-C Technology Resource Center, Paralayunan, Mabalacat City, Pampanga</td>
<td>045-4366008</td>
<td><a href="mailto:safewaste@ymail.com">safewaste@ymail.com</a></td>
<td>10-Feb-21</td>
<td>M501</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>VAG General Merchandise</td>
<td>Brgy. Gutad, Floridablanca, Pampanga</td>
<td>09171680400; 09323623872</td>
<td><a href="mailto:vag_genmerchandise@yahoo.com">vag_genmerchandise@yahoo.com</a></td>
<td>12-Dec-20</td>
<td>M503</td>
<td>D, E</td>
</tr>
<tr>
<td>III</td>
<td>RMS Petroleum Technology and Waste Management Corporation</td>
<td>Brgy. San Nicolas, Mexico, Pampanga</td>
<td>(02) 710-5660</td>
<td><a href="mailto:rmspetroleumtechnology@gmail.com">rmspetroleumtechnology@gmail.com</a></td>
<td>20-Nov-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Metro Clark Waste Management Corporation</td>
<td>Clark Special Economic Zone, Sub-zone D, Sitio Kalangitan, Cutcut II, Capas, Tarlac</td>
<td>(045) 606-8830, 599-6317</td>
<td><a href="mailto:info@mcwm.net">info@mcwm.net</a>; <a href="mailto:joseantonioramos@yahoo.com">joseantonioramos@yahoo.com</a></td>
<td>04-Jul-20</td>
<td>M501, M503</td>
<td>C</td>
</tr>
<tr>
<td>III</td>
<td>Tarlac Provincial Hospital</td>
<td>San Vicente, Tarlac City, Tarlac</td>
<td>045-9821234</td>
<td><a href="mailto:enro_tarlac@yahoo.com">enro_tarlac@yahoo.com</a></td>
<td>07-Feb-21</td>
<td>M501</td>
<td>A</td>
</tr>
<tr>
<td>III</td>
<td>Clean Leaf International Corporation</td>
<td>Brgy. Anupul, Bamban, Tarlac</td>
<td>(02) 990-6607, 962-8313</td>
<td><a href="mailto:cleanleaf@gmail.com">cleanleaf@gmail.com</a></td>
<td>20-Nov-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Cleanway Environmental Management Solutions, Inc</td>
<td>Brgy. Cutcut II, Capas, Tarlac</td>
<td>(02) 529-8329 (046) 865-2952</td>
<td><a href="mailto:marosel@cleanway.com.ph">marosel@cleanway.com.ph</a></td>
<td>31-Jul-20</td>
<td>M501</td>
<td>B</td>
</tr>
<tr>
<td>IV-A</td>
<td>Republic Cement &amp; Building Materials, Inc.</td>
<td>Brgy. Mapulo, Taysan, Batangas</td>
<td>(02) 887-5116 (02) 815-2678 to 79</td>
<td><a href="mailto:sharry.apud@republiccement.com">sharry.apud@republiccement.com</a></td>
<td>01-Aug-20</td>
<td>M503</td>
<td>A/D</td>
</tr>
<tr>
<td>IV-A</td>
<td>Green Eco Techwin Inc.</td>
<td>Block 2 Lot 8 Phase 2, Golden gate Business Park, Brgy. Buena Vista II, Gen. Trias, Cavite</td>
<td>(046) 470-1846</td>
<td><a href="mailto:orly.julian@yahoo.com">orly.julian@yahoo.com</a></td>
<td>30-Aug-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>IV-A</td>
<td>Green Horizon Environmental Management, Inc.</td>
<td>223 Ilaya St., Brgy. Niog II, Bacoor City, Cavite</td>
<td>(046) 417-0317</td>
<td><a href="mailto:mugar.angie@gmail.com">mugar.angie@gmail.com</a></td>
<td>08-Nov-20</td>
<td>M503</td>
<td>E</td>
</tr>
<tr>
<td>IV-A</td>
<td>HAZCHEM,INC.</td>
<td>0947 Purok V, Brgy. Makiling, Calamba City, Laguna</td>
<td>(049) 502-6989</td>
<td><a href="mailto:hazcheminc@yahoo.com.ph">hazcheminc@yahoo.com.ph</a></td>
<td>12-Dec-20</td>
<td>M501, M503</td>
<td>B, E</td>
</tr>
<tr>
<td>IV-A</td>
<td>AUGUST-10 ENTERPRISE CO.</td>
<td>192 Brgy. Sto. Tomas Binan Laguna</td>
<td>(049) 542-9693</td>
<td><a href="mailto:august_10_enterprises@yahoo.com.ph">august_10_enterprises@yahoo.com.ph</a></td>
<td>13-Aug-20</td>
<td>M503</td>
<td>B</td>
</tr>
<tr>
<td>IV-A</td>
<td>Green Resource &amp; Environmental Management Solutions, Inc</td>
<td>Warehouse 6, MMG 3 Industrial Compound, E. Gerodias St., San Antonio, San Pedro City, Laguna</td>
<td>632-4034096</td>
<td><a href="mailto:info@greenresourceincph.com">info@greenresourceincph.com</a>; <a href="mailto:jabacunawapco@greenresourceincph.com">jabacunawapco@greenresourceincph.com</a></td>
<td>02-Jul-20</td>
<td>M503</td>
<td>E</td>
</tr>
<tr>
<td>IV-B</td>
<td>Pollution Abatement Systems Specialists, Inc.</td>
<td>Sanitary Landfill, Brgy. Sta. Lourdes, Puerto Princesa City, Palawan</td>
<td></td>
<td><a href="mailto:mail.fwd@gmail.com">mail.fwd@gmail.com</a></td>
<td>28-Apr-21</td>
<td>M501</td>
<td>B</td>
</tr>
<tr>
<td>VI</td>
<td>Pollution Abatement Systems Specialists, Inc.</td>
<td>Calajanunan Dumpsite, Mandurriao, Iloilo City, Iloilo</td>
<td></td>
<td></td>
<td>14-Feb-21</td>
<td>M501</td>
<td>B</td>
</tr>
<tr>
<td>VII</td>
<td>Davao City Environmental Care, Inc.</td>
<td>Dumpsite Road, Plaridel St., Brgy. Paknaan, Mandaue City, Cebu</td>
<td>(032) 236-2011</td>
<td><a href="mailto:dceci_ph2012@yahoo.com.ph">dceci_ph2012@yahoo.com.ph</a></td>
<td>12-Feb-21</td>
<td>M501</td>
<td>B</td>
</tr>
<tr>
<td>VIII</td>
<td>Cleanway Philippines Inc.</td>
<td>LIDE, Brgy. Libertad, Isabel, Leyte</td>
<td>053-556 8705</td>
<td><a href="mailto:jqmoraleta@cleanway.com.ph">jqmoraleta@cleanway.com.ph</a>, <a href="mailto:cheryl.mahusay@cleanway.com.ph">cheryl.mahusay@cleanway.com.ph</a></td>
<td>20-Dec-20</td>
<td>M503</td>
<td>E</td>
</tr>
<tr>
<td>X</td>
<td>Republic Cement</td>
<td>Iligan, Inc. Kiwalan, Iligan City</td>
<td>(063) 222-0801 loc 3114; 0917-8245370</td>
<td><a href="mailto:nisa.sampaco@republiccement.com">nisa.sampaco@republiccement.com</a></td>
<td>09-Jan-21</td>
<td>M503</td>
<td>B/D</td>
</tr>
<tr>
<td>X</td>
<td>Philippine Sinter Corporation</td>
<td>PHIVIDEC Industrial Estate, Villanueva, Misamis Oriental</td>
<td>(088) 565-0005, 565-0026</td>
<td><a href="mailto:bernard.baobao@philsinter.com.ph">bernard.baobao@philsinter.com.ph</a></td>
<td>03-Mar-21</td>
<td>M501</td>
<td>A</td>
</tr>
<tr>
<td>XI</td>
<td>Maya Med Waste Corporation</td>
<td>Brgy. New Carmen, Tugbok District, Davao City</td>
<td>(082) 224-2505, 224-2538</td>
<td><a href="mailto:gel.radgreendavao@gmail.com">gel.radgreendavao@gmail.com</a></td>
<td>01-Aug-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>XIII</td>
<td>Taganito HPAL Nickel Corporation</td>
<td>Taganito Special Economic Zone, Brgy. Taganito, Claver, Surigao del Norte</td>
<td>(02) 548-7140; 548-7141; 856-7170</td>
<td><a href="mailto:Osamu.Nakai@smm.com.ph">Osamu.Nakai@smm.com.ph</a></td>
<td>08-Nov-20</td>
<td>M501, M503</td>
<td>A</td>
</tr>
</tbody>
</table>
L Vaccine Introduction Readiness Assessment Tool (VIRAT)/ Vaccine Readiness Assessment Framework (VRAF) Tool

Updated COVID-19 Vaccine Introduction Readiness Assessment Tool (VIRAT/VRAF 2.0) - Version 3 December 2020

1. This Readiness Assessment tool is a national level tool. Data inputs should be entered into the worksheet 'National Readiness'. Suggestions for timing and intervals to implement activities and assess progress are provided in the timeline.

2. Pre-planning activities should be initiated as early as Sept 2020 (earliest time interval provided) as COVID-19 vaccines may be available for introduction by early 2021. The tool will be updated as soon as more certainty about global vaccine supply availability becomes available.

3. The reference page (Tab 2) contains a list of planning and technical documents that can be used for guidance in completing some of the activities.

4. Equivalence Tables are included to streamline a transition from either the old VIRAT or the VRAF to the new VIRAT/VRAF 2.0 tool. Tab 3 contains a full equivalency table.

5. Additional information on the purpose of this tool and how to use it is available on the Information Note provided in the accompanying document.

1. National Readiness Tool

<table>
<thead>
<tr>
<th>Country: Philippines</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Category</td>
</tr>
<tr>
<td>--------------------------------</td>
</tr>
<tr>
<td>A. PLANNING &amp; COORDINATION</td>
</tr>
</tbody>
</table>

| Sep-Oct 20                  | Nov-Dec 20                  | Jan 21          | Feb 21          | Mar 21          | Administrative, organizational, regulatory and coordination actions at Central level | Administrative, organizational, regulatory and coordination actions at subnational level | Medical supplies, equipment and contract services requirements | Staffing and training requirements | Total financing needed to undertake the administrative actions, procure the medical supplies and equipment, and hire and train staff to get to a 'completed' or 'more than 90%' status |

<p>| Department of Health         |                           |               |               |               |                                                                                      |                                                                                           |                                                                                           |                                                                                           |                                                                                                                                                  |</p>
<table>
<thead>
<tr>
<th></th>
<th>A.2 Establish (or engage an existing working group) a National Technical Working Group (NTWG) for COVID-19 vaccine introduction with terms of reference, roles and responsibilities and regular meetings.</th>
<th>Completed</th>
<th>None</th>
<th>None</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A.3 Establish or engage existing NTWG subcommittees, if required, to cover the following workstreams: 1) service delivery 2) vaccine, cold chain &amp; logistics, 3) demand generation &amp; communication (4) prioritization, targeting and COVID-19 surveillance, (5) Monitoring and Evaluation: determination and proof of eligibility, proof of vaccination, monitoring of coverage among at-risk groups, and monitoring of vaccine impact (6) Safety, including injury prevention and AEFI detection and response.</td>
<td>Completed</td>
<td>None</td>
<td>None</td>
<td>None (All Meetings and consultations are done virtually)</td>
</tr>
</tbody>
</table>
A.4 Brief key ministries, NITAG, stakeholders and partners about COVID-19 vaccine introduction and their expected roles. Inform regularly & disseminate global and regional guidance (i.e. SAGE) with NITAGs & RITAGs and support NITAG working groups on COVID-19 vaccines.

| In progress-maturity stage | Need to establish the NITAG for COVID-19 Vaccine. Five members have already been confirmed by the DOH Execom last December 15, 2020. Deadline to convene the first NITAG Meeting on Wednesday, December 23, 2020. With other stakeholders, the Department of Health has been conducting several public consultations and consultative meetings with other agencies. Further, a public consultation will be conducted on the 1st week | None (All Meetings and consultations are done virtually) |
and 2nd week of January and table top exercises will be conducted with other partners, government agencies, NGOs and private sector on the 1st week and 2nd week of January as well. (To include subnational level meeting)

<p>| A.5 Identify and plan for the national vaccine access/procurement approach (e.g. COVAX Facility, bilateral purchase agreement, procurement through UN agency, self-procurement), including costs of items, due diligence mechanisms; identify key needs, ensure regulatory compliance, and complete required paperwork. Ensure that the procurement plan and purchasing strategy includes vaccines, ancillary supplies, and Personal Protective Equipment. Budget in progress-maturity stage | Signing of the loan agreement with ADB and World Bank, other bilateral agreements, and indemnification agreement as part of the COVAX Facility application, and passage and signing of the General Appropriations | None | None | To accomplish the procurement plan, none. |</p>
<table>
<thead>
<tr>
<th>Activity</th>
<th>Progress Maturity Stage</th>
<th>Description</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.6 Plan and procure waste management supplies and equipment for appropriate implementation of waste management protocols.</td>
<td>In progress-maturity stage</td>
<td>Waste management policy and plan in place. Inclusion of the plan on waste management in the NVDP. Ongoing consolidation of the NVDP.</td>
<td>Sharps pit vault</td>
</tr>
<tr>
<td>A.7 Ensure that program objectives are defined and agreed to by key stakeholders at the central and sub-national levels, including representatives of target populations, community leaders, religious leaders, etc., and reflect the epidemiological situation and are adaptable to vaccine supply scenarios (protection of vulnerable populations, continuity of essential services, equity).</td>
<td>In progress-maturity stage</td>
<td>Public consultation to be conducted on the 1st week and 2nd week of January, and table top exercises with other partners, government agencies, NGOs and private sector on the 1st week and 2nd week of January.</td>
<td>Orientation and policy advocacy to Local Chief Executives and local leaders once national policies are cascaded from the national to regional level.</td>
</tr>
</tbody>
</table>

Act by President Roa Duterte.
<table>
<thead>
<tr>
<th>A.8 Develop the National Deployment and Vaccination Plan (NDVP) with input from relevant bodies (National COVID-19 Response Coordinating Committee, CNCC, CTWG, NITAG, National Immunization Programme, National Regulatory Authority, AEFI committee and other relevant groups such as private sector). The NDVP should be in line with WHO guidance and SAGE recommendations (plan can be developed by adapting the Pandemic Influenza NDVP, if existing).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Currently, the National Deployment and Vaccination Plan is being drafted by each TGs and STGs. A team is being assigned to consolidate all inputs of the TGs and STGs. The STG Planning and Policy is expecting to receive all inputs this week. The TG Immunization Program is aiming to release the NDVP before the end of December 2020. The National Government is also being assisted by our partners, the World Health Organization.</td>
</tr>
<tr>
<td>The Department of Health shall cascade the NVDP to the Centers for Health Development and they shall cascade it to the Local Government Units.</td>
</tr>
<tr>
<td>None</td>
</tr>
<tr>
<td>B. BUDGETING</td>
</tr>
<tr>
<td>C. REGULATORY</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>C.2 Ensure the national regulatory authority or other concerned authority has clarified the regulatory requirements, and documents needed for regulatory approvals of COVID-19 vaccines and related supplies.</td>
</tr>
<tr>
<td>C.3 Ensure that regulatory procedures are in place for import permit of COVID-19 vaccines and related supplies, and identify the requirements and documents needed to import COVID-19 vaccines and related supplies, including for taxes and tariffs.</td>
</tr>
<tr>
<td>C.4 Confirm to WHO the existence of an expedited import approval from appropriate authorities. Time lines and maximum number of days should be mentioned.</td>
</tr>
</tbody>
</table>
(expected timeline: maximum 5 working days).

<table>
<thead>
<tr>
<th>D. PRIORITIZATION, TARGETING &amp; COVID-19 SURVEILLANCE</th>
<th></th>
<th></th>
<th></th>
<th>Logistics and cold chain management training / orientation</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>D.1 Monitor progress of NITAG working groups on COVID-19 vaccines and interim recommendations focusing on prioritization and risk groups.</td>
<td>Not started</td>
<td>As mentioned above, the NITAG is still to be established.</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>D.2 Identify potential target populations that will be prioritized for access to vaccines, estimate their numbers, and identify their geographic location, i.e. prepare first to define, identify and estimate no. of HCWs.</td>
<td>Completed</td>
<td>None</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>D.3 Coordinate with national COVID-19 disease surveillance group to ensure relevant epidemiological data will be collected to inform planning of</td>
<td>Completed</td>
<td>None</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
E. SUBSEQUENT ROUNDS OF COVAX VACCINATION

- If applicable, including outbreak responses.

**E. SERVICE DELIVERY**

<p>| E.1 Update protocols for infection prevention and control measures including adequate personal protection equipment (PPE) to minimize exposure risk during immunization sessions. | In progress-maturity stage | The DPCB/NIP has established protocols on IPC for a nationwide immunization campaign which was previously utilized during the MR-OPV SIA last November 2020. The protocols will be adapted in the COVID-19 immunization program. The IPC protocols for COVID-19 immunization program is already available. It shall be incorporated in the COVID-19 Vaccine operational guidelines and disseminated accordingly. | The protocols shall be adapted in the regional and local levels. | None |</p>
<table>
<thead>
<tr>
<th>E.2 Identify potential COVID-19 vaccine delivery strategies and outreach strategies leveraging both existing vaccination platforms and non-vaccination delivery approaches to best reach identified target groups. Develop a master list and strategy of service providers, points of delivery, including fixed and outreach (e.g. health facilities, community centers, by appointments, house-to-house) and associated medical supplies that could effectively deliver COVID-19 vaccine to target populations, and ensure that the necessary planning for locations and logistics is carried out.</th>
<th>In progress-maturity stage</th>
<th>Incorporation of the COVID-19 vaccine delivery strategies and outreach strategies in the NDVP and operational guidelines.</th>
<th>The COVID-19 vaccine delivery strategies and outreach strategies and guidelines shall be adapted in the regional and local level.</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>E.3 Identify implementing agencies and establish contractual agreements to prepare for vaccine introduction (e.g., vaccine warehousing, transport, waste management, cold chain capacity, etc.) where applicable. For delivery through private facilities, develop and approve Standard Operating Procedures,</td>
<td>In progress-maturity stage</td>
<td>Ongoing drafting of the NDVP, Manual Operating Procedures and operational guidelines.</td>
<td>Adaption of the NDVP, Manual Operating Procedures and operational guidelines in the regional and local level.</td>
<td>Warehousing and cold chain equipments</td>
</tr>
</tbody>
</table>
including service quality and performance and reporting standards and mechanisms for complaints-handling, certification of facilities, financing, performance monitoring and integrity checks.

| E.4 Ensure existence of protocols regarding consent to vaccinations, process for agreeing to or refusing to be vaccinated, and measures to protect those that refuse to be vaccinated are in place. | In progress-maturity stage | Incorporation of the consent guidelines in the Operational Guidelines and NVDP. | Adaption of protocols for consent prior to vaccination in the regional and local level. | Part of the Vaccine administration training. No staffing required. | None |

<p>| F. TRAINING &amp; SUPERVISION F.1 Develop a training plan across all participating facilities to prepare for COVID-19 vaccine introduction that includes key groups of participants, content topic areas (including safe injection practices), key training partners and training methods (in-person or virtual). WHO will provide a template for guidance. | ComPLETED | None | Adaption of national training plan by the regional and implementing units as inclusion in their microplans | 20 DOH personnel with support from the World Health Organization and Unicef. No training required. | None | (All Meetings and consultations are done virtually) |</p>
<table>
<thead>
<tr>
<th>F.2 Adapt and translate training materials developed by WHO and develop additional training materials as outlined in the training plan.</th>
<th>Not started</th>
<th>Collation and editing of content of Training Modules. Continuous consultation with content experts and WHO/Unicef partners. Develop presentation slides per module, scripts and conduct pre- and post-tests. Conduct pre-testing of training modules/materials. Approval of training materials by principals.</th>
<th>The training materials developed in the Central Level shall be provided to the regional counterparts and the implementing units.</th>
<th>50 DOH Central Office personnel in contact consultation with experts and WHO/Unicef. Personnel are previously trained on learning development.</th>
</tr>
</thead>
<tbody>
<tr>
<td>F.3 Ensure availability of plans to safeguard the security of staff (e.g. during an emergency or major campaign) as well as security at the central and/or regional storage facilities and for in-transit of products. Ensure</td>
<td>Not started</td>
<td>Conduct consultative meeting with security personnel such as PNP and AFP. Draft a safety and security</td>
<td>20 DOH Central office for planning and drafting of regulations. Utilize the expertise of None. All Meetings and consultations are done virtually. Equipment and technology used are already provided previously.</td>
<td></td>
</tr>
<tr>
<td>regulations are in place regarding personnel who will be carrying out vaccinations, including all staff/personnel/consultants etc. engaged in such activities (cover military personnel also, if relevant), and include requirements relating to chemical, physical and biological substances, not engaging in sexual exploitation and abuse and sexual harassment, participation in training, reporting and non-retaliation.</td>
<td>plan for safety of health workers and personnel. Have the plan approved by principals by December 4th week. Cascade the plan to regional counterparts.</td>
<td>security sector.</td>
<td>provided previously.</td>
<td></td>
</tr>
<tr>
<td>F.4 Conduct virtual and/or in person trainings as outlined in the training plan.</td>
<td>Not started</td>
<td>Completion of the training modules. December 28-29: Training of Core Trainers; January 6-9 and 11-13, Regional Training of Trainers; January: cascading (roll out trainings) to implementing units.</td>
<td>Permanent representatives in STG on Cap Dev partners'meetings, as well as, regional trainors for the roll out trainings at the implementors level should be identified. A training plan shall be required from each CHD at the end of each regional TOT, that is, how they will roll out the trainings at the implementors/vaccinators level (i.e: # of batches, dates, etc). Cascade of the training down to the implementing units will be in January 2020. Microplanning</td>
<td>941 trainers requiring training.</td>
</tr>
</tbody>
</table>
|   |   |   | at the end of each batch of implementors
trg shall be required per LGU which shall provide operational details corresponding to each module (i.e. # of vaccination teams, vaccinator and vaccine deployment, cold chain requirements, AEFI mgmt and where to refer patients, logistic requirements, disposal of immunization wastes, etc.) |

| G. MONITORING & EVALUATION | G.1. Develop or adapt existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc. for COVID-19 vaccine including | In progress - early stage | Adapt the monitoring framework currently being used by the National | Adaption of the monitoring framework by the regional and local level | None |
gathering information from facilities and contractors participating in vaccine delivery, and ensuring necessary human resource capacity is in place. Determine whether registration and reporting will be individual or aggregate, and to what extent existing tools and systems can be used.

<p>| G.2 Develop or adapt necessary paper-based and/or electronic monitoring tools and appropriate institutional arrangements, including vaccination cards/certificates, facility-based nominal registers and/or tally sheets, vaccination reports, medical records, immunization records, systems entry and analytical tools to monitor progress and coverage among different at-risk categories and facilitate vaccine delivery and timely reporting. | In progress-early stage | Ongoing development of paper-based and/or electronic monitoring tools. The electronic information system has been developed and is ready for pilot testing. A pre-testing of the system will be conducted in the DOH-Central Office on December 21-23 | Adaption of the monitoring tools by the regional and local level | Electronic data management system | IT support Information systems and data management training | To be determined. |</p>
<table>
<thead>
<tr>
<th>Task</th>
<th>Status</th>
<th>Progress Details</th>
<th>Measures</th>
<th>IT Support</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>G.3 Ensure measures are in place for data protection, and appropriate data governance regulation is in place to monitor legitimate, appropriate and proportionate use and processing of data which may be routinely collected and managed in health information systems.</td>
<td>In progress-early stage</td>
<td>Part of the consideration in the development of monitoring and data management tools</td>
<td>Adaption of the monitoring tools by the regional and local level</td>
<td>Existing ICT equipment shall be utilized at all levels; Additional ICT equipment shall be procured after funding has been provided.</td>
<td>IT support Information systems and data management training</td>
</tr>
<tr>
<td>G.4 Produce and distribute monitoring tools to eligible vaccination providers, develop, test and roll-out any changes to electronic systems, provide training for use of these tools and processes to traditional and new providers.</td>
<td>Not started</td>
<td>To complete the data management system and the monitoring tools. To set schedule for pretesting. Two batches of virtual public consultation is planned and yet to take place by the end of 2020</td>
<td>Adaption of the monitoring tools by the regional and local level. Monitoring tools are scheduled to be rolled out after pilot testing has been conducted by and necessary revision had been done by the end of 2020.</td>
<td>Electronic data management system</td>
<td>To be determined.</td>
</tr>
<tr>
<td>G.5 Ensure a mechanism with multiple intake points has been designed and is in place, and is operational for feedback and grievances in</td>
<td>Not started</td>
<td>To establish the Emergency Operations Center with complete data</td>
<td>Establishment of the subnational, regional and local level.</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Relation to the Vaccine Program</td>
<td>Management Systems and Tool Starting on January</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------------------------------------------</td>
<td>------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H. VACCINE, COLD CHAIN, LOGISTICS &amp; INFRASTRUCTURE</td>
<td>H.1 Establish/strengthen the national logistics working group with appropriate terms of reference and standard operating procedures to coordinate COVID-19 vaccines and ancillary products deployment.</td>
<td>Compl eted</td>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H.2 Map key roles and responsibilities needed for vaccine and ancillary products deployment; collect and confirm contact information for key personnel and facilities.</td>
<td>In progress-maturity stage</td>
<td>With proposed process flow of the vaccines and other immunization supplies at the national level from the notification of delivery up to the reverse logistics for the final disposal of the immunization wastes gathered from all the vaccination sites CHDs and LGUs as well as those that will be identified as recipients of the immunization commodities shall likewise develop their distribution plan appropriate to their situation.</td>
<td>None</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Page 184 of 215
<p>| H.3 Create a distribution strategy, including mapping the potential port(s) of entry, points of storage (stores) and stocking, and fallback facilities in the country with their respective cold chain storage (2-8C, -20C, -60/70C) and transportation capacity for vaccines and ancillary products, and ensure necessary human resource capacity is in place. | In progress-maturity stage | With draft guidelines on the distribution of COVID-19 Vaccines and Ancillary Immunization Supplies; With draft contract agreements with the TPL for the vaccine warehousing, transport, waste management, cold chain capacity, etc. where applicable | Ongoing coordination with CHDs through the Supply Officers to gather data on cold chain and dry storage capacity Issuance of memo to CHDs on the submission of cold chain and dry storage capacity | Partnered with other agencies through the TG on Cold Chain and Logistics Management (AFP, DILG, DND, DICT, DOTr, RITM, FDA, DTI, DBM) to ensure efficient distribution of vaccines and ancillary supplies | To be determined. |
| H.4 Map and develop plan to provide for infrastructure needs, including for energy (primary and back-up power, especially in cold chain), IT/communications (including internet connectivity) and water. | In progress-early stage | Requested additional funding from external partners (UNICEF and WHO) for additional storage capacity. Ongoing data gathering on the storage capacity, transportation services, and other logistics management assets of CHDs, other government agencies (AFP, | To be determined. |</p>
<table>
<thead>
<tr>
<th>Requirement</th>
<th>Status</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>H.5 Assess dry storage and cold chain capacity and infrastructure needs at all levels with regards to the COVID-19 vaccines characteristics and fill the identified supply and logistics gaps.</td>
<td>Compl eted</td>
<td>Ongoing conduct of storage capacity assessment at all levels with regards to the COVID-19 vaccines characteristics including the military (AFP, PNP, OCD) DepEd, DSWD and private sectors. Capacity of CHD warehouses were provided, on-going assessment on the Provincial and RHU level.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Logistics and cold chain management training / orientation</td>
</tr>
<tr>
<td>H.6</td>
<td>Provide COVID-appropriate standard operating procedures (SOPs), protocols, or guidelines for collection and disposal of medical waste, both hazardous and non-hazardous, to the relevant stakeholders. Assure that properly-licensed waste management providers (especially for hazardous waste storage, transportation and disposal) are identified and can be operationalized.</td>
<td>In progress-maturity stage</td>
</tr>
<tr>
<td>H.7</td>
<td>Update and implement systems and protocols for tracking and monitoring the stock management and distribution of vaccines and key supplies through the Government’s existing Vaccine Logistics Management and Information System (VLMIS), including operating procedures to reflect the characteristics of COVID-19</td>
<td>In progress-maturity stage</td>
</tr>
<tr>
<td>Vaccines (i.e. vial size, VVM,...)</td>
<td>Another system for consideration is the Vaccine Information Management System (VIMS) developed by DICT</td>
<td>Inclusion of track and trace in the TOR for the 3PL</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------------------------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>H.8 Disseminate delivery and acceptance protocols, ensure monitoring arrangements are in place, and identify supervisory focal points at each facility. Establish security arrangements to ensure the integrity of COVID-19 vaccines and ancillary products throughout the supply chain.</td>
<td>In progress-maturity stage</td>
<td>Implementation of Delivery Notification to include the estimated warehouse space requirement</td>
</tr>
<tr>
<td></td>
<td></td>
<td>For the +2C to +8C and -20C vaccines, distribution shall follow the pathway from the national cold storage facilities up to the service delivery points, the health centers, and hospitals allow the cold chain storage and distribution in NIP pathway of the current</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Logistics and cold chain management training/orientation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>None.</td>
</tr>
<tr>
<td>vaccines in the NIP of the DOH. Special distribution protocols for the -70C to -80C vaccine temperature requirements.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>I. SAFETY SURVEILLANCE</td>
<td>I.1 Ensure that guidelines, documented procedures and tools for planning and conducting vaccine pharmacovigilance activities (i.e. AEFI reporting, investigation, causality assessment, risk communication and response), have been developed and disseminated to surveillance facilities/sites.</td>
<td>AO 2016-0006 discusses the guidelines on AEFI surveillance and response; AO 2016-0025 discusses the guidelines on AEFI referral system.</td>
</tr>
<tr>
<td></td>
<td>In progress-early stage</td>
<td>Upcoming NAEFIC reconstitution on December 2020 through Department Personnel Order (for signing). NAEFIC was initially trained for causality assessment using a real death AEFI case. RAEIFCs: to follow up from the central level on the official document / issuance on</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
officially designating RAEFIC members

DPO of National AEFI Response Team (NART) shall assist AEFI response for regions needing assistance.

Amendment of Department Memorandum 2011-0308 to align with RA 11332 on the mandatory submission of medical records and appropriate data for all immediately notifiable diseases and health event of public health concern including AEFI
<table>
<thead>
<tr>
<th>I.2 Ensure adequate and trained human resources are available to conduct surveillance of events attributable to vaccination.</th>
<th>In progress-early stage</th>
<th>Develop training modules through inputting of core content of existing manuals by DOH AEFI, WHO, and administrative issuances Consultations on training modules in partnership with WHO Hiring of additional safety surveillance officers</th>
<th>Conduct orientation/training sessions Deployment of safety surveillance officers</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.3 Expedite appropriate representation, well defined ToRs and training the AEFI committee to review COVID-19 Vaccine safety data (e.g., causality assessment of serious AEFI, clusters of AEFI, emerging safety concerns etc.).</td>
<td>In progress-maturity stage</td>
<td>NAEFIC are having continuous causality assessment training through workshops, and e-learning courses pending</td>
<td>Causality assessment training with special focus on COVID-19 Access to online training,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Access fund for e-learning paid modules, seminars, etc. 200,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Fund for emergency</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>179 Safety Surveillance Officer - Health Program Officer I, SG 11 56,695,565.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>179 Health Promotion Officer - Health Program Officer I, SG 11 56,695,565.00</td>
</tr>
<tr>
<td>2 per province (2*81=162) + 1 per region (17)</td>
</tr>
<tr>
<td>Printing of modules 1,000,000.00 Distribution of modules 200,000.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>179 Safety Surveillance Officer - Health Program Officer I, SG 11 56,695,565.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>179 Health Promotion Officer - Health Program Officer I, SG 11 56,695,565.00</td>
</tr>
<tr>
<td>2 per province (2*81=162) + 1 per region (17)</td>
</tr>
<tr>
<td>Printing of modules 1,000,000.00 Distribution of modules 200,000.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>179 Safety Surveillance Officer - Health Program Officer I, SG 11 56,695,565.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>179 Health Promotion Officer - Health Program Officer I, SG 11 56,695,565.00</td>
</tr>
<tr>
<td>2 per province (2*81=162) + 1 per region (17)</td>
</tr>
<tr>
<td>Printing of modules 1,000,000.00 Distribution of modules 200,000.00</td>
</tr>
<tr>
<td>I.4 Identify provisions that require manufacturers to implement risk management plans and collect and report COVID-19 vaccine safety data to the NRA.</td>
</tr>
</tbody>
</table>
I.5 Plan active surveillance of specific COVID-19 vaccine related adverse events. If this is not possible, develop provisions that allow reliance on active surveillance data, decisions, and information from other countries or regional or international bodies.

<table>
<thead>
<tr>
<th>Task</th>
<th>Status</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOH to request technical assistance for harmonization of AEFI surveillance system</td>
<td>In progress - early stage</td>
<td>Consultations on current systems and guidance on improvements</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Develop / adapt AEFI database specific for COVID vaccine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consultation with CHDs, Hospitals, and Experts on AEFI database</td>
</tr>
<tr>
<td>Pretesting on safety surveillance officers Roll-out database</td>
<td></td>
<td>Virtual training (none)</td>
</tr>
<tr>
<td>Resource speaker from Upsalla</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

I.6 Define roles and responsibilities and establish a coordination mechanism between relevant stakeholders (NRA, EPI, MAH, MOH, WHO and others) for exchange of COVID-19 Vaccine safety information.

<table>
<thead>
<tr>
<th>Task</th>
<th>Status</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orientation and training for local and regional response for AEFI, esp for emergency response.</td>
<td>Completed</td>
<td>Technical assistance on emergency response mechanism and flow for handling serious AEFI: cost to be determined</td>
</tr>
<tr>
<td>Virtual training (none)</td>
<td></td>
<td>Resource speaker from Upsalla</td>
</tr>
<tr>
<td>I.7 Identify and secure channels of data sharing mechanisms to share COVID-19 vaccine safety data and findings with relevant regional and international partners.</td>
<td>In progress-early stage</td>
<td>DOH International Health Regulation Standard Operating Procedures on establishing mechanisms and communication channels shall be established. AEFI platform to be agreed upon must have adequate sharing mechanism and platform access in the different national and sub-national level and the global level.</td>
</tr>
</tbody>
</table>
I.8 Establish compensation schemes in the event that there are unintended health consequences as result of vaccines, including no-fault liability funds, and ensure that associated policies are in place.

<table>
<thead>
<tr>
<th>J. DEMAND &amp; GENERATION &amp; COMMUNICATION</th>
<th>J.1 Design and distribute a social mobilization and engagement strategy/demand plan and information awareness program (including advocacy, communications, social mobilization, risk and safety comms, community engagement, and training) to generate confidence, acceptance and demand for COVID-19 vaccines, including for engaging with national and local media, NGOs, social</th>
</tr>
</thead>
<tbody>
<tr>
<td>In progress-early stage</td>
<td>National government shall determine indemnity concerns and policies. Review existing policies on compensations for clinical trials, and public access programs. Policy drafting, orientation sessions, legal consultations, president’s endorsement.</td>
</tr>
<tr>
<td></td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>To be determined.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>J. DEMAND &amp; GENERATION &amp; COMMUNICATION</th>
<th>J.1 Design and distribute a social mobilization and engagement strategy/demand plan and information awareness program (including advocacy, communications, social mobilization, risk and safety comms, community engagement, and training) to generate confidence, acceptance and demand for COVID-19 vaccines, including for engaging with national and local media, NGOs, social</th>
</tr>
</thead>
<tbody>
<tr>
<td>In progress-maturity stage</td>
<td>Concurrence of PIA and private sector partners</td>
</tr>
<tr>
<td></td>
<td>Orientation of regional staff</td>
</tr>
<tr>
<td></td>
<td>Orientation of partners</td>
</tr>
<tr>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>Hiring of community organizers (number to be determined)</td>
</tr>
<tr>
<td></td>
<td>TA on crisis communication</td>
</tr>
<tr>
<td></td>
<td>Php 625M for community organizers</td>
</tr>
<tr>
<td></td>
<td>Php 75M for adverts etc.</td>
</tr>
</tbody>
</table>
platforms, etc. and human resources for community outreach and risk communication management that also explains how complaints may be lodged and how they will be resolved, are available at all levels. Must include crisis communications preparedness planning.

<table>
<thead>
<tr>
<th>J.2 Establish data collection systems, including 1) social media listening and rumor management, and 2) assessing behavioral and social data.</th>
<th>In progress - early stage</th>
<th>Completion of FAQs - in line with scenarios Updating of KIRA ChatBot backend</th>
<th>Not applicable</th>
<th>Contract on 3rd party survey</th>
<th>Hiring of regional staff (at least 1 per region) TA on infodemic management TA on in-house social listening</th>
<th>Php 30M for regional staff</th>
</tr>
</thead>
</table>

| J.3 Develop key messages and materials for public communications and advocacy, in alignment with demand plan. | In progress - early stage | Concurrence of PIA Branding guidelines from PIA Production Pre-testing in communities | Not applicable | Not applicable | Training of regional and local HEPOs | None |
# Reference Page

## Inventory of immunization related documents during COVID19

### Current December 2020

<table>
<thead>
<tr>
<th>Global guidance documents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No</strong></td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>8</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>12</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>14</td>
</tr>
<tr>
<td>16</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>17</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>18</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>20</td>
</tr>
<tr>
<td>21</td>
</tr>
</tbody>
</table>
programme in the context of COVID-19 vaccination and COVID-19 underway, and WHO will evaluate the evidence when it is available. In the absence of evidence, WHO does not recommend BCG vaccination for the prevention of COVID-19. WHO continues to recommend neonatal BCG vaccination in countries or settings with a high incidence of tuberculosis.

22 3. COVID-19 response Monitoring and Evaluation Framework COVID-19 Strategic Preparedness and Response (SPRP) 22-May-20 https://www.who.int/publications-detail/monitoring-and-evaluation-framework Guidelines The COVID 19 Strategic Preparedness and Response Plan (SPRP) Monitoring and Evaluation Framework (COVID 19 M&E Framework) lists key public health and essential health services and systems indicators to monitor preparedness, response, and situations during the COVID 19 pandemic. Indicators have been grouped around nine pillars and one thematic area. Immunization indicators, in the ninth pillar - Maintaining essential health services and systems include (i) DTP3 vaccination coverage in children under 12 months of age (ii) Percentage of countries where at least one VPD-immunization campaign was affected (suspended or postponed partially or fully) by COVID 19.

23 3. COVID-19 response Clinical management of COVID-19 27-May-20 https://www.who.int/publications-detail/clinical-management-of-covid-19 Interim Guidance At the time of discharge, the patient’s ongoing primary health care needs should be reviewed, including ensuring an up-to-date immunization status. This is especially important for children who may have missed immunizations. If needed, individuals should be offered referrals for immunization services.

24 3. COVID-19 response Maintaining essential health services in the COVID-19 context: Implementing the WHO operational guidance 01-Jun-20 https://www.who.int/publications-detail/WHO-2019-nCoV-essential-health-services-2020.1 Interim Guidance This document expands on the original operational guidance on maintaining essential health services during an outbreak. It provides implementation guidance on a set of targeted immediate actions that countries should consider at national, sub-national and local levels to reorganize and maintain access to high-quality, essential health services. This document outlines needed adaptations to keep people safe, maintain continuity of essential services, and ensure effective response to COVID-19.
<table>
<thead>
<tr>
<th></th>
<th>3. COVID-19 response</th>
<th>Continuity of essential health services: Facility assessment tool</th>
<th>20-Nov-20</th>
<th><a href="https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-HCF_assessment-EHS-2020_1">https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-HCF_assessment-EHS-2020_1</a></th>
<th>Interim Guidance</th>
<th>The Continuity of essential health services: Facility Assessment Tool can be used by countries to rapidly assess the capacity of health facilities to maintain the provision of essential health services during the COVID-19 pandemic. It can help to alert the authorities and other stakeholders about where service delivery and utilization may require modification and/or investment</th>
<th>Essential Health Services</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>4. Polio programme in the context of COVID-19</td>
<td>Polio Eradication Programme continuity planning measures to ensure continuity of operations in the context of the COVID-19</td>
<td>May 2020 (update)</td>
<td><a href="http://polioeradication.org/wp-content/uploads/2020/03/COVID-POL-programme-continuity-planning-20200325.pdf">http://polioeradication.org/wp-content/uploads/2020/03/COVID-POL-programme-continuity-planning-20200325.pdf</a></td>
<td>Interim Guidance</td>
<td>The purpose of this document is to provide guidance to polio programme continuity planning in the context of the COVID-19 pandemic. Its intended users are the polio programme planners and managers in the GPEI target countries and regional offices. Considering the global nature of the polio eradication programme, it also provides recommendations for the areas of work relevant to the global level planning.</td>
<td>Polio</td>
</tr>
<tr>
<td>No.</td>
<td>Title</td>
<td>Interim Guidance Details</td>
<td>Purpose of Document</td>
<td>Topic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>-------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>4. Polio programme in the context of COVID-19</td>
<td>Interim Guidance for the Polio Surveillance Network in the context of Coronavirus (COVID 19)</td>
<td>The document aims to provide global guidance to Polio Surveillance activities in the context of the COVID-19 pandemic. It comes as a complement of the Polio Eradication Programme continuity Planning and aligns with the full support that the GPEI has announced to the COVID-19 pandemic.</td>
<td>Polio</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>4. Polio programme in the context of COVID-19</td>
<td>Interim Guidance for Frontline Workers on Safe Implementation of H-T-H Vaccination campaigns (COVID 19)</td>
<td>The purpose of this document is to provide specific guidance to national and sub-national programme managers who will be supporting frontline workers for the safe implementation of house-to-house polio immunization campaigns in the context of the COVID-19 pandemic.</td>
<td>Polio</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Equivalence table of new VIRAT/VRAF 2.0 with old VIRAT and VRAF Indicator Codes

<table>
<thead>
<tr>
<th>Category</th>
<th>VIRAT/VRAF 2.0 Indicator Code</th>
<th>Old VIRAT Indicator Code</th>
<th>VRAF Indicator Code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A. PLANNING &amp; COORDINATION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A.1</td>
<td>A.1</td>
<td>A.1.4</td>
<td></td>
</tr>
<tr>
<td>A.2</td>
<td>A.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A.3</td>
<td>A.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A.4</td>
<td>A.4, A.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A.5</td>
<td>A.7</td>
<td>B.1.1, B.1.2</td>
<td></td>
</tr>
<tr>
<td>A.6</td>
<td></td>
<td>B.1.3</td>
<td></td>
</tr>
<tr>
<td>A.7</td>
<td></td>
<td>A.1.1</td>
<td></td>
</tr>
<tr>
<td>A.8</td>
<td></td>
<td>A.6</td>
<td></td>
</tr>
<tr>
<td><strong>B. BUDGETING</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.1</td>
<td>B.1, B.2, B.3, B.4</td>
<td>A.4.1</td>
<td></td>
</tr>
<tr>
<td>B.2</td>
<td>B.1, B.2, B.3, B.4</td>
<td>A.4.2</td>
<td></td>
</tr>
<tr>
<td><strong>C. REGULATORY</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C.1</td>
<td>C.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C.2</td>
<td>C.2</td>
<td>A.2.1</td>
<td></td>
</tr>
<tr>
<td>C.3</td>
<td>C.3</td>
<td>A.2.2, A.2.3</td>
<td></td>
</tr>
<tr>
<td>C.4</td>
<td>C.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C.5</td>
<td>C.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D. PRIORITIZATION, TARGETING &amp; COVID19 SURVEILLANCE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D.1</td>
<td>D.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D.2</td>
<td>D.2</td>
<td>A.1.3</td>
<td></td>
</tr>
<tr>
<td>D.3</td>
<td>D.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>E. SERVICE DELIVERY</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E.1</td>
<td>E.1</td>
<td>B.1.2</td>
<td></td>
</tr>
<tr>
<td>E.2</td>
<td>E.2, E.3</td>
<td>A.3.2, B.2.1, C.2.1</td>
<td></td>
</tr>
<tr>
<td>E.3</td>
<td>H.5</td>
<td>A.2.8, A.1.2</td>
<td></td>
</tr>
<tr>
<td>E.4</td>
<td></td>
<td>A.2.6</td>
<td></td>
</tr>
<tr>
<td><strong>F. TRAINING &amp; SUPERVISION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F.1</td>
<td>F.1</td>
<td>C.2.3</td>
<td></td>
</tr>
<tr>
<td>F.2</td>
<td>F.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F.3</td>
<td>E.4</td>
<td>A.2.7</td>
<td></td>
</tr>
<tr>
<td>F.4</td>
<td>F.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>G. MONITORING &amp; EVALUATION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G.1</td>
<td>G.1</td>
<td>A.3.5</td>
<td></td>
</tr>
<tr>
<td>G.2</td>
<td>G.2</td>
<td>D.1.1, C.2.2</td>
<td></td>
</tr>
<tr>
<td>G.3</td>
<td></td>
<td>A.2.4</td>
<td></td>
</tr>
<tr>
<td>G.4</td>
<td>G.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G.5</td>
<td></td>
<td>A.3.4</td>
<td></td>
</tr>
<tr>
<td><strong>H. VACCINE, COLD CHAIN, LOGISTICS &amp; INFRASTRUCTURE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H.1</td>
<td>H.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H.2</td>
<td>H.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H.3</td>
<td>H.3</td>
<td>B.2.1, B.2.2</td>
<td></td>
</tr>
<tr>
<td>H.4</td>
<td></td>
<td>D.2.1, D.2.2</td>
<td></td>
</tr>
<tr>
<td>H.5</td>
<td>H.4</td>
<td>A.3.1, B.2.2</td>
<td></td>
</tr>
<tr>
<td>H.6</td>
<td>H.6</td>
<td>B.3.1, B.3.2, B.3.3</td>
<td></td>
</tr>
<tr>
<td>H.7</td>
<td>H.7</td>
<td>B.2.3</td>
<td></td>
</tr>
<tr>
<td>H.8</td>
<td>H.8</td>
<td>C.2.4</td>
<td></td>
</tr>
<tr>
<td><strong>I. SAFETY SURVEILLANCE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.1</td>
<td>I.1</td>
<td>C.3.1</td>
<td></td>
</tr>
<tr>
<td>I.2</td>
<td>I.2</td>
<td>C.3.1</td>
<td></td>
</tr>
<tr>
<td>I.3</td>
<td>I.3</td>
<td>C.3.2</td>
<td></td>
</tr>
<tr>
<td>I.4</td>
<td>I.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.5</td>
<td>I.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.6</td>
<td>I.6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
M Resource List: COVID-19 Guidance

World Bank Environmental and Social Management Framework for COVID-19 Response, April 20, 2020

Given the COVID-19 situation is rapidly evolving, a version of this resource list will be regularly updated and made available on the World Bank COVID-19 operations intranet page (http://covidoperations/).

WHO Guidance

Advice for the Public

- WHO advice for the public, including on social distancing, respiratory hygiene, self-quarantine, and seeking medical advice, can be consulted on this WHO website: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public

Technical guidance

- Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected, issued on March 19, 2020
- Recommendations to Member States to Improve Hygiene Practices, issued on April 1, 2020
- Severe Acute Respiratory Infections Treatment Center, issued on March 28, 2020
- Infection prevention and control at health care facilities (with a focus on settings with limited resources), issued in 2018
- Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19), issued on March 18, 2020
- Laboratory Biosafety Manual, 3rd edition, issued in 2014
- Laboratory testing for COVID-19, including specimen collection and shipment, issued on March 19, 2020
- Prioritized Laboratory Testing Strategy According to 4Cs Transmission Scenarios, issued on March 21, 2020
- Infection Prevention and Control for the safe management of a dead body in the context of COVID-19, issued on March 24, 2020
Key considerations for repatriation and quarantine of travelers in relation to the outbreak COVID-19, issued on February 11, 2020

Preparedness, prevention and control of COVID-19 for refugees and migrants in non-camp settings, issued on April 17, 2020

Coronavirus disease (COVID-19) outbreak: rights, roles and responsibilities of health workers, including key considerations for occupational safety and health, issued on March 18, 2020

Oxygen sources and distribution for COVID-19 treatment centers, issued on April 4, 2020


Considerations for quarantine of individuals in the context of containment for coronavirus disease (COVID-19), issued on March 19, 2020

Operational considerations for case management of COVID-19 in health facility and community, issued on March 19, 2020

Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19), issued on February 27, 2020

Getting your workplace ready for COVID-19, issued on March 19, 2020

Water, sanitation, hygiene and waste management for COVID-19, issued on March 19, 2020

Safe management of wastes from health-care activities, issued in 2014

Advice on the use of masks in the community, during home care and in healthcare settings in the context of the novel coronavirus (COVID-19) outbreak, issued on March 19, 2020

Disability Considerations during the COVID-19 outbreak, issued on March 26, 2020

WORLD BANK GROUP GUIDANCE

Technical Note: Public Consultations and Stakeholder Engagement in WB-supported operations when there are constraints on conducting public meetings, issued on March 20, 2020

Technical Note: Use of Military Forces to Assist in COVID-19 Operations, issued on March 25, 2020

ESF/Safeguards Interim Note: COVID-19 Considerations in Construction/Civil Works Projects, issued on April 7, 2020

Technical Note on SEA/H for HNP COVID Response Operations, issued in March 2020

Interim Advice for IFC Clients on Preventing and Managing Health Risks of COVID-19 in the Workplace, issued on April 6, 2020

Interim Advice for IFC Clients on Supporting Workers in the Context of COVID-19, issued on April 6, 2020
• IFC Tip Sheet for Company Leadership on Crisis Response: Facing the COVID-19 Pandemic, issued on April 6, 2020

• WBG EHS Guidelines for Healthcare Facilities, issued on April 30, 2007

ILO GUIDANCE

• ILO Standards and COVID-19 FAQ, issued on March 23, 2020 (provides a compilation of answers to most frequently asked questions related to international labor standards and COVID-19)

MFI GUIDANCE

• ADB Managing Infectious Medical Waste during the COVID-19 Pandemic

• IDB Invest Guidance for Infrastructure Projects on COVID-19: A Rapid Risk Profile and Decision Framework

• KfW DEG COVID-19 Guidance for employers, issued on March 31, 2020

• CDC Group COVID-19 Guidance for Employers, issued on March 23, 2020